<SEC-DOCUMENT>0001493152-24-015137.txt : 20240418
<SEC-HEADER>0001493152-24-015137.hdr.sgml : 20240418
<ACCEPTANCE-DATETIME>20240418105359
ACCESSION NUMBER:		0001493152-24-015137
CONFORMED SUBMISSION TYPE:	S-3
PUBLIC DOCUMENT COUNT:		22
FILED AS OF DATE:		20240418
DATE AS OF CHANGE:		20240418

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			JanOne Inc.
		CENTRAL INDEX KEY:			0000862861
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				411454591
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-278784
		FILM NUMBER:		24853294

	BUSINESS ADDRESS:	
		STREET 1:		325 E. WARM SPRINGS ROAD
		STREET 2:		SUITE 102
		CITY:			LAS VEGAS
		STATE:			NV
		ZIP:			89119
		BUSINESS PHONE:		702-997-5968

	MAIL ADDRESS:	
		STREET 1:		325 E. WARM SPRINGS ROAD
		STREET 2:		SUITE 102
		CITY:			LAS VEGAS
		STATE:			NV
		ZIP:			89119

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	APPLIANCE RECYCLING CENTERS OF AMERICA INC /MN
		DATE OF NAME CHANGE:	19930328
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-3
<SEQUENCE>1
<FILENAME>forms-3.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>As
filed with the Securities and Exchange Commission on April 17, 2024</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registration
No. 333-</B></FONT><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: bold 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: bold 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: bold 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>FORM
S-3</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">REGISTRATION
STATEMENT UNDER THE SECURITIES ACT OF 1933</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>JANONE
INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Exact
name of registrant as specified in its charter)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nevada</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5700
    </FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>41-1454591</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
                                            or other jurisdiction of</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">incorporation
    or organization)</FONT></P></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Primary
                                            Standard Industrial</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Classification
    Code Number)</FONT></P></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S.
                                            Employer</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
    Number)</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>325
E. Warm Springs Road, Suite 102</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Las
Vegas, Nevada 89119</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(702)
997-5968</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Address,
including zip code, and telephone number, including area code, of registrant&rsquo;s principal executive offices)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Tony
Isaac</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>President
and Chief Executive Officer</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>JanOne
Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>325
E. Warm Springs Road, Suite 102</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Las
Vegas, Nevada 89119</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(702)
997-5968</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Name,
address, including zip code, and telephone number, including area code, of agent for service)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>With
Copies to:</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 75%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 100%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Randolf
                                            W. Katz, Esq.</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Clark
    Hill PLC</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>555
    South Flower Street, 24<SUP>th</SUP> Floor</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Los
    Angeles, California 90071</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>213-891-9100</B></FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Approximate
date of commencement of proposed sale to the public:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time after this registration statement is declared effective.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check
the following box. &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the
Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following
box. &#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the
following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering. &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this Form is a post-effective amendment filed pursuant to Rule 462I under the Securities Act, check the following box and list the Securities
Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective
upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional
securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo;
&ldquo;smaller reporting company&rdquo; and &ldquo;emerging growth company in Rule 12b-2 of the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    accelerated filer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
    filer</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated
    filer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
    reporting company</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
    growth company</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the
registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective
in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the registration statement shall become effective
on such date as the Commission, acting pursuant to said Section 8(a), may determine.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; border-bottom: Black 4pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><B>The
information contained in this prospectus is not complete and may be changed. We may not sell these securities until the Registration
Statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and
is not a solicitation of an offer to buy these securities in any jurisdiction where such offer or sale is not permitted.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><B>Preliminary
Prospectus Subject to completion, Dated April 17, 2024</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><IMG SRC="forms-3_001.jpg" ALT=""></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$100,000,000.00</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Preferred
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Debt
Securities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Rights</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Units</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may offer and sell from time to time shares of our common stock, par value $0.001 per share (our &ldquo;Common Stock&rdquo;), shares
of our preferred stock, par value $0.001 per share (our &ldquo;Preferred Stock&rdquo;), debt securities, warrants, rights, and units
that include any of these securities. The Preferred Stock or warrants may be convertible into or exercisable for shares of our Common
Stock or shares of our Preferred Stock or other of our securities registered hereunder. The debt securities may be convertible into or
exchangeable for shares of our Common Stock or shares of our Preferred Stock. Our Common Stock is listed on The Nasdaq Capital Market
and trades under the symbol &ldquo;JAN.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may offer and sell these securities to or through one or more underwriters, dealers, and agents, or directly to purchasers, on a continuous
or delayed basis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate market value of our outstanding Common Stock held by non-affiliates was approximately $274,320, based on 8,593,636 shares of
outstanding Common Stock as of April 8, 2024, of which approximately 108,000 shares were held by affiliates, and based on the closing
sale price of our Common Stock of $2.54 on April 8, 2024. Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell
securities pursuant to this prospectus with a value of more than one-third of the aggregate market value of our Common Stock held by
non-affiliates in any 12-month period, so long as the aggregate market value of our Common Stock held by non-affiliates is less than
$75,000,000. In the event that, subsequent to the date of this prospectus, the aggregate market value of our outstanding Common Stock
held by non-affiliates equals or exceeds $75,000,000, then the one-third limitation on sales shall not apply to additional sales made
pursuant to this prospectus. During the prior 12 calendar months prior to, and including, the date of this prospectus, we have not sold
any securities pursuant to General Instruction I.B.6 of Form S-3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus describes some of the general terms that may apply to these securities and the general manner in which they may be offered.
The specific terms of any securities to be offered, and the specific manner in which they may be offered, will be described in a supplement
to this prospectus. You should read this prospectus and any applicable prospectus supplement carefully before you invest.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>See
the &ldquo;Risk Factors&rdquo; section of this prospectus on page 3, our filings with the SEC, and the applicable prospectus supplement
for certain risks that you should consider before investing in our securities.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>None
of the Securities and Exchange Commission, any state securities commission, or any other regulatory body has approved or disapproved
of these securities nor passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
date of this prospectus is April [-], 2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TABLE
OF CONTENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#nd_001">ABOUT THIS PROSPECTUS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#nd_002">AVAILABLE INFORMATION</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#nd_003">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#nd_004">FORWARD-LOOKING STATEMENTS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#nd_005">RISK FACTORS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#nd_006">BUSINESS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#Su_002">SELECTED CONSOLIDATED FINANCIAL DATA</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">31</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#Su_003">DESCRIPTION OF SECURITIES WE MAY OFFER</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#Su_004">DESCRIPTION OF CAPITAL STOCK</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">33</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#Su_005">DESCRIPTION OF PREFERRED STOCK</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">36</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#Su_006">DESCRIPTION OF DEBT SECURITIES</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">37</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#Su_007">DESCRIPTION OF WARRANTS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">43</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#Su_008">DESCRIPTION OF RIGHTS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">45</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#Su_009">DESCRIPTION OF UNITS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">46</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#Su_010">USE OF PROCEEDS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">46</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#Su_011">PLAN OF DISTRIBUTION</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">46</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#Su_012">LEGAL MATTERS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">48</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#Su_013">EXPERTS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">48</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="nd_001"></A>ABOUT
THIS PROSPECTUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
document is called a prospectus and is part of a Registration Statement on Form S-3 that we have filed with the Securities and Exchange
Commission (the &ldquo;SEC&rdquo;) using a &ldquo;shelf&rdquo; registration process. Under this shelf registration process, we may, from
time to time, sell any combination of the securities described in this prospectus in one or more offerings in amounts that we will determine
from time to time, up to a total dollar amount of $100,000,000.00.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus provides you with a general description of the securities we may offer. Each time we offer a type or series of securities
described in this prospectus we will provide a prospectus supplement, incorporate information or document by reference into this prospectus
or a related free writing prospectus or use other offering materials, as applicable, containing more specific information about the terms
of the securities that are then being offered. We may also authorize one or more related free writing prospectuses to be provided to
you that may contain material information relating to these offerings and securities. This prospectus, together with applicable prospectus
supplements, any information or document incorporated by reference, and any related free writing prospectus or other offering materials,
as applicable, we file with the SEC, includes all material information relating to these offerings and securities. We may also add, update,
or change in the prospectus supplement any of the information contained in this prospectus or in the documents that we incorporate by
reference into this prospectus, including, without limitation, a discussion of any risk factors or other special considerations that
apply to these offerings or securities or the specific plan of distribution. If there is any inconsistency between the information in
this prospectus and a prospectus supplement or information or document incorporated by reference having a later date, you should rely
on the information in that prospectus supplement or incorporated information having a later date. We urge you to read carefully this
prospectus, any applicable prospectus supplement, and any related free writing prospectus or other offering materials, as applicable,
together with the information incorporated herein by reference as described under the heading &ldquo;Incorporation of Certain Information
by Reference,&rdquo; before buying any of the securities being offered.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should rely only on the information we have provided in, or incorporated by reference into, this prospectus, any applicable prospectus
supplement, and any related free writing prospectus or other offering materials, as applicable. We have not authorized anyone to provide
you with different information. No dealer, salesperson, or other person is authorized to give any information or to represent anything
not contained in this prospectus, any applicable prospectus supplement, any related free writing prospectus, or other offering materials,
as applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Neither
the delivery of this prospectus nor any sale made under it implies that there has not been any change in our business or affairs or that
the information in this prospectus is correct as of any date after the date of this prospectus. You should assume that the information
in this prospectus, any applicable prospectus supplement, any related free writing prospectus, or other offering materials, as applicable,
is accurate only as of the date on the front of the document and that any information we have incorporated by reference is accurate only
as of the date of the document incorporated by reference, regardless of the time of delivery of this prospectus, any applicable prospectus
supplement, any related free writing prospectus, or other offering materials, as applicable, or any sale of a security.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Registration Statement containing this prospectus, including exhibits to the Registration Statement, provides additional information
about us and the securities offered under this prospectus and any prospectus supplement. We have filed and plan to continue to file other
documents with the SEC that contain information about us and our business. Also, we will file legal documents that control the terms
of the securities offered by this prospectus as exhibits to the reports that we file with the SEC. The Registration Statement and other
reports can be read at the SEC Internet site or at the SEC offices mentioned under the heading &ldquo;Available Information.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus contains summaries of certain provisions contained in some of the documents described herein; but, reference is made to the
actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some
of the documents referred to herein have been filed, will be filed, or will be incorporated by reference as exhibits to the Registration
Statement of which this prospectus is a part, and you may obtain copies of those documents as described below under &ldquo;Available
Information.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="nd_002"></A>AVAILABLE
INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have filed with the SEC a Registration Statement on Form S-3 under the Securities Act with respect to the securities covered by this
prospectus. This prospectus, which is a part of that Registration Statement, does not contain all of the information set forth in the
Registration Statement or the exhibits and schedules filed therewith. For further information with respect to us and the securities covered
by this prospectus, please see the Registration Statement and the exhibits filed with the Registration Statement. A copy of the Registration
Statement and the exhibits filed with the Registration Statement may be inspected without charge at the Public Reference Room maintained
by the SEC, located at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for more information about the
operation of the Public Reference Room. The SEC also maintains an Internet website that contains reports, proxy and information statements,
and other information regarding registrants that file electronically with the SEC. The address of the website is http://www.sec.gov.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to the information and periodic reporting requirements of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange
Act&rdquo;), and, in accordance therewith, we file periodic reports, proxy statements, and other information with the SEC. Such periodic
reports, proxy statements, and other information are available for inspection and copying at the Public Reference Room and website of
the SEC referred to above. We maintain a website at http://www.janone.com. You may access our Annual Reports on Form 10-K, Quarterly
Reports on Form 10-Q, Current Reports on Form 8-K, and amendments to those reports filed pursuant to Sections 13(a) or 15(d) of the Exchange
Act with the SEC free of charge at our website as soon as reasonably practicable after such material is electronically filed with, or
furnished to, the SEC. Our website and the information contained on that site, or connected to that site, are not incorporated into and
are not a part of this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="nd_003"></A>INCORPORATION
OF CERTAIN INFORMATION BY REFERENCE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
SEC&rsquo;s rules allow us to incorporate by reference information into this prospectus. This means that we can disclose important information
to you by referring you to another document. Any information referred to in this way is considered part of this prospectus from the date
we file that document. Any reports filed by us with the SEC after the date of this prospectus and before the date that the offering of
the securities by means of this prospectus is terminated will automatically update and, where applicable, supersede any information contained
in this prospectus or incorporated by reference in this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
incorporate by reference into this prospectus the following documents or information filed with the SEC (other than, in each case, documents
or information deemed to have been furnished and not filed in accordance with SEC rules):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    Annual Report on <A HREF="https://www.sec.gov/Archives/edgar/data/862861/000162828024015260/jan-20231230.htm" STYLE="-sec-extract: exhibit">Form 10-K</A> for the year ended December 30, 2023, filed with the SEC on April 8, 2024;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    description of our Common Stock is filed as <A HREF="https://www.sec.gov/Archives/edgar/data/862861/000156459020015355/jan-ex41_182.htm" STYLE="-sec-extract: exhibit">Exhibit 4.1</A> to our Annual Report on Form 10-K for the year ended December 28, 2019, filed
    with the SEC on April 6, 2020. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
all documents filed by us with the SEC under Sections 13(a), 13(c), 14, or 15(d) of the Exchange Act, after (i) the date of the initial
Registration Statement and prior to effectiveness of the Registration Statement and (ii) the date of this prospectus and before the termination
or completion of this offering, shall be deemed to be incorporated by reference into this prospectus from the respective dates of filing
of such documents, except that we do not incorporate any document or portion of a document that is &ldquo;furnished&rdquo; to the SEC,
but not deemed &ldquo;filed.&rdquo; Any information that we subsequently file with the SEC that is incorporated by reference as described
above will automatically update and supersede any previous information that is part of this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will provide without charge to each person, including any beneficial owner, to whom this prospectus is delivered, upon his or her written
or oral request, a copy of any or all documents referred to above that have been or may be incorporated by reference into this prospectus,
excluding exhibits to those documents unless they are specifically incorporated by reference into those documents. Written or telephone
requests should be directed to JanOne Inc., 325 E. Warm Springs Road, Suite 102, Las Vegas, Nevada 89119, Attention: Corporate Secretary;
telephone: (702) 997-5968.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="nd_004"></A>FORWARD-LOOKING
STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus, including the documents we incorporate by reference into it, contains forward-looking statements within the meaning of Section
27A of the Securities Act, and Section 21E of the Exchange Act, the Private Securities Litigation Reform Act of 1995 (the &ldquo;PSLRA&rdquo;)
or in releases made by the SEC. Such statements include, without limitation, statements regarding our expectations, hopes, or intentions
regarding the future. Statements that are not historical fact are forward-looking statements. These forward looking statements can often
be identified by their use of words such as &ldquo;expect,&rdquo; &ldquo;believe,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;outlook,&rdquo;
&ldquo;could,&rdquo; &ldquo;target,&rdquo; &ldquo;project,&rdquo; &ldquo;intend,&rdquo; &ldquo;plan,&rdquo; &ldquo;seek,&rdquo; &ldquo;estimate,&rdquo;
&ldquo;should,&rdquo; &ldquo;will,&rdquo; &ldquo;may,&rdquo; and &ldquo;assume,&rdquo; as well as variations of such words and similar
expressions referring to the future. These cautionary statements are being made pursuant to the Securities Act, the Exchange Act, and
the PSLRA with the intention of obtaining the benefits of the &ldquo;safe harbor&rdquo; provisions of such laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
forward-looking statements contained in or incorporated by reference into this prospectus are largely based on our expectations, which
reflect estimates and assumptions made by our management. These estimates and assumptions reflect our best judgment based on currently
known market conditions and other factors. Although we believe such estimates and assumptions to be reasonable, they are inherently uncertain
and involve certain risks and uncertainties, many of which are beyond our control. If any of those risks and uncertainties materialize,
actual results could differ materially from those discussed in any such forward-looking statement. Among the factors that could cause
actual results to differ materially from those discussed in forward-looking statements are those discussed under the heading &ldquo;Risk
Factors&rdquo; below, those discussed under the heading &ldquo;Risk Factors&rdquo; and in other sections of our Annual Report on Form
10-K for the year ended December 30, 2023, as well as in our other reports filed from time to time with the SEC that are incorporated
by reference into this prospectus. See &ldquo;Available Information&rdquo; and &ldquo;Incorporation of Certain Information by Reference&rdquo;
for information about how to obtain copies of those documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
readers are cautioned that the forward-looking statements contained in this prospectus and in the documents incorporated by reference
into this prospectus are not guarantees of future performance, and we cannot assure any reader that such statements will be realized
or that the forward-looking events and circumstances will occur. Actual results may differ materially from those anticipated or implied
in the forward-looking statements. All forward-looking statements in this prospectus and the documents incorporated by reference into
it are made only as of the date of the document in which they are contained, based on information available to us as of the date of that
document, and we caution you not to place undue reliance on forward-looking statements in light of the risks and uncertainties associated
with them. Except as required by law, we undertake no obligation to update any forward-looking statements, whether as a result of new
information, future events, or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="nd_005"></A>RISK
FACTORS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investing
in our securities involves significant risks. You should review carefully the risks and uncertainties described under the heading &ldquo;Risk
Factors&rdquo; contained in, or incorporated into, the applicable prospectus supplement, any related free writing prospectus, or other
offering materials, as applicable, and under similar headings in the other documents that are incorporated by reference herein or therein.
Each of the referenced risks and uncertainties could adversely affect our business, operating results, and financial condition, as well
as adversely affect the value of an investment in our securities. When we offer and sell any securities pursuant to a prospectus supplement,
we may include additional risk factors relevant to such securities in the prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="nd_006"></A>BUSINESS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>General</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JanOne
Inc. (formerly known as Appliance Recycling Centers of America, Inc.) and subsidiaries (collectively, &ldquo;we,&rdquo; the &ldquo;Company,&rdquo;
or &ldquo;JanOne&rdquo;) is focused on being a clinical-stage pharmaceutical company committed to finding treatments for conditions that
cause severe pain and bringing drugs to market with non-addictive pain-relieving properties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">One
of the Company&rsquo;s goals is to reduce the need for prescriptions for dangerous opioid drugs by treating underlying diseases that
cause severe pain. The Company&rsquo;s first drug candidate is a treatment for Peripheral Artery Disease (&ldquo;PAD&rdquo;), a condition
that can cause severe pain and affects over 8.5 million people in the United States. The Company intends to champion new initiatives&mdash;digital
technologies, educational advocacy, and revolutionary painkilling drugs that address what we believe is a multibillion dollar a year
market&mdash;to help combat the opioid crisis, which claims tens of thousands of lives each year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 28, 2022, we entered into a Purchase Agreement (the &ldquo;Soin Purchase Agreement&rdquo;) with Soin Therapeutics, LLC. Under
the Soin Purchase Agreement, the Company acquired Soin Therapeutics and its LDN product, now known as JAN123. JAN123 is a novel formulation
of 2.0 mg of LDN that results in a biphasic release of the product. The release properties of JAN123 provide for an immediate release
of less than half the product with a slow, sustained release of the remaining product. Importantly, the rapid release of LDN has been
reported to lead to vivid and lucid unpleasant dreams, which should be eliminated with the formulation of JAN123. Initially, a single
tablet of JAN123 will be administered orally, once a day before sleep, with eventual titration up to two tablets (4 mg) before sleep.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
name of the Company, JanOne Inc., was strategically chosen to express the start of a new day in the fight against the opioid epidemic.
January one is the first day of a New Year&mdash;universally considered as a day of optimism, resolution, and hope. JanOne stands by
its strategic commitment to fresh thinking and innovative means to assist in ending the worst drug crisis in our nation&rsquo;s history.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Through
March 8, 2023, the Company operated its legacy businesses through its Recycling Subsidiaries, consisting of: (a) ARCA Recycling, Inc.,
a California corporation (&ldquo;ARCA Recycling&rdquo;), (b) ARCA Canada Inc., a corporation organized under the laws of Ontario, Canada
(&ldquo;ARCA Canada&rdquo;), and (c) Customer Connexx, LLC, a Nevada limited liability company (&ldquo;Connexx&rdquo;). ARCA Recycling
and ARCA Canada recycle major household appliances in North America by providing turnkey appliance recycling and replacement services
for utilities and other sponsors of energy efficiency programs. Connexx is a company that provides call center services for recycling
businesses. On March 9, 2023, we entered into a Stock Purchase Agreement (the &ldquo;Recycling Purchase Agreement&rdquo;) with VM7 Corporation,
a Delaware corporation (&ldquo;VM7&rdquo;), under which it agreed to acquire all of the outstanding equity interests of the Recycling
Subsidiaries. The principal of VM7 is Virland A. Johnson, our Chief Financial Officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information contained in or accessible from our website is not incorporated into this Annual Report on Form 10-K (the &ldquo;Form 10-K&rdquo;),
and it should not be considered part of this Form 10-K. We have included our website address in this Form 10-K solely as an inactive
textual reference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company was incorporated in Minnesota in 1983, although, through its predecessors, began operating its legacy recycling business in 1976.
In 2018, the Company reincorporated in the State of Nevada. The Company&rsquo;s principal office is located at 325 E. Warm Springs Road,
Suite 102, Las Vegas, Nevada 89119.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Biotechnology</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Overview</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical-stage biopharmaceutical company focused on becoming the leader in identifying, acquiring, licensing, developing, partnering,
and commercializing novel, non-opioid, and non-addictive therapies to address the large, unmet medical need for the treatment of pain
and addiction. JAN101 (formerly known as TV1001SR) is a potential treatment for PAD, a vascular disease that affects more than 8.5 million
people in the U.S. and more than 60 million people worldwide. We expect to commence Phase IIb/III clinical trials for the treatment of
PAD in 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>JAN101</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Generally</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JAN101,
formerly known as TV1001SR, is a patented oral, sustained-release pharmaceutical composition of sodium nitrite that targets poor blood
flow to the extremities, such as those with vascular complications of diabetes or PAD and treats pain. A conclusion from a round of human
studies found JAN101 prevents the prevalent reports of headaches by patients treated with an immediate release formulation of sodium
nitrite. In a previous study of patients with PAD, a 40 mg BID treatment with immediate release sodium nitrite led to a statistically
significant reduction in reported pain, while an 80 mg BID treatment had a more pronounced effect on bioactivity and Flow Mediated Dilation,
a measure of vascular function. However, a number of subjects in both treatment groups reported headaches and dizziness following treatment.
Although this did not result in subjects discontinuing treatment, JAN101 was developed to overcome this side effect. JAN101 was tested
in a bridging study of diabetic neuropathy subjects and, during that bridging study, the subjects did not report headaches or dizziness.
Subjects in this bridging study also reported less pain following treatment and improvements in bioactivity (quantitative sensory testing,
a measure of nerve function) were similar to the PAD study, where the 80 mg dosing group had the greatest improvement in Flow Mediated
Dilation. The ability to alleviate pain with BID treatment of JAN101 offers promise for a new non-addictive, non-sedating treatment of
chronic pain.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Clinical
Studies in Humans JAN101 Attributes</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Well-established
    safety profile</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Excellent
    bioavailability</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lack
    of induced tolerance</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-narcotic</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JAN101
does not mask pain, but instead treats the cause of pain by improving tissue and vascular function.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Benefits
of Sodium Nitrite on Vascular Health</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
initial research studies, sodium nitrite effectively restored ischemic tissue blood flow and was effective in a wide range of pathologies
involving alterations of angiogenesis &ndash; development of new blood vessels &ndash; including diabetes, wound healing, and tissue
necrosis. Beneficial effects include enhancing angiogenesis, endothelial cell proliferation, and arteriogenesis. There is also a strong
association between reduced circulating nitrite levels and cardiovascular diseases in humans. We describe some of the associations and
beneficial effects of sodium nitrite/nitrite below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Plasma
nitrite levels are negatively correlated to cardiovascular disease</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><IMG SRC="forms-3_002.jpg" ALT=""></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><IMG SRC="forms-3_003.jpg" ALT=""></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Plasma
nitrite levels were inversely related to number of cardiovascular risk factors a subject had and decreased plasma nitrite was associated
with decreased flow mediated vasodilation (FMD) and increased intimal medial thickness (IMT) (both are indicators of vascular pathology).
Kleinbongard, et al. (2006) Free Radic Biol and Medicine 40:295-302.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Plasma
nitrite levels are reduced in diabetic and PAD patients</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><IMG SRC="forms-3_004.jpg" ALT=""></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise
is a well-known stimulator of endothelial nitric oxide synthase activity, an enzyme that enhances nitric oxide (NO) production, which
leads to increased plasma nitrite. In the study by Allen, et al., these authors revealed that baseline plasma levels of nitrite were
less in patients with diabetes mellitus (DM) or DM + PAD. Importantly, increases in plasma nitrite levels were not observed in either
DM, PAD, or DM + PAD patients after supervised exercise. These data reveal that baseline nitrite availability is compromised in DM patients
and that supervised exercise is unable to increase plasma nitrite levels but actually results in a decrease in nitrite, highlighting
a physiological efficiency of this molecule. Allen, et al., Nitric Oxide 2009 20:231-2377.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Skeletal
Muscle Nitrite and Metabolite Levels are Reduced in Critical Limb Ischemia (CLI) Patients</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><IMG SRC="forms-3_005.jpg" ALT=""></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Skeletal
muscle nitrite, nitrosothiol (RSNO), nitric oxide-heme, and cGMP are all significantly reduced in CLI (the most severe form of PAD) patients.
Diabetic patients with CLI show even further nitrite reductions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
summary, nitrite levels in various cardiovascular and vascular diseases appear to be inversely related to the severity of the disease
in humans:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lower
    nitrite levels are associated with higher level of heart failure;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lower
    nitrite levels are observed in diabetic patients with PAD and are not compensated by exercise; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nitrite
    levels are lower in the muscles of patients with critical limb ischemia and are further reduced in diabetic subjects with critical
    limb ischemia.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Given
the association between low levels of circulating nitrite and human diseases, supplementation with sodium nitrite has been studied preclinically
in animals. Below are summaries of some of the more important findings:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Promotes
    angiogenesis</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stimulates
    wound healing</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prevents
    tissue necrosis</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
Arya, et al.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nitrite
Therapy Selectively Increases Ischemic Tissue Vascular Density in a NO-dependent Manner</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><IMG SRC="forms-3_006.jpg" ALT=""></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chronic
sodium nitrite therapy increases ischemic tissue vascular density in a NO-dependent manner. A and B show representative images of CD31
(red) and DAPI nuclear (blue) staining from sodium nitrite and sodium nitrate ischemic gastrocnemius muscle tissue at day 7. C and D
report the vascular density of ischemic gastrocnemius muscle tissue at days 3 and 7 for 165 &mu;g/kg sodium nitrite and nitrate treatments,
respectively. E and F demonstrate the vascular density of ischemic gastrocnemius muscle tissue at days 3 and 7 from 165 &mu;g/kg sodium
nitrite plus carboxy PTIO. (Scale bar, 150 &mu;m.) n = 10 mice per treatment group. Kumar D., et al., PNAS; 2008; 105:7540-7545.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nitrite
Therapy Augments Arterial Perfusion of Ischemic Tissue</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><IMG SRC="forms-3_007.jpg" ALT=""></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chronic
sodium nitrite therapy acutely increases ischemic tissue blood flow and stimulates arteriogenesis. A and B report 165 &mu;g/kg sodium
nitrite-induced acute changes in blood flow of chronically ischemic tissues at various time points with or without cPTIO, respectively.
C reports the number of arterial branches between PBS and nitrite therapies. D and E illustrate vascular casting of the arterial vasculature
in ischemic hind limbs of day 7 nitrite or PBS-treated mice, respectively. *, P &lt; 0.01 vs. sodium nitrite. N = 10 mice per treatment
group. Kumar D., et.al., PNAS;2008; 105:7540-7545.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nitrite
Therapy Restores Diabetic Ischemic Hind-Limb Blood Flow and Promotes Wound Heal</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><IMG SRC="forms-3_008.jpg" ALT=""></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unilateral
femoral artery ligation was performed on 18-20 week old male Db/Db mice. Mice were randomized to PBS or sodium nitrite (165 &mu;g/kg)
therapy twice daily via I.P. injection. Laser doppler flowmetry was performed at the indicated time points. Increased wound dehiscence
was noted in the PBS treated animals at day 7 but not in nitrite treated animals. (Bir, et al., Diabetes 2014, 63(1):270-81).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nitrite
Therapy Increases Diabetic Ischemia Induced Angiogenesis</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><IMG SRC="forms-3_009.jpg" ALT=""></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nitrite
therapy prevented ischemia mediated endothelial cell density loss in normal C57BL/6J ischemic limbs. Nitrite therapy significantly restored
endothelial cell density in ischemic limbs of diabetic mice to normal C57BL/6J levels compared to PBS therapy of non-ischemic and ischemic
conditions. These data suggest that nitrite therapy may be useful in attenuating microvascular rarefaction due to loss of nitric oxide
that is observed during metabolic dysfunction (Frisbee JC AJP Integr Comp Physiol 2005 289(2):R307-16; Stepp et al. Microcirculation
2007 14(4-5): 311-6).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delayed
Nitrite Therapy Restores Ischemic Hind-Limb Blood Flow</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><IMG SRC="forms-3_010.jpg" ALT=""></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Studies
were performed to determine whether nitrite mediated therapy would be effective in tissue that had been left ischemic for 5 days after
femoral artery ligation. Femoral artery ligation was performed in C57BL/6J mice and the animals randomized to either PBS or sodium nitrite
therapy 5 days after artery ligation. Treatments were given b.i.d. via I.P. injection. Ischemic limb blood flow was measured using laser
doppler flowmetry. (Bir, et al., Diabetes 2014, 63(1):270-81).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delayed
nitrite therapy increases SPY angiogram arteriogenesis</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><IMG SRC="forms-3_011.jpg" ALT=""></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delayed
nitrite therapy increases SPY angiogram arteriogenesis. Representative temporal SPY angiogram image stills (3&ndash;6s) are shown at
11 days following ligation and 6 days after beginning therapy (either PBS or sodium nitrite). <I>Left</I>: PBS control angiogram. <I>Right</I>:
sodium nitrite angiogram following injection of ICG. <I>n </I>= 5 animals per cohort. Circles identify limb anatomical regions of vascular
blush, whereas arrows indicate perfused vessels that progressively occur over time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bir,
et al., Am J Physiol Heart Circ Physiol 2012;303:H178-H188.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nitrite
Therapy Prevents Tissue Necrosis in Aged Db/Db Mice</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><IMG SRC="forms-3_012.jpg" ALT=""></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delayed
sodium nitrite (165 ug/kg) or control PBS therapy was stated 5 days post-femoral artery ligation in nine-month old Db/Db mice. Nitrite
therapy significantly prevented tissue necrosis (panel B) compared to control PBS therapy (panel A). Panel D reports tissue necrosis
severity as a function of degree of limb and digit involvement. Nitrite therapy, but not PBS control or sodium nitrate, significantly
prevented tissue necrosis. (Bir, et al., Diabetes 2014, 63(1):270-81).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Nitrite
and Hind Limb Ischemia Summary</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sodium
nitrite has long been known to be a potent vasodilator (transiently increasing blood vessel diameter) that can lead to a drop in blood
pressure when given acutely. The above studies indicate that chronic administration at low doses promotes angiogenesis, unlike one-time
nitrite therapy, which does not stimulate angiogenesis. In addition, these studies and a large number of other studies not reviewed above
show:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nitrite
    therapy is very specific, acting only in damaged, ischemic tissue;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delayed
    nitrite therapy effectively restores ischemic tissue blood flow;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nitrite
    therapy is effective in a wide range of pathologies involving alterations of angiogenesis including critical limb ischemia, heart
    failure, and tissue necrosis;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nitrite
    supplementation has had positive effects in various diabetes models, including diabetic nephropathy and diabetic wound healing;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficial
    effects center on enhancing angiogenesis, endothelial cell proliferation, and arteriogenesis; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sustained
    release nitrite therapy, unlike immediate release therapy, does not lead to vasodilation or a drop in blood pressure.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>JAN101</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JAN
101 is designed to treat diseases associated with poor vascular function. The following table summarizes our current product candidate:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><IMG SRC="forms-3_013.jpg" ALT=""></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Pain</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pain
is a protective reaction that alerts the body to the presence of actual or potential tissue damage so that necessary corrective responses
can be mounted. The National Institutes of Health (the &ldquo;NIH&rdquo;) defines chronic pain as pain that persists beyond the normal
healing time of an injury or that persists longer than three months. It is estimated that chronic pain affects 100 million individuals
in the United States and over 1.5 billion people worldwide; thus, more people suffer from chronic pain than diabetes, heart disease,
and cancer combined (Cowen Therapeutic Categories Outlook, March 2019). Chronic pain exacts a tremendous cost in terms of direct treatment
and rehabilitation expenditures, lost worker productivity, prevalent addiction to opioid-based drugs, and emotional and financial burden
for patients and their families. According to an Institute of Medicine of the National Academies report, pain is a significant public
health problem in the United States that costs society between $560 billion and $635 billion annually. Despite the magnitude of the pain
problem, innovation in the development of therapeutic solutions has been largely absent. Since 2010, there have been 20 approvals by
the FDA for the treatment of pain, of which 12 were opioid variants, one was an extended-release generic corticosteroid, five were variants
of aspirin, and two were variants of other existing drugs. We are developing a novel product candidate designed to overcome the limitations
of current treatment options for patients with PAD who suffer from chronic pain. According to a research study by Stanford University,
more than 24% of patients with PAD are at risk of high opioid use. By treating pain at the source and presenting patients and physicians
with better and safer treatment alternatives, we expect to minimize opioids at the prescription pad. Given the properties of JAN101,
we have made the strategic decision to focus initially on pain associated with PAD by treating the underlying cause of PAD.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Peripheral
artery disease</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Peripheral
artery disease (&ldquo;PAD&rdquo;) is a general term for conditions in which arterial blood flow to the limbs is partially blocked. When
there is less blood present in the extremities relative to demand, muscle pain and fatigue result, especially in the calf, which is also
known as &ldquo;intermittent claudication.&rdquo; In many patients, pain and fatigue are relieved through rest. Roughly half of patients
with PAD are asymptomatic. The most common cause of PAD / intermittent claudication is atherosclerosis. Diabetes, chronic kidney disease,
hypertension, and smoking are all risk factors that can increase the likelihood of PAD. In atherosclerosis, fat deposits (plaques) build
up along arterial walls, resulting in a reduction in blood flow in the legs. This same process can cause strokes if the arteries leading
up to the brain are affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
of the high rate of asymptomatic patients, prevalence figures vary widely. Some estimate that up to 200 million people worldwide have
PAD, ranging from asymptomatic disease to severe. Prevalence increases as a function of patient age, rising sharply after the age of
60. Thus, in countries with an aging population, it is expected that the prevalence of PAD will only increase. There is also a strong
ethnic and racial component to PAD prevalence, which may be due to cultural differences in diet and exercise, along with genetic differences.
Some suggest a prevalence of eight to 12 million in the United States alone, with roughly one-third experiencing pain when walking, which
improves upon resting. The diagnosis of PAD usually begins with patient complaints of pain in the extremities. If the patient is already
being treated or monitored for diabetes or other risk factors, then the physician will check for a weak or absent pulse in the extremity.
Decreased blood pressure, poor wound healing, and whooshing sounds (via stethoscope) in the legs are also tell-tale signs of PAD / intermittent
claudication. Angiograms, electrocardiograms, and ultrasounds can also be used to image and confirm the diagnosis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><IMG SRC="forms-3_014.jpg" ALT=""></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Figure
1: Ethnic-specific prevalence of PAD in men in the US, by age. NHW = Non-Hispanic Whites, AA = African American, HS = Hispanics, AS
= Asian Americans, AI = American Indians. Source: (Criqui, 2015)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
non-drug treatment of PAD / intermittent claudication may be divided into four general categories:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Lifestyle
    </I>&ndash; Primarily changes in diet and smoking cessation.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Exercise
    </I>&ndash; Patients who walk, cycle, stretch, or swim can experience marked improvement. Formal programs involving treadmills and
    track walking (usually three to five times per week) are frequently provided to patients. However, if the pain is triggered by exercise
    (claudication) and is significant, it can discourage the patient from exercise.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Angioplasty
    </I>&ndash; A procedure by which the affected artery is stretched with a balloon-like device. This procedure has limited effectiveness
    and is reserved for severely blocked arteries.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Bypass
    Surgery </I>&ndash; Arteries that are beyond angioplasty can be bypassed entirely. This procedure is typically reserved for cases
    where the blockage is considered very long (~10 centimeters) and nearly complete.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underlying condition is not addressed by surgery. Surgical approaches will not, in the long run, improve exercise capacity and walking
distance. Only exercise itself, coupled with lifestyle changes and drug approaches, has this benefit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prescription
drugs for the treatment of the underlying PAD may be divided into multiple categories, depending on the underlying condition and severity:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Cholesterol-Lowering
                                            Agents &ndash;</I> Statins and bile acid sequestrants.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Antiplatelet
    Medications </I>&ndash; Aspirin and related drugs, such as clopidogrel. Cilostazol also has antiplatelet properties.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Antihypertensives
    </I>&ndash; Patients with underlying high blood pressure can and will receive any number of medications to reduce blood pressure,
    such as ACE inhibitors and diuretics.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Diabetes
    Therapies </I>&ndash; While a substantial portion of PAD patients may have pre-diabetes or fulminant diabetes, it is unknown if aggressive
    treatment of diabetes has a positive effect on PAD.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Pain
    </I>&ndash; To our knowledge, no drugs are specifically indicated for PAD-associated pain. Pentoxifylline, for example, is indicated
    &ldquo;&hellip;for the treatment of patients with intermittent claudication on the basis of chronic occlusive arterial disease of
    the limbs.&rdquo; (Sanofi-Aventis U.S. LLC, 2010). However, the evidence supporting the effectiveness of pentoxifylline is mixed.
    Short-term courses of NSAIDs, such as ibuprofen, may be used, provided the patient is not on another anticoagulant, like aspirin.
    Non-drug pain relievers, such as TENS and massage therapy, may also be used in these patients. Opioids may also be used, which creates
    a risk for addiction and potential misuse at the medicine cabinet by family members.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="forms-3_015.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
lack of any truly effective treatment of PAD, along with encouraging early trial results using JAN101 on both improving vascular function
and reducing pain in PAD patients, has created an opportunity potentially to treat this large unmet medical need. By improving vascular
function, JAN101 has the potential to reduce associated pain and improve PAD patients&rsquo; quality of life.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Our
Strategy</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
focus is to develop and commercialize novel, non-opioid, and non-addictive therapies to address, safely and effectively, the significant
unmet medical need of chronic pain or treat conditions that cause pain. The principal elements of our strategy to achieve this mission
are the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>License,
    acquire, develop, and create novel, non-opioid and non-addictive therapies by leveraging our understanding of pain biology to address
    the large and growing problem of pain.</B> While innovation in medical sciences has led to exciting new treatment options in many
    disease areas, pain has seen limited innovation in recent years. We have a deep understanding of the pathophysiology of pain and
    diseases that cause pain. We intend to leverage this understanding to bring innovation in the pain treatment paradigm through targeted
    acquisitions of companies or assets in development. Our advisors and doctors have years of collective experience in leadership positions
    at institutions and substantial scientific experience and understand the complexity of designing and executing clinical trials for
    and developing therapies.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Advance
    the development of JAN101, designed for the treatment of patients with PAD and pain associated with the disease.</B> There are limited
    therapeutic options available for patients with PAD and we believe that JAN101 has the potential to transform the standard of care
    to a twice-a-day pill to improve moderate-to-severe PAD substantially.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Leverage
    clinical activity of JAN101 possibly to expand into new indications. </B>The Company is in discussion with multiple researchers about
    expanding JAN101&rsquo;s use into other indications. JanOne will provide the researchers previously manufactured clinical supplies
    of JAN101 for use in their clinical trials.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Advance
    JAN101 through clinical development and pursue development of additional product candidates through acquisitions.</B> Our objective
    is to build a well-balanced, multi-asset portfolio targeting the large population of patients with chronic and acute pain. To achieve
    this, in addition to JAN101, we intend to pursue partnerships, licensing agreements, and potential acquisitions of other pharma companies.
    We continue our search for assets with indications where we believe they could have meaningful impact and address the large unmet
    medical need. In addition, we may choose to selectively in-license or acquire complementary product candidates by leveraging the
    insights, network, and experience of our team.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Maximize
    the commercial potential of all our product candidates. </B>We currently intend to retain all commercial rights to JAN101 in the
    United States and selectively partner outside of the United States. Because we believe that PAD is an attractive market for many
    major pharmaceutical companies, we may sub-license or partner certain indications if we believe it may enhance stockholder value.
    As we continue to build and develop our product portfolio, we may opportunistically pursue strategic partnerships that maximize the
    value of our pipeline while seeking to develop other indications.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Leverage
    our management team background and expertise. </B>We have assembled a team with extensive experience described above.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Chronic
Pain</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
NIH defines chronic pain as pain that persists either beyond the normal healing time of an injury or longer than three months. We believe
that chronic pain represents a significant public health crisis. It is estimated that chronic pain affects 100 million individuals in
the United States and over 1.5 billion people worldwide; thus, more people suffer from chronic pain than diabetes, heart disease, and
cancer combined (Cowen Therapeutic Categories Outlook, March 2019). Chronic pain exacts a tremendous cost in terms of direct treatment
and rehabilitation expenditures, lost worker productivity, prevalent addiction to opioid-based drugs, and emotional and financial burden
for patients and their families. According to an Institute of Medicine of the National Academies report, pain is a significant public
health problem in the United States that costs society between $560 billion and $635 billion annually. Chronic pain is the leading cause
of long-term disability in the United States, and approximately 23 million adults in the United States experience severe pain over a
three-month period. Globally, the prevalence of chronic pain is even larger, with over one billion people worldwide affected each year.
Common types of chronic pain include those of neuropathic and inflammatory origin and may involve the skin, muscles, joints, bones, tendons,
ligaments, and other soft tissues. Chronic pain is associated with a variety of clinical conditions including, but not limited to, arthritis,
spinal conditions, cancer, fibromyalgia, diabetes, surgical recovery, visceral injury, and general trauma.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pain
is a necessary protective reaction that alerts the body to the presence of actual or potential tissue damage so that necessary corrective
responses can be mounted. Pain is signaled by specialized cells in the peripheral nervous system called nociceptors, or pain-sensing
fibers. These pain-sensing fibers normally transmit information about stimuli that approach or exceed harmful intensity from different
locations in the body to the brain, which registers this information as a sensation of pain. In the case of tissue injury due to trauma
or infection, pain accompanies the associated inflammation, persists for the duration of the inflammatory response, and aids healing
by inhibiting use of the affected body part.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pain
also can modify the central nervous system, such that the brain becomes sensitized and registers more pain with less provocation. This
is called central sensitization. When central sensitization occurs, the nervous system goes through a process called wind-up and gets
regulated in a persistent state of high reactivity. This persistent, or up-regulated, state of reactivity lowers the threshold for what
triggers the sensation of pain and can result in the sensation of pain even after the initial injury might have healed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
there is dysfunction in pain signaling, injury to the nervous system, or an unhealed injury, pain becomes no longer just a symptom, but
a disease in itself.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Current
Therapeutic Approaches to Treating Chronic Pain and Their Limitations</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>NSAIDs</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
of the most widely used therapies to treat chronic inflammatory pain are non-steroidal anti-inflammatory drugs (&ldquo;NSAIDs&rdquo;).
NSAIDs can have significant side effects that include gastrointestinal bleeding, gastritis, high blood pressure, fluid retention, kidney
problems, heart problems, and rashes. On April 7, 2005, the FDA announced a decision to require boxed warnings of potential cardiovascular
risk for all NSAIDs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Corticosteroids</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corticosteroids,
or steroids, also possess anti-inflammatory properties and are commonly used in the practice of pain management, either systemically
or locally, depending on the condition. Steroids work by decreasing inflammation and reducing the activity of the immune system. While
steroids are commonly used, they may have numerous and serious side effects. These side effects may include allergic or hypersensitivity
reactions, increased risk for infection, adrenal insufficiency, diabetes or decreased glucose tolerance, hypertension, loss of bone density,
and loss of joint cartilage volume. In addition, steroids should not be administered when there is an infection present because steroids
can inhibit the body&rsquo;s natural infection-fighting immune response. Also, if a joint is already damaged or is subject to chronic
deterioration, intra-articular, or IA steroid injections are not likely to provide any long-term restorative benefit. For the above reasons,
IA steroid injections are generally recommended to be administered no more often than every six weeks and not more than three to four
times per year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Opioids</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opioids
are some of the most widely prescribed therapeutics for chronic and acute pain, and sales of these drugs have quadrupled between 1999
and 2010. According to a National Survey on Drug Use and Health report, in 2016 more than one-third of adult Americans were prescribed
opioids and 230 million opioid prescriptions were written that year in the United States. Opioids act by binding to specific receptors
located on neurons in both the central and peripheral nervous system throughout the body including in the brain, spinal cord, and other
nervous tissue. Although they can be effective in providing pain relief, the increased medical use of opioids has been accompanied by
an increase in the abuse and misuse of prescription opioids. In addition, for most patients, chronic opioid use is a poor option due
to an intolerance to the many side effects, including nausea, vomiting, drowsiness, and constipation, and the propensity for opioids
to become less effective with long-term use. According to the Centers for Disease Control and Prevention (the &ldquo;CDC&rdquo;), almost
two million individuals abused or were dependent on prescription opioids in 2014. CDC figures show that the number of opioid-related
overdose deaths has quadrupled between 1999 and 2010, and currently approximately 40% of opioid overdose deaths in the United States
involve a prescription opioid. This increase in prescription opioid-related deaths in the United States prompted former President Trump
to declare the opioid crisis a national Public Health Emergency in October 2017. Opioid abuse has become an epidemic in the United States,
ranking as the nation&rsquo;s second most prevalent illegal drug problem. These major issues create the need to find new approaches to
treating chronic pain.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Our
Approach to Treating PAD and Chronic Pain</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unmet medical need for treating PAD and chronic pain reflects the historic failure to develop novel classes of analgesics with comparable
or greater efficacy, an acceptable level of adverse effects and a lower abuse liability than those currently available. Some of the reasons
for this include the heterogeneity of chronic pain and its related conditions, and the complexity and diversity of the underlying pathophysiological
mechanisms for pain. However, recent advances in the understanding of the neurobiology of pain are beginning to offer opportunities to
identify new drug targets and develop new therapeutic strategies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have taken an innovative and targeted approach to identifying treatments for chronic pain that leverages our understanding of the pathophysiology
of pain. Pain is variable. For example, it can be inflammatory or neuropathic in nature, and it may be localized to a specific area of
the body or it may be generalized throughout. We believe that the most effective way to treat chronic pain is through therapies that
specifically target the origin of the pain signal. We strive to maximize JAN 101&rsquo;s potential based on its unique mechanism of action
related to the origin of the pain signal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>A
Randomized, Double-Blind Study of the Effects of a Sustained Release Formulation of Sodium Nitrite (SR-nitrite) on Patients with Diabetic
Neuropathy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Background:
</B>Sodium nitrite has been reported to be effective in reducing chronic peripheral pain.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Objectives:
</B>To evaluate the safety and efficacy of 40 and 80 mg, BID, of an oral sustained-release formulation of sodium nitrite (SR-nitrite)
in patients suffering from diabetic neuropathy, and to determine whether SR-nitrite would reduce the frequency of headaches reported
previously by subjects receiving the same doses of an immediate release formulation. Study Design: Phase II, single-center, randomized,
double-blind, placebo-controlled clinical trial. Setting: The Ohio Pain Clinic and Kettering Medical Center.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Methods:
</B>Twenty-four patients were randomized to 40 mg or 80 mg SR-nitrite or placebo twice daily for 12 weeks. The primary objective was
to determine whether headaches would be reduced using SR-nitrite. The primary efficacy endpoint was the mean difference in the change
of the Neuropathic Pain Symptom Inventory (NPSI) pain score from baseline to that reported after 12 weeks of treatment. Secondary endpoints
included changes from baseline for the Brief Pain Inventory (BPI) Scale, the RAND 36 questionnaire, Short-Form McGill Questionnaire,
daily patient reported score for neuropathic pain, changes in HbA1c, PulseOx, and quantitative sensory testing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Results:
</B>The number of subjects reporting adverse events and the number of adverse events did not change with dose. There were no reports
of treatment-related headaches. Although no significant differences were identified in patient responses to the questionnaires, a trend
was observed. In the NPSI assessment, patients in the 40 mg and 80 mg dosing groups reported a 12.7% and 22.0% reduction in pain, respectively,
compared to an 8.4% reduction by patients in the placebo group. A trend was also observed with the BPI total severity score. However,
the 40 mg dosing group reported the greatest reduction in pain using the McGill Pain index and via patient logs of daily pain scores,
where the mean of pain scores reported by subjects in the 40 mg group dropped by day 41 and generally stayed lower than the mean of scores
reported by subjects in either of the other two groups. Patients in the 80 mg SR-nitrite group had an improvement in both Nerve Sensory
Conductance and Nerve Sensory Velocity. No changes were observed in HbA1c levels or PulseOx.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Limitations:
</B>Small sample size.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Conclusion:
</B>Sustained release sodium nitrite prevents the prevalent reports of headaches by patients treated with an immediate release formulation
of sodium nitrite. In a previous study of patients with peripheral arterial disease (PAD), 40 mg BID treatment led to a statistically
significant reduction in reported pain. Similar trends were observed at the end of the trial period for most of the pain questionnaires
used in the study. The 80 mg BID treatment had the more pronounced effect on bioactivity (quantitative sensory testing), which was similar
to the PAD study, where this dosing group had the greatest improvement in Flow Mediated Dilation . The ability to alleviate pain with
BID treatment of SR-nitrite offers promise for a new non-addictive, non-sedating treatment of chronic pain and warrants further study.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microcirculatory
injury, which is common in diabetic patients, can lead to a number of problems. Prominent among these is diabetic peripheral neuropathy
(DPN). About 10% of patients will have evidence of DPN at the time they are initially evaluated, and almost 50% of diabetic patients
will ultimately develop DPN. Of diabetic patients with DPN, 40% to 50% suffer from chronic pain, as well as paresthesia, sensory loss,
and weakness, and have at least an eight-fold increased risk of undergoing a distal lower extremity amputation compared to similar non-diabetics.
Endothelial cells play an important part in the regulation of microcirculation, as they maintain vascular tone by secreting both vasodilators
and vasoconstrictors. A central feature of diabetic microvascular disease (MVD) is endothelial dysfunction, which, in turn, plays an
important role in the development and progression of DPN. The pathophysiological factors leading to endothelial dysfunction in diabetes
include chronic hyperglycemia and protein glycosylation, insulin resistance, inflammation, and increased oxidative stress. Studies have
now shown a close relationship between endothelial dysfunction and diminished nitric oxide (NO) bioavailability. Endogenously produced
NO has a half-life measured in seconds, and is rapidly oxidized to nitrite (NO<SUB>2</SUB>&ndash;) and nitrate (NO<SUB>3</SUB>&ndash;)
end-products, the latter of which is biologically inert. In the presence of microcirculatory ischemia and endothelial cell dysfunction,
however, endogenous NO production by eNOS is much more limited. In such circumstances, circulating NO<SUB>2</SUB> can be non-enzymatically
reduced to increase NO availability. In addition to serving as a circulating NO reservoir, nitrite itself has also been shown to have
direct and potent vasodilatory effects in vitro and in vivo. The findings that NO<SUB>2</SUB>&ndash; mediates vasodilatation, both directly
and through NO generation, has led to growing interest in the potential effectiveness of nitrite as a therapeutic agent in conditions
associated with DPN and endothelial dysfunction. Such conditions include diabetic microvascular disease, DPN, and retinopathy, in which
low levels of NO and NO<SUB>2</SUB>&ndash;, as well as elevated levels of nitrate (NO<SUB>3</SUB>&ndash;), suggest that the complete
oxidation of NO occurs during diabetes with insufficient NO<SUB>2</SUB>&ndash; reserves to restore NO bioavailability. Previous human
studies with an oral formulation of NaNO<SUB>2</SUB> have shown that administration twice daily improves vascular function. In the peripheral
arterial disease study, subjects who received the lower dose of NaNO<SUB>2</SUB> reported a significant reduction in pain. Although side
effects were minimal, headaches and dizziness were reported by a large number of subjects, likely due to the rapid release of NaNO<SUB>2
</SUB>leading to vasodilation. An oral, sustained-release formulation of NaNO<SUB>2</SUB> (SR-nitrite) was developed in an attempt to
overcome these problems and was tested in a porcine model of metabolic syndrome with critical limb ischemia. SR-nitrite-treated animals
showed increased myocardial NO bioavailability, diminished oxidative stress, and cytoprotection in ischemic tissue. Importantly, 24-hour
telemetry recordings of blood pressure showed no evidence of vasodilation. In the above study, we hypothesized that the SR-nitrite would
reduce or eliminate headaches reported in patients following administration of the immediate release formulation. Given the promising
results on reducing pain in diabetic patients with PAD reported in the previous study, patients with diabetic neuropathy were utilized
in this study to determine whether any trends in reducing pain could be observed. The study design was a randomized, placebo controlled,
double-blind phase II study was carried out to investigate the safety and potential biological activity of multiple doses of an oral,
sustained-release formulation of sodium nitrite (SR-nitrite; TheraVasc Inc., Cleveland, OH, USA), BID in doses of 40 mg and 80 mg over
a 12-week treatment period, in human subjects with diabetes and neuropathic pain in the lower extremities and feet. The trial was approved
by the Copernicus Group Institutional Review Board and listed on ClinicalTrials.gov: www.clinicaltrials.gov/ct2/show/NCT02412852. The
study was funded by TheraVasc Inc. (&ldquo;TheraVasc&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>JAN101&mdash;Regulatory
Strategy</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sodium
nitrite has been previously approved as one of the active components of cyanide poisoning antidote. This means the approval path for
JAN101 is through a 505(b)(2) (&ldquo;NDA&rdquo;), which we intend to pursue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>JAN101&mdash;Commercial
Strategy</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently intend to use third-party providers and manufacturers to support the commercialization JAN101, if we are successful in obtaining
FDA approval. We believe that we can promote JAN101 to the patients suffering from PAD in a cost effective manner. We anticipate our
commercial operation will include outside sales management, outside sales support, distribution support, and an internal marketing group.
Additional requisite capabilities will include focused management of key accounts, such as managed-care organizations, group purchasing
organizations, and government accounts. We intend selectively to partner with third parties with vast experience in the space, as we
have been partnering for every aspect of development.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Competition</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
biotechnology and pharmaceutical industries are characterized by extensive research and development efforts, rapidly advancing technologies,
intense competition, and a strong emphasis on proprietary products. We are currently focused on the development and commercialization
of our asset pipeline of novel, non-opioid, and non-addictive therapies for PAD. The number of patients suffering from chronic PAD is
large and growing. While we believe that JAN 101 and our Chief Scientific Officer&rsquo;s development experience and scientific knowledge
provide us with competitive advantages, we face potential competition from many different sources, including pharmaceutical, biotechnology,
and specialty pharmaceutical companies that market or develop therapeutics to treat chronic pain. Academic research institutions, governmental
agencies, as well as public and private institutions are also potential sources of competitive products and technologies. Our competitors
may have significantly greater financial resources, robust drug pipelines, established presence in the market, and expertise in research
and development, manufacturing, pre-clinical and clinical testing, obtaining regulatory approvals and reimbursement, and marketing approved
products than we do. These competitors also compete with us in recruiting and retaining qualified clinical, regulatory, scientific, sales,
marketing, and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring
technologies complementary to, or necessary for, our programs. Smaller or early-stage companies may also prove to be significant competitors,
particularly through collaborative arrangements with large and established companies. The key competitive factors affecting the success
of JAN 101 (as well as other subsequent product candidates), if and when approved, is likely to be its efficacy, durability, safety,
price, and the availability of reimbursement from government and other third-party payors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
competition exists in the PAD pain field. Although we believe our approach to developing novel treatments for pain is unique from most
other existing or investigational therapies, such as NSAIDs, corticosteroids, and opioids, we will need to compete with all currently
available and future therapies within the indications where our development is focused. With respect to JAN101, the main classes of marketed
products that are available for the treatment of PAD pain include NSAIDs and opioids. Furthermore, numerous monoclonal antibodies targeting
nerve growth factor, or NGF inhibitors, are in clinical development, including two product candidates in Phase III.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are a number of companies developing or marketing therapies for the treatment and management of pain that may compete with JAN 101, including
many major pharmaceutical and biotechnology companies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Intellectual
Property</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success depends in large part upon our ability to obtain and maintain proprietary protection for our products and technologies, and to
operate without infringing or otherwise violating the proprietary rights of others. We endeavor to protect our products using a combination
of intellectual property protections and available government regulatory and marketing exclusivities afforded to new medicines. For example,
we endeavor to protect our products by, among other methods, filing United States and foreign patent applications related to our proprietary
technology, inventions, and improvements that are important to the development and implementation of our business. We also use other
forms of protection, such as confidential information, trade secrets, and know-how, and trademarks to protect our intellectual property,
particularly where we do not believe patent protection is appropriate or obtainable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
proprietary nature of, and protection for, JAN 101, processes, and know-how are important to our business. Our policy is to pursue, maintain,
and defend intellectual property rights, and to protect the technology, inventions, and improvements that are commercially important
to our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Trade
Secrets and Other Proprietary Information</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to patents, we rely on trade secrets and know-how to develop and maintain our competitive position. For example, we have developed
methods for more efficient manufacture of sustained released sodium nitrite tablets. We seek to protect our proprietary information,
in part, by confidentiality agreements and invention assignment agreements with our employees, consultants, scientific advisors, contractors,
and commercial partners.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>License
Agreement</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 19, 2019, we entered into a Patent and Know How License Agreement (the &ldquo;License Agreement&rdquo;) with UAB Research Foundation
(&ldquo;UABRF&rdquo;), TheraPAD, and the Board of Supervisors of Louisiana State University and Agricultural and Mechanical College,
acting on behalf of LSU Health Shreveport, together with UABRF and TheraPAD collectively, the &ldquo;Licensors&rdquo;). Under the License
Agreement, the Licensors have agreed to grant to JanOne an exclusive, worldwide license, including the right to sublicense, to the Licensors&rsquo;
patent rights and know-how related to the Licensors&rsquo; sustained release formulation of sodium nitrite. Under the License Agreement,
we have agreed to pay a non-refundable upfront license fee and certain milestone payments upon the achievement of certain milestones
of up to approximately $6.5 million and certain royalty payments and annual license maintenance fees. The License Agreement requires
us to use commercially reasonable efforts to develop and commercialize JAN101.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Soin
Therapeutics</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JanOne
acquired Soin Therapeutics, a company focused on the development of a novel formulation of low-dose naltrexone (&ldquo;LDN&rdquo;) for
the treatment of chronic regional pain syndrome (&ldquo;CRPS&rdquo;) in 2022. CRPS is a rare pain disorder, characterized by a complex
set of symptoms, affecting approximately 200,000 patients annually in the US. There are currently no approved treatments for patients
with CRPS. Prior to the acquisition, Soin Therapeutics received Orphan Drug Designation for the product, which provides a variety of
incentives for developing the product in this indication.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>JAN123</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Generally</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JAN123
is a novel formulation of 2.0 mg of LDN that results in a biphasic release of the product. The release properties of JAN123 provide for
an immediate release of less than half the product with a slow, sustained release of the remaining product. Importantly, the rapid release
of LDN has been reported to lead to vivid and lucid unpleasant dreams, which should be eliminated with the formulation of JAN123. Initially,
a single tablet of JAN123 will be administered orally, once a day before sleep, with eventual titration up to two tablets (4 mg) before
sleep.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Naltrexone</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Naltrexone
was first synthesized in 1965 and approved by the FDA for the oral treatment of opioid dependence in 1984, with the brand name Trexan.
Later it was approved for the oral treatment of alcohol dependence in 1995, when the brand name was changed by DuPont to ReVia. A depot
formulation for intramuscular injection was approved by the FDA under the brand name Vivitrol for alcohol dependence in 2006 and opioid
dependence in 2010. Typical oral doses are 50 to 100 mg daily, with a once-monthly intramuscular formulation also available. At these
doses, Naltrexone has been shown to function as a nonselective opioid antagonist with a high affinity for &micro; opioid receptors, which
decreases addiction cravings (Schumacher, Basbaum et al. 2017, Opioid Agonists &amp;amp; Antagonists. <U>Basic &amp;amp; Clinical Pharmacology,
14e</U>. B. G. Katzung. New York, NY, McGraw-Hill Education). However, there is a risk that patients who are non-compliant with oral
naltrexone may experience opioid intoxication simply by skipping doses of naltrexone. Oral bioavailability is also variable from patient
to patient, largely due to first-pass metabolism. Thus, naltrexone is pharmacologically effective, but may be ineffective in a real world
setting without counseling and strong patient support (Minozzi, 2011, Oral naltrexone maintenance treatment for opioid dependence. <I>Chchrane
Database Syst Rev</I>(4), CD001333). There are also multiple generic Naltrexone tablets available on the market for oral administration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Low-Dose
Naltrexone (LDN)</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compared
to the standard dose, LDN is defined as a daily dose of Naltrexone of 1 to 5 mg, which is 10- to 100-fold lower than the dose used to
manage substance use disorders (LDN Research Trust, Toljan and Vrooman 2018, Low-Dose Naltrexone (LDN)-Review of Therapeutic Utilization.
<U>Med Sci (Basel)</U> 6(4)). Off-label uses of Naltrexone at lower doses have been explored based on a different mechanism of action
for the treatment of inflammatory, rheumatologic, and neurologic conditions. These include multiple sclerosis, fibromyalgia, Crohn disease,
chronic fatigue syndrome (CFS), and, more recently, CRPS. At the low doses used for these conditions, Naltrexone is thought to act as
an immune modulator. Some speculate that this effect is related to reduced neuroinflammation in the case of disorders like CFS (Cant,
Dalgleish et al. 2017, Naltrexone Inhibits IL-6 and TNFalpha Production in Human Immune Cell Subsets following Stimulation with Ligands
for Intracellular Toll-Like Receptors. <U>Front Immunol</U> 8: 809).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evidence
suggests that, at low doses, Naltrexone antagonizes TLR4 on activated glial cells without the previously mentioned function as a mu-opioid
receptor antagonist (Chopra and Cooper 2013, Treatment of Complex Regional Pain Syndrome (CRPS) using low-dose naltrexone LDN). <U>J
Neuroimmune Pharmacol</U> <B>8</B>(3): 470-476.). TLR4 has been shown to be a key mediator of microglial activation, which has been identified
as a causal mechanism of neuropathic pain in CRPS. Microglial activation is associated with the release of pro-inflammatory cytokines,
reactive oxygen species, and prostaglandins, which amplify the inflammatory response (Carniglia, Ram&iacute;rez et al. 2017, Neuropeptides
and Microglial Activation in Inflammation, Pain, and Neurodegenerative Diseases. <U>Mediators of Inflammation</U> <B>2017</B>: 5048616).
Thus, LDN presents a promising therapeutic avenue for the treatment of CRPS, a condition in which TLR4 upregulation is a primary pathway,
through attenuation of glial activation and direct targeting of TLR4 activity (Del Valle, Schwartzman et al. 2009, Spinal cord histopathological
alterations in a patient with longstanding complex regional pain syndrome. <U>Brain Behav Immun</U> 23(1): 85-91. By downregulating the
inflammatory cytokine release, LDN should be beneficial for CRPS patients.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CRPS
patients suffer from severe debilitating pain, and even light touch or benign stimulation elicits extreme amounts of pain. Microglial
cells and glial cells oftentimes are involved in this pain-signaling pathway. By reducing glial cell activation, Low-dose Naltrexone
can treat this pain syndrome. Another potential mechanism of action of LDN treatment on pain is a paradoxical upregulation of opioid
signaling. It is noted that, when taken at bedtime, the short-acting low-dose Naltrexone binds to receptors, which leads to a brief blockade
of opioid receptors between 2 and 4 a.m. This blockade is believed to upregulate vital life elements of the body and cause an increase
in endorphin and enkephalin production. This increase in endorphins and enkephalins will likely cause a decrease in pain that the patient
experiences overall. Therefore, LDN leads to transient opioid receptor blockade, which triggers a positive feedback mechanism that increases
the production of endogenous opioids (endogenous endorphins and enkephalins) and opioid signaling (Ludwig, Zagon et al. 2017, Serum [Met(5)]-enkephalin
levels are reduced in multiple sclerosis and restored by low-dose naltrexone. <U>Exp Biol Med (Maywood)</U> 242(15): 1524-1533; Toljan
and Vrooman 2018, Low-Dose Naltrexone (LDN)-Review of Therapeutic Utilization. <U>Med Sci (Basel)</U> 6(4)). Together, these mechanisms
may work to alleviate pain associated with CRPS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interestingly,
low-dose Naltrexone also has effects on the peripheral nervous system. In the peripheral nervous system, it was found that low-dose Naltrexone
can modulate T and B lymphocyte production. And it was noticed that low-dose Naltrexone could reduce interleukin 6, interleukin 12, and
tumor necrosis factor alpha in the periphery regarding peripheral nervous systems. CRPS patients often have an increase in inflammatory
cytokines and may often note an increase in interleukin 6, 12, and tumor necrosis factor alpha. By reducing these inflammatory cytokines
back to a normal state, it is predicted that low-dose Naltrexone could treat the actual disease state of CRPS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
summary, low-dose Naltrexone has a very specific mechanism of action that will distinctly treat CRPS through inhibition of inflammatory
cytokines, glial cell activation, neuroinflammation, and increase of endogenous enkephalins and endorphins. In other words, low-dose
Naltrexone is not just treating the symptoms with this medication but also treating the underlying disease state and process specific
to CRPS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Chronic
Regional Pain Syndrome (CRPS)</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CRPS,
also termed reflex sympathetic dystrophy (RSD), is a chronic, orphan neurologic condition that typically affects the extremities after
trauma or nerve injury, and can cause severe pain. As the most common and prominent symptom of CRPS, the pain is often deep inside the
limbs with a burning, stinging, or tearing sensation. Sensory changes are also common and may include increased sensitivity to painful
stimuli, feeling pain from stimuli that are usually non-painful, and in some instances, sensory loss (<I>e.g.</I>, numbness). In addition
to pain, patients commonly experience an affected extremity that is warm, red, and swollen, at least initially. As CRPS progresses, it
becomes refractory to sympathetic nerve blocks, conventional analgesics, anticonvulsants, and antidepressants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CRPS
is a rare neurologic disease. It is a painful progressive condition and is listed in the rare disease database of the National Organization
for Rare Disorders (NORD). CRPS is subdivided into two categories: type I and type II CRPS. In CRPS type I, there are no nerve injuries
or lesions identified. CRPS type I is also known as &ldquo;reflex sympathetic dystrophy,&rdquo; and it comprises about 90 percent of
all cases of CRPS. CRPS type II (causalgia), on the other hand, is diagnosed when there is evidence of nerve damage. As described in
the NORD, it was found that CRPS type I developed in 5.46 persons out of every 100,000 per year and the incidence rate of CRPS type 2
was 0.82 persons out of every 100,000 per year, giving rise to a combined incidence rate for both CRPS types I and II of 6.28 per 100,000
person-years (Sandroni, Benrud-Larson et al. 2003, Complex regional pain syndrome type I: incidence and prevalence in Olmsted county,
a population-based study. <U>Pain</U> 103(1-2): 199-207; Goh, Chidambaram et al. 2017, Complex regional pain syndrome: a recent update.
<U>Burns Trauma</U> 5:2.).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underlying cause of CRPS is not well understood. In most cases, it occurs after an illness or injury that did not directly damage the
nerves in the affected area (Type I). In some cases, it occurs after a specific nerve injury (Type II). The exact trigger of CRPS after
an injury is not known, but it may be due to abnormal interactions between the central and peripheral nervous systems and/or inappropriate
inflammatory responses. There are multiple factors that may contribute to CRPS development, including immobilization, alterations to
the nervous system of the body, and inflammation. Genetic factors and psychological factors, such as anxiety, depression, and anger,
may also contribute to the symptoms of CRPS. However, there is no evidence that CRPS is a disease that can be caused by genetic factors
alone, and the role of psychological factors in CRPS development remains unproven.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CRPS
is treated by approaching it from different areas: physical therapy (PT), occupational therapy (OT), medications for pain management,
neuromodulation through implantable devices, and/or nerve blocks targeting the sympathetic chain. Neridronate and zoledronate D,L-lysine
monohydrate (ZLM) has been designated as an orphan drugs for the treatment of CRPS in 2013 and 2015, respectively. However, neither of
them has been approved. Thus, there is no current FDA-approved drug for CRPS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Clinical
Studies of LDN on CRPS</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LDN
has been widely used for chronic pain and inflammatory condition and has been shown to alleviate symptoms of pain in patients with chronic
pain. A number of case studies have also reported positive effects for LDN in the treatment of CRPS. Chopra et al. reported 2 patient
case studies with CRPS who experienced significantly less pain with 4.5 mg daily LDN treatment (Chopra and Cooper 2013, Treatment of
Complex Regional Pain Syndrome (CRPS) using low-dose naltrexone (LDN). <U>J Neuroimmune Pharmacol</U> 8(3): 470-476). The remission of
pain and dystonic spasms in Case 1, as well as remission of all CRPS symptoms (including fixed dystonia) in Case 2, provide evidence
that a multi-modal interventional approach, which includes low-dose Naltrexone (a known glial attenuator), should be considered as a
treatment option for the treatment of CRPS patients, particularly those patients with dystonic movement disorders. In another CRPS case
study, Sturn and Collin found alleviation of pain symptoms as early as 2 days after beginning LDN therapy, with significantly less pain
at 4 weeks (Sturn and Collin 2016, Low-Dose Naltrexone: A New Therapy Option for Complex Regional Pain Syndrome Type I Patients. <U>Int
J Pharm Compd</U> 20(3): 197-201). Weinstock et al. reported alleviation of pain symptoms within one month of LDN treatment, with complete
remission of CRPS leg symptoms by 16 months (Weinstock, Myers et al. 2016, Identification and Treatment of New Inflammatory Triggers
for Complex Regional Pain Syndrome: Small Intestinal Bacterial Overgrowth and Obstructive Sleep Apnea. <U>A A Case Rep</U> 6(9): 272-276).
In a recent case study, an CRPS patient was able to discontinue gabapentin and amitriptyline via the use of LDN, while simultaneously
achieving superior pain relied (Soin, 2021, Management of pediatric complex regional pain syndrome with low-dose naltrexone. <I>Pain
Medicine Case Reports, 5</I>(3), 109-113). LDN has been reported to have benefits related to other symptoms of chronic pain syndromes
as well, including dystonic spasms, CRPS flares, energy, sleep disturbances, and mood.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Systematic
literature review of LDN use showed that the most commonly reported AEs with LDN use were dizziness, vomiting, nausea, and vivid dreams
(Soin et al. 2021, Low-Dose Naltrexone Use for Patients with Chronic Regional Pain Syndrome: A Systematic Literature Review. <U>Pain
Physician</U> 24(4): E393-E406.). Other reported AEs included headaches, abdominal pain, gastrointestinal issues, peripheral edema, restlessness,
falls, somnolence, irritability, hematological abnormalities, urinary infection, difficulty concentrating, anxiety, sleepiness, hot flashes/sweating,
tachycardia, depression, muscle and joint pain, fatigue, tinnitus, heartburn, dry mouth, and joint pain. Another systematic review also
evaluated occurrence of adverse events (AEs) and serious adverse events (SAEs) with LDN use and found that only mild AEs reported among
the included studies (89 studies), including nausea, vomiting, and dizziness (Bolton, Hodkinson et al. 2019, Serious adverse events reported
in placebo randomized controlled trials of oral naltrexone: a systematic review and meta-analysis. <U>BMC Med</U> 17(1): 10). Although
119 patients reported at least one SAE in the naltrexone study arm, meta-analysis found no difference between occurrence of SAEs in naltrexone
and placebo groups. Furthermore, secondary analysis found only 6 AEs that were statistically significant: decreased appetite, dizziness,
nausea, sleepiness, sweating, and vomiting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Efficacy
of low-dose naltrexone treatment on CRPS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif; width: 14%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Author
    (year)</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left; width: 2%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif; width: 30%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Symptoms</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left; width: 2%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif; width: 16%; vertical-align: bottom"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Symptoms</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">alleviated</FONT></P></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left; width: 2%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif; width: 10%; vertical-align: bottom"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Time
                                            to</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">alleviation&nbsp;of
                                            symptoms</FONT></P></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left; width: 2%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif; width: 10%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dose</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left; width: 2%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif; width: 10%; vertical-align: bottom"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AEs
                                            and</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SAEs</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chopra
    et al. (2013)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">swelling,
    allodynia, color change, temperature change, some weakness, blisters, skin ulceration, dystonic spasms, dysesthesia</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dystonic
    spasms, CRPS flares, energy, pain tolerance, sleep disturbances, pain, mood</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&lt;
    2 months</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5
    mg/day</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sturn
    et al. (2016)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pain</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pain</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2
    days</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.5
    mg</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weinstock
    et al. (2016)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Severe
    leg pain, episodic pain in arms and nose, asymmetric and shiny skin with fluctuating temperature changes, color change, edema, IBS,
    atypical chest pain and fatigue, edema, blue discoloration, tenderness, joint hypermobility with EDS diagnosis</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leg
    and bowel symptoms; all CRPS pain, bowel symptoms, and fatigue</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&lt;
    1 month</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5
    mg/day</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Orphan
Drug Designation</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
orphan disease is a rare disease affecting fewer than 200,000 people in the US. It is often a serious or fatal condition for which there
are no effective therapies. In 1983, the Orphan Drug Act was passed to incentivize companies to develop drugs for patients with rare
diseases. Orphan drug designation provides incentives to companies, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax
    credits for qualifies clinical trials</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exemption
    from user fees</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Potential
    for seven years of market exclusivity after approval</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, given the small number of patients with a disease and the severity of the disease, approvals are often granted with fewer and
smaller trials, saving costs and time. JAN123 was granted Orphan Status for the treatment of CRPS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Clinical
Development Plan</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LDN
can be rapidly developed in the US via the 505(b)(2) regulatory pathway. This pathway is used for candidates that contain drugs that
are already approved but come in a dosage form or delivery system that is different than the original, approved product. In this case,
JAN123 fits these criteria perfectly. LDN has the added benefit of being developed at a much lower dose (&lt; 5 milligrams) compared
to approved naltrexone products, which are 50 milligrams per tablet. Therefore, it is likely that product development will consist of
the following general steps:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manufacturing
    and approval of clinical batches of LDN tablets prior to clinical studies;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    I pharmacokinetic study(ies) to confirm the release profile of LDN; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    single Phase III study to demonstrate efficacy in CRPS.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
protocol synopsis of the development plan is presented below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title
    of study </B></FONT></TD>
    <TD STYLE="width: 0.1in">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
                                            I: The Pharmacokinetincs of LDN in the fed and fasted state of a Single Oral Dose of LDN,
                                            4 mg</FONT></P>
                                                                                          <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    III: Double-Blind Placebo-Controlled Trial of Low-Dose Naltrexone to Treat Complex Regional Pain Syndrome (CRPS)</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Clinical
    Phase </B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
                                            I: The Pharmacokinetincs of LDN in the fed and fasted state</FONT></P>
                                                                              <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    III: Registration/Efficacy Study to hopefully facilitate an NDA application for the use of low-dose naltrexone to treat CRPS</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Objectives:</B></FONT></TD>
    <TD STYLE="width: 0.1in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
                                            I: To determine pharmacokinetics of single oral low-dose naltrexone in healthy participants
                                            in fasting and fed state</FONT></P>
                                                         <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase3:
    The primary objective is to assess the efficacy of low-dose naltrexone in treating complex regional pain syndrome symptoms (CRPS).</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    plan to conduct a double-blind, randomized, placebo-controlled trial to treat CRPS using low-dose naltrexone.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    Efficacy:</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1-
    Assess daily NRS (numerical pain scale 0 &ndash; 10) scores through the 3-month study</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2-
    Study the possible changes or improvement in the Brief Pain Inventory (BPI) and Oswestry Disability Index (ODI) over the three-month
    study</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    Safety:</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    will also monitor safety labs on enrollment and termination of the study. However, we would like to point out that this drug has
    been available and FDA approved at much higher doses (50 &ndash; 150mg or higher) orally with a long-standing proven safety track
    record. The drug has been available with multiple different embodiments, route of administration and at much higher doses for quite
    a long time and the safety of the drug has already been extensively established and published.</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investigational
    product </B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JAN123</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Study
    Design</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
                                            1: Single-center, dual-arm, cross-over, open-label study</FONT></P>
                                                         <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    3: Study Description</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    plan to conduct a randomized, double blind placebo controlled trial to treat Complex Regional Pain Syndrome. The study duration will
    be three months long. Patients in the treatment group will receive a single tablet for the first month of a 2mg dose of Naltrexone.
    Then, after 1 month, the patient will take 2 tablets for a total of 4mg for months 2 and 3. Study conclusion will be after 3 months.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patients
    in the placebo group will take a single tablet for 1 month followed by 2 tablets for month 2 and 3.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    total number of 200 patients with a 1:1 randomization will used. Since CRPS is an orphan disease, we will likely have to use a total
    of 25 clinical sites or more to be able to adequately recruit the study.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Safety
    labs will be completed prior to first dose and upon study completion.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    clinical efficacy, we will be assessing daily NRS (1-10) pain scores, a brief pain inventory (BPI) at enrollment and at months 1,
    2, and 3 (study completion) and Oswestry Disability Index (ODI) at enrollment and at months 1, 2, and 3 (study completion). Statistically
    significant improvement in pain scores or any scales in the BPI or ODI are desired outcomes.</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Treatment
    Regimen and Route of Administration</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Study
                                            Drugs are as follows:</FONT></P>
                                                         <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    I: Single Oral dose of JAN123, 4 mg given on separate days with and without food separated by a washout period of no less than 7
    days</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    III: Patients will be dosed with either the low-dose naltrexone or placebo for three months. Initially for the first month patients
    will take 1 tablet at bedtime (typically in the evenings) for the first month and then increase to 2 tablets for month 2 and 3. Specifically
    the Naltrexone will be 2mg tablets, such that for the first month with the 1 tablet per day the patient will be on 2mg doses and
    subsequently increase to 2 tablets in the evening for a total of 4mg.</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Duration
    of treatment: </B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
                                            I: One day for each dose. Two doses of 2 mg each, in total, separated by a washout period
                                            of no less than 7 days.</FONT></P>
                                                         <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    III: This will be a 3 month trial or approximately 90 days. Upon enrollment, patients will be on either low-dose naltrexone or placebo
    for 90 days.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Participant
    duration is expected to be 121 days, and at the conclusion of the study (approximately day 90 post-treatment) patients will come
    in for a final site visit to complete remaining surveys and within 7 days of completion the patients will obtain final safety labs
    which are anticipated to be a complete blood count and a comprehensive metabolic panel. Since Naltrexone is non-opioid based and
    does not have withdrawal issues, patients can immediately discontinue the therapy without concerns. As referenced earlier, the safety
    of Naltrexone orally is already well established and our tested doses are low.</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number
    of Centers </B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
                                            1: Single Center Clinical Trial</FONT></P>
                                                                     <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    3: Multicenter Clinical Trial</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Likely
    25 total sites. Keeping in mind this is an Orphan Disease state and recruitment may be quite difficult, we feel the need to have
    25 clinical sites to enroll 200 patients.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
    sites will be likely Pain Management Centers, both academic and private practice facilities that have access to patients who suffer
    from CRPS and also include local PIs who have the skill set and ability to properly diagnose CRPS.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Local
    or regional clinical trial coordinators will be assigned to each site as well.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enrolling
    participants are those who meet the diagnosis criteria of CRPS. Typically CRPS is diagnosed using the Budapest Criteria. Age range
    of 18 - 65 for enrollment, negative pregnancy test, and stable therapy for 3 months.</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Subjects:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
                                            I: Adult male and female healthy subjects, 18-65 years of age, satisfying all inclusion and
                                            exclusion criteria.</FONT></P>
                                                                                             <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    III: Patients diagnosed with CRPS (Complex Regional Pain Syndrome), Adult male and female patients, 18-65 years of age.</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number
                                            of</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Subjects</B></FONT></P></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
                                            I: 10 patients</FONT></P>
                                                                                             <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    III: 200 patients</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Endpoints</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase1:
    Primary Outcome Measure:</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PK
    profile for low-dose naltrexone (Time Frame: Day 1: predose and at multiple time points after low-dose naltrexone administration).</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.1in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.5in">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C<SUB>max
    </SUB>(Maximum observed plasma concentration)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </FONT>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">T<SUB>max
    </SUB>(Time to reach maximum plasma concentration)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AUC<SUB>0-t
    </SUB>(Area under the plasma concentration-time curve from 0 hour to the time of the last quantifiable concentration)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AUC<SUB>0-inf
    </SUB>(Area under the plasma concentration-time curve from 0 hour extrapolated to infinity)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CL/F
    (Oral clearance)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
                                            3:</FONT></P>
                                                                                             <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Primary
    Outcome Measure: Improvement in NRS pain scores over a 3-month time period.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Secondary
    Outcome Measure: Improvement in Brief Pain Inventory and Oswestry Disability Index (ODI) or other verified pain scales.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">End
    of Study will occur upon completion of the 90-day trial of the low-dose naltrexone or placebo. It is expected that patients will
    complete all required surveys and testing requirements of the study. Through March 8, 2023, the Company operated its legacy businesses,
    ARCA Recycling, Inc. (&ldquo;ARCA Recycling&rdquo;), ARCA Canada Inc. (&ldquo;ARCA Canada&rdquo;), and Customer Connexx, LLC (&ldquo;Connexx&rdquo;),
    in its Recycling segment. ARCA Recycling and ARCA Canada recycle major household appliances in North America by providing turnkey
    appliance recycling and replacement services for utilities and other sponsors of energy efficiency programs. Connexx is a company
    that provides call center services for recycling businesses. On March 9, 2023, we entered into a Stock Purchase Agreement with VM7
    Corporation, a Delaware corporation, under which the Buyer agreed to acquire all of the outstanding equity interests of (a) ARCA
    Recycling, Inc., a California corporation, (b) Customer Connexx LLC, a Nevada limited liability company, and (c) ARCA Canada Inc.,
    a corporation organized under the laws of Ontario, Canada. The principal of the Buyer is Virland A. Johnson, our Chief Financial
    Officer</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Early
    termination is also a possible way to end the study due to issues such as side effects, adverse events, or patient desire to withdraw
    from the study, among other reasons.</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Safety</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Assessments
    </B></FONT></P></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Standard
    clinical evaluation and objective measures will be employed to monitor and assess safety during the conduct of the trial. Furthermore,
    the results of safety assessments will be used during the trial to monitor and protect the safety of enrolled subjects. Strict subject
    and study stopping criteria will be implemented to protect the subject&rsquo;s well-being.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Intellectual
Property</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
composition of Naltrexone is off-patent and generic versions of the drug are available at 50 mg doses. LDN has been routinely compounded
in compounding pharmacies and used clinically off-label. However, the 4.5 mg compounded tablets are associated with sleep disturbances,
manifested in vivid and lucid unpleasant dreams. For these reasons, JAN-123 was developed as a biphasic release, orally available tablet
to reduce the likelihood of unpleasant dreams. A provisional patent was filed in December 2020 and converted to a PCT application in
November 2021 (Pub. No. US 2022/0202807 A1). US Patent number 11,752,143 B2 issued on September 12, 2023. The issued claims in this patent
cover the use of the biphasic LDN formulation for treatment of patients with chronic pain. In addition, claims are made to the titration
of the LDN for treating chronic pain. While there is no guarantee that the pending applications or future pending claims will issue,
the issued US patent will provide protection of JAN123 through 2040 and the Orphan Drug Designation provides 7 years of market exclusivity
after drug approval in the event that there are any challenges to this patent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Trade
Secrets and Other Proprietary Information</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to patents, we rely on trade secrets and know-how to develop and maintain our competitive position. For example, we have developed
methods for more efficient manufacture of the biphasic LDN. We seek to protect our proprietary information, in part, by confidentiality
agreements and invention assignment agreements with our employees, consultants, scientific advisors, contractors, and commercial partners.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Soin
Purchase Agreement</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 28, 2022, we entered into a Purchase Agreement (the &ldquo;Soin Purchase Agreement&rdquo;) with Soin Therapeutics, LLC. Under
the Soin Purchase Agreement, JanOne acquired Soin Therapeutics and its LDN product, now known as JAN123. This all- stock transaction
has a value of $13M, with up to an additional $17M depending on revenues generated by the product, for a total value of up to $30M. The
transaction includes restrictions on the maximum number of shares of preferred stock and common stock that can be issued to or transferred
by Soin Therapeutics at any given time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Our
Team</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Tony
Giordano, Ph.D.</B>, our Chief Scientific Officer, joined the Company in December 2019 from the Cleveland Clinic, the No.2 rated hospital
in the country, where he served as Senior Director of Special Projects in the Business Development group. Dr. Giordano has extensive
experience in drug development, having served as Vice President or President of seven different biotechnology companies he co-founded,
including companies developing platform technologies, a cancer vaccine, and Alzheimer&rsquo;s Disease and cardiovascular therapies. He
has managed numerous clinical trials and the launch of a medical food product. Dr. Giordano has also served as an Associate Professor
and Assistant Dean of Research and Business Development at LSU Health Sciences Center in Shreveport, Louisiana (&ldquo;LSU Health Shreveport&rdquo;),
at which he led the licensing efforts at the campus and at Abbott Labs, where, in addition to serving as a Senior Research Scientist,
he was involved in technology assessment activities. Dr. Giordano has a Ph.D. focused in Molecular Genetics from The Ohio State University
and completed Fellowships at the NIH National Cancer Institute and the NIH National Institute of Aging.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2019, we formed a Scientific Board of Advisors (the &ldquo;SBA&rdquo;) and the following doctors and scientists currently are
members of our SBA:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Chris
Kevil, Ph.D., Chair of the Scientific Board of Advisors &ndash; </B>Dr. Kevil, an internationally known expert in vascular pathophysiology,
PAD, and nitric oxide biology, discovered the role of sodium nitrite in promoting angiogenesis that led to the development of TV1001,
now known as JAN101. Dr. Kevil earned his Ph.D. from LSU Health Shreveport in Molecular and Cellular Physiology, followed by a fellowship
at the University of Alabama at Birmingham (UAB) with an emphasis on redox pathophysiology. Returning to LSU Health Shreveport in the
Department of Pathology, he established cutting edge research programs regarding redox biology regulation of peripheral vascular diseases.
This led to ground-breaking insights on how glutathione, nitrite/nitric oxide, and hydrogen sulfide regulate vascular health during ischemia.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Edgar
Ross, MD &ndash;</B> Dr. Ross is the current Director of the Pain Management Center at Brigham and Women&rsquo;s Hospital and a professor
of anesthesia at Harvard Medical School. Dr. Ross is recognized as Castle Connolly&rsquo;s America&rsquo;s top doctors for the fifth
year in a row. In addition to serving as chairman of Pfizer&rsquo;s partnership on pain, Dr. Ross also has served as a member of the
Blue Cross and Blue Shield Opioid Prescribing Policy Committee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>John
Cooke, MD, Ph.D. &ndash; </B>Dr. Cooke is the Chair of the Department of Cardiovascular Sciences at the Houston Methodist Research Institute,
Director of the Center for Cardiovascular Regeneration, and Medical Director of the RNA Therapeutics Program in the Houston Methodist
DeBakey Heart &amp; Vascular Center in Houston, Texas. He trained in cardiovascular medicine and obtained a Ph.D. in physiology at the
Mayo Clinic. He was recruited to Harvard Medical School as an assistant professor of medicine. In 1990, he was recruited to Stanford
University to spearhead its program in vascular biology and medicine, and was appointed professor in the Division of Cardiovascular Medicine
at Stanford University School of Medicine, and associate director of the Stanford Cardiovascular Institute until his recruitment to Houston
Methodist in 2013. Dr. Cooke has published over 500 research papers, position papers, reviews, book chapters, and patents in the arena
of vascular medicine and biology with over 30,000 citations. He has served on national and international committees that deal with cardiovascular
diseases, including the American Heart Association, American College of Cardiology, Society for Vascular Medicine, and the National Heart,
Lung and Blood Institute. He has served as president of the Society for Vascular Medicine, as a director of the American Board of Vascular
Medicine, and as an associate editor of Vascular Medicine.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Joshua
Beckman, MD &ndash; </B>Dr. Beckman is the Director of Vascular Medicine and the Gayle and Paul Stoffel Distinguished Chair in Cardiology
at UT Southwestern Medical Center. Prior to this, he founded and is director of the Section of Vascular Medicine in the Division of Cardiovascular
and is Professor of Medicine at Vanderbilt University Medical Center. The overriding theme linking all of his career activities is vascular
function in health and disease. Dr. Beckman&rsquo;s primary research focuses on the mechanisms by which diabetes mellitus impairs vascular
function. Secondary investigations involve studying the effect on endothelial function of non-diabetes-related insulin resistance, androgen
deprivation, and vascular function in venous bypass grafts. Dr. Beckman has been involved in numerous clinical studies and has published
over 300 research papers with over 30,000 citations. In addition to a number of other journals, Dr. Beckman serves in editorial roles
at <I>Vascular Medicine </I>and <I>Circulation, </I>two of the premier journals in the cardiovascular space.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nicolas
Goeders, Ph.D. &ndash;</B> Dr. Goeders is a Professor and Head of the Department of Pharmacology, Toxicology and Neuroscience at LSU
Health Shreveport. He has conducted addiction research for the past 30 years and is regarded as one of the world&rsquo;s leaders on the
role for stress in substance abuse disorder. His work has helped to determine the mechanisms responsible for how stress contributes to
relapse to drug use. He has published over 100 manuscripts, has written 15 book chapters, and was issued five patents, one of which is
a drug currently in clinical development. Dr. Goeders also serves as the Executive Director of the Louisiana Addiction Research Center.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Commercial
Operations</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently do not have any marketing and sales organization. We have retained global rights to JAN-101 and JAN123, and, if either of them
or one of our potential subsequent product candidates is approved by the FDA to market in the United States, we expect that our sales
force will be supported by sales management, internal sales support, an outside marketing group, and distribution support. We intend
to invest in our commercial capabilities prudently by focusing our marketing efforts on the physician subspecialties that treat patients
with PAD. These physicians include, but are not limited to, pain management specialists, rheumatologist, surgeons, and sports medicine
physicians. We will also evaluate licensing and partnering with third parties to help us reach other sales channels and geographic markets
inside and outside of the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Government
Regulation</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA and comparable regulatory authorities in state and local jurisdictions and in other countries impose substantial and burdensome requirements
upon companies involved in the clinical development, manufacture, marketing, and distribution of drugs, such as those we are developing.
These agencies, and other federal, state, and local entities regulate, among other things, the research and development, testing, manufacture,
quality control, safety, effectiveness, labeling, storage, record keeping, approval, advertising and promotion, distribution, post-approval
monitoring and reporting, sampling, and export and import of product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>U.S.
Government Regulation of Drug Products</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act (the &ldquo;FDCA&rdquo;) and its implementing
regulations. The process of obtaining regulatory approvals and the subsequent compliance with applicable federal, state, local, and foreign
statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable
United States requirements at any time during the product development process, the approval process, or thereafter, may subject an applicant
to a variety of administrative or judicial sanctions, such as the FDA&rsquo;s refusal to approve pending applications, withdrawal of
an approval, imposition of a clinical hold, issuance of warning letters, product recalls, product seizures, total or partial suspension
of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement, or civil or criminal
penalties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
process required by the FDA before a drug may be marketed in the United States generally involves the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">completion
    of pre-clinical laboratory tests, animal studies, and formulation studies in compliance with the FDA&rsquo;s good laboratory practice
    (&ldquo;GLP&rdquo;), regulations;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission
    to the FDA of an Investigational New Drug Application (&ldquo;IND&rdquo;), which must become effective before human clinical trials
    may begin;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">approval
    by an institutional research board (&ldquo;IRB&rdquo;) at each clinical site before each trial may be initiated;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">performance
    of adequate and well-controlled human clinical trials in accordance with good clinical practice (&ldquo;GCP&rdquo;) requirements
    to establish the safety and efficacy of the proposed drug product for each indication;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission
    to the FDA of a new drug application (NDA);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory
    completion of an FDA advisory committee review, if applicable;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory
    completion of an FDA inspection of the manufacturing facility or facilities at which the product is produced to assess compliance
    with current good manufacturing practices (&ldquo;cGMP&rdquo;) requirements and to assure that the facilities, methods, and controls
    are adequate to preserve the drug&rsquo;s identity, strength, quality, and purity;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory
    completion of FDA audits of clinical trial sites to assure compliance with GCPs and the integrity of the clinical data;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">payment
    of user fees and securing FDA and approval of the NDA; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">compliance
    with any post-approval requirements, including the potential requirement to implement a risk evaluation and mitigation strategy (&ldquo;REMS&rdquo;),
    and the potential requirement to conduct post-approval studies.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Pre-clinical
Studies</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-clinical
studies include laboratory evaluation of product chemistry, toxicity, and formulation, as well as animal studies to assess potential
safety and efficacy. An IND sponsor must submit the results of the pre-clinical tests, together with manufacturing information, analytical
data, and any available clinical data or literature, among other things, to the FDA as part of an IND. Some pre-clinical testing may
continue even after the IND is submitted. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that
time the FDA raises concerns or questions related to one or more proposed clinical trials and places the clinical trial on a clinical
hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result,
submission of an IND may not result in the FDA allowing clinical trials to commence. Clinical holds also may be imposed by the FDA at
any time before or during clinical trials, due to safety concerns about on-going or proposed clinical trials, or non-compliance with
specific FDA requirements, and the trials may not begin or continue until the FDA notifies the sponsor that the hold has been lifted.
Through the 505(b)2 regulatory path, the FDA allows a sponsor to rely on well documented, published studies to support the clinical development
of the product. The FDA has indicated that it will accept published data in support of the Company&rsquo;s development program for JAN101
but prior to filing an NDA would require the Company to complete developmental and reproductive toxicology studies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Clinical
Trials</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
trials involve the administration of the investigational new drug to human subjects under the supervision of qualified investigators
in accordance with GCP requirements, which include the requirement that all research subjects provide their informed consent in writing
for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives
of the trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. A protocol for each clinical
trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. In addition, an IRB at each institution
participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution.
Information about certain clinical trials must be submitted within specific timeframes to the NIH for public dissemination on their www.clinicaltrials.gov
website. The information contained in, or accessible through, this website does not constitute a part of this Annual Report. We have
included this website address solely as an inactive, textual reference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Human
clinical trials are typically conducted in three sequential phases, which may overlap or be combined:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    I: The drug is initially introduced into healthy human subjects or patients with the target disease or condition and tested for safety,
    dosage tolerance, absorption, metabolism, distribution, and excretion and, if possible, to gain an early indication of its effectiveness.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    II: The drug is administered to a limited patient population to identify possible adverse effects and safety risks, to evaluate the
    efficacy of the product for specific targeted diseases preliminarily, and to determine dosage tolerance and optimal dosage.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    III: The drug is administered to an expanded patient population, generally at geographically dispersed clinical trial sites, in well-controlled
    clinical trials to generate sufficient data statistically to evaluate the efficacy and safety of the product for approval, to establish
    the overall risk-benefit profile of the product, and to provide adequate information for the labeling of the product.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Post-approval
trials, sometimes referred to as Phase IV clinical trials, may be conducted after initial marketing approval. These trials are used to
gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate
the performance of Phase IV clinical trials as a condition of approval of an NDA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the research subjects or patients
are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution
if the clinical trial is not being conducted in accordance with the IRB&rsquo;s requirements or if the drug has been associated with
unexpected serious harm to patients. In addition, some clinical trials are overseen by an independent group of qualified experts organized
by the sponsor, known as a data safety monitoring board or committee. Depending on its charter, this group may determine whether a trial
may move forward at designated check points based on access to certain data from the trial.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the development of a new drug, sponsors are given opportunities to meet with the FDA at certain points. These points may be prior to
submission of an IND, at the end of Phase II, and before an NDA is submitted. Meetings at other times may be requested. These meetings
can provide an opportunity for the sponsor to share information about the data gathered to date, for the FDA to provide advice, and for
the sponsor and the FDA to reach agreement on the next phase of development. Sponsors typically use the meetings at the end of the Phase
II clinical trial to discuss Phase II clinical results and present plans for the pivotal Phase III clinical trials that they believe
will support approval of the new drug. JanOne submitted briefing materials in 2021 describing the previous research and development activities
and planned clinical trials. The Company is now working to implement suggestions by the FDA to be ready to submit a protocol amendment
in late 2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concurrently
with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry
and physical characteristics of the drug and finalize a process for manufacturing the product in commercial quantities in accordance
with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of product candidates and,
among other things, the manufacturer must develop methods for testing the identity, strength, quality, and purity of the final drug.
In addition, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product
candidate does not undergo unacceptable deterioration over its shelf life.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
the IND is active and before approval, progress reports summarizing the results of the clinical trials and non-clinical studies performed
since the last progress report must be submitted at least annually to the FDA, and written IND safety reports must be submitted to the
FDA and investigators for serious and unexpected suspected adverse events, findings from other studies suggesting a significant risk
to humans exposed to the same or similar drugs, findings from animal or in vitro testing suggesting a significant risk to humans, and
any clinically important increased incidence of a serious suspected adverse reaction compared to that listed in the protocol or investigator
brochure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>United
States Review and Approval Process</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
results of product development, pre-clinical, and other non-clinical studies and clinical trials, along with descriptions of the manufacturing
process, analytical tests conducted on the chemistry of the drug, proposed labeling, and other relevant information are submitted to
the FDA as part of an NDA requesting approval to market the product. The submission of an NDA is subject to the payment of substantial
user fees; a waiver of such fees may be obtained under certain limited circumstances. The FDA reviews an NDA to determine, among other
things, whether a product is safe and effective for its intended use and whether its manufacturing is cGMP-compliant to assure and preserve
the product&rsquo;s identity, strength, quality, and purity. Under the Prescription Drug User Fee Act (the &ldquo;PDUFA&rdquo;), guidelines
that are currently in effect, the FDA has a goal of 10 months from the date of &ldquo;filing&rdquo; of a standard NDA for a new molecular
entity to review and act on the submission. This review typically takes 12 months from the date the NDA is submitted to FDA because the
FDA has approximately two months to make a &ldquo;filing&rdquo; decision after the application is submitted. The FDA conducts a preliminary
review of all NDAs within the first 60 days after submission, before accepting them for filing, to determine whether they are sufficiently
complete to permit substantive review. The FDA may request additional information rather than accept an NDA for filing. In this event,
the NDA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts
it for filing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA may refer an application for a novel drug to an advisory committee. An advisory committee is a panel of independent experts, including
clinicians and other scientific experts, that reviews, evaluates, and provides a recommendation as to whether the application should
be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee; but, it considers such recommendations
carefully when making decisions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
approving an NDA, the FDA will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application
unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure
consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA may inspect one or
more clinical trial sites to assure compliance with GCP requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
the FDA evaluates an NDA, it will issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing
of the drug with prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the
application is complete and the application will not be approved in its present form. A Complete Response Letter usually describes the
specific deficiencies in the NDA identified by the FDA and may require additional clinical data, such as an additional Phase III trial
or other significant and time-consuming requirements related to clinical trials, non-clinical studies, or manufacturing. If a Complete
Response Letter is issued, the sponsor must resubmit the NDA that addresses all of the deficiencies identified in the letter, or withdraw
the application. Even if such additional data and information are submitted, the FDA may decide that the NDA does not satisfy the criteria
for approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a product receives regulatory approval, the approval may be significantly limited to specific diseases and dosages or the indications
for use may otherwise be limited, which could restrict the commercial value of the product. In addition, the FDA may require a sponsor
to conduct Phase IV clinical testing, which involves clinical trials designed to assess a drug&rsquo;s safety and effectiveness further
after NDA approval, and may require testing and surveillance programs to monitor the safety of approved products that already have been
commercialized. The FDA may also place other conditions on approval, including the requirement for REMS, to assure the safe use of the
drug. If the FDA concludes a REMS is needed, the sponsor of the NDA must submit a proposed REMS. The FDA will not approve the NDA without
an approved REMS, if required. A REMS could include medication guides, physician communication plans, or elements to assure safe use,
such as restricted distribution methods, patient registries, and other risk minimization tools. Any of these limitations on approval
or marketing could restrict the commercial promotion, distribution, prescription, or dispensing of products. Marketing approval may be
withdrawn for non-compliance with regulatory requirements or if problems occur following initial marketing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Food and Drug Administration Safety and Innovation Act (the &ldquo;FDASIA&rdquo;) made permanent the Pediatric Research Equity Act (the
&ldquo;PREA&rdquo;), which requires a sponsor to conduct pediatric clinical trials for most drugs, for a new active ingredient, new indication,
new dosage form, new dosing regimen, or new route of administration. Under PREA, original NDAs and supplements must contain a pediatric
assessment unless the sponsor has received a deferral or waiver. The required assessment must evaluate the safety and effectiveness of
the product for the claimed indications in all relevant pediatric subpopulations and support dosing and administration for each pediatric
subpopulation for which the product is safe and effective. The sponsor or the FDA may request a deferral of pediatric clinical trials
for some or all of the pediatric subpopulations. A deferral may be granted for several reasons, including a finding that the drug is
ready for approval for use in adults before pediatric clinical trials are complete or that additional safety or effectiveness data needs
to be collected before the pediatric clinical trials begin. The FDA must send a non-compliance letter to any sponsor that fails to submit
the required assessment, keep a deferral current or fails to submit a request for approval of a pediatric formulation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Special
FDA Expedited Review and Approval Programs</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA has various programs, including Fast Track Designation, accelerated approval, priority review, and breakthrough therapy designation,
which are intended to expedite or simplify the process for the development and FDA review of drugs that are intended for the treatment
of serious or life-threatening diseases or conditions and demonstrate the potential to address unmet medical needs. The purpose of these
programs is to provide important new drugs to patients earlier than under standard FDA review procedures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
be eligible for a Fast Track Designation, the FDA must determine, based on the request of a sponsor, that a product is intended to treat
a serious or life-threatening disease or condition and demonstrates the potential to address an unmet medical need. The FDA will determine
that a product will fill an unmet medical need if it will provide a therapy where none exists or provide a therapy that may be potentially
superior to existing therapy based on efficacy or safety factors. The FDA may review sections of the NDA for a fast track product on
a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of
the NDA, the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required
user fees upon submission of the first section of the NDA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA may give a priority review designation to drugs that offer major advances in treatment, or provide a treatment where no adequate
therapy exists. A priority review means that the goal for the FDA to review an application is six months, rather than the standard review
of 10 months under current PDUFA guidelines. Under the new PDUFA agreement, these six- and 10-month review periods are measured from
the &ldquo;filing&rdquo; date, rather than the receipt date for NDAs for new molecular entities, which typically adds approximately two
months to the timeline for review and decision from the date of submission. Most products that are eligible for Fast Track Designation
are also likely to be considered appropriate to receive a priority review.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, products studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful
therapeutic benefit over existing treatments may be eligible for accelerated approval and may be approved on the basis of adequate and
well-controlled clinical trials that establish that the drug product has an effect (i) on a surrogate endpoint that is reasonably likely
to predict clinical benefit or (ii) on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality that
is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, including taking into account
the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval,
the FDA may require a sponsor of a drug receiving accelerated approval to perform post-marketing studies to verify and describe the predicted
effect on irreversible morbidity or mortality or other clinical endpoint, and the drug may be subject to accelerated withdrawal procedures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
under the provisions of the FDASIA, a sponsor can request designation of a product candidate as a &ldquo;breakthrough therapy.&rdquo;
A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious
or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement
over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical
development. Drugs designated as breakthrough therapies are also eligible for accelerated approval. The FDA must take certain actions,
such as holding timely meetings and providing advice, intended to expedite the development and review of an application for approval
of a breakthrough therapy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for
qualification or decide that the time period for FDA review or approval will not be shortened. We may explore some of these opportunities
for our initial (or subsequent) product candidates, as appropriate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Post-Approval
Requirements</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Drugs
manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among
other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion
and reporting of adverse experiences with the product. After approval, most changes to the approved product, such as adding new indications
or other labeling claims are subject to prior FDA review and approval. There also are continuing, annual user program fee requirements
for any marketed products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA may impose a number of post-approval requirements as a condition of approval of an NDA. For example, the FDA may require post-marketing
testing, including Phase IV clinical trials, and surveillance to assess further and monitor the product&rsquo;s safety and effectiveness
after commercialization.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register
their establishments with the FDA and state agencies, and are subject to periodic unannounced inspections by the FDA and these state
agencies for compliance with cGMP requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA
approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP requirements
and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to
use. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain
cGMP compliance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once
an approval of a drug or medical device is granted, the FDA may withdraw the approval if compliance with regulatory requirements and
standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems
with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply
with regulatory requirements, may result in mandatory revisions to the approved labeling to add new safety information; imposition of
post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program.
Other potential consequences include, among other things:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
    on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">fines,
    warning letters or holds on post-approval clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal
    of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product approvals;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
    seizure or detention, or refusal to permit the import or export of products; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">injunctions
    or the imposition of civil or criminal penalties.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA strictly regulates marketing, labeling, advertising, and promotion of products that are placed on the market. Drugs or devices may
be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies
actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have promoted off-label
uses improperly may be subject to significant liability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>The
Hatch-Waxman Amendments</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Drug Price Competition and Patent Term Restoration Act of 1984, known as the Hatch-Waxman Act, added two pathways for FDA drug approval.
First, the Hatch-Waxman amendments to the FDCA authorized the FDA to approve an alternative type of NDA under Section 505(b)(2) of the
FDCA. Section 505(b)(2) permits the filing of an NDA where at least some of the information required for approval comes from trials not
conducted by or for the applicant and for which the applicant has not obtained a right of reference from the data owner. The applicant
may rely upon the FDA&rsquo;s findings of safety and efficacy for an approved product that acts as the &ldquo;listed drug.&rdquo; The
FDA may also require 505(b)(2) applicants to perform additional studies or measurements to support the change from the listed drug. The
FDA may then approve a new product candidate for all, or some, of the label indications for which the branded reference drug has been
approved, as well as for any new indication sought by the 505(b)(2) applicant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Second,
the Hatch-Waxman amendments to the FDCA also established a statutory procedure for submission and FDA review and approval of abbreviated
new drug applications (&ldquo;ANDAs&rdquo;) for generic versions of branded drugs previously approved by the FDA (such previously approved
drugs are referred to as &ldquo;listed drugs&rdquo;). An ANDA is a comprehensive submission that contains, among other things, data and
information pertaining to the active pharmaceutical ingredient, drug product formulation, specifications, and stability of the generic
drug, as well as analytical methods, manufacturing process validation data and quality control procedures. Premarket applications for
generic drugs are termed abbreviated because they generally do not include pre-clinical and clinical data to demonstrate safety and effectiveness.
However, a generic manufacturer is typically required to conduct bioequivalence studies of its test product against the listed drug.
The bioequivalence studies for orally administered, systemically available drug products assess the rate and extent to which the active
pharmaceutical ingredient (the &ldquo;API&rdquo;) is absorbed into the bloodstream from the drug product and becomes available at the
site of action. Bioequivalence is established when there is an absence of a significant difference in the rate and extent for absorption
of the generic product and the listed drug. For some drugs, other means of demonstrating bioequivalence may be required by the FDA, especially
where rate and/or extent of absorption are difficult or impossible to measure. The FDA will approve the generic product as suitable for
an ANDA application if it finds that the generic product does not raise new questions of safety and effectiveness as compared to the
innovator product. A product is not eligible for ANDA approval if the FDA determines that it is not bioequivalent to the referenced innovator
drug, if it is intended for a different use, or if it is not subject to an approved Suitability Petition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
seeking approval for a drug through an NDA, including a 505(b)(2) NDA, applicants are required to list with the FDA certain patents whose
claims cover the applicant&rsquo;s product. Upon approval of an NDA, each of the patents listed in the application for the drug is then
published in the Orange Book. Any applicant who files an ANDA seeking approval of a generic equivalent version of a drug listed in the
Orange Book or a 505(b)(2) NDA that references a drug listed in the Orange Book must certify to the FDA that (1) no patent information
on the drug product that is the subject of the application has been submitted to the FDA; (2) such patent has expired; (3) the date on
which such patent expires; or (4) such patent is invalid or will not be infringed upon by the manufacture, use, or sale of the drug product
for which the application is submitted. This last certification is known as a paragraph IV certification. A notice of the paragraph IV
certification must be provided to each owner of the patent that is the subject of the certification and to the holder of the approved
NDA to which the ANDA or 505(b)(2) application refers. The applicant may also elect to submit a &ldquo;section viii&rdquo; statement
certifying that its proposed label does not contain (or carves out) any language regarding the patented method-of-use rather than certify
to a listed method-of-use patent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the referenced NDA holder and patent owners assert a patent challenge directed to one of the Orange Book-listed patents within 45 days
of the receipt of the paragraph IV certification notice, the FDA is prohibited from approving the application until the earlier of 30
months from the receipt of the paragraph IV certification expiration of the patent, settlement of the lawsuit, or a decision in the infringement
case that is favorable to the applicant. The ANDA or 505(b)(2) application also will not be approved until any applicable non-patent
exclusivity listed in the Orange Book for the branded reference drug has expired.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Marketing
Exclusivity</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market
exclusivity provisions under the FDCA can delay the submission or the approval of certain marketing applications. The FDCA provides a
five-year period of non-patent marketing exclusivity within the United States to the first applicant to obtain approval of an NDA for
a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same
active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA
may not approve or even accept for review an abbreviated new drug application, or ANDA, or a NDA submitted under Section 505(b)(2), or
505(b)(2) NDA, submitted by another company for another drug based on the same active moiety, regardless of whether the drug is intended
for the same indication as the original innovative drug or for another indication, where the applicant does not own or have a legal right
of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification
of patent invalidity or non-infringement to one of the patents listed with the FDA by the innovator NDA holder. The FDCA alternatively
provides three years of marketing exclusivity for an NDA, or supplement to an existing NDA if new clinical investigations, other than
bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the
application, for example new indications, dosages, or strengths of an existing drug. This three-year exclusivity covers only the modification
for which the drug received approval on the basis of the new clinical investigations and does not prohibit the FDA from approving ANDAs
or 505(b)(2) NDAs for drugs containing the active agent for the original indication or condition of use. Five-year and three-year exclusivity
will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or
obtain a right of reference to all of the pre-clinical studies and adequate and well-controlled clinical trials necessary to demonstrate
safety and effectiveness. Pediatric exclusivity is another type of marketing exclusivity available in the United States. Pediatric exclusivity
provides for an additional six months of marketing exclusivity attached to another period of exclusivity if a sponsor conducts clinical
trials in children in response to a written request from the FDA. The issuance of a written request does not require the sponsor to undertake
the described clinical trials. In addition, orphan drug exclusivity, as described above, may offer a seven-year period of marketing exclusivity,
except in certain circumstances.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>United
States Coverage and Reimbursement</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
uncertainty exists as to the coverage and reimbursement status of any therapeutic product candidate for which we may seek regulatory
approval. Sales in the United States will depend in part on the availability of adequate financial coverage and reimbursement from third-party
payors, which include government health programs such as Medicare, Medicaid, TRICARE, and the Veterans Administration, as well as managed
care organizations and private health insurers. Prices at which we or our customers seek reimbursement for our initial or subsequent
therapeutic product candidates can be subject to challenge, reduction, or denial by payors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
process for determining whether a payor will provide coverage for a product is typically separate from the process for setting the reimbursement
rate that the payor will pay for the product. A payor&rsquo;s decision to provide coverage for a product does not imply that an adequate
reimbursement rate will be available. Third-party payors are increasingly challenging the price and examining the medical necessity and
cost-effectiveness of medical products and services, in addition to their safety and efficacy. In order to obtain coverage and reimbursement
for any product that might be approved for marketing, we may need to conduct expensive pharmacoeconomic studies in order to demonstrate
the medical necessity and cost-effectiveness of any products, which would be in addition to the costs expended to obtain regulatory approvals.
Third-party payors may not consider our initial or subsequent product candidates to be medically necessary or cost-effective compared
to other available therapies, or the rebate percentages required to secure favorable coverage may not yield an adequate margin over cost
or may not enable us to maintain price levels sufficient to realize an appropriate return on our investment in drug development.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Healthcare
Reform</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States and some foreign jurisdictions, there have been, and continue to be, several legislative and regulatory changes and
proposed changes regarding the healthcare system that could prevent or delay marketing approval of drug product candidates, restrict
or regulate post-approval activities, and affect the profitable sale of drug product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Among
policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems
with the stated goals of containing healthcare costs, improving quality, and/or expanding access. In the United States, the pharmaceutical
industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives. In March
2010, the Affordable Care Act, formally known as the Patient Protection and Affordable Care Act (the &ldquo;ACA&rdquo;), was enacted
by Congress, and signed into law by the President. It substantially changed the methods by which healthcare is financed by both the government
and private insurers, and significantly impacted the United States pharmaceutical industry. The ACA, among other things: (i) increased
the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extended the rebate program to individuals
enrolled in Medicaid-managed care organizations; (ii) established an annual, nondeductible fee on any entity that manufactures or imports
certain specified branded prescription drugs and biologic agents apportioned among these entities according to their market share in
some government healthcare programs; (iii) expanded the availability of lower pricing under the 340B drug pricing program by adding new
entities to the program; (iv) increased the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program;
(v) expanded the eligibility criteria for Medicaid programs; (vi) created a new Patient-Centered Outcomes Research Institute to oversee,
identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and (vii) established
a Center for Medicare &amp; Medicaid Innovation to test innovative payment and service delivery models to lower Medicare and Medicaid
spending, potentially including prescription drugs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
of the provisions of the ACA have yet to be implemented, and there have been judicial and Congressional challenges to certain aspects
of the ACA. While Congress has not passed comprehensive repeal legislation, bills affecting the implementation of certain taxes under
the ACA have been signed into law. The Tax Cuts and Jobs Act of 2017 includes a provision repealing, effective January 1, 2019, the tax-based
shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part
of a year that is commonly referred to as the &ldquo;individual mandate.&rdquo; Additionally, on January 22, 2018, former President Trump
signed a continuing resolution on appropriations for fiscal year 2018 that delayed the implementation of certain ACA-mandated fees, including
the so-called &ldquo;Cadillac&rdquo; tax on certain high-cost employer-sponsored insurance plans, the annual fee imposed on certain health
insurance providers based on market share, and the medical device excise tax on non-exempt medical devices.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
legislative changes have been proposed and adopted since the ACA was enacted, including aggregate reductions of Medicare payments to
providers of two percent per fiscal year and reduced payments to several types of Medicare providers. Moreover, there has recently been
heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in
several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency
to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement
methodologies for drug products. At the state level, legislatures have increasingly passed legislation and implemented regulations designed
to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product
access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries
and bulk purchasing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>United
States Healthcare Fraud and Abuse Laws and Compliance Requirements</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Federal
and state healthcare laws and regulations restrict business practices in the pharmaceutical industry. The United States laws that may
affect our ability to operate include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            federal Anti-Kickback Statute, which prohibits, among other things, persons from soliciting,
                                            receiving, offering, or paying remuneration, directly or indirectly, to induce, or in return
                                            for, the purchase or recommendation of an item or service reimbursable under a federal healthcare
                                            program, such as the Medicare and Medicaid programs;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 81pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            federal civil and criminal false claims laws and civil monetary penalty laws, which prohibit,
                                            among other things, individuals, or entities from knowingly presenting, or causing to be
                                            presented, claims for payment from Medicare, Medicaid or other third-party payors that are
                                            false or fraudulent;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 81pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIPAA,
                                            which created new federal criminal statutes that prohibit executing a scheme to defraud any
                                            healthcare benefit program and making false statements relating to healthcare matters;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 81pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIPAA,
                                            as amended by the federal Health Information Technology for Economic and Clinical Health
                                            Act and its implementing regulations, also imposes certain requirements relating to the privacy,
                                            security, and transmission of individually identifiable health information;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 81pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            federal Physician Payments Sunshine Act, which among other things, requires certain manufacturers
                                            of drugs, devices, and biologics that are reimbursable by a federal healthcare program to
                                            report annually to the United States Department of Health and Human Services information
                                            related to payments and other transfers of value to physicians and teaching hospitals, and
                                            ownership and investment interests held by physicians and their immediate family members;
                                            and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 81pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">similar
                                            federal laws and state law equivalents of each of the above federal laws.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 81pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Regulation
Outside of the United States</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent that our initial or subsequent product candidates, if and when approved, are sold in a foreign country, we may be subject
to similar foreign laws and regulations, which may include, for instance, applicable post-marketing requirements, including safety surveillance,
anti-fraud and abuse laws and implementation of corporate compliance programs and reporting of payments or other transfers of value to
healthcare professionals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to market our future products in the European Economic Area (the &ldquo;EEA&rdquo;) and many other foreign jurisdictions, we must
obtain separate regulatory approvals. More concretely, in the EEA, medicinal products can only be commercialized after obtaining a Marketing
Authorization (an &ldquo;MA&rdquo;). There are two types of Marketing Authorizations:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Community MA, which is issued by the European Commission through the Centralized Procedure,
                                            based on the opinion of the Committee for Medicinal Products for Human Use of the European
                                            Medicines Agency (the &ldquo;EMA&rdquo;) and which is valid throughout the entire territory
                                            of the EEA. The Centralized Procedure is mandatory for certain types of products, such as
                                            biotechnology medicinal products, orphan medicinal products, advanced therapy products, and
                                            medicinal products containing a new active substance indicated for the treatment certain
                                            diseases, such as AIDS, cancer, neurodegenerative disorders, diabetes, and auto-immune and
                                            viral diseases. The Centralized Procedure is optional for products that contain a new active
                                            substance not yet authorized in the EEA, or for products that constitute a significant therapeutic,
                                            scientific, or technical innovation or that are in the interest of public health in the EU;
                                            and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 81pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">National
                                            MAs, which are issued by the competent authorities of the Member States of the EEA and only
                                            cover their respective territory, are available for products not falling within the mandatory
                                            scope of the Centralized Procedure. Where a product has already been authorized for marketing
                                            in a Member State of the EEA, a National MA can be recognized in another Member State through
                                            the Mutual Recognition Procedure. If the product has not received a National MA in any Member
                                            State at the time of application, it can be approved simultaneously in various Member States
                                            through the Decentralized Procedure.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 81pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the above-described procedures, before granting the MA, the EMA or the competent authorities of the Member States of the EEA make an
assessment of the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety, and efficacy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Data
and Marketing Exclusivity</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the EEA, new products authorized for marketing, or reference products, qualify for eight years of data exclusivity and an additional
two years of market exclusivity upon marketing authorization. The data exclusivity period prevents generic or biosimilar applicants from
relying on the pre-clinical and clinical trial data contained in the dossier of the reference product when applying for a generic or
biosimilar marketing authorization in the EU during a period of eight years from the date on which the reference product was first authorized
in the EU. The market exclusivity period prevents a successful generic or biosimilar applicant from commercializing its product in the
EU until 10 years have elapsed from the initial authorization of the reference product in the EU. The 10-year market exclusivity period
can be extended to a maximum of 11 years if, during the first eight years of those 10 years, the marketing authorization holder obtains
an authorization for one or more new therapeutic indications that, during the scientific evaluation prior to their authorization, are
held to bring a significant clinical benefit in comparison with existing therapies. In Japan, medicinal products approved for administration
to a patient via a new route of administration qualify for six years of market exclusivity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Clinical
Trials</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
trials of medicinal products in the European Union must be conducted in accordance with European Union and national regulations and the
International Conference on Harmonization (the &ldquo;ICH&rdquo;) guidelines on GCPs. Additional GCP guidelines from the European Commission,
focusing in particular on traceability, apply to clinical trials of advanced therapy medicinal products. If the sponsor of the clinical
trial is not established within the European Union, it must appoint an entity within the European Union to act as its legal representative.
The sponsor must purchase a clinical trial insurance policy and, in most EU countries, the sponsor is liable to provide &ldquo;no fault&rdquo;
compensation to any study subject injured in the clinical trial.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to commencing a clinical trial, the sponsor must obtain a clinical trial authorization from the competent authority, and a positive opinion
from an IEC. The application for a clinical trial authorization must include, among other things, a copy of the trial protocol and an
investigational medicinal product dossier that contains information about the manufacture and quality of the medicinal product under
investigation. Currently, clinical trial authorization applications must be submitted to the competent authority in each EU Member State
in which the trial will be conducted. Under the new Clinical Trials Regulation (Regulation (EU) No 536/2014), which took effect on January
31, 2022, there will be a centralized application procedure where one national authority takes the lead in reviewing the application
and the other national authorities have only a limited involvement. Any substantial changes to the trial protocol or other information
submitted with the clinical trial applications must be notified to or approved by the relevant competent authorities and ethics committees.
Medicines used in clinical trials must be manufactured in accordance with cGMP. Other national and European Union-wide regulatory requirements
also apply.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Recycling</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
started our business in 1976 as a used appliance retailer that reconditioned old appliances to sell in our stores. Under contracts with
national and regional retailers of new appliances, we collected the replaced appliance from the retailer&rsquo;s customer&rsquo;s residence
when one of their stores delivered a new appliance. Any old appliances that we could not sell in our stores were sold to scrap metal
processors. In the late 1980s, stricter environmental regulations began to affect the disposal of unwanted appliances and we were no
longer able to take appliances that contained hazardous components to scrap metal processors. At that time, we began to develop systems
and equipment to remove the harmful materials so that metal processors would accept the appliance shells for processing. We then offered
our services for disposing of appliances in an environmentally sound manner to appliance manufacturers and retailers, waste hauling companies,
rental property managers, local governments, and the public. In 1989, we began contracting with electric utility companies to provide
turnkey appliance recycling services to support their energy conservation efforts. Since that time, through March 8, 2023, we provided
our services to approximately 400 utilities and other providers of energy efficiency programs throughout North America.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Through
March 8, 2023, when we disposed of our recycling business, we had contracts to recycle, or to replace and recycle, major household appliances
for approximately 100 utilities and other providers of energy efficiency services across North America. We operate 17 recycling centers
in the United States and Canada to process and recycle old appliances according to all federal, state, provincial, and local rules, and
regulations. We used United States Environmental Protection Agency (the &ldquo;EPA&rdquo;) Responsible Appliance Disposal (&ldquo;RAD&rdquo;)
Program-compliant methods to remove and manage hazardous components and materials properly, including CFC refrigerants, mercury, polyurethane
foam insulation, and recyclable materials, such as ferrous and nonferrous metals, plastics, and glass. During our operations of the recycling
business, all of our facilities complied with licensing and permitting requirements, and employees who process appliances receive extensive
safety and hazardous materials training.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
wholly-owned Recycling Subsidiaries in our Recycling segment included ARCA Recycling and ARCA Canada, which recycle major household appliances
in North America by providing turnkey appliance recycling and replacement services for utilities and other sponsors of energy efficiency
programs, and Connexx, which provides call center services for the recycling segment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Disposition
of our Recycling Business</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 19, 2023, the Company entered into a Stock Purchase Agreement (the &ldquo;Recycling Purchase Agreement&rdquo;) with VM7 Corporation
(&ldquo;VM7&rdquo;), under which it agreed to acquire all of the outstanding equity interests of the Recycling Subsidiaries, consisting
of: (a) ARCA Recycling, (b) ARCA Canada, and (c) Connexx. The principal of VM7 is Virland A. Johnson, our Chief Financial Officer. The
sale of all of the outstanding equity interests of the Recycling Subsidiaries to VM7 under the Recycling Purchase Agreement (the &ldquo;Disposition
Transaction&rdquo;) was consummated simultaneously with the execution of the Recycling Purchase Agreement. Our Board of Directors unanimously
approved the Recycling Purchase Agreement and the Disposition Transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
economic aspects of the Disposition Transaction are: (i) we reduced the liabilities on our consolidated balance sheets by approximately
$17.6 million (excluding those related to the California Business Fee and Tax Division, as discussed below); (ii) we will receive not
less than $24.0 million in aggregate monthly payments from VM7, which payments are subject to potential increase due to the Recycling
Subsidiaries&rsquo; future performance; and (iii) during the next five years, we may request that VM7 prepay aggregate monthly payments
in the aggregate amount of $1 million. We also received one thousand dollars for the equity of each of the Recycling Subsidiaries at
the closing. Each monthly payment is to be the greater of (a) $140,000 (or $100,000 for each January and February during the 15-year
payment period) or (b) a monthly percentage-based payment, which is an amount calculated as follows: (i) 5% of the Recycling Subsidiaries&rsquo;
aggregate gross revenues up to $2,000,000 for the relevant month, plus (ii) 4% of the Recycling Subsidiaries&rsquo; aggregate gross revenues
between $2,000,000 and $3,000,000 for the relevant month, plus (iii) 3% of the Recycling Subsidiaries aggregate gross revenues over $3,000,000
for the relevant month. VM7 will receive credit toward the payment of the first monthly payment (March of 2023) for any payments, distributions,
or cash dividends paid by any of the Recycling Subsidiaries to the Company on or after March 19, 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">VM7
may prepay, at any time and in total, the estimated aggregate of the future monthly payments. That amount will be an amount equal to
the then-present value of the estimated future monthly payments, discounted at the rate of 5% per annum (the &ldquo;Prepayment Price&rdquo;).
Furthermore, VM7 will be required to pay the Prepayment Price upon the earliest of (i) Mr. Johnson holding less than 75% of the capital
stock of VM7, (ii) VM7 selling substantially all of its assets, (iii) VM7 holding less than 50% of the capital stock of the Recycling
Subsidiaries, or (iv) the Recycling Subsidiaries selling substantially all of their respective assets. Upon payment of the Prepayment
Price, VM7 will have no further purchase price payment obligations to the Company.&zwnj;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
terms of the Disposition Transaction are: (i) we have the right to appoint one member of VM7&rsquo;s board of directors until the sooner
of VM7 having paid the Prepayment Price or having tendered all of the monthly payments; (ii) Mr. Johnson&rsquo;s annual salary as Chief
Executive Officer of VM7 shall be $400,000, prorated, for the remainder of the 2023 calendar year, and then adjusted annually to an amount
equal to 1% of the Recycling Subsidiaries&rsquo; aggregate gross revenues, until the sooner of VM7 having paid the Prepayment Price or
having tendered all of the monthly payments; and (iii) we will receive additional payments from VM7 (that are not related to the on-going
monthly payments) that relate to certain taxing agency issues. Upon settlement of the continuing dispute between ARCA Recycling and the
California Business Fee and Tax Division (as to which settlement, there can be no assurance), ARCA Recycling will pay to us 50% of the
amount of the reduction between the current assessment and any such settlement. The payment will be memorialized by a three-year promissory
note with interest at five percent per annum. The first payment under the note will be on the last day of VM7&rsquo;s fiscal year in
which the settlement occurs and the remaining payments each year thereafter. If ARCA Recycling receives a refund from the agency for
payments previously made, it shall pay to us an amount equivalent to 25% of such refund after reduction for the legal fees payable to
counsel for this proceeding. ARCA Recycling and Connexx are due to receive from the Internal Revenue Service two payments in the aggregate
amount of approximately $931,000 in connection with the Employee Retention Credit provisions of the Coronavirus Aid, Relief, and Economic
Security Act and the Taxpayer Certainty and Disaster Tax Relief Act of 2020. Those payments are to be tendered to us within 10 days of
receipt by ARCA Recycling or Connexx.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
secure VM7&rsquo;s obligations under the Recycling Purchase Agreement and pursuant to a Stock and Membership Interests Pledge Agreement
dated March 19, 2023 (the &ldquo;Pledge Agreement&rdquo;), Mr. Johnson pledged to us all of the capital stock in VM7 (&ldquo;VM7&rsquo;s
Capital Stock&rdquo;) and VM7 pledged to us all of the equity interests of the Recycling Subsidiaries (the &ldquo;Subject Securities&rdquo;).
Under the terms of the Pledge Agreement, upon an Event of Default (as defined in the Pledge Agreement), among other remedies in our favor,
we may foreclose on any or all of VM7&rsquo;s Capital Stock and the Subject Securities. We may also cause the ownership of VM7&rsquo;s
Capital Stock and of the Subject Securities to be transferred to us automatically, pursuant to an irrevocable transfer entered in our
favor, as referenced in the Pledge Agreement. In the event of an automatic transfer, all of the monthly payments previously made by VM7
pursuant to the terms of the Recycling Purchase Agreement will then be characterized as contributions to the capital of the Company without
dilution of the Company&rsquo;s capital stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
parties have made customary representations, warranties, covenants, and indemnities in connection with the Disposition Transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Recycling Purchase Agreement contains certain representations and warranties that the parties made to each other as of the date of the
Recycling Purchase Agreement or such other date as explicitly referenced therein. The representations and warranties were made solely
for purposes of the Recycling Purchase Agreement and (i) are subject to limitations agreed by the parties in negotiating the terms and
conditions thereof, (ii) may not be accurate or complete as of any specified date, (iii) will be qualified by the underlying disclosure
schedules, (iv) may be subject to a contractual standard of materiality different from those generally applicable to investors, and (v)
may have been used for the purpose of allocating risk among the parties thereto, rather than for establishing any matters as facts. Information
concerning the subject matter of the representations and warranties may change after March 8, 2023, and subsequent information may or
may not be fully reflected in JanOne&rsquo;s public disclosures. For the foregoing reasons, the representations and warranties contained
in the Recycling Purchase Agreement should not be relied upon as statements of factual information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequent
to the closing of the Disposition Transaction, VM7 determined that, after expending significant amounts of time and resources, it was
unable to obtain sufficient equity or debt financing to continue the operations of the Recycling Subsidiaries. Accordingly, we were advised
that the operations of the Recycling Subsidiaries were wound down and, ultimately, ceased. Because we did not receive all of the economic
benefits of the Disposition Transaction and understand that we will not receive any future benefits of the Disposition Transaction, we
determined to fully impair the approximately $5.3 million carrying value of the Disposition Transaction on our balance sheet. We also
determined not to exercise any of our remedies under the Recycling Purchase Agreement so that we could maintain our focus on our clinical-stage
biopharmaceutical activities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Technology</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended January 1, 2022, the Company took a full write-down of the unamortized portion of the GeoTraq intangible asset of approximately
$9.8 million, and then on May 24, 2022, the Company entered into an Asset Purchase Agreement with SPYR Technologies Inc., pursuant to
which the Company sold to SPYR substantially all the assets and assigned none of the liabilities of the Company&rsquo;s wholly-owned
subsidiary, GeoTraq Inc. The aggregate purchase price for the GeoTraq assets was $13.5 million, payable in cash and shares of SPYR&rsquo;s
capital stock. As of the closing of the transaction on May 24, 2022, SPYR issued to the Company 30,000,000 shares of its common stock
at $0.03 per share, and delivered a five-year Promissory Note in the initial principal amount of $12.6 million. The Promissory Note bears
simple interest at the rate of 8% per annum, provides quarterly interest payments due the first day of each calendar quarter, and may
be prepaid at any time without penalty. Quarterly interest payments may be made in cash or in shares of SPYR&rsquo;s restricted common
stock or preferred stock. The Promissory Note matures on May 23, 2027.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Employees</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of April 8, 2024, the Company had five employees, all of whom were full-time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="Su_002"></A>SELECTED
CONSOLIDATED FINANCIAL DATA</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following tables set forth selected consolidated financial data for the periods ended or as of the dates indicated. Such historical consolidated
financial data should be read in conjunction with the information set forth in our <U>Annual Report on Form 10-K for the year ended December
30, 2023</U>, filed with the SEC on April 8, 2024, and incorporated herein by reference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
statement of operations data presented below for each of the years ended December 30, 2023 and December 31, 2022, and the balance sheet
data as of December 30, 2023 and December 31, 2022, are derived from the audited &ldquo;Consolidated Financial Statements&rdquo; contained
in our Annual Report on Form 10-K for the year ended December 30, 2023. Our historical results are not necessarily indicative of the
results to be expected for any future periods.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(in
thousands, except per share)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid">For the 52-Week Period Ended</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">December 30, 2023</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">December 31, 2022</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Revenues</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">Cost of revenues</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Gross profit</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Operating expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; width: 64%; text-align: left">Sales, general and administrative expenses</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">4,746</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">3,149</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Impairment expense</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">15,100</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Total operating expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">19,486</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,149</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Operating loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(19,486</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,149</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Other income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Interest expense, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,250</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">468</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Gain on litigation settlement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,950</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Gain on reversal of contingent liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">637</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Unrealized loss on marketable securities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(926</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(631</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Other income, net</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">998</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,124</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Total other income, net</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,322</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4,548</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">(Loss) Income before income taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(17,524</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,399</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Income tax benefit</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(429</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(6,621</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Net (loss) income from continuing operations</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(17,095</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">8,020</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Income from discontinued operations</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">10,254</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,081</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Income tax provision for discontinued operations</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">971</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,109</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Net income from discontinued operations</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">9,283</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,972</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Net (Loss) income</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(7,812</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">10,992</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Income (Loss) per share:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Net (loss) income per share from continuing operations, basic and diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4.27</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.55</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Net income per share from discontinued operations, basic</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.32</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.94</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Net income per share from discontinued operations, diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.09</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.94</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Net (loss) income per share, basic and diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(1.95</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3.49</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Weighted average common shares outstanding:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt">Basic</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,005,334</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,150,230</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt">Diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,444,361</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,150,230</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(7,812</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">10,992</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Effect of foreign currency translation adjustments</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(4</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Total other comprehensive loss, net of tax</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(4</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Comprehensive (loss) income</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(7,812</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">10,988</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">December 30, 2023</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">December 31, 2022</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Balance Sheet Data</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 64%; text-align: left">Total assets</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">18,847</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">46,756</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,905</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23,938</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Total liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,285</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">29,939</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Mezzanine equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,510</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,510</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Total stockholders&rsquo; equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,308</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,307</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Total liabilities, mezzanine equity, and stockholders&rsquo; equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">18,487</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">46,756</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="Su_003"></A>DESCRIPTION
OF SECURITIES WE MAY OFFER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may issue from time to time, in one or more offerings the following securities:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
    of Common Stock;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
    of Preferred Stock, which may be convertible into shares of Common Stock;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">debt
    securities, which may be senior or subordinated and may be convertible into or exchangeable for shares of Common Stock or shares
    of Preferred Stock;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">warrants
    exercisable for debt securities, shares of Common Stock, or shares of Preferred Stock;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">rights
    to purchase any of such securities; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">units
    composed of our debt securities, shares of Common Stock, shares of Preferred Stock, and warrants, in any combination.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus contains a summary of the material general terms of the various securities that we may offer. The specific terms of the securities
will be described in a prospectus supplement, information or document incorporated by reference, related free writing prospectus, or
other offering materials, which may be in addition to or different from the general terms summarized in this prospectus. Where applicable,
the prospectus supplement, information or document incorporated by reference, related free writing prospectus, or other offering materials
will also describe any material United States federal income tax considerations relating to the securities offered and indicate whether
the securities offered are or will be listed on any securities exchange. The summaries contained in this prospectus and in any prospectus
supplement, information or document incorporated by reference, related free writing prospectus, or other offering materials, as applicable,
may not contain all of the information that you would find useful. Accordingly, you should read the actual documents relating to any
securities sold pursuant to this prospectus. See &ldquo;Available Information&rdquo; and &ldquo;Incorporation of Certain Information
by Reference&rdquo; for information about how to obtain copies of those documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
terms of any particular offering, the initial offering price, and the net proceeds to us will be contained in the prospectus supplement,
information or document incorporated by reference, related free writing prospectus, or other offering materials, as applicable, relating
to such offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="Su_004"></A>DESCRIPTION
OF CAPITAL STOCK</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
following summary of terms of our Common Stock and our Preferred Stock is based upon our Articles of Incorporation (our &ldquo;Charter&rdquo;)
and Bylaws (our &ldquo;Bylaws&rdquo;), currently in effect, and under Chapter 78 of the Nevada Revised Statutes (the &ldquo;NRS&rdquo;).
This summary is not complete and is subject to, and qualified in its entirety by reference to, our Charter and our Bylaws. For a complete
description of the terms and provisions of our Common Stock, please refer to our Charter and Bylaws, which are filed as exhibits to Registration
Statement of which this prospectus forms a part. Throughout this section, references to &ldquo;we,&rdquo; &ldquo;our,&rdquo; and &ldquo;us&rdquo;
refer to JanOne Inc. and its subsidiaries. We encourage you to carefully read these documents and the applicable provisions of the NRS.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>General</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
authorized capital stock consists of 200,000,000 shares of Common Stock, par value $0.001 per share, and 2,000,000 shares of Preferred
Stock, par value $0.001 per share, of which 259,729 shares are designated as Series A-1 Convertible Preferred Stock (our &ldquo;Series
A-1 Preferred Stock&rdquo;), and 200,000 shares are designated as Series S Convertible Preferred Stock (our &ldquo;Series S Preferred
Stock&rdquo;), which have a stated value of $300.00 per share (the &ldquo;Stated Value&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of April 8, 2024, we had 8,593,636 shares of our Common Stock issued and outstanding, 156,630 shares of our Series A-1 Preferred Stock
issued and outstanding, and 100,000 shares of our Series S Preferred Stock issued and outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
authorized and unissued shares of Common Stock and Preferred Stock are available for issuance without further action by our stockholders,
unless such action is required by applicable law or the rules of any stock exchange on which our securities may then be listed. Unless
approval of our stockholders is so required, our Board of Directors (our &ldquo;Board&rdquo;) does not currently intend to seek stockholder
approval for the issuance and sale of our Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of our issued and outstanding shares of our capital stock are fully paid and non-assessable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Voting,
Dividend, and Liquidation Rights</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
holder of our Common Stock is entitled to one vote for each share issued and outstanding held on all matters to be voted upon by the
stockholders. Each holder of our Series A-1 Preferred Stock is entitled to 17 votes for each share issued and outstanding held on all
matters to be voted upon by the stockholders. Each holder of our Series S Preferred Stock is entitled to one vote for each share issued
and outstanding held on all matters to be voted upon by the stockholders. Our Charter does not provide for cumulative voting in the election
of directors. Subject to the rights of the holders of the Series A-1 Preferred Stock to their preferential dividend in accordance with
the provisions of our Charter, the holders of shares of our Common Stock and Series A-1 Preferred Stock (on an as-if-converted to Common
Stock basis in accordance with the terms of our Charter) will be entitled to such cash dividends as may be declared from time to time
by our Board from funds available therefor. Upon liquidation, dissolution, or winding up of the Company, and after all liquidation preferences
payable to any series of Preferred Stock entitled thereto have been satisfied, our remaining assets shall be distributed to all holders
of Common Stock and any similarly situated stockholders who are not entitled to any liquidation preference or, if there be an insufficient
amount to pay all such stockholders, then ratably among such holders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Preemptive,
Conversion, or Other Rights</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
shares of Common Stock do not have any preemptive, conversion, or redemption rights. Our shares of Series A-1 Preferred Stock do not
have any preemptive or redemption rights and each share of which is convertible into 20 shares of our Common Stock. Our shares of Series
S Preferred do not have any preemptive or redemption rights and, subject to the provisions of the Certificate of Designation in respect
of the Series S Preferred Stock, each share of which is convertible into shares of our Common Stock at a conversion price of $1.66 per
share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Stockholder
Action; Special Meetings</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholders&rsquo;
actions can only be taken at an annual or special meeting of our stockholders. Our Bylaws provide that special meetings of the stockholders
may be called at any time only by (i) our Chief Executive Officer, (ii) two of the members of the Board, or (iii) upon a written request
of stockholders holding 10% or more of the capital stock entitled to vote.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Board
of Directors; Removal; Vacancies</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Bylaws specify that the number of directors is to be determined by a majority vote of the Board. Our Board is currently composed of four
directors. We do not have a classified Board. Pursuant to our Bylaws and the NRS, a director serves until the regular meeting next following
or closely coinciding with the expiration of his or her term of office and until his or her successor has been elected and qualified,
or until his or her earlier death, removal, or resignation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Newly
created directorships resulting from an increase in the number of directors and vacancies occurring on our Board for any reason may be
filled by a vote of a majority of the directors then in office, although less than a quorum exists. A director that is appointed or elected
to fill a vacancy shall hold office for the remaining term of his or her predecessor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Limitation
of Liability and Indemnification</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Charter provides that none of our directors and officers shall be personally liable to us or our stockholders for damages for breach
of fiduciary duty as a director or officer, except for liability for (i) acts or omissions that involve intentional misconduct, fraud,
or knowing violation of law or (ii) for authorizing any distribution in violation of Section 78.300 of the NRS. Our Bylaws provide that
any officer or director who is made a party or witness to an action, suit, or proceeding, whether civil, criminal, administrative, or
investigative, by reason of the fact that he or she is or was one of our directors or officers or serving at our request as a director,
officer, employee, or agent, shall be indemnified and held harmless by us to the fullest extent authorized by the NRS. The right to indemnification
shall include the right of advancement of expenses to the extent permitted under the NRS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Listing
and Transfer Agent</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is listed on The Nasdaq Capital Market under the symbol &ldquo;JAN.&rdquo; The transfer agent and registrar for our common
stock is EQ Shareowner Services.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Series
A-1 Convertible Preferred Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Dividends</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot declare, pay, or set aside any dividends on shares of any other class or series of our capital stock unless (in addition to the
obtaining of any consents required by our Articles of Incorporation) the holders of the Series A-1 Preferred Stock then outstanding shall
first receive, or simultaneously receive, a dividend in the aggregate amount of $1.00, regardless of the number of then-issued and outstanding
shares of Series A-1 Preferred Stock. Any remaining dividends allocated by the Board of Directors shall be distributed in an equal amount
per share to the holders of outstanding Common Stock and Series A-1 Preferred Stock (on an as-if-converted to Common Stock basis pursuant
to the Conversion Ratio as defined below).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Conversion</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
share of Series A-1 Preferred Stock has the right to be converted into 20 shares of Common Stock of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Redemption</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shares of Series A-1 Preferred Stock have no redemption rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Preemptive
Rights</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of shares of Series A-1 Preferred Stock are not entitled to any preemptive rights in respect to any securities of the Company, except
as set forth in the Series A-1 Certificate of Designation or any other document agreed to by us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Voting
Rights</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
holder of a share of Series A-1 Preferred Stock has that number of votes as is determined by multiplying (i) the number of shares of
Series A Preferred Stock held by such holder and (ii) 17. The holders of Series A-1 Preferred Stock vote together with all other classes
and series of Common Stock and Preferred Stock of the Company as a single class on all actions to be taken by the holders of Common Stock
of the Company, except to the extent that voting as a separate class or series is required by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Protective
Provisions</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Without
first obtaining the affirmative approval of a majority of the holders of the shares of Series A-1 Preferred Stock, we may not directly
or indirectly (i) increase or decrease (other than by redemption or conversion) the total number of authorized shares of Series A-1 Preferred
Stock; (ii) effect an exchange, reclassification, or cancellation of all or a part of the Series A-1 Preferred Stock, but excluding a
stock split or reverse stock split or combination of the Common Stock or preferred stock; (iii) effect an exchange, or create a right
of exchange, of all or part of the shares of another class of shares into shares of Series A-1 Preferred Stock; or (iv) alter or change
the rights, preferences, or privileges of the shares of Series A-1 Preferred Stock so as to affect adversely the shares of such series,
including the rights set forth in the Series A-1 Certificate of Designation; <I>provided</I>, <I>however</I>, that we may, without any
vote of the holders of shares of the Series A-1 Preferred Stock, make technical, corrective, administrative, or similar changes to the
Series A-1 Certificate of Designation that do not, individually or in the aggregate, materially adversely affect the rights or preferences
of the holders of shares of the Series A-1 Preferred Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Series
S Convertible Preferred Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 28, 2022 the Company acquired Soin Therapeutics LLC, a Delaware limited liability company (&ldquo;STLLC&rdquo;) by way of merger.
In connection with this transaction, with a potential value of up to $30 million, the Company tendered 100,000 shares of the Company&rsquo;s
Series S Convertible Preferred Stock to Amol Soin, M.D., the sole stockholder of STLLC (&ldquo;Dr. Soin&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Dividends</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shares of Series S Preferred Stock have no dividend rights.</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Conversion</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Soin may convert up to $10 million of value of the Series S Preferred Stock into shares of the Company&rsquo;s Common Stock from and
after the sooner of (y) the issuance by the FDA of New Drug Approval for low-dose naltrexone for treating pain or (z) 10 years from the
closing of the acquisition of STLLC. Further, during the 10-year period following the closing, Dr. Soin may convert up to an additional
$17 million of value of shares of Series S Preferred Stock at a rate of five percent of the gross revenues that the Company receives
in connection with sales or license revenue from STLLC-related products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Soin further agreed to certain restrictions on the maximum number of shares of Series S Preferred Stock that he may ultimately keep or
that he may convert into shares of our Common Stock or sell into the public markets at any given time: (i) Dr. Soin may not convert shares
of Series S Preferred Stock into shares of the Company&rsquo;s Common Stock in an amount such that, upon any such conversion, he beneficially
own shares of the Company&rsquo;s Common Stock in excess of 4.99% of the Company&rsquo;s then-outstanding Common Stock and (ii) during
the five-year period that commences on the date that Dr. Soin is first eligible to convert any shares of Series S Preferred Stock into
shares of the Company&rsquo;s Common Stock, he will not dispose of any of such shares into the public markets in an amount that exceeds
five percent of the daily trading volume of the Company&rsquo;s common stock during any trading day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
lieu of Dr. Soin exercising his initial conversion rights in respect of up to $3 million in value of his Series S Preferred Stock, Dr.
Soin and we agreed that we will tender to him $3 million in three payments: the first payment of $100,000 was made in March 2024, the
second payment in the amount of $100,000 is due on July 31, 2024, and the third payment of $2,800,000 is due on December 31, 2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Redemption</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shares of Series S Preferred Stock have no redemption rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Preemptive
Rights</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of shares of Series S Preferred Stock are not entitled to any preemptive rights in respect to any securities of the Company, except as
set forth in the Series S Certificate of Designation or any other document agreed to by us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Voting
Rights</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
share of Series S Preferred Stock has one vote. The holders of Series S Preferred Stock vote together with all other classes and series
of Common Stock and Preferred Stock of the Company as a single class on all actions to be taken by the holders of Common Stock of the
Company, except to the extent that voting as a separate class or series is required by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Liquidation
Preference</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
a voluntary or involuntary liquidation, dissolution or winding up of the Company, the Holders of Series S Preferred Stock have preferential
rights to holders of junior securities and shall be entitled to payments in an amount equal to the Stated Value for each share of Series
S Preferred Stock that is eligible to be converted into the Company&rsquo;s Common Stock at such time, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Protective
Provisions</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Without
first obtaining the affirmative approval of a majority of the holders of the shares of Series S Preferred Stock, we may not directly
or indirectly (i) increase or decrease (other than by redemption or conversion) the total number of authorized shares of Series S Preferred
Stock; (ii) effect an exchange, reclassification, or cancellation of all or a part of the Series S Preferred Stock, but excluding a stock
split or reverse stock split or combination of the Common Stock or preferred stock; (iii) effect an exchange, or create a right of exchange,
of all or part of the shares of another class of shares into shares of Series S Preferred Stock; or (iv) alter or change the rights,
preferences, or privileges of the shares of Series S Preferred Stock so as to affect adversely the shares of such series, including the
rights set forth in the Series S Certificate of Designation; <I>provided</I>, <I>however</I>, that we may, without any vote of the holders
of shares of the Series S Preferred Stock, make technical, corrective, administrative, or similar changes to the Series S Certificate
of Designation that do not, individually or in the aggregate, materially adversely affect the rights or preferences of the holders of
shares of the Series S Preferred Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Anti-Takeover
Effects of Certain Provisions of our Charter, our Bylaws, and the NRS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
provisions of the NRS and our Charter and Bylaws could make more difficult the acquisition of us by means of a tender offer or otherwise,
and the removal of incumbent officers and directors. These provisions are expected to discourage certain types of coercive takeover practices
and inadequate takeover bids and to encourage persons seeking to acquire control of us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Advance
Notice of Stockholder Proposals</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholder
proposals must be submitted to the Chairman of our Board, our Chief Executive Officer, our President, or our Secretary not less than
120 days before the one-year anniversary of the date on which we released our proxy statement in connection with the previous year&rsquo;s
annual meeting of stockholders. In the event that our annual meeting date has been changed by more than 30 days from the date of the
prior year&rsquo;s annual meeting, written proposals must be submitted within a reasonable time before we begin to print and mail our
proxy materials. To be in proper form, a stockholder&rsquo;s written proposal must be in compliance with Rule 14a-8 under the Exchange
Act and must include: (i) a brief description of the business desired to be brought before the annual meeting and the reasons for conducting
such business at the annual meeting, (ii) the name and record address of such stockholder, (iii) the class or series and number of shares
of our capital stock that are owned beneficially or of record by such stockholder, (iv) a description of all arrangements or understandings
between such stockholder and any other person or persons (including their names) in connection with the proposal of such business by
such stockholder and any material interest of such stockholder in such business, and (v) a representation that such stockholder intends
to appear in person or by proxy at the annual meeting to bring such business before the meeting. This provision could make it more difficult
for stockholders to submit proposals for consideration and nominees for director at an annual meeting of our stockholders<I>.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Business
Combinations</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
&ldquo;business combination&rdquo; provisions of Sections 78.411 to 78.444, inclusive, of the NRS prohibit a Nevada corporation with
at least 200 stockholders (at least 100 of whom are stockholders of record and residents of the State of Nevada) from engaging in various
&ldquo;combination&rdquo; transactions with any interested stockholder for a period of three years after the date of the transaction
in which the person became an interested stockholder, unless the transaction is approved by the entity&rsquo;s board of directors prior
to the date the interested stockholder obtained such status; or after the expiration of the three-year period, unless:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    transaction is approved by the entity&rsquo;s board of directors or a majority of the voting power held by disinterested stockholders
    of the entity, or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    the consideration to be paid by the interested stockholder is at least equal to the highest of: (a) the highest price per share paid
    by the interested stockholder within the three years immediately preceding the date of the announcement of the combination or in
    the transaction in which it became an interested stockholder, whichever is higher, (b) the market value per share of common stock
    on the date of announcement of the combination and the date the interested stockholder acquired the shares, whichever is higher,
    or (c) for holders of preferred stock, the highest liquidation value of the preferred stock, if it is higher.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
&ldquo;combination&rdquo; is defined to include mergers or consolidations or any sale, lease exchange, mortgage, pledge, transfer, or
other disposition, in one transaction or a series of transactions, with an &ldquo;interested stockholder&rdquo; having: (a) an aggregate
market value equal to 5% or more of the aggregate market value of the assets of the corporation, (b) an aggregate market value equal
to 5% or more of the aggregate market value of all outstanding shares of the corporation, or (c) 10% or more of the earning power or
net income of the corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, an &ldquo;interested stockholder&rdquo; is a person who, together with affiliates and associates, owns (or within three years,
did own) 10% or more of an entity&rsquo;s voting stock. The statute could prohibit or delay mergers or other takeover or change in control
attempts and, accordingly, may discourage attempts to acquire us even though such a transaction may offer our stockholders the opportunity
to sell their stock at a price above the prevailing market price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Acquisitions
of Controlling Interest</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nevada&rsquo;s
&ldquo;acquisition of controlling interest&rdquo; statutes (NRS 78.378 through 78.3793, inclusive) contain provisions governing the acquisition
of a controlling interest in certain Nevada corporations. These &ldquo;control share&rdquo; laws provide generally that any person who
acquires a &ldquo;controlling interest&rdquo; in certain Nevada corporations may be denied voting rights, unless a majority of the disinterested
stockholders of the corporation elects to restore such voting rights. These laws would apply to us as of a particular date if we were
to have 200 or more stockholders of record (at least 100 of whom have addresses in Nevada appearing on our stock ledger at all times
during the 90 days immediately preceding that date) and do business in the State of Nevada directly or through an affiliated corporation,
unless our Charter or Bylaws in effect on the tenth day after the acquisition of a controlling interest provide otherwise. These laws
provide that a person acquires a &ldquo;controlling interest&rdquo; whenever a person acquires shares of a subject corporation that,
but for the application of these provisions of the NRS, would enable that person to exercise (1) one-fifth or more, but less than one-third,
(2) one-third or more, but less than a majority, or (3) a majority or more of all of the voting power of that corporation in the election
of its directors. Once an acquirer crosses one of these thresholds, shares that it acquired in the transaction that took it over the
threshold and shares that it acquired within the 90 days immediately preceding the date when it acquired or offered to acquire a controlling
interest become &ldquo;control shares&rdquo; to which the voting restrictions described above apply.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="Su_005"></A>DESCRIPTION
OF PREFERRED STOCK</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
of our Preferred Stock may be issued in one or more series, and our Board is authorized to determine the designation and to fix the number
of shares of each series. Our Board is further authorized to fix and determine the dividend rate, premium or redemption rates, conversion
rights, voting rights, preferences, privileges, restrictions, and other variations granted to or imposed upon any wholly unissued series
of our Preferred Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the issuance of shares of a series of Preferred Stock, our Board will adopt resolutions and file a certificate of designation with
the Secretary of State of the State of Nevada. The certificate of designation will fix for each series the designation and number of
shares and the rights, preferences, privileges, and restrictions of the shares including, but not limited to, the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    voting rights, if any, of the Preferred Stock;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    rights and terms of redemption;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    dividend rate(s), period(s), and/or payment date(s) or method(s) of calculation applicable to the Preferred Stock;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    dividends are cumulative or non-cumulative and, if cumulative, the date from which dividends on the Preferred Stock will accumulate;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    relative ranking and preferences of the preferred stock as to dividend rights and rights upon the liquidation, dissolution, or winding
    up of our affairs;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    terms and conditions, if applicable, upon which the Preferred Stock will be convertible into Common Stock, another series of Preferred
    Stock, or any other class of securities, including the conversion price (or manner of calculation) and conversion period;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    provision for redemption, if applicable, of the Preferred Stock;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    provisions for a sinking fund, if any, for the Preferred Stock;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    liquidation preferences, if any, for the Preferred Stock;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    limitations on the issuance of any class or series of Preferred Stock ranking senior to or on a parity with the class or series of
    Preferred Stock as to dividend rights and rights upon liquidation, dissolution, or winding up of our affairs; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    other specific terms, preferences, rights, limitations, or restrictions of the Preferred Stock.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the terms listed above, we will set forth in a prospectus supplement, information or document incorporated by reference,
related free writing prospectus, or other offering materials, as applicable, the following terms relating to the series of Preferred
Stock being offered:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    number of shares of the preferred stock offered, the liquidation preference per share, the conversion rights, and the offering price
    of the Preferred Stock;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    procedures for any auction and remarketing, if any, for the Preferred Stock;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    listing of the Preferred Stock on any securities exchange; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    discussion of any material and/or special United States federal income tax considerations applicable to the Preferred Stock.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="Su_006"></A>DESCRIPTION
OF DEBT SECURITIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following description, together with the additional information we include in any applicable prospectus supplements or any related free
writing prospectus or other offering materials, as applicable, summarizes the material terms and provisions of the debt securities that
we may offer under this prospectus. While the terms we have summarized below will apply generally to any future debt securities we may
offer pursuant to this prospectus, we will describe the particular terms of any debt securities that we may offer in more detail in the
applicable prospectus supplement. If we so indicate in a prospectus supplement, the terms of any debt securities offered under such prospectus
supplement may differ from the terms we describe below, and to the extent the terms set forth in a prospectus supplement differ from
the terms described below, the terms set forth in the prospectus supplement or any related free writing prospectus or other offering
materials, as applicable, shall control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may sell from time to time, in one or more offerings under this prospectus, debt securities, in one or more series. These debt securities
that we may issue include senior debt securities, senior subordinated debt securities, subordinated debt securities, convertible debt
securities, and exchangeable debt securities. We will issue any such senior debt securities under a senior indenture that we will enter
into with a trustee to be named in the senior indenture. We will issue any such subordinated debt securities under a subordinated indenture,
which we will enter into with a trustee to be named in the subordinated indenture. We use the term &ldquo;indentures&rdquo; to refer
to either the senior indenture or the subordinated indenture, as applicable. The indentures will be qualified under the Trust Indenture
Act of 1939, as amended (the &ldquo;Trust Indenture Act&rdquo;), as in effect on the date of the indenture. We use the term &ldquo;debenture
trustee&rdquo; to refer to either the trustee under the senior indenture or the trustee under the subordinated indenture, as applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following summary description, together with the additional information we may include in any applicable prospectus supplement, information
or document incorporated by reference, related free writing prospectus, or other offering materials, as applicable, does not purport
to be complete and is subject to, and qualified in its entirety by reference to, the form of indenture filed as an exhibit to the Registration
Statement of which the prospectus is a part, as it may be supplemented, amended, or modified from time to time, as well as the notes
and supplemental agreement relating to each series of debt securities that will be incorporated by reference as exhibits to the Registration
Statement that includes the prospectus or as exhibits to a Current Report on Form 8-K if we offer debt securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>General</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
indenture does not limit the amount of debt securities that may be issued thereunder, and each indenture provides that the specific terms
of any series of debt securities shall be set forth in, or determined pursuant to, an authorizing resolution and/or a supplemental indenture,
if any, relating to such series.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may issue the debt securities issued under the indentures as &ldquo;discount securities,&rdquo; which means they may be sold at a discount
below their stated principal amount. These debt securities, as well as other debt securities that are not issued at a discount, may be
issued with &ldquo;original issue discount,&rdquo; or &ldquo;OID,&rdquo; for U.S. federal income tax purposes because of interest payment
and other characteristics or terms of the debt securities. Material U.S. federal income tax considerations applicable to debt securities
issued with OID will be described in more detail in any applicable prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will describe in the applicable prospectus supplement, the related free writing prospectus, or other offering materials, as applicable,
the terms of the series of debt securities being offered, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    title or designation;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    aggregate principal amount and any limit on the aggregate principal amount that may be issued;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    maturity date or dates on which principal will be payable;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    form of the debt securities of the series;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.45in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    applicability of any guarantees;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    or not the debt securities will be secured or unsecured, and the terms of any secured debt;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    the debt securities rank as senior debt, senior subordinated debt, subordinated debt, or any combination thereof, and the terms of
    any subordination;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    the price (expressed as a percentage of the aggregate principal amount thereof) at which such debt securities will be issued is a
    price other than the principal amount thereof, the portion of the principal amount thereof payable upon declaration of acceleration
    of the maturity thereof, or, if applicable, the portion of the principal amount of such debt securities that is convertible into
    another security or the method by which any such portion shall be determined;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    interest rate or rates, which may be fixed or variable, or the method for determining the rate and the date interest will begin to
    accrue, the dates interest will be payable, and the regular record dates for interest payment dates or the method for determining
    such dates;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    right, if any, to defer payment of interest and the maximum length of any such deferral period;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    applicable, the date or dates after which, or the period or periods during which, and the price or prices at which, we may, at our
    option, redeem the series of debt securities pursuant to any optional or provisional redemption provisions and the terms of those
    redemption provisions;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    date or dates, if any, on which, and the price or prices at which we are obligated, pursuant to any mandatory sinking fund or analogous
    fund provisions or otherwise, to redeem, or at the holder&rsquo;s option to purchase, the series of debt securities and the currency
    or currency unit in which the debt securities are payable;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    denominations in which we will issue the series of debt securities, if other than denominations of $1,000 and any integral multiple
    thereof;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    place or places where payments will be payable;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    the debt securities of that series shall be issued in whole or in part in the form of a global security or securities, the terms
    and conditions, if any, upon which such global security or securities may be exchanged in whole or in part for other individual securities;
    and the depositary for such global security or securities;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    the indenture will restrict our ability to pay dividends or will require us to maintain any asset ratios or reserves;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if,
    other than the full principal amount thereof, the portion of the principal amount of debt securities of the series that shall be
    payable upon declaration of acceleration of the maturity thereof;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    we will be restricted from incurring any additional indebtedness;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.45in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">additions
    to or changes in the events of default with respect to the securities and any change in the right of the trustee or the holders to
    declare the principal, premium, if any, and interest, if any, with respect to such securities to be due and payable;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">additions
    to or changes in the provisions relating to satisfaction and discharge of the indenture;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">additions
    to or changes in the provisions relating to the modification of the indenture both with and without the consent of holders of debt
    securities issued under the indenture;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    interest will be payable in cash or additional debt securities at our or the holders&rsquo; option and the terms and conditions upon
    which the election may be made;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    terms and conditions, if any, upon which we will pay amounts in addition to the stated interest, premium, if any, and principal amounts
    of the debt securities of the series to any holder that is not a &ldquo;United States person&rdquo; for federal tax purposes;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    restrictions on transfer, sale, or assignment of the debt securities of the series;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    discussion on any material or special U.S. federal income tax considerations applicable to a series of debt securities; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    other specific terms, preferences, rights, or limitations of, or restrictions on, the debt securities, any other additions or changes
    in the provisions of the indenture, and any terms that may be required by us or advisable under applicable laws or regulations.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may issue debt securities that provide for an amount less than their stated principal amount to be due and payable upon declaration of
acceleration of their maturity pursuant to the terms of the indenture. We will provide you with information on the federal income tax
considerations and other special consideration applicable to any of these debt securities in the applicable prospectus supplement, related
free writing prospectus, or other offering materials, as applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Conversion
or Exchange Rights</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will set forth in the applicable prospectus supplement, related free writing prospectus, or other offering materials, as applicable,
the terms on which a series of debt securities may be convertible into or exchangeable for shares of our Common Stock, shares of our
Preferred Stock, or other securities. We will include provisions as to settlement upon conversion or exchange and whether conversion
or exchange is mandatory, at the option of the holder, or at our option. We may include provisions pursuant to which the number of shares
of our Common Stock, shares of our Preferred Stock, or our other securities that the holders of the series of debt securities receive
would be subject to adjustment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Consolidation,
Merger, or Sale; No Protection in Event of a Change of Control or Highly Leveraged Transaction</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
we provide otherwise in the prospectus supplement, information or document incorporated by reference, related free writing prospectus,
or other offering materials, as applicable, applicable to a particular series of debt securities, the indenture will contain covenant
that restricts our ability to merge or consolidate, or sell, convey, transfer, or otherwise dispose of our assets as an entirety or substantially
as an entirety, unless we are the surviving corporation or the successor to or acquirer of such assets (other than a subsidiary of ours)
expressly assumes all of our obligations under the indenture or the debt securities, as appropriate. In addition, we cannot complete
such a transaction unless immediately after completing the transaction, no event of default under the indenture, and no event that, after
notice or lapse of time or both, would become an event of default under the indenture, has occurred and is continuing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
we provide otherwise in the prospectus supplement, information or document incorporated by reference, related free writing prospectus,
or other offering materials, as applicable to a particular series of debt securities, the debt securities will not contain any provisions
that may afford holders of the debt securities protection in the event we have a change of control or in the event of a highly leveraged
transaction (whether or not such transaction results in a change of control), which could adversely affect holders of debt securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Events
of Default Under the Indentures</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
we provide otherwise in the prospectus supplement, information or document incorporated by reference, related free writing prospectus,
or other offering materials, as applicable to a particular series of debt securities, the following are events of default under the indentures
with respect to any series of debt securities that we may issue:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    we fail to pay interest when due and our failure continues for a period of 90 days; <I>provided</I>, <I>however</I>, that a valid
    extension of an interest payment period by us in accordance with the terms of any indenture supplement thereto shall not constitute
    a default in the payment of interest for this purpose;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.45in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    we fail to pay the principal of, or premium, if any, on any series of debt securities as and when the same shall become due and payable
    whether at maturity, upon redemption, by declaration or otherwise, or in any payment required by any sinking or analogous fund established
    with respect to such series; <I>provided</I>, <I>however</I>, that a valid extension of the maturity of such debt securities in accordance
    with the terms of any indenture supplement thereto shall not constitute a default in the payment of principal or premium, if any;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    we fail to observe or perform any other covenant or agreement contained in the debt securities or the indenture, other than a covenant
    specifically relating to another series of debt securities, and our failure continues for 90 days after we receive written notice
    of such failure, requiring the same to be remedied and stating that such is a notice of default thereunder, from the trustee or holders
    of at least 25% in aggregate principal amount of the outstanding debt securities of the applicable series; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    specified events of bankruptcy, insolvency, or reorganization occur as to us.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
event of default with respect to a particular series of debt securities (except as to certain events of bankruptcy, insolvency, or reorganization)
necessarily constitutes an event of default with respect to any other series of debt securities. The occurrence of an event of default
may constitute an event of default under any bank credit agreements we may have in existence from time to time. In addition, the occurrence
of certain events of default or acceleration under the indenture may constitute an event of default under certain of our other indebtedness
outstanding from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an event of default with respect to debt securities of any series at the time outstanding occurs and is continuing, then the trustee
or the holders of at least 25% in principal amount of the outstanding debt securities of that series may, by a notice in writing to us
(and to the debenture trustee if given by the holders), declare to be due and payable immediately the principal (or, if the debt securities
of that series are discount securities, that portion of the principal amount as may be specified in the terms of that series) of and
premium and accrued and unpaid interest, if any, on all debt securities of that series. Before a judgment or decree for payment of the
money due has been obtained with respect to debt securities of any series, the holders of a majority in principal amount of the outstanding
debt securities of that series (or, at a meeting of holders of such series at which a quorum is present, the holders of a majority in
principal amount of the debt securities of such series represented at such meeting) may rescind and annul the acceleration if all events
of default, other than the non-payment of accelerated principal, premium, if any, and interest, if any, with respect to debt securities
of that series, have been cured or waived as provided in the applicable indenture (including payments or deposits in respect of principal,
premium or interest that had become due other than as a result of such acceleration). We refer you to the prospectus supplement, information
or document incorporated by reference, related free writing prospectus, or other offering materials, as applicable, relating to any series
of debt securities that are discount securities for the particular provisions relating to acceleration of a portion of the principal
amount of such discount securities upon the occurrence of an event of default.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the terms of the indentures, if an event of default under an indenture shall occur and be continuing, the debenture trustee will be
under no obligation to exercise any of its rights or powers under such indenture at the request or direction of any of the holders of
the applicable series of debt securities, unless such holders have offered the debenture trustee reasonable indemnity. The holders of
a majority in principal amount of the outstanding debt securities of any series will have the right to direct the time, method, and place
of conducting any proceeding for any remedy available to the debenture trustee, or exercising any trust or power conferred on the debenture
trustee, with respect to the debt securities of that series, provided, that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    direction so given by the holder is not in conflict with any law or the applicable indenture; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">subject
    to its duties under the Trust Indenture Act, the debenture trustee need not take any action that might involve it in personal liability
    or might be unduly prejudicial to the holders not involved in the proceeding.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
holder of the debt securities of any series will only have the right to institute a proceeding under the indentures or to appoint a receiver
or trustee, or to seek other remedies if:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    holder previously has given written notice to the debenture trustee of a continuing event of default with respect to that series;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series have made written request,
    and such holders have offered reasonable indemnity to the debenture trustee to institute the proceeding as trustee; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    debenture trustee does not institute the proceeding, and does not receive from the holders of a majority in aggregate principal amount
    of the outstanding debt securities of that series (or at a meeting of holders of such series at which a quorum is present, the holders
    of a majority in principal amount of the debt securities of such series represented at such meeting) other conflicting directions
    within 60 days after the notice, request, and offer.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
limitations do not apply to a suit instituted by a holder of debt securities if we default in the payment of the principal, premium,
if any, or interest on, the debt securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will periodically file statements with the applicable debenture trustee regarding our compliance with specified covenants in the applicable
indenture.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Modification
of Indentures; Waiver</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
and the debenture trustee may change the applicable indenture without the consent of any holders with respect to specific matters, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    evidence the succession of another corporation to us and the assumption by any such successor of our covenants in such indenture
    and in the debt securities issued thereunder;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    add to our covenants or to surrender any right or power conferred on us pursuant to the indenture;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    establish the form and terms of debt securities issued thereunder;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    evidence and provide for a successor trustee under such indenture with respect to one or more series of debt securities issued thereunder
    or to provide for or facilitate the administration of the trusts under such indenture by more than one trustee;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    cure any ambiguity, to correct or supplement any provision in the indenture that may be defective or inconsistent with any other
    provision of the indenture or to make any other provisions with respect to matters or questions arising under such indenture; provided
    that no such action adversely affects the interests of the holders of any series of debt securities issued thereunder in any material
    respect;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 81pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    add to, delete from, or revise the conditions, limitations, and restrictions on the authorized amount, terms, or purposes of issue,
    authentication, and delivery of securities under the indenture;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    add any additional events of default with respect to all or any series of debt securities;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    supplement any of the provisions of the indenture as may be necessary to permit or facilitate the defeasance and discharge of any
    series of debt securities, provided that such action does not adversely affect the interests of any holder of an outstanding debt
    security of such series or any other security in any material respect;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    make provisions with respect to the conversion or exchange rights of holders of debt securities of any series;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    pledge to the trustee as security for the debt securities of any series any property or assets;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 81pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    add guarantees in respect of the debt securities of one or more series;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    change or eliminate any of the provisions of the indenture, provided that any such change or elimination becomes effective only when
    there is no security of any series outstanding created prior to the execution of such supplemental indenture that is entitled to
    the benefit of such provision;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    provide for certificated securities in addition to or in place of global securities;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    qualify such indenture under the Trust Indenture Act;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">with
    respect to the debt securities of any series, to conform the text of the indenture or the debt securities of such series to any provision
    of the description thereof in our offering memorandum or prospectus relating to the initial offering of such debt securities, to
    the extent that such provision, in our good faith judgment, was intended to be a verbatim recitation of a provision of the indenture
    or such securities; or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    make any other change that does not adversely affect the rights of holders of any series of debt securities issued thereunder in
    any material respect.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, under the indentures, the rights of holders of a series of debt securities may be changed by us and the debenture trustee with
the written consent of the holders of at least a majority in aggregate principal amount of the outstanding debt securities of each series
(or, at a meeting of holders of such series at which a quorum is present, the holders of a majority in principal amount of the debt securities
of such series represented at such meeting) that is affected. However, the debenture trustee and we may make the following changes only
with the consent of each holder of any outstanding debt security affected:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">extending
    the fixed maturity of the series of debt securities;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reducing
    the principal amount, reducing the rate of, or extending the time of payment of interest, or any premium payable upon the redemption
    of any debt securities;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reducing
    the principal amount of discount securities payable upon acceleration of maturity;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">making
    the principal of or premium or interest on any debt security payable in currency other than that stated in the debt security;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">impair
    the right to institute suit for the enforcement of any payment on any debt security when due;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    applicable, adversely affect the right of a holder to confer or exchange a debt security; or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reducing
    the percentage of debt securities, the holders of which are required to consent to any amendment or waiver.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
for certain specified provisions, the holders of at least a majority in principal amount of the outstanding debt securities of any series
(or, at a meeting of holders of such series at which a quorum is present, the holders of a majority in principal amount of the debt securities
of such series represented at such meeting) may on behalf of the holders of all debt securities of that series waive our compliance with
provisions of the indenture. The holders of a majority in principal amount of the outstanding debt securities of any series may, on behalf
of the holders of all the debt securities of such series, waive any past default under the indenture with respect to that series and
its consequences, except a default in the payment of the principal of, premium, or any interest on any debt security of that series or
in respect of a covenant or provision, which cannot be modified or amended without the consent of the holder of each outstanding debt
security of the series affected; <I>provided</I>, <I>however</I>, that the holders of a majority in principal amount of the outstanding
debt securities of any series may rescind an acceleration and its consequences, including any related payment default that resulted from
the acceleration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Discharge,
Defeasance, and Covenant Defeasance</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
can discharge or decrease our obligations under the indenture as stated below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may discharge obligations to holders of any series of debt securities that have not already been delivered to the trustee for cancellation
and that have either become due and payable or are by their terms to become due and payable, or are scheduled for redemption, within
one year. We may effect a discharge by irrevocably depositing with the trustee cash or government obligations, as trust funds, in an
amount certified to be enough to pay, when due, whether at maturity, upon redemption or otherwise, the principal of, and any premium
and interest on, the debt securities and any mandatory sinking fund payments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise provided in the applicable prospectus supplement, information or document incorporated by reference, related free writing prospectus,
or other offering materials, we may also discharge any and all of our obligations to holders of any series of debt securities at any
time, which we refer to as defeasance. We may also be released from the obligations imposed by any covenants of any outstanding series
of debt securities and provisions of the indenture, and we may omit to comply with those covenants without creating an event of default
under the trust declaration, which we refer to as covenant defeasance. We may effect defeasance and covenant defeasance only if, among
other things:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    irrevocably deposit with the trustee cash or government obligations denominated in the currency of the debt securities, as trust
    funds, in an amount certified to be enough to pay at maturity, or upon redemption, the principal (including any mandatory sinking
    fund payments) of, and any premium and interest on, all outstanding debt securities of the series; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    deliver to the trustee an opinion of counsel from a nationally recognized law firm to the effect that the holders of the series of
    debt securities will not recognize income, gain or loss for U.S. federal income tax purposes as a result of the defeasance or covenant
    defeasance and that defeasance or covenant defeasance will not otherwise alter the holders&rsquo; U.S. federal income tax treatment
    of principal, and any premium and interest payments on, the series of debt securities.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the case of a defeasance by us, the opinion we deliver must be based on a ruling of the Internal Revenue Service issued, or a change
in U.S. federal income tax law occurring, after the date of the indenture, since such a result would not occur under the U.S. federal
income tax laws in effect on that date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we may discharge or decrease our obligations under the indenture as described in the two preceding paragraphs, we may not avoid, among
other things, our duty to register the transfer or exchange of any series of debt securities, to replace any temporary, mutilated, destroyed,
lost, or stolen series of debt securities or to maintain an office or agency in respect of any series of debt securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registered
Global Securities and Book Entry System</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
debt securities of a series may be issued in whole or in part in book-entry form and will be represented by one or more fully registered
global securities. We will deposit any registered global securities with a depositary or with a nominee for a depositary identified in
the applicable prospectus supplement, information or document incorporated by reference, related free writing prospectus, or other offering
materials and registered in the name of such depositary or nominee. In such case, we will issue one or more registered global securities
denominated in an amount equal to the aggregate principal amount of all of the debt securities of the series to be issued and represented
by such registered global security or securities. This means that we will not issue certificates to each holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
and until it is exchanged in whole or in part for debt securities in definitive registered form, a registered global security may not
be transferred except as a whole:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by
    the depositary for the registered global security to its nominee;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by
    a nominee of the depositary to the depositary or another nominee of the depositary; or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by
    the depositary or its nominee to a successor of the depositary or a nominee of the successor.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
prospectus supplement, information or document incorporated by reference, related free writing prospectus, or other offering materials,
as applicable, relating to a series of debt securities will describe the specific terms of the depositary arrangement involving any portion
of the series represented by a registered global security. We anticipate that the following provisions will apply to all depositary arrangements
for debt securities:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ownership
    of beneficial interests in a registered global security will be limited to persons that have accounts with the depositary for such
    registered global security, these persons being referred to as &ldquo;participants,&rdquo; or persons that may hold interests through
    participants;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">upon
    the issuance of a registered global security, the depositary for the registered global security will credit, on its book-entry registration
    and transfer system, the participants&rsquo; accounts with the respective principal amounts of the debt securities represented by
    the registered global security beneficially owned by the participants;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    dealers, underwriters, or agents participating in the distribution of the debt securities will designate the accounts to be credited;
    and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ownership
    of beneficial interest in the registered global security will be shown on, and the transfer of the ownership interest will be effected
    only through, records maintained by the depositary for the registered global security for interests of participants, and on the records
    of participants for interests of persons holding through participants.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
laws of some states may require that specified purchasers of securities take physical delivery of the securities in definitive form.
These laws may limit the ability of those persons to own, transfer, or pledge beneficial interests in registered global securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">So
long as the depositary for a registered global security, or its nominee, is the registered owner of the registered global security, the
depositary or such nominee, as the case may be, will be considered the sole owner or holder of the debt securities represented by the
registered global security for all purposes under the indenture. Except as stated below, owners of beneficial interests in a registered
global security:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">will
    not be entitled to have the debt securities represented by a registered global security registered in their names;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">will
    not receive or be entitled to receive physical delivery of the debt securities in the definitive form; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">will
    not be considered the owners or holders of the debt securities under the relevant indenture.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accordingly,
each person owning a beneficial interest in a registered global security must rely on the procedures of the depositary for the registered
global security and, if the person is not a participant, on the procedures of a participant through which the person owns its interest,
to exercise any rights of a holder under the indenture.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
understand that, under existing industry practices, if we request any action of holders or if an owner of a beneficial interest in a
registered global security desires to give or take any action that a holder is entitled to give or take under the indenture, the depositary
for the registered global security would authorize the participants holding the relevant beneficial interests to give or take the action,
and the participants would authorize beneficial owners owning through the participants to give or take the action or would otherwise
act upon the instructions of beneficial owners holding through them.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will make payments of principal and premium, if any, and interest, if any, on debt securities represented by a registered global security
registered in the name of a depositary or its nominee to the depositary or its nominee, as the case may be, as the registered owners
of the registered global security. Neither we nor the trustee, or any other agent of ours or the trustee will be responsible or liable
for any aspect of the records relating to, or payments made on account of, beneficial ownership interests in the registered global security
or for maintaining, supervising, or reviewing any records relating to the beneficial ownership interests.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that the depositary for any debt securities represented by a registered global security, upon receipt of any payments of principal
and premium, if any, and interest, if any, in respect of the registered global security, will immediately credit participants&rsquo;
accounts with payments in amounts proportionate to their respective beneficial interests in the registered global security as shown on
the records of the depositary. We also expect that standing customer instructions and customary practices will govern payments by participants
to owners of beneficial interests in the registered global security held through the participants, as is now the case with the securities
held for the accounts of customers in bearer form or registered in &ldquo;street name.&rdquo; We also expect that any of these payments
will be the responsibility of the participants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the depositary for any debt securities represented by a registered global security is at any time unwilling or unable to continue as
depositary or stops being a clearing agency registered under the Exchange Act, we will appoint an eligible successor depositary. If we
fail to appoint an eligible successor depositary within 90 days, we will issue the debt securities in definitive form in exchange for
the registered global security. In addition, we may at any time and in our sole discretion decide not to have any of the debt securities
of a series represented by one or more registered global securities. In that event, we will issue debt securities of the series in a
definitive form in exchange for all of the registered global securities representing the debt securities. The trustee will register any
debt securities issued in definitive form in exchange for a registered global security in the name or names as the depositary, based
upon instructions from its participants, shall instruct the trustee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Information
Concerning the Debenture Trustee</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
debenture trustee, other than during the occurrence and continuance of an event of default under the applicable indenture, undertakes
to perform only those duties as are specifically set forth in the applicable indenture. Upon an event of default under an indenture,
the debenture trustee under such indenture must use the same degree of care as a prudent person would exercise or use in the conduct
of his or her own affairs. Subject to this provision, the debenture trustee is under no obligation to exercise any of the powers given
it by the indentures at the request of any holder of debt securities unless it is offered reasonable security and indemnity against the
costs, expenses, and liabilities that it might incur.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Payment
and Paying Agents</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
we other indicate in the applicable prospectus supplement, information or document incorporated by reference, related free writing prospectus,
or other offering materials, we will make payment of the interest on any debt securities on any interest payment date to the person in
whose name the debt securities, or one or more predecessor securities, are registered at the close of business on the regular record
date for the interest.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will pay principal of and any premium and interest on the debt securities of a particular series at the office of the paying agents designated
by us, except that unless we otherwise indicate in the applicable prospectus supplement, information or document incorporated by reference,
related free writing prospectus, or other offering materials, we will make interest payments by check which we will mail to the holder.
Unless we otherwise indicate in a prospectus supplement, information or document incorporated by reference, related free writing prospectus,
or other offering materials, as applicable, we will designate the corporate trust office of the debenture trustee as our sole paying
agent for payments with respect to debt securities of each series. We will name in the applicable prospectus supplement, information
or document incorporated by reference, related free writing prospectus, or other offering materials, any other paying agents that we
initially designate for the debt securities of a particular series. We will maintain a paying agent in each place of payment for the
debt securities of a particular series.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
money we pay to a paying agent or the debenture trustee for the payment of the principal of or any premium or interest on any debt securities
which remains unclaimed at the end of two years after such principal, premium, or interest has become due and payable will be repaid
to us, and the holder of the security thereafter may look only to us for payment thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Governing
Law</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
indentures and the debt securities will be governed by and construed in accordance with the laws of the State of New York, except to
the extent that the Trust Indenture Act is applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Subordination
of Subordinated Debt Securities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
obligations pursuant to any subordinated debt securities will be unsecured and will be subordinate and junior in priority of payment
to certain of our other indebtedness to the extent described in a prospectus supplement, information or document incorporated by reference,
related free writing prospectus, or other offering materials, as applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Outstanding
Debt Securities</B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of April 8, 2024, we had the following debt securities outstanding:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/862861/000162828024003865/ex10101_icgjanonefourthame.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Fourth Amendment to</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> Secured Revolving Line
    of Credit Promissory Note, amendment dated February 7, 2024, issued to Isaac Capital Group LLC [filed as Exhibit 10.101
    to the Company&rsquo;s Form 10-K filed April 8, 2024 (File No. 0-19621) and incorporated herein by reference]. </FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/862861/000162828024003865/ex10102_livejanonefirstame.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of First Amendment to Promissory Note in favor of Live Ventures Incorporated, dated February 7, 2024 [filed as Exhibit
    10.102 to the Company&rsquo;s Form 10-K filed April 8, 2024 (File No. 0-19621) and incorporated herein by reference].</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/862861/000162828024003865/ex10103_janonepromissoryno.htm" STYLE="-sec-extract: exhibit">Form
    of Promissory Note in favor of Isaac Capital Group LLC, dated February 7, 2024 [filed as Exhibit 10.103 to the Company&rsquo;s Form
    10-K filed April 8, 2024 (File No. 0-19621) and incorporated herein by reference].</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/862861/000162828024003865/ex10104_janonepromissoryno.htm" STYLE="-sec-extract: exhibit">Form
    of Promissory Note in favor of Live Ventures Incorporated, dated February 7, 2024 [filed as Exhibit 10.104 to the Company&rsquo;s
    Form 10-K filed April 8, 2024 (File No. 0-19621) and incorporated herein by reference].</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/862861/000162828024015260/ex10106_janonepromissoryno.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Promissory Note in favor of Jon Isaac, dated March 4, 2024 [filed as Exhibit 10.106 to the Company&rsquo;s Form 10-K filed
    April 8, 2024 (File No. 0-19621) and incorporated herein by reference].</FONT></A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="Su_007"></A>DESCRIPTION
OF WARRANTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>General</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may issue warrants to purchase debt securities, shares of our Common Stock, shares of our Preferred Stock, or any combination of these
securities. We may issue the warrants independently or together with any underlying securities, and the warrants may be attached or separate
from the underlying securities. We may also issue a series of warrants under a separate warrant agreement to be entered into between
a warrant agent and us. The warrant agent will act solely as our agent in connection with the warrants of such series and will not assume
any obligation or relationship of agency for or with holders or beneficial owners of warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following description is a summary of selected provisions relating to the warrants that we may issue. The summary is not complete. When
warrants are offered in the future, a prospectus supplement, information, or document incorporated by reference, related free writing
prospectus, or other offering materials, as applicable, will explain the particular terms of those securities and the extent to which
these general provisions may apply. The specific terms of the warrants as described in the applicable prospectus supplement, information
or document incorporated by reference, related free writing prospectus, or other offering materials will supplement and, if applicable,
may modify or replace the general terms described in this section.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
summary and any description of warrants in the applicable prospectus supplement, information or document incorporated by reference, related
free writing prospectus, or other offering materials is subject to and is qualified in its entirety by reference to all the provisions
of any specific warrant document or agreement, which we will file with the SEC for incorporation by reference into this prospectus. See
&ldquo;Available Information&rdquo; and &ldquo;Incorporation of Certain Information by Reference&rdquo; for information on how to obtain
a copy of a warrant document when it is filed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
we refer to a series of warrants, we mean all warrants issued as part of the same series under the applicable warrant agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Terms</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
applicable prospectus supplement, information or document incorporated by reference, related free writing prospectus, or other offering
materials may describe the terms of any warrants that we may offer, including but not limited to the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    title of the warrants;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    total number of warrants;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    price or prices at which the warrants will be issued;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    currency or currencies that investors may use to pay for the warrants;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    date on which the right to exercise the warrants will commence and the date on which the right will expire;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    the warrants will be issued in registered form or bearer form;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">information
    with respect to book-entry procedures, if any;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    applicable, the minimum or maximum amount of warrants that may be exercised at any one time;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    applicable, the designation and terms of the underlying securities with which the warrants are issued and the number of warrants
    issued with each underlying security;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    applicable, the date on and after which the warrants and the related underlying securities will be separately transferable;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    applicable, a discussion of material United States federal income tax considerations;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    applicable, the terms of redemption of the warrants;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    identity of the warrant agent, if any;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    procedures and conditions relating to the exercise of the warrants; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    other terms of the warrants, including terms, procedures, and limitations relating to the exchange and exercise of the warrants.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Warrant
Agreements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may issue the warrants in one or more series under one or more warrant agreements, each to be entered into between a bank, trust company,
or other financial institution as warrant agent, and us. We may add, replace, or terminate warrant agents from time to time. We may also
choose to act as our own warrant agent or may choose one of our subsidiaries to do so.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
warrant agent under a warrant agreement will act solely as our agent in connection with the warrants issued under that agreement. The
warrant agent will not assume any obligation or relationship of agency or trust for or with any holders of those warrants. Any holder
of warrants may, without the consent of any other person, enforce by appropriate legal action, on its own behalf, its right to exercise
those warrants in accordance with their terms. Until the warrant is properly exercised, no holder of any warrant will be entitled to
any rights of a holder of the warrant property purchasable upon exercise of the warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Form,
Exchange, and Transfer</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may issue the warrants in registered form or bearer form. Warrants issued in registered form, <I>i.e.</I>, book-entry form, will be represented
by a global security registered in the name of a depository, which will be the holder of all the warrants represented by the global security.
Those investors who own beneficial interests in a global warrant will do so through participants in the depository&rsquo;s system, and
the rights of these indirect owners will be governed solely by the applicable procedures of the depository and its participants. In addition,
we may issue warrants in non-global form, <I>i.e.</I>, bearer form. If any warrants are issued in non-global form, warrant certificates
may be exchanged for new warrant certificates of different denominations, and holders may exchange, transfer, or exercise their warrants
at the warrant agent&rsquo;s office or any other office indicated in the applicable prospectus supplement, information or document incorporated
by reference, related free writing prospectus, or other offering materials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the exercise of their warrants, holders of warrants exercisable for debt securities will not have any of the rights of holders of
the debt securities purchasable upon such exercise and will not be entitled to payments of principal (or premium, if any) or interest,
if any, on the debt securities purchasable upon such exercise. Prior to the exercise of their warrants, holders of warrants exercisable
for shares of Common Stock or shares of Preferred Stock will not have any rights of holders of the shares of Common Stock or the shares
of Preferred Stock purchasable upon such exercise and will not be entitled to dividend payments, if any, or voting rights of the shares
of Common Stock or the shares of Preferred Stock purchasable upon such exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exercise
of Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
warrant will entitle the holder to purchase for cash an amount of securities at an exercise price that will be stated in, or that will
be determinable as described in, the applicable prospectus supplement, information or document incorporated by reference, related free
writing prospectus, or other offering materials. Warrants may be exercised at any time from the initial exercise date and time through
and including the close of business on the expiration date set forth in the applicable prospectus supplement, information or document
incorporated by reference, related free writing prospectus, or other offering materials. After the close of business on the expiration
date, unexercised warrants will become void. Warrants may be redeemed as set forth in the applicable prospectus supplement, information
or document incorporated by reference, related free writing prospectus, or other offering materials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
may be exercised as set forth in the applicable prospectus supplement, information or document incorporated by reference, related free
writing prospectus, or other offering materials. Upon receipt of payment and the warrant certificate properly completed and duly executed
at the corporate trust office of the warrant agent or any other office indicated in the prospectus supplement, information or document
incorporated by reference, related free writing prospectus, or other offering materials, as applicable, we will forward, as soon as practicable,
the securities purchasable upon such exercise. If less than all of the warrants represented by such warrant certificate are exercised,
a new warrant certificate will be issued for the remaining warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="Su_008"></A>DESCRIPTION
OF RIGHTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may issue rights to purchase our debt securities, shares of our Common Stock, or shares of our Preferred Stock. These rights may be issued
independently or together with any other security offered hereby and may or may not be transferable by the stockholder receiving the
rights in such offering. In connection with any offering of such rights, we may enter into a standby arrangement with one or more underwriters
or other purchasers pursuant to which the underwriters or other purchasers may be required to purchase any securities remaining unsubscribed
for after such offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
series of rights will be issued under a separate rights agreement that we will enter with a bank or trust company, as rights agent, all
of which will be set forth in the relevant offering material. The rights agent will act solely as our agent in connection with the certificates
relating to the rights and will not assume any obligation or relationship of agency or trust with any holders of rights certificates
or beneficial owners of rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following description is a summary of selected provisions relating to rights that we may offer. The summary is not complete. When rights
are offered in the future, a prospectus supplement, information, or document incorporated by reference, related free writing prospectus,
or other offering materials, as applicable, will explain the particular terms of those securities and the extent to which these general
provisions may apply. The specific terms of the rights as described in a prospectus supplement, information or document incorporated
by reference, related free writing prospectus, or other offering materials, as applicable, will supplement and, if applicable, may modify
or replace the general terms described in this section.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
summary and any description of rights in the applicable prospectus supplement, information or document incorporated by reference, related
free writing prospectus, or other offering materials is subject to and is qualified in its entirety by reference to the rights agreement
and the rights certificates. We will file each of these documents, as applicable, with the SEC and incorporate them by reference as an
exhibit to the Registration Statement of which this prospectus is a part on or before the time we issue a series of rights. See &ldquo;Available
Information&rdquo; and &ldquo;Incorporation of Certain Documents by Reference&rdquo; above for information on how to obtain a copy of
a document when it is filed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
applicable prospectus supplement, information or document incorporated by reference, related free writing prospectus, or other offering
materials may describe:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    the case of a distribution of rights to our stockholders, the date of determining the stockholders entitled to the rights distribution;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    the case of a distribution of rights to our stockholders, the number of rights issued or to be issued to each stockholder;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    exercise price payable for the underlying debt securities, shares of our Common Stock or shares of our Preferred Stock upon the exercise
    of the rights;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    number and terms of the underlying debt securities, shares of our Common Stock or shares of our Preferred Stock that may be purchased
    per each right;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    extent to which the rights are transferable;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    date on which the holder&rsquo;s ability to exercise the rights shall commence, and the date on which the rights shall expire;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    extent to which the rights may include an over-subscription privilege with respect to unsubscribed securities;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    applicable, the material terms of any standby underwriting or purchase arrangement entered into by us in connection with the offering
    of such rights; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    other terms of the rights, including, but not limited to, the terms, procedures, conditions, and limitations relating to the exchange
    and exercise of the rights.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
provisions described in this section, as well as those described under &ldquo;&mdash;Description of Debt Securities&rdquo; and &ldquo;&mdash;Description
of Capital Stock&rdquo; above, will apply, as applicable, to any rights we offer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="Su_009"></A>DESCRIPTION
OF UNITS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>General</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may issue units composed of (i) our debt securities, (ii) shares of our Common Stock, (iii) shares of our Preferred Stock, (iv) warrants
to purchase our debt securities, shares of our Common Stock, or shares of our Preferred Stock or any combination of these securities,
and (v) rights to purchase our debt securities, shares of our Common Stock, or shares of our Preferred Stock in any combination. We will
issue each unit so that the holder of the unit is also the holder of each security included in the unit. As a result, the holder of a
unit will have the rights and obligations of a holder of each included security. The unit agreement under which a unit is issued may
provide that the securities included in the unit may not be held or transferred separately, at any time or at any time before a specified
date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following description is a summary of selected provisions relating to units that we may offer. The summary is not complete. When units
are offered in the future, a prospectus supplement, information, or document incorporated by reference, related free writing prospectus,
or other offering materials, as applicable, will explain the particular terms of those securities and the extent to which these general
provisions may apply. The specific terms of the units as described in a prospectus supplement, information or document incorporated by
reference, related free writing prospectus, or other offering materials, as applicable, will supplement and, if applicable, may modify
or replace the general terms described in this section.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
summary and any description of units in the applicable prospectus supplement, information or document incorporated by reference, related
free writing prospectus, or other offering materials is subject to and is qualified in its entirety by reference to the unit agreement,
collateral arrangements, and depositary arrangements, if applicable. We will file these documents with the SEC for incorporation by reference
into this prospectus, as applicable. See &ldquo;Available Information&rdquo; and &ldquo;Incorporation of Certain Information by Reference&rdquo;
for information on how to obtain a copy of a document when it is filed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
applicable prospectus supplement, information or document incorporated by reference, related free writing prospectus, or other offering
materials may describe:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    designation and terms of the units and of the securities comprising the units, including whether and under what circumstances those
    securities may be held or transferred separately;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    provisions for the issuance, payment, settlement, transfer, or exchange of the units or of the securities composing the units;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    the units will be issued in fully registered or global form; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    other terms of the units.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
applicable provisions described in this section, as well as those described under &ldquo;Description of Debt Securities,&rdquo; &ldquo;Description
of Capital Stock&rdquo; and &ldquo;Description of Warrants,&rdquo; will apply to each unit and to each security included in each unit,
respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="Su_010"></A>USE
OF PROCEEDS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise indicated in the applicable prospectus supplement, information or document incorporated by reference, related free writing
prospectus, or other offering materials, as applicable, we intend to use the net proceeds from the sale of securities for general corporate
purposes, which may include capital expenditures, working capital and general and administrative expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="Su_011"></A>PLAN
OF DISTRIBUTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may sell the securities through underwriters or dealers, through agents, directly to one or more purchasers, through a rights offering,
or otherwise. We will describe the terms of the offering of the securities in a prospectus supplement, information or document incorporated
by reference, related free writing prospectus, or other offering materials, as applicable, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    name or names of any underwriters, if any;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    purchase price of the securities and the proceeds we will receive from the sale;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    underwriting discounts and other items constituting underwriters&rsquo; compensation;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    public offering price;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    discounts or concessions allowed or reallowed or paid to dealers; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    securities exchange or market on which the securities may be listed.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Only
underwriters we name in the prospectus supplement, information or document incorporated by reference, related free writing prospectus,
or other offering materials, as applicable, are underwriters of the securities offered thereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
distribution of securities may be effected, from time to time, in one or more transactions, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">block
    transactions (which may involve crosses) and transactions on The Nasdaq Capital Market or any other organized market on which the
    securities may be traded;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">purchases
    by a broker-dealer as principal and resale by the broker-dealer for its own account pursuant to a prospectus supplement, information
    or document incorporated by reference, related free writing prospectus, or other offering materials, as applicable;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ordinary
    brokerage transactions and transactions in which a broker-dealer solicits purchasers;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">sales
    &ldquo;at the market&rdquo; to or through a market maker or into an existing trading market, on an exchange or otherwise; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">sales
    in other ways not involving market makers or established trading markets, including direct sales to purchasers.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
securities may be sold at a fixed price or prices, which may be changed, or at market prices prevailing at the time of sale, at prices
relating to the prevailing market prices, or at negotiated prices. The consideration may be cash or another form negotiated by the parties.
Agents, underwriters, or broker-dealers may be paid compensation for offering and selling the securities. That compensation may be in
the form of discounts, concessions, or commissions to be received from us or from the purchasers of the securities. Dealers and agents
participating in the distribution of the securities may be deemed to be underwriters and compensation received by them on resale of the
securities may be deemed to be underwriting discounts and commissions under the Securities Act. If such dealers or agents were deemed
to be underwriters, they may be subject to statutory liabilities under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may also make direct sales through subscription rights distributed to our existing stockholders on a pro rata basis, which may or may
not be transferable. In any distribution of subscription rights to our stockholders, if all of the underlying securities are not subscribed
for, we may then sell the unsubscribed securities directly to third parties or may engage the services of one or more underwriters, dealers,
or agents, including standby underwriters, to sell the unsubscribed securities to third parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
or all of the securities that we offer though this prospectus may be new issues of securities with no established trading market. Any
underwriters to whom we sell our securities for public offering and sale may make a market in those securities, but they will not be
obligated to do so and they may discontinue any market making at any time without notice. Accordingly, we cannot assure you of the liquidity
of, or continued trading markets for, any securities that we offer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agents
may, from time to time, solicit offers to purchase the securities. If required, we will name in the applicable prospectus supplement,
information or document incorporated by reference, related free writing prospectus or other offering materials, as applicable, any agent
involved in the offer or sale of the securities and set forth any compensation payable to the agent. Unless otherwise indicated, any
agent will be acting on a best efforts basis for the period of its appointment. Any agent selling the securities covered by this prospectus
may be deemed to be an underwriter, as that term is defined in the Securities Act, of the securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
underwriters are used in an offering, securities will be acquired by the underwriters for their own account and may be resold, from time
to time, in one or more transactions, including negotiated transactions, at a fixed public offering price, or at varying prices determined
at the time of sale, or under delayed delivery contracts or other contractual commitments. Securities may be offered to the public either
through underwriting syndicates represented by one or more managing underwriters or directly by one or more firms acting as underwriters.
If an underwriter or underwriters are used in the sale of securities, an underwriting agreement will be executed with the underwriter
or underwriters at the time an agreement for the sale is reached. The applicable prospectus supplement, information or document incorporated
by reference, related free writing prospectus, or other offering materials will set forth the managing underwriter or underwriters, as
well as any other underwriter or underwriters, with respect to a particular underwritten offering of securities, and will set forth the
terms of the transactions, including compensation of the underwriters and dealers and the public offering price, if applicable. The prospectus,
and the applicable prospectus supplement, information or document incorporated by reference, related free writing prospectus, or other
offering materials will be used by the underwriters to resell the securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a dealer is used in the sale of the securities, we or an underwriter will sell the securities to the dealer, as principal. The dealer
may then resell the securities to the public at varying prices to be determined by the dealer at the time of resale. To the extent required,
we will set forth in the prospectus supplement, information or document incorporated by reference, related free writing prospectus, or
other offering materials, as applicable, the name of the dealer and the terms of the transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may directly solicit offers to purchase the securities and may make sales of securities directly to institutional investors or others.
These persons may be deemed to be underwriters within the meaning of the Securities Act with respect to any resale of the securities.
To the extent required, the prospectus supplement, information or document incorporated by reference, related free writing prospectus,
or other offering materials, as applicable, will describe the terms of any such sales, including the terms of any bidding or auction
process, if used.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agents,
underwriters, and dealers may be entitled under agreements that may be entered into with us to indemnification against specified liabilities,
including liabilities incurred under the Securities Act, or to contribution to payments they may be required to make in respect of such
liabilities. If required, the prospectus supplement, information or document incorporated by reference, related free writing prospectus,
or other offering materials, as applicable, will describe the terms and conditions of such indemnification or contribution. Some of the
agents, underwriters or dealers, or their affiliates may be customers of, engage in transactions with or perform services for us, our
subsidiaries, or affiliates in the ordinary course of business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the securities laws of some states, the securities offered by this prospectus may be sold in those states only through registered or
licensed brokers or dealers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
person participating in the distribution of Common Stock registered under the Registration Statement that includes this prospectus will
be subject to applicable provisions of the Exchange Act, and the applicable SEC rules and regulations, including, among others, Regulation
M, which may limit the timing of purchases and sales of any of our Common Stock by any such person. Furthermore, Regulation M may restrict
the ability of any person engaged in the distribution of our Common Stock to engage in market-making activities with respect to our Common
Stock. These restrictions may affect the marketability of our Common Stock and the ability of any person or entity to engage in market-making
activities with respect to our Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
persons participating in an offering may engage in over-allotment, stabilizing transactions, short-covering transactions, and penalty
bids in accordance with Regulation M under the Exchange Act that stabilize, maintain, or otherwise affect the price of the offered securities.
If any such activities occur, they will be described in the applicable prospectus supplement, information or document incorporated by
reference, related free writing prospectus, or other offering materials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent required, this prospectus may be amended or supplemented from time to time to describe a specific plan of distribution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
securities we offer other than shares of Common Stock will be new issues of securities with no established trading market. Any underwriters
may make a market in these securities but will not be obligated to do so and may discontinue any market making at any time without notice.
We cannot guarantee the liquidity of the trading markets for any securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="Su_012"></A>LEGAL
MATTERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise indicated in the applicable prospectus supplement, Clark Hill PLC, Los Angeles, California, will provide opinions regarding
the validity of any securities offered by this prospectus. Clark Hill PLC may also provide opinions regarding certain other matters.
The legality of the securities for any underwriters, dealers, or agents will be passed upon by counsel as may be specified in the applicable
prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="Su_013"></A>EXPERTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements of the Registrant as of and for the year ended December 30, 2023, incorporated by reference in this prospectus,
have been audited by Hudgens, LLC, an independent registered public accounting firm, as stated in its report incorporated by reference
herein, and have been incorporated in reliance upon the authority of such firm as experts in accounting and auditing. This report
on the consolidated financial statements contains an explanatory paragraph regarding the Company&rsquo;s ability to continue as a going
concern.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements of the Registrant as of and for the year ended December 31, 2022, incorporated by reference in this
prospectus, have been audited by Frazier &amp; Deeter, LLC, an independent registered public accounting firm, as stated in their report.
Such consolidated financial statements are incorporated by reference herein, and have been incorporated in reliance upon the firm given
their authority as experts in accounting and auditing. This report on the consolidated financial statements contains an explanatory paragraph
regarding the Company&rsquo;s ability to continue as a going concern.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PART</B>&nbsp;
<B>II. INFORMATION NOT REQUIRED IN THE PROSPECTUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ITEM
14. OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth all expenses to be paid by the Registrant in connection with this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">Fee</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 84%; text-align: left">SEC registration fee</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">14,750</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">FINRA filing fee</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Nasdaq listing fee</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Printing</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Legal fees and expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">22,500</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Accounting fees and expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Transfer agent and registrar fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Miscellaneous</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font-weight: bold">Total</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <B>*</B></FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
Fees and expenses (other than the SEC registration fee to be paid upon filing of this registration statement) will depend on the securities
offered, the number of issuances and the nature of the offerings, and cannot be estimated at this time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ITEM
15. INDEMNIFICATION OF DIRECTORS AND OFFICERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nevada
Revised Statutes (&ldquo;NRS&rdquo;) 78.138(7) provides that, subject to limited statutory exceptions and unless the Articles of Incorporation
or an amendment thereto (in each case filed on or after October 1, 2003) provide for greater individual liability, a director or officer
is not individually liable to a corporation or its stockholders or creditors for any damages as a result of any act or failure to act
in his or her capacity as a director or officer unless determined that the presumption that directors and officers are presumed to act
in good faith, on an informed basis and with a view to the interest of the corporation has been rebutted and it is proven that: (i) the
act or failure to act constituted a breach of his or her fiduciary duties as a director or officer and (ii) the breach of those duties
involved intentional misconduct, fraud, or a knowing violation of law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NRS
78.7502(1) provides that a corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened,
pending or completed action, suit, or proceeding, whether civil, criminal, administrative, or investigative (other than an action by
or in the right of the corporation), by reason of the fact that the person is or was a director, officer, employee, or agent of the corporation,
or is or was serving at the request of the corporation as a director, officer, employee, or agent of another corporation, partnership,
joint venture, trust, or other enterprise, against expenses, including attorneys&rsquo; fees, judgments, fines, and amounts paid in settlement
actually and reasonably incurred by the person in connection with the action, suit, or proceeding if the person (i) is not liable pursuant
to NRS 78.138 or (ii) acted in good faith and in a manner which he or she reasonably believed to be in or not opposed to the best interests
of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe the conduct was unlawful.
NRS 78.7502(2) provides that a corporation may indemnify any person who was or is a party or is threatened to be made a party to any
threatened, pending, or completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason of
the fact that the person is or was a director, officer, employee, or agent of the corporation, or is or was serving at the request of
the corporation as a director, officer, employee, or agent of another corporation, partnership, joint venture, trust, or other enterprise
against expenses, including amounts paid in settlement and attorneys&rsquo; fees actually and reasonably incurred by the person in connection
with the defense or settlement of the action or suit if the person (a) is not liable pursuant to NRS 78.138 or (b) acted in good faith
and in a manner which he or she reasonably believed to be in or not opposed to the best interests of the corporation. Any discretionary
indemnification pursuant to NRS 78.7502, unless ordered by a court or advanced pursuant to NRS 78.751(2), may be made by the corporation
only as authorized in each specific case upon a determination that the indemnification of a director, officer, employee, or agent of
a corporation is proper under the circumstances. Such determination must be made by (x) the stockholders, (y) the board of directors,
by majority vote of a quorum consisting of directors who were not parties to the action, suit, or proceeding, or (z) independent legal
counsel, in a written opinion, if (1)&ensp;a majority vote of a quorum consisting of directors who were not parties to the action, suit,
or proceeding so orders or (2) a quorum consisting of directors who were not parties to the action, suit, or proceeding cannot be obtained.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
termination of any action, suit, or proceeding by judgment, order, settlement, conviction, or upon a plea of nolo contendere or its equivalent,
does not, of itself, create a presumption that the person is liable pursuant to NRS 78.138 or did not act in good faith and in a manner
that he or she reasonably believed to be in or not opposed to the best interests of the corporation or that, with respect to any criminal
action or proceeding, he or she had reasonable cause to believe that the conduct was unlawful.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NRS
78.7502(2)(b) provides that indemnification may not be made for any claim, issue, or matter as to which such a person has been adjudged
by a court of competent jurisdiction, after exhaustion of all appeals therefrom, to be liable to the corporation or for amounts paid
in settlement to the corporation, unless and only to the extent that the court in which the action or suit was brought or other court
of competent jurisdiction determines upon application that in view of all the circumstances of the case, the person is fairly and reasonably
entitled to indemnity for such expenses as the court deems proper.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NRS
78.751(1), requiring mandatory indemnification of officers, directors, employees, and agents, provides that a corporation shall indemnify
any person in such a role to the extent that the person is successful on the merits or otherwise in defense of: (a)&ensp;any threatened,
pending or completed action, suit, or proceeding, whether civil, criminal, administrative or investigative, including, without limitation,
an action by or in the right of the corporation, by reason of the fact that the person is or was a director, officer, employee, or agent
of the corporation, or is or was serving at the request of the corporation as a director, officer, employee, or agent of another corporation,
partnership, joint venture, trust, or other enterprise or (b)&ensp;any claim, issue, or matter therein, against expenses actually and
reasonably incurred by the person in connection with defending the action, including, without limitation, attorney&rsquo;s fees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NRS
78.751(2) provides that, unless otherwise restricted by the corporation&rsquo;s articles of incorporation or bylaws, or an agreement
made by the corporation, the corporation may pay expenses of officers and directors incurred in defending a civil or criminal action,
suit, or proceeding as they are incurred and in advance of the final disposition of the action, suit, or proceeding, upon receipt of
an undertaking by or on behalf of the director or officer to repay the amount if it is ultimately determined by a court of competent
jurisdiction that the director or officer was not entitled to be indemnified by the corporation. The articles of incorporation, the bylaws,
or an agreement made by the corporation may require the corporation to pay such expenses upon receipt of such an undertaking.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 52; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the NRS, the indemnification pursuant to NRS 78.7502 and advancement of expenses authorized in or ordered by a court pursuant to NRS
78.751:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Does
    not exclude any other rights to which a person seeking indemnification or advancement of expenses may be entitled under the articles
    of incorporation or any bylaw, agreement, vote of stockholders or disinterested directors or otherwise, for either an action in the
    person&rsquo;s official capacity or an action in another capacity while holding office, except that indemnification, unless ordered
    by a court pursuant to NRS 78.7502 or for the advancement of expenses made pursuant to NRS 78.751(2), may not be made to or on behalf
    of any director or officer finally adjudged by a court of competent jurisdiction, after exhaustion of any appeals taken therefrom,
    to be liable for intentional misconduct, fraud or a knowing violation of the law, and such misconduct, fraud or violation was material
    to the cause of action; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Continues
    for a person who has ceased to be a director, officer, employee, or agent and inures to the benefit of the heirs, executors, and
    administrators of such a person.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
the articles of incorporation, the bylaws, or an agreement made by a corporation provide otherwise, if a person is entitled to indemnification
or the advancement of expenses from the corporation and any other person, the corporation is the primary obligor with respect to such
indemnification or advancement. A right to indemnification or to advancement of expenses arising under a provision of the articles of
incorporation or any bylaw is not eliminated or impaired by an amendment to such provision after the occurrence of the act or omission
that is the subject of the civil, criminal, administrative or investigative action, suit, or proceeding for which indemnification or
advancement of expenses is sought, unless the provision in effect at the time of such act or omission explicitly authorizes such elimination
or impairment after such act or omission has occurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s Articles of Incorporation provide that, to the fullest extent permitted under the NRS (including, without limitation,
to the fullest extent permitted under NRS 78.7502 and 78.751(3)) and other applicable law, the Company shall indemnify its directors
and officers in their respective capacities as such. The Company&rsquo;s Articles of Incorporation further provide that the liability
of its directors and officers shall be eliminated or limited to the fullest extent permitted by the NRS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Registrant intends to maintain insurance on behalf of the Registrant and any person who is or was a director or officer against any loss
arising from any claim asserted against him or her and incurred by him or her in that capacity, subject to certain exclusions and limits
of the amount of coverage.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ITEM
16. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Exhibits</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
    No.</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; width: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Underwriting Agreement with respect to Debt Securities</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Underwriting Agreement with respect to Common Stock</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.3*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Underwriting Agreement with respect to Preferred Stock</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.4*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Underwriting Agreement with respect to Warrants</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.5*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Underwriting Agreement with respect to Units</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/862861/000168316818000651/arca_8k-ex0303.htm" STYLE="-sec-extract: exhibit">Articles of Incorporation of Appliance Recycling Centers of America, Inc. (incorporated by reference to Exhibit 3.3 of the Company&rsquo;s Current Report on Form 8-K filed with the SEC on March 13, 2018)</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/862861/000168316818000651/arca_8k-ex0301.htm" STYLE="-sec-extract: exhibit">Articles of Conversion (incorporated by reference to Exhibit 3.1 of the Company&rsquo;s Current Report on Form 8-K filed with the SEC on March 13, 2018)</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/862861/000168316818000651/arca_8k-ex0302.htm" STYLE="-sec-extract: exhibit">Articles of Conversion (incorporated by reference to Exhibit 3.2 of the Company&rsquo;s Current Report on Form 8-K filed with the SEC on March 13, 2018)</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/862861/000168316818002311/arca_10q-ex0301.htm" STYLE="-sec-extract: exhibit">Certificate of Correction to Articles of Incorporation (incorporated by reference to Exhibit 3.1 of the Company&rsquo;s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2018)</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/862861/000168316819001137/arca_ex0301.htm" STYLE="-sec-extract: exhibit">Certificate of Change (incorporated by reference to Exhibit 3.1 of the Company&rsquo;s Current Report on Form 8-K filed with the SEC on April 22, 2019)</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.6</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/862861/000168316819001983/arca_8k-ex0307.htm" STYLE="-sec-extract: exhibit">Certificate of Correction to Articles of Incorporation of Appliance Recycling Centers of America, Inc. (incorporated by reference to Exhibit 3.7 of the Company&rsquo;s Current Report on Form 8-K filed with the SEC on June 24, 2019)</A></FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.7</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/862861/000168316819001983/arca_8k-ex0308.htm" STYLE="-sec-extract: exhibit">Certificate of Designation of Powers, Preferences, and Rights of Series A-1 Convertible Preferred Stock of JanOne Inc. (formerly known as Appliance Recycling Centers of America, Inc.) (incorporated by reference to Exhibit 3.8 of the Company&rsquo;s Current Report on Form 8-K filed with the SEC on June 24, 2019)</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.8</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/862861/000168316819002925/janone_ex0309.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Articles of Incorporation of JanOne Inc. (the Name Change Subsidiary), filed with the Secretary of State of the State of Nevada on September 6, 2019 (incorporated by reference to Exhibit 3.9 of the Company&rsquo;s Current Report on Form 8-K filed with the SEC on September 13, 2019)</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.9</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/862861/000168316819002925/janone_ex0310.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Articles of Merger for JanOne Inc. into Appliance Recycling Centers of America, Inc., filed with the Secretary of the State of Nevada on September 9, 2019, and effective on September 10, 2019 (incorporated by reference to Exhibit 3.10 of the Company&rsquo;s Current Report on Form 8-K filed with the SEC on September 13, 2019)</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.10</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/862861/000168316820003334/janone_8k-ex0308a.htm" STYLE="-sec-extract: exhibit">Amended and Restated Certificate of Designation for the Preferences, Rights, and Limitations of the Series A-1 Convertible Preferred Stock of JanOne Inc., dated October 1, 2020 (incorporated by reference to Exhibit 3.8(a) of the Company&rsquo;s Current Report on Form 8-K filed with the SEC on October 2, 2020)</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.11</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/862861/000168316818000651/arca_8k-ex0304.htm" STYLE="-sec-extract: exhibit">Bylaws of Appliance Recycling Centers of America, Inc. (incorporated by reference to Exhibit 3.4 of the Company&rsquo;s Current Report on Form 8-K filed with the SEC on March 13, 2018)</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.12</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/862861/000168316818003829/arca_8k-ex0301.htm" STYLE="-sec-extract: exhibit">First Amendment to Bylaws of Appliance Recycling Centers of America, Inc. (incorporated by reference to Exhibit 3.1 of the Company&rsquo;s Current Report on Form 8-K filed with the SEC on December 31, 2018)</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1^</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex4-1.htm">Form of Indenture with respect to Debt Securities</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/862861/000156459020015355/jan-ex42_109.htm" STYLE="-sec-extract: exhibit">Form of Specimen Common Stock Certificate (incorporated by reference to Exhibit 4.2 of JanOne Inc.&rsquo;s Annual Report on Form 10-K for the fiscal year ended December 28, 2019, filed with the SEC on April 6, 2020)</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Specimen Preferred Stock Certificate</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Certificate of Designation of Preferred Stock</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Warrant Agreement (including Warrant Certificate) with respect to Warrants to purchase Debt Securities</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Warrant Agreement (including Warrant Certificate) with respect to Warrants to purchase Common Stock</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Warrant Agreement (including Warrant Certificate) with respect to Warrants to purchase Preferred Stock</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Warrant Agreement (including Warrant Certificate) with respect to Warrants to purchase Units</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Unit Agreement (including Unit Certificate)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Rights Agreement (including Form of Rights Certificate)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1^</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex5-1.htm">Opinion of Clark Hill PLC</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1^</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex5-1.htm">Consent of Clark Hill PLC (included in Exhibit 5.1)</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2^</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex23-2.htm">Consent of Hudgens, LLC</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.3^</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex23-3.htm">Consent of Frazier &amp; Deeter, LLC</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.1^</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#Su_001">Powers of Attorney (included on applicable signature page to this registration statement)</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25.1**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    T-1 Statement of Eligibility under Trust Indenture Act of 1939 of Debt Trustee (to be filed prior to any issuance of Senior Debt
    Securities)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25.2**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    T-1 Statement of Eligibility under Trust Indenture Act of 1939 of Debt Trustee (to be filed prior to any issuance of Subordinated
    Debt Securities)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">107^</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex107.htm">Filing Fee Table</A></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">^</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
    herewith</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    be filed as an amendment or as an exhibit to a document filed under the Exchange Act and incorporated by reference into this registration
    statement.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">**
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    be filed in accordance with the requirements of Section 305(b)(2) of the Trust Indenture Act of 1939.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ITEM
17. UNDERTAKINGS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned Registrant hereby undertakes:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement: </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    include any prospectus required by Section 10(a)(3) of the Securities Act of 1933; </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
                                            reflect in the prospectus any facts or events arising after the effective date of the registration
                                            statement (or the most recent post-effective amendment thereof) which, individually or in
                                            the aggregate, represent a fundamental change in the information set forth in the registration
                                            statement. Notwithstanding the foregoing, any increase or decrease in volume of securities
                                            offered (if the total dollar value of securities offered would not exceed that which was
                                            registered) and any deviation from the low or high end of the estimated maximum offering
                                            range may be reflected in the form of prospectus filed with the Commission pursuant to Rule
                                            424(b) if, in the aggregate, the changes in volume and price represent no more than a 20
                                            percent change in the maximum aggregate offering price set forth in the &ldquo;Calculation
                                            of Registration Fee&rdquo; table in the effective registration statement;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    include any material information with respect to the plan of distribution not previously disclosed in the registration statement
    or any material change to such information in the registration statement;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>provided</I>,
<I>however</I>, that paragraphs (1)(i), (1)(ii) and (1)(iii) above do not apply if the information required to be included in a post-effective
amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section
13 or Section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the registration statement, or is contained
in a form of prospectus filed pursuant to Rule 424(b) that is part of the registration statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">That,
    for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed
    to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall
    be deemed to be the initial <I>bona fide</I> offering thereof.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.6pt; text-align: justify; text-indent: -16.2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the
    termination of the offering.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.6pt; text-align: justify; text-indent: -16.2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">That,
    for the purpose of determining liability under the Securities Act of 1933 to any purchaser:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
    prospectus filed by the Registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the
    date the filed prospectus was deemed part of and included in the registration statement; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
    prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5) or (b)(7) as part of a registration statement in reliance on Rule
    430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii) or (x) for the purpose of providing the information required
    by Section 10(a) of the Securities Act of 1933 shall be deemed to be part of and included in the registration statement as of the
    earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities
    in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is
    at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities
    in the registration statement to which the prospectus relates, and the offering of such securities at that time shall be deemed to
    be the initial <I>bona fide</I> offering thereof. <I>Provided, however</I>, that no statement made in a registration statement or
    prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into
    the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract
    of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus
    that was part of the registration statement or made in any such document immediately prior to such effective date.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">That,
    for the purpose of determining liability of the Registrant under the Securities Act of 1933 to any purchaser in the initial distribution
    of the securities, the undersigned Registrant undertakes that in a primary offering of securities of the undersigned Registrant pursuant
    to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities
    are offered or sold to such purchaser by means of any of the following communications, the undersigned Registrant will be a seller
    to the purchaser and will be considered to offer or sell such securities to such purchaser:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    preliminary prospectus or prospectus of the undersigned Registrant relating to the offering required to be filed pursuant to Rule
    424;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    free writing prospectus relating to the offering prepared by or on behalf of the undersigned Registrant or used or referred to by
    the undersigned Registrant;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    portion of any other free writing prospectus relating to the offering containing material information about the undersigned Registrant
    or its securities provided by or on behalf of the undersigned Registrant; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    other communication that is an offer in the offering made by the undersigned Registrant to the purchaser.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">That,
    for purposes of determining any liability under the Securities Act of 1933, each filing of the Registrant&rsquo;s annual report pursuant
    to Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan&rsquo;s
    annual report pursuant to Section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration
    statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such
    securities at that time shall be deemed to be the initial <I>bona fide</I> offering thereof.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">That,
    for purposes of determining any liability under the Securities Act, (i) the information omitted from the form of prospectus filed
    as part of the registration statement in reliance upon Rule 430A and contained in the form of prospectus filed by the registrant
    pursuant to Rule 424(b)(l) or (4) or 497(h) under the Securities Act shall be deemed to be a part of the registration statement as
    of the time it was declared effective; and (ii) each post-effective amendment that contains a form of prospectus shall be deemed
    to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall
    be deemed to be the initial bona fide offering thereof.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    file an application for the purpose of determining the eligibility of the trustee to act under subsection (a) of Section 310 of the
    Trust Indenture Act in accordance with the rules and regulations prescribed by the Commission under Section 305(b)(2) of the Trust
    Indenture Act.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">That,
    insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling
    persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion
    of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act of 1933
    and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment
    by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense
    of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities
    being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent,
    submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed
    in the Securities Act of 1933 and will be governed by the final adjudication of such issue.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="Su_001"></A>SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all
of the requirements for filing on Form S-3 and has duly caused this registration statement to be signed on its behalf by the undersigned,
thereunto duly authorized, in the City of Las Vegas, State of Nevada, on this 18<SUP>th</SUP> day of April, 2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>JANONE
    INC.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Tony Isaac</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tony
    Isaac</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President
    and Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
person whose signature appears below hereby constitutes and appoints Tony Isaac and Virland A. Johnson, and each of them, as his true
and lawful attorney-in-fact and agent with full power of substitution, for him in any and all capacities, to sign any and all amendments
to this registration statement (including post-effective amendments or any abbreviated registration statement and any amendments thereto
filed pursuant to Rule 462(b) increasing the number of securities for which registration is sought), and to file the same, with all exhibits
thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact
and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith,
as fully for all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact
and agent, or his substitute, may lawfully do or cause to be done by virtue hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities
and on the dates indicated:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Signature</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 42%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 21%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Tony Isaac</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tony
    Isaac</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President
    and Chief Executive Officer and Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    18, 2024</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Virland A. Johnson</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Virland
    A. Johnson</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    18, 2024</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Accounting and Financial Officer)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Tony Isaac</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tony
    Isaac</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    18, 2024</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Richard D. Butler, Jr.</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Richard
    D. Butler, Jr.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    18, 2024</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    John Bitar</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">John
    Bitar</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    18, 2024</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Nael Hajjar</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nael
    Hajjar</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    18, 2024</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 56; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>


























</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>ex4-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
4.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JANONE
INC.</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AND</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[INSERT
NAME OF TRUSTEE],</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TRUSTEE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INDENTURE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DATED
AS OF ___________ __, 202___</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provisions
of Trust Indenture Act of 1939 and Indenture to be dated as of ___________ __, 202___, between JANONE INC. and [INSERT NAME OF TRUSTEE],
Trustee:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cross
references between the provisions of the Trust Indenture Act of 1939 and the Indenture dated as of ___________ __, 202__ between JANONE
INC. and [INSERT NAME OF TRUSTEE], Trustee:</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    OF THE ACT</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    OF INDENTURE</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">310(a)(1)
    and (2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.8</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">310(a)(3)
    and (4)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inapplicable</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">310(a)(5)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.8</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">310(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.9(a),
    (b) and (d)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">310(b)(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.13</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">310I</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inapplicable</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">311(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.12</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">311(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.12</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">311(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inapplicable</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">312(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1
    and 4.2</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">312(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">312(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">313(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">313(b)(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inapplicable</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">313(b)(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">313(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">313(d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">314(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">314(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inapplicable</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">314(c)(1)
    and (2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.5</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">314(c)(3)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inapplicable</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">314(d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inapplicable</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">314(e)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.5</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">314(f)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inapplicable</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    OF THE ACT</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    OF INDENTURE</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">315(a),
    (c) and (d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.1</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">315(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.11</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">315(e)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.12</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">316(a)(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.9</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">316(a)(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
    required</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">316(a)(last
    sentence)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.4</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">316(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.7</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">317(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">317(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4(a)
    and (b)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">318(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.7</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 97%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
    cross-reference sheet is not part of the indenture.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 16.2pt; text-indent: -16.2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>TABLE
OF CONTENTS</U></B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
    One Definitions</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    1.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
    Terms Defined</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
    Two Securities</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    2.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forms
    Generally</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    2.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Trustee&rsquo;s Certificate of Authentication</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    2.3</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount
    Unlimited; Issuable in Series</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    2.4</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authentication
    and Delivery of Securities</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    2.5</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Execution
    of Securities</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    2.6</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate
    of Authentication</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    2.7</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Denomination
    and Date of Securities; Payments of Interest</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    2.8</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registration,
    Transfer and Exchange</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    2.9</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mutilated,
    Defaced, Destroyed, Lost and Stolen Securities</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    2.10</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cancellation
    of Securities; Destruction Thereof</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    2.11</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Temporary
    Securities</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    2.12</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Global
    Securities</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    2.13</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CUSIP
    Numbers</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
    Three Covenants of the Issuer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">7</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    3.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment
    of Principal and Interest</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">7</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    3.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Offices
    for Payments, etc.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    3.3</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Appointment
    to Fill a Vacancy in Office of Trustee</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    3.4</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paying
    Agents</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    3.5</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
    Statement to Trustee</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">8</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
    Four Securityholders&rsquo; Lists and Reports by the Issuer and the Trustee</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">8</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    4.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuer
    to Furnish Trustee Names and Addresses of Holders</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    4.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preservation
    of Information; Communications to Holders</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    4.3</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reports
    by Trustee</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    4.4</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reports
    by Issuer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
    Five Events of Default; Remedies</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">9</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    5.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Event
    of Default Defined; Acceleration of Maturity; Waiver of Default</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">9</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    5.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Collection
    of Indebtedness by Trustee; Trustee May Prove Debt</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    5.3</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Application
    of Proceeds</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    5.4</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Suits
    for Enforcement</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">11</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    5.5</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restoration
    of Rights on Abandonment of Proceedings</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    5.6</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Limitations
    on Suits by Securityholders</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    5.7</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unconditional
    Right of Securityholders to Institute Certain Suits</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    5.8</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Powers
    and Remedies Cumulative; Delay or Omission Not Waiver of Default</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    5.9</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Control
    by Securityholders</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    5.10</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Waiver
    of Past Defaults</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    5.11</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trustee
    to Give Notice of Default, But May Withhold in Certain Circumstances</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    5.12</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Right
    of Court to Require Filing of Undertaking to Pay Costs</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
    Six Concerning the Trustee</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    6.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Duties
    and Responsibilities of the Trustee; During Default; Prior to Default</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    6.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
    Rights of the Trustee</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    6.3</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trustee
    Not Responsible for Recitals, Disposition of Securities or Application of Proceeds Thereof</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    6.4</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trustee
    and Agents May Hold Securities; Collections, etc.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    6.5</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moneys
    Held by Trustee</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    6.6</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation
    and Indemnification of Trustee and Its Prior Claim</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    6.7</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Right
    of Trustee to Rely on Officers&rsquo; Certificate, etc.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    6.8</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Persons
    Eligible for Appointment as Trustee</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    6.9</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Resignation
    and Removal; Appointment of Successor Trustee</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>TABLE
OF CONTENTS&mdash;(Continued)</U></B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    6.10</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acceptance
    of Appointment by Successor Trustee</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    6.11</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Merger,
    Conversion, Consolidation or Succession to Business of Trustee</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">15</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    6.12</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preferential
    Collection of Claims Against the Issuer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
    Seven Concerning the Securityholders</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">15</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    7.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evidence
    of Action Taken by Securityholders</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">15</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    7.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proof
    of Execution of Instruments and of Holding of Securities</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">15</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    7.3</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
    to Be Treated as Owners</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">15</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    7.4</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
    Owned by Issuer Deemed Not Outstanding</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">15</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    7.5</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Right
    of Revocation of Action Taken</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">16</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
    Eight Supplemental Indentures</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">16</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    8.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supplemental
    Indentures Without Consent of Securityholders</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">16</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    8.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supplemental
    Indentures With Consent of Securityholders</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">17</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    8.3</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effect
    of Supplemental Indenture</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">17</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    8.4</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Documents
    to Be Given to Trustee</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">17</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    8.5</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notation
    on Securities in Respect of Supplemental Indentures</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">17</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
    Nine Consolidation, Merger, Sale, or Conveyance</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">17</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    9.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuer
    May Consolidate, etc., on Certain Terms</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">17</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    9.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Successor
    Corporation Substituted</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">17</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    9.3</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion
    of Counsel to Trustee</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">18</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
    Ten Satisfaction and Discharge; Indenture; Unclaimed Moneys</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">18</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    10.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Satisfaction
    and Discharge of Indenture</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">18</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    10.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Application
    by Trustee of Funds Deposited for Payment of Securities</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">18</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    10.3</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Repayment
    of Moneys Held by Paying Agent</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">19</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    10.4</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Return
    of Moneys Held by Trustee and Paying Agent Unclaimed for Two Years</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">19<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    10.5</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indemnity
    for U.S. Government Obligations</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">19</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
    Eleven Miscellaneous Provisions</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">19</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    11.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporators,
    Stockholders, Officers, and Directors of Issuer Exempt from Individual Liability</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">19</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    11.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provisions
    of Indenture for the Sole Benefit of Parties and Securityholders</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">19</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    11.3</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Successors
    and Assigns of Issuer Bound by Indenture</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">19</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    11.4</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notices
    and Demands on Issuer, Trustee and Securityholders</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">19</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    11.5</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Officers&rsquo;
    Certificates and Opinions of Counsel; Statements to Be Contained Therein</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">19</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    11.6</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payments
    Due on Saturdays, Sundays, and Holidays</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    11.7</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conflict
    of Any Provision of Indenture with Trust Indenture Act</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    11.8</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
    York Law to Govern</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    11.9</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Counterparts</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    11.10</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effect
    of Headings</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    11.11</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
    in Foreign Currencies</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
    Twelve Redemption of Securities and Sinking Funds</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    12.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Applicability
    of Article</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    12.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notice
    of Redemption; Partial Redemptions</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    12.3</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment
    of Securities Called for Redemption</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    12.4</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exclusion
    of Certain Securities from Eligibility for Selection for Redemption</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    12.5</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mandatory
    and Optional Sinking Funds</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS
INDENTURE, dated as of ___________ __, 202__, between JANONE INC. , a Nevada corporation (the &ldquo;Issuer&rdquo;), and [INSERT NAME
OF TRUSTEE], a national banking association (the &ldquo;Trustee&rdquo;),</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WITNESSETH:</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
the Issuer has duly authorized the issue from time to time of its unsecured debentures, notes, or other evidences of indebtedness to
be issued in one or more series (the &ldquo;Securities&rdquo;) up to such principal amount or amounts as may from time to time be authorized
in accordance with the terms of this Indenture, and to provide, among other things, for the authentication, delivery, and administration
thereof, the Issuer has duly authorized the execution and delivery of this Indenture; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
all things necessary to make this Indenture a valid indenture and agreement according to its terms have been done.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOW,
THEREFORE:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
consideration of the premises and the purchases of the Securities by the Holders thereof, the Issuer and the Trustee mutually covenant
and agree for the equal and proportionate benefit of the respective Holders from time to time of the Securities as follows:</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
ONE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DEFINITIONS</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
1.1 <U>Certain Terms Defined</U>. The following terms (except as otherwise expressly provided or unless the context otherwise clearly
requires) for all purposes of this Indenture and of any indenture supplemental hereto shall have the respective meanings specified in
this Section. All other terms used in this Indenture that are defined in the Trust Indenture Act or the definitions of which in the Securities
Act are referred to in the Trust Indenture Act including terms defined therein by reference to the Securities Act (except as herein otherwise
expressly provided or unless the context otherwise clearly requires) shall have the meanings assigned to such terms in the Trust Indenture
Act and in the Securities Act, as applicable, as in force at the date of this Indenture. All accounting terms used herein and not expressly
defined shall have the meanings assigned to such terms in accordance with generally accepted accounting principles, and the term &ldquo;generally
accepted accounting principles&rdquo; means such accounting principles as are generally accepted at the time of any computation. The
words &ldquo;herein,&rdquo; &ldquo;hereof,&rdquo; and &ldquo;hereunder&rdquo; and other words of similar import refer to this Indenture
as a whole and not to any particular Article, Section, or other subdivision. The terms defined in this Article have the meanings assigned
to them in this Article and include the plural as well as the singular. Words of the masculine gender shall be deemed and construed to
include correlative words of the feminine and neuter genders, and words of the neuter gender shall be deemed and construed to include
correlative words of the masculine and feminine genders.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Agent&rdquo;
means any Securities Registrar or paying agent.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Applicable
Procedures&rdquo; mean, with respect to any matter at any time, the policies and procedures of the Depository that are applicable to
such mater any such time.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Board
of Directors&rdquo; means either the Board of Directors of the Issuer or any committee of such Board of Directors duly authorized to
act hereunder.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Board
Resolution&rdquo; means a copy of a resolution certified by the secretary or an assistant secretary of the Issuer to have been duly adopted
by the Board of Directors and to be in full force and effect on the date of such certification and delivered to the Trustee.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Business
Day&rdquo; means, with respect to any Security, a day that in the city (or in any of the cities, if more than one) in which amounts are
payable, as specified in the form of such Security, is not a day on which banking institutions are authorized by law or regulation to
close or a day on which transactions in the currency in which the Securities are payable are not conducted.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Commission&rdquo;
means the Securities and Exchange Commission, as from time to time constituted, created under the Exchange Act, or if at any time after
the execution and delivery of this Indenture such Commission is not existing and performing the duties now assigned to it under the Trust
Indenture Act, then the body performing such duties on such date.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Corporate
Trust Office&rdquo; means the designated office of the Trustee at which the corporate trust business of the Trustee shall, at any particular
time, be principally administered, which office is, at the date as of which this Indenture is dated, located at _______________, _________,
___________ _______.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Depository&rdquo;
means, with respect to the Securities of any series issuable or issued in whole or in part in the form of one or more Global Securities,
the clearing agency registered under the Exchange Act specified for that purpose as contemplated by <U>Section 2.3</U>.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Dollar&rdquo;
or&rdquo;$&rdquo; means a dollar or other equivalent unit of legal tender for payment of public or private debts in the United States.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Euro&rdquo;
means the single currency of the European Union as constituted by the Treaty on European Union and as referred to in the legislative
measures of the European Union for the introduction of, changeover to or operation of the Euro in one or more member states, being in
part legislative measures to implement the European and Monetary Union as contemplated in the Treaty on European Union.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Event
of Default&rdquo; means any event or condition specified as such in <U>Section 5.1</U>.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Exchange
Act&rdquo; means the Securities Exchange Act of 1934 as it may be amended and any successor act thereto and the rules and regulations
promulgated thereunder.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Foreign
Currency&rdquo; means a currency, currency unit or composite currency, including, without limitation, the Euro or Pounds Sterling, issued
by the government of one or more countries other than the United States or by any recognized confederation or association of such governments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Global
Security&rdquo; means a security bearing the legend specified in <U>Section 2.12I</U> evidencing all or part of a series of Securities,
authenticated and delivered to the Depository for such series or its nominee, and registered in the name of such Depository or nominee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Holder,&rdquo;
&ldquo;Holder of Securities,&rdquo; &ldquo;Securityholder&rdquo; or other similar terms mean the Person in whose name such Security is
registered in the Security Register.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Indenture&rdquo;
means this instrument as originally executed and delivered or, if amended or supplemented as herein provided, as so amended or supplemented
or both, and shall include the forms and terms of particular series of Securities established as contemplated hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Issuer&rdquo;
means JanOne Inc., a Nevada corporation, and, subject to Article Nine, its successors and assigns.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Issuer
Request&rdquo; or &ldquo;Issuer Order&rdquo; means a written request or order signed in the name of the Issuer by any two of the following
officers: the chairman of the Board of Directors, its president, any vice president, its treasurer, an assistant treasurer, its secretary,
or an assistant secretary and delivered to the Trustee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Notice
of Default&rdquo; has the meaning set forth in <U>Section 5.1(d)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Officers&rsquo;
Certificate&rdquo; means a certificate signed by any two of the following officers: the chairman of the Board of Directors, the president,
any vice president, the treasurer, an assistant treasurer, the secretary, or an assistant secretary of the Issuer and delivered to the
Trustee. Each such certificate shall include the statements provided for in <U>Section 11.5</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Opinion
of Counsel&rdquo; means an opinion in writing signed by legal counsel who may be an employee of or counsel to the Issuer or other counsel
who shall be satisfactory to the Trustee. Each such opinion shall include the statements provided for in <U>Section 11.5</U>, unless
otherwise provided herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Original
issue date&rdquo; of any Security (or portion thereof) means the earlier of (a) the date of such Security or (b) the date of any Security
(or portion thereof) for which such Security was issued (directly or indirectly) on registration of transfer, exchange, or substitution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Original
Issue Discount Security&rdquo; means any Security that provides for an amount less than the principal amount thereof to be due and payable
upon a declaration of acceleration of the maturity thereof pursuant to <U>Section 5.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Outstanding&rdquo;
when used with reference to Securities, subject to the provisions of <U>Section 7.4</U>, means, as of any particular time, all Securities
authenticated and delivered by the Trustee under this Indenture, except</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Securities theretofore canceled by the Trustee or delivered to the Trustee for cancellation;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Securities, or portions thereof, for the payment or redemption of which moneys in the necessary amount shall have been deposited in trust
with the Trustee or with any paying agent (other than the Issuer) or shall have been set aside, segregated and held in trust by the Issuer
for the Holders of such Securities (if the Issuer shall act as its own paying agent), provided that if such Securities, or portions thereof,
are to be redeemed prior to the maturity thereof, notice of such redemption shall have been given as herein provided, or provision satisfactory
to the Trustee shall have been made for giving such notice; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Securities in substitution for which other Securities shall have been authenticated and delivered, or which shall have been paid, pursuant
to the terms of <U>Section 2.9</U> (except with respect to any such Security as to which proof satisfactory to the Trustee is presented
that such Security is held by a person in whose hands such Security is a legal, valid, and binding obligation of the Issuer).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
determining whether the Holders of the requisite principal amount of Outstanding Securities of any or all series have given any request,
demand, authorization, direction, notice, consent or waiver hereunder, the principal amount of an Original Issue Discount Security that
shall be deemed to be Outstanding for such purposes shall be the amount of the principal thereof that would be due and payable as of
the date of such determination upon a declaration of acceleration of the maturity thereof pursuant to <U>Section 5.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Person&rdquo;
means any individual, corporation, partnership, joint venture, association, joint stock company, trust, unincorporated organization,
limited liability company or government or any agency or political subdivision thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Place
of Payment&rdquo; means, when used with respect to the Securities of any series, the place or places where the principal of and interest
on the Securities of that series are payable as specified as contemplated by <U>Section 2.8</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Pounds
Sterling&rdquo; means pounds sterling or other equivalent unit in such coin or currency of the United Kingdom as at the time shall be
legal tender for the payment of public and private debts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Principal&rdquo;
shall, whenever used with reference to the Securities or any Security or any portion thereof, be deemed to include &ldquo;and premium,
if any.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Regulation
S&rdquo; means Regulation S under the Securities Act (including any successor regulation thereto), as it may be amended from time to
time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Responsible
Officer&rdquo; means, when used with respect to the Trustee, any officer of the Trustee within the Corporate Trust Office with direct
responsibility to administer its corporate trust matters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Securities
Act&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations of the Commission promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Security&rdquo;
or &ldquo;Securities&rdquo; has the meaning set forth in the first recital of this Indenture or, as the case may be, Securities that
have been authenticated and delivered under this Indenture.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Security
Register&rdquo; and &ldquo;Security Registrar&rdquo; have the meanings set forth in <U>Section 2.8.</U></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Trust
Indenture Act&rdquo; (except as otherwise provided in <U>Sections 8.1</U> and <U>8.2</U>) means the Trust Indenture Act of 1939 as in
force at the date as of which this Indenture was originally executed, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Trustee&rdquo;
means the Person identified as &ldquo;Trustee&rdquo; in the first paragraph hereof and, subject to the provisions of Article Six, shall
also include any successor trustee.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;U.S.&rdquo;
or &ldquo;United States&rdquo; means the United States of America.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;U.S.
Government Obligations&rdquo; means direct obligations of, or obligations guaranteed by, the United States, backed by its full faith
and credit.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Vice
president&rdquo; means, when used with respect to the Issuer, any vice president, whether or not designated by a number or a word or
words added before or after the title of &ldquo;vice president.&rdquo;</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Yield
to Maturity&rdquo; means the yield to maturity on a series of securities, calculated at the time of issuance of such series or, if applicable,
at the most recent redetermination of interest on such series and calculated in accordance with accepted financial practice.</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
TWO</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECURITIES</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
2.1 <U>Forms Generally</U>. The Securities of each series shall be substantially in such form (not inconsistent with this Indenture)
as shall be established by or pursuant to a Board Resolution and set forth in an Officers&rsquo; Certificate or in one or more indentures
supplemental hereto, in each case with such appropriate insertions, omissions, substitutions and other variations as are required or
permitted by this Indenture, and may have imprinted or otherwise reproduced thereon such legend or legends, not inconsistent with the
provisions of this Indenture, as may be required to comply with any law or with any rules or regulations pursuant thereto, or with any
rules of any securities exchange or depository therefor or to conform to general usage, all as may be determined by the officers executing
such Securities, as evidenced by their execution of the Securities.</FONT></P>

<P STYLE="text-align: justify; text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
definitive Securities shall be printed, lithographed, or engraved on steel engraved borders or may be produced in any other manner, all
as determined by the officers executing such Securities, as evidenced by their execution of such Securities.</FONT></P>

<P STYLE="text-align: justify; text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
2.2 <U>Form of Trustee</U>&rsquo;s <U>Certificate of Authentication</U>. The Trustee&rsquo;s certificate of authentication on all Securities
shall be in substantially the following form:</FONT></P>

<P STYLE="text-align: justify; text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
is one of the Securities, of the series designated herein, referred to in the within-mentioned Indenture.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TRUSTEE,</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">as Trustee</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authorized
    Signatory</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
2.3 <U>Amount Unlimited; Issuable in Series</U>. The aggregate principal amount of Securities which may be authenticated and delivered
under this Indenture is unlimited.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Securities may be issued in one or more series. There shall be established in or pursuant to a Board Resolution and, subject to Section
2.4, set forth, or determined in the manner provided, in an Officers&rsquo; Certificate, or established in one or more indentures supplemental
hereto, prior to the issuance of Securities of any series,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
the title of the Securities of the series (which shall distinguish the Securities of the series from all other Securities);</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
any limit upon the aggregate principal amount of the Securities of the series that may be authenticated and delivered under this Indenture
(except for Securities authenticated and delivered upon registration of transfer of, or in exchange for, or in lieu of, other Securities
of the series pursuant to <U>Section 2.8</U>, <U>2.9</U>, <U>2.11</U>, <U>8.5</U>, or <U>12.3</U> and except for any Securities that,
pursuant to <U>Section 2.4</U>, are deemed never to have been authenticated and delivered hereunder);</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
The date or dates on which the principal of the Securities of the series is payable or the method by which such date or dates shall be
determined;</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
the rate or rates at which the Securities of the series shall bear interest, if any, or the method by which such rate or rates shall
be determined, the date or dates from which such interest shall accrue, the interest payment dates on which such interest shall be payable
and the record dates for the determination of Holders to whom interest is payable;</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
the place or places (each, a &ldquo;Place of Payment&rdquo;) where the principal and any interest on Securities of the series shall be
payable;</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
whether any Securities of the series shall be redeemable at the option of the Issuer and, if so, the date or dates on which, the period
or periods within which, the price or prices at which, the currencies in which and the other terms and conditions upon which Securities
of the series may be redeemed, in whole or in part, at the option of the Issuer, pursuant to any sinking fund or otherwise;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
the obligation, if any, of the Issuer to redeem, purchase or repay Securities of the series pursuant to any sinking fund or analogous
provisions or at the option of a Holder thereof and the price or prices at which and the period or periods within which and the terms
and conditions upon which Securities of the series shall be redeemed, purchased, or repaid, in whole or in part, pursuant to such obligation;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
any provisions necessary to permit or facilitate the issuance, payment, or conversion of any Securities of the series that may be converted
into securities or other property other than Securities of the same series (including shares of the Issuer&rsquo;s common or preferred
stock or other securities of the Issuer) and of like tenor, whether in addition to, or in lieu of, any payment of principal or other
amount and whether at the option of the Issuer or otherwise;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
if other than denominations of $1,000 and any integral multiple thereof, the denominations in which Securities of the series shall be
issuable;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
if other than the principal amount thereof, the portion of the principal amount of Securities of the series which shall be payable upon
declaration of acceleration of the maturity thereof pursuant to <U>Section 5.1</U> or provable in bankruptcy pursuant to <U>Section 5.2
</U>;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)
any authenticating or paying agents, transfer agents or registrars or any other agents with respect to the Securities of such series;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)
the Foreign Currency in which payment of the principal of and interest on the Securities of the series shall be payable if other than
Dollars;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)
if the principal of or interest, if any, on the Securities of that series are to be payable, at the election of the Issuer or a Holder
thereof, in currencies other than that in which the Securities are stated to be payable, the currencies in which the principal of or
interest on such Securities as to which such election is made shall be payable, the period or periods within which, and the terms and
conditions upon which, such election may be made and the amount so payable (or the manner in which such amount shall be determined);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)
if the amount of payments of principal of or interest, if any, on the Securities of the series may be determined with reference to an
index, formula or other method, the manner in which such amounts shall be determined;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o)
whether the Securities of the series shall be issued in whole or in part in the form of one or more Global Securities and, in such case,
the Depository with respect to such Global Security or Securities and the circumstances under which any such Global Security may be exchanged
for Securities registered in the name of, and any transfer of such Global Security may be registered in the name of, a Person other than
such Depository or its nominee, if other than as set forth in <U>Section 2.12(b)</U> ;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(p)
whether and under what circumstances the Issuer will pay additional amounts on the Securities of the series held by a Person who is not
a U.S. person (as defined in Regulation S) in respect of any tax, assessment or governmental charge withheld or deducted and, if so,
whether the Issuer will have the option to redeem such Securities rather than pay such additional amounts;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(q)
if the Securities of such series are to be issuable in definitive form (whether upon original issue or upon exchange of a temporary Security
of such series) only upon receipt of certain certificates or other documents or satisfaction of other conditions not otherwise set forth
herein, then the form and terms of such certificates, documents, or conditions;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(r)
any proposed listing on any national or foreign securities exchange of the Securities of the series; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(s)
any other terms of the series, including provisions for payment by wire transfers, if any, or modifications of the definition of Business
Day (which terms shall not be inconsistent with the provisions of this Indenture).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
Securities of any one series shall be substantially identical except as to denomination and except as may otherwise be provided in or
pursuant to the Board Resolution referred to above and (subject to <U>Sections 2.4</U> ) set forth in the Officers&rsquo; Certificate
or in any such indenture supplemental hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
2.4 <U>Authentication and Delivery of Securities</U>. At any time and from time to time after the execution and delivery of this Indenture,
the Issuer may deliver Securities of any series executed by the Issuer to the Trustee for authentication, and the Trustee shall thereupon
authenticate and deliver such Securities, to or upon an Issuer Order, without any further action by the Issuer. In authenticating such
Securities and accepting the additional responsibilities under this Indenture in relation to such Securities the Trustee shall be entitled
to receive and (subject to <U>Section 6.1</U>) shall be fully protected in relying upon:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
any Board Resolution by or pursuant to which the form and terms of such series were established;</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
an executed supplemental indenture, if any;</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
an Officers&rsquo; Certificate setting forth the form and terms of the Securities as required pursuant to <U>Section 2.3</U> and prepared
in accordance with <U>Section 11.5;</U></FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
an Opinion of Counsel, prepared in accordance with <U>Section 11.5</U>, which shall state</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
that the form or forms and terms of such Securities have been established by or pursuant to a Board Resolution or by a supplemental indenture
as permitted by <U>Sections 2.1</U> and <U>2.3</U> in conformity with the provisions of this Indenture;</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
that such Securities, when authenticated and delivered by the Trustee and issued by the Issuer in the manner and subject to any conditions
specified in such Opinion of Counsel, will constitute valid and binding obligations of the Issuer, enforceable against the Issuer in
accordance with their terms; and</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
that all laws and requirements in respect of the execution and delivery by the Issuer of the Securities have been complied with.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Trustee shall have the right to decline to authenticate and deliver any Securities under this Section if the Trustee, being advised by
counsel, determines that such action may not lawfully be taken by the Issuer or if the Trustee in good faith by its board of directors
or board of trustees, executive committee, or a trust committee of directors, trustees or Responsible Officers shall determine that such
action would expose the Trustee to personal liability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
the provisions of <U>Section 2.3</U> and of this <U>Section 2.4</U> , if all Securities of a series are not to be originally issued at
one time, it shall not be necessary to deliver the Officers&rsquo; Certificate otherwise required pursuant to <U>Section 2.3</U> or the
Opinion of Counsel otherwise required pursuant to this <U>Section 2.4</U> at or prior to the time of authentication of each Security
of such series if such documents are delivered at or prior to the time of authentication upon original issuance of the first Security
of such series to be issued.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
the foregoing, if any Security shall have been authenticated and delivered hereunder but never issued and sold by the Issuer, and the
Issuer shall deliver such Security to the Trustee for cancellation as provided in <U>Section 2.10</U> together with a written statement
(which need not comply with <U>Section 11.5</U> and need not be accompanied by an Opinion of Counsel) stating that such Security has
never been issued and sold by the Issuer, for all purposes of this Indenture such Security shall be deemed never to have been authenticated
and delivered hereunder and shall never be entitled to the benefits of this Indenture.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
2.5 <U>Execution of Securities</U>. The Securities shall be signed on behalf of the Issuer by both the chairman of its Board of Directors,
its president, any vice president, its treasurer or an assistant treasurer and its secretary or an assistant secretary. Such signatures
may be the manual or facsimile signatures of the present or any future such officers.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
case any officer of the Issuer who shall have signed any of the Securities shall cease to be such officer before the Security so signed
shall be authenticated and delivered by the Trustee or disposed of by the Issuer, such Security nevertheless may be authenticated and
delivered or disposed of as though the person who signed such Security had not ceased to be such officer of the Issuer, and any Security
may be signed on behalf of the Issuer by such persons as, at the actual date of the execution of such Security, shall be the proper officers
of the Issuer, although at the date of the execution and delivery of this Indenture any such person was not such an officer.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
2.6 <U>Certificate of Authentication</U>. Only such Securities as shall bear thereon a certificate of authentication substantially in
the form hereinbefore recited, executed by the Trustee by the manual signature of one of its authorized signatories, shall be entitled
to the benefits of this Indenture or be valid or obligatory for any purpose. Such certificate by the Trustee upon any Security executed
by the Issuer shall be conclusive evidence that the Security so authenticated has been duly authenticated and delivered hereunder and
that the Holder is entitled to the benefits of this Indenture.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
2.7 <U>Denomination and Date of Securities; Payments of Interest</U>. The Securities of each series shall be issuable in registered form
without coupons and only in such denominations as shall be specified as contemplated by <U>Section 2.3</U>. In the absence of any such
specification with respect to the Securities of any series, the Securities of such series shall be issuable in dominations of $1,000
and any integral multiple thereof. The Securities shall be numbered, lettered, or otherwise distinguished in such manner or in accordance
with such plan as the officers of the Issuer executing the same may determine with the approval of the Trustee as evidenced by the execution
and authentication thereof.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
Security shall be dated the date of its authentication. The Securities of each series shall bear interest, if any, from the date, and
such interest shall be payable on the dates, established as contemplated by <U>Section 2.3</U>.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
person in whose name any Security on the Security Register maintained by the Issuer pursuant to <U>Section 2.8</U> of any series is registered
at the close of business on any record date applicable to a particular series with respect to any interest payment date for such series
shall be entitled to receive the interest, if any, payable on such interest payment date notwithstanding any transfer or exchange of
such Security subsequent to the record date and prior to such interest payment date, except if and to the extent the Issuer shall default
in the payment of the interest due on such interest payment date for such series, in which case such defaulted interest shall be paid
to the persons in whose names Outstanding Securities for such series are registered at the close of business on a subsequent record date
(which shall be not less than five Business Days prior to the date of payment of such defaulted interest) established by notice given
by mail by or on behalf of the Issuer to the Holders of Securities not less than 15 days preceding such subsequent record date. The term
&ldquo;record date&rdquo; as used with respect to any interest payment date (except a date for payment of defaulted interest) shall mean
the date specified as such in the terms of the Securities of any particular series or, if no such date is so specified, if such interest
payment date is the first day of a calendar month, then the fifteenth day of the next preceding calendar month or, if such interest payment
date is the fifteenth day of a calendar month, the first day of such calendar month, whether or not such record date is a Business Day.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
2.8 <U>Registration, Transfer and Exchange</U>. The Issuer will keep or cause to be kept at each office or agency to be maintained for
the purpose as provided in <U>Section 3.2</U> a register or registers for each series of Securities issued hereunder (collectively, the
&ldquo;Security Register&rdquo;) in which, subject to such reasonable regulations as it may prescribe, it will register, and will register
the transfer of, or cause the registration of transfer of, Securities as in this Article provided. Such register shall be in written
form in the English language or in any other form capable of being converted into such form within a reasonable time. At all reasonable
times such register or registers shall be open for inspection by the Trustee. Unless the Issuer appoints another entity as Security Registrar,
the Trustee is hereby appointed &ldquo;Security Registrar&rdquo; for the purpose of registering Securities and transfers of Securities
as herein provided.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
due presentation for registration of transfer of any Security of any series at any such office or agency in a Place of Payment for that
series, the Issuer shall execute, and the Trustee shall authenticate and deliver, in the name of the transferee or transferees a new
Security or Securities of the same series in authorized denominations for a like aggregate principal amount and tenor.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
Security or Securities of any series may be exchanged for a Security or Securities of the same series in other authorized denominations,
in an equal aggregate principal amount and like tenor. Securities of any series to be exchanged shall be surrendered at any office or
agency in a Place of Payment for that series, and the Issuer shall execute, and the Trustee shall authenticate and deliver, in exchange
therefor the Security or Securities of the same series which the Securityholder making the exchange shall be entitled to receive, bearing
numbers not contemporaneously outstanding. All Securities surrendered upon any exchange or transfer provided for in this Indenture shall
be promptly canceled and disposed of by the Trustee and, upon request, the Trustee will deliver a certificate of disposition thereof
to the Issuer.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
Securities presented for registration of transfer, exchange, redemption, or payment shall (if so required by the Issuer or the Trustee)
be duly endorsed by, or be accompanied by a written instrument or instruments of transfer in form satisfactory to the Issuer and the
Trustee duly executed by, the Holder or his attorney duly authorized in writing.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Issuer may require payment of a sum sufficient to cover any tax or other governmental charge that may be imposed in connection with any
exchange or registration of transfer of Securities and shall not be required to exchange or register a transfer of any Securities until
such payment is made. No service charge shall be made for any such transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
the Issuer nor the Trustee shall be required to issue, exchange, or register a transfer of (a) any Securities of any series for a period
of 15 days next preceding the first mailing of notice of redemption of Securities of such series to be redeemed or (b) any Securities
selected, called, or being called for redemption except, in the case of any Security to be redeemed in part, the portion thereof not
so to be redeemed.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
Securities issued upon any registration of transfer or exchange of Securities shall be valid obligations of the Issuer, evidencing the
same debt, and entitled to the same benefits under this Indenture, as the Securities surrendered upon such registration of transfer or
exchange.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
2.9 <U>Mutilated, Defaced, Destroyed, Lost, and Stolen Securities</U>. In case any temporary or definitive Security shall become mutilated,
defaced or be destroyed, lost or stolen, the Issuer in its discretion may execute, and upon receipt of an Issuer Order the Trustee shall
authenticate and deliver, a new Security of the same series, of like tenor and principal amount and bearing a number not contemporaneously
outstanding, in exchange and substitution for the mutilated or defaced Security, or in lieu of and substitution for the Security so destroyed,
lost or stolen. In every case, the applicant for a substitute Security shall furnish to the Issuer and to the Trustee and any agent of
the Issuer or the Trustee such security or indemnity as may be required by them to indemnify and defend and to save each of them harmless
and, in every case of destruction, loss or theft, evidence to their satisfaction of the destruction, loss or theft of such Security and
of the ownership thereof.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the issuance of any substitute Security, the Issuer may require the payment of a sum sufficient to cover any tax or other governmental
charge that may be imposed in relation thereto and any other expenses (including the fees and expenses of the Trustee) connected therewith.
In case any Security which has matured or is about to mature or has been called for redemption in full shall become mutilated or defaced
or be destroyed, lost or stolen, the Issuer may, at its sole discretion, instead of issuing a substitute Security, pay or authorize the
payment of the same (without surrender thereof except in the case of a mutilated or defaced Security), if the applicant for such payment
shall furnish to the Issuer and to the Trustee and any agent of the Issuer or the Trustee such security or indemnity as any of them may
require to save each of them harmless, and, in every case of destruction, loss or theft, the applicant shall also furnish to the Issuer
and the Trustee and any agent of the Issuer or the Trustee evidence to their satisfaction of the destruction, loss or theft of such Security
and of the ownership thereof.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Every
substitute Security of any series issued pursuant to the provisions of this Section by virtue of the fact that any such Security is destroyed,
lost or stolen shall constitute an original additional contractual obligation of the Issuer, whether or not the destroyed, lost or stolen
Security shall be at any time enforceable by anyone, and shall be entitled to all the benefits of (but shall be subject to all the limitations
of rights set forth in) this Indenture equally and proportionately with any and all other Securities of such series duly issued, authenticated
and delivered hereunder. All Securities shall be held and owned upon the express condition that, to the extent permitted by law, the
foregoing provisions are exclusive with respect to the replacement or payment of mutilated, defaced or destroyed, lost or stolen Securities
and shall preclude any and all other rights or remedies notwithstanding any law or statute existing or hereafter enacted to the contrary
with respect to the replacement or payment of negotiable instruments or other securities without their surrender.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
2.10 <U>Cancellation of Securities; Destruction Thereof</U>. All Securities surrendered for payment, redemption, registration of transfer
or exchange or for credit against any payment in respect of a sinking or analogous fund, if surrendered to the Issuer or any agent of
the Issuer or the Trustee, shall be delivered to the Trustee for cancellation or, if surrendered to the Trustee, shall be canceled by
it; and no Securities shall be issued in lieu thereof except as expressly permitted by any of the provisions of this Indenture. The Trustee
shall destroy cancelled Securities held by it and, upon request, deliver a certificate of destruction to the Issuer. If the Issuer shall
acquire any of the Securities, such acquisition shall not operate as a redemption or satisfaction of the indebtedness represented by
such Securities unless and until the same are delivered to the Trustee for cancellation.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
2.11 <U>Temporary Securities</U>. Pending the preparation of definitive Securities for any series, the Issuer may execute, and upon Issuer
Order the Trustee shall authenticate and deliver, temporary Securities for such series in form reasonably acceptable to the Trustee.
Temporary Securities of any series shall be issuable as Securities without coupons of any authorized denomination, and substantially
in the form of the definitive Securities of such series, but with such omissions, insertions and variations as may be appropriate for
temporary Securities, all as may be determined by the Issuer as evidenced by the execution of such Securities. Temporary Securities may
contain such reference to any provisions of this Indenture as may be appropriate. Every temporary Security shall be executed by the Issuer
and be authenticated by the Trustee upon the same conditions and in substantially the same manner, and with like effect, as the definitive
Securities. Without unreasonable delay, the Issuer shall execute and shall furnish definitive Securities of such series, and thereupon
temporary Securities of such series may be surrendered in exchange therefor without charge at the office or agency in each Place of Payment
for such series, and the Trustee shall authenticate and deliver in exchange for such temporary Securities of such series a like aggregate
principal amount and tenor of definitive Securities of the same series of authorized denominations. Until so exchanged, the temporary
Securities of any series shall be entitled to the same benefits under this Indenture as definitive Securities of such series.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
2.12 <U>Global Securities</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Terms of Securities</U>. A Board Resolution, a supplemental indenture hereto, or an Officer&rsquo;s Certificate shall establish whether
the Securities of a series shall be issued in whole or in part in the form of one or more Global Securities and shall name the Depositary
for such Global Security or Securities. Except as provided herein, each Global Security shall be (i) registered in the name of the Depositary
or its nominee, (ii) deposited with the Depositary or its nominee, and (iii) bear the legend indicated in Section 2.12(c).</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Transfer and Exchange</U>. Notwithstanding any provisions to the contrary contained in Section 2.08 and in addition thereto, any Global
Security shall be exchangeable pursuant to Section 2.08 for Securities registered in the names of Holders other than the Depositary for
such Security or its nominee only if (i) such Depositary notifies the Issuer that it is unwilling or unable to continue as Depositary
for such Global Security or if at any time such Depositary ceases to be a clearing agency registered under the Exchange Act, and, in
either case, the Issuer fails to appoint a successor Depositary registered as a clearing agency under the Exchange Act within 90 days
of such event, (ii) the Issuer executes and delivers to the Trustee an Officer&rsquo;s Certificate to the effect that such Global Security
shall be so exchangeable or (iii) an Event of Default with respect to the Securities represented by such Global Security shall have occurred
and be continuing. Any Global Security that is exchangeable pursuant to the preceding sentence shall be exchangeable for Securities registered
in such names as the Depositary shall direct in writing in an aggregate principal amount equal to the principal amount of the Global
Security with like tenor and terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as provided in this Section 2.12(b), a Global Security may not be transferred except as a whole by the Depositary with respect to such
Global Security to a nominee of such Depositary, by a nominee of such Depositary to such Depositary or another nominee of such Depositary
or by the Depositary, or any such nominee to a successor Depositary or a nominee of such a successor Depositary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Legend</U>. Any Global Security issued hereunder shall bear a legend in substantially the following form:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;This
Security is a Global Security within the meaning of the Indenture hereinafter referred to and is registered in the name of the Depositary
or a nominee of the Depositary. This Security is exchangeable for Securities registered in the name of a person other than the Depositary
or its nominee only in the limited circumstances described in the Indenture, and may not be transferred except as a whole by the Depositary
to a nominee of the Depositary, by a nominee of the Depositary to the Depositary or another nominee of the Depositary or by the Depositary
or any such nominee to a successor Depositary or a nominee of such a successor Depositary.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>Payments</U>. Notwithstanding the other provisions of this Indenture, payment of the principal of and interest, if any, on any Global
Security shall be made to the Holder thereof. Prior to due presentment of a Security for registration of transfer, the Issuer, the Trustee,
any Agent and any other agent of the Issuer or the Trustee may treat the Person in whose name such Security is registered as the owner
of such Security for the purpose of receiving payment of principal of and any premium and any interest on such Security and for all other
purposes whatsoever, and neither the Issuer, the Trustee nor any Agent or other agent of the Issuer or the Trustee will be affected by
notice to the contrary.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<U>Responsibility of Trustee or Agents</U>. Neither the Trustee nor any Agent shall have any responsibility for any actions taken or
not taken by the Depositary. The Issuer has entered into a letter of representations with the Depositary in the form provided by the
Depositary and the Trustee and each Agent is hereby authorized to act in accordance with such letter and the Applicable Procedures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
the Trustee nor any Agent shall have any responsibility or obligation to any beneficial owner in a Global Security, a Depositary participant
or other Person with respect to (i) the accuracy of the records of the Depositary or its nominee or of any Depositary participant with
respect to any ownership interest in the Securities, (ii) the delivery to any Depositary participant, beneficial owner or other Person
(other than the Depositary) of any notice (including any notice of redemption) or (iii) the payment of any amount under or with respect
to such Securities. All notices and communications to be given to the Holders and all payments to be made to Holders under the Securities
and this Indenture shall be given or made only to or upon the order of the registered holders (which shall be the Depositary or its nominee
in the case of the Global Security). The rights of beneficial owners in the Global Security shall be exercised only through the Depositary
subject to the Applicable Procedures. The Trustee and each Agent shall be entitled to rely and shall be fully protected in relying upon
information furnished by the Depositary with respect to its members, participants, and any beneficial owners. The Trustee and each Agent
shall be entitled to deal with the Depositary, and any nominee thereof, that is the registered holder of any Global Security for all
purposes of this Indenture relating to such Global Security (including the payment of principal, premium, if any, and interest and additional
amounts, if any, and the giving of instructions or directions by or to the owner or holder of a beneficial ownership interest in such
Global Security) as the sole Holder of such Global Security and shall have no obligations to the beneficial owners thereof. Neither the
Trustee nor any Agent shall have any responsibility or liability for any acts or omissions of the Depositary with respect to such Global
Security, for the records of any such depositary, including records in respect of beneficial ownership interests in respect of any such
Global Security, for any transactions between the Depositary and any Depositary participant or between or among the Depositary, any such
Depositary participant and/or any holder or owner of a beneficial interest in such Global Security, or for any transfers of beneficial
interests in any such Global Security.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
the foregoing, with respect to any Global Security, nothing herein shall prevent the Issuer, the Trustee, any Agent or any other agent
of the Issuer or the Trustee from giving effect to any written certification, proxy or other authorization furnished by any Depositary
(or its nominee), as a Holder, authorizing any Person to take any action which a Holder is entitled to take under this Indenture or the
Securities, including providing consents, declarations, waivers or directions, with respect to such Global Security or shall impair,
as between such Depositary and owners of beneficial interests in such Global Security, the operation of customary practices governing
the exercise of the rights of such Depositary (or its nominee) as Holder of such Global Security.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
2.13 <U>CUSIP Numbers</U>. The Company in issuing the Securities may use &ldquo;CUSIP&rdquo; numbers (if then generally in use), and
if so, the Trustee shall use &ldquo;CUSIP&rdquo; numbers in notices of redemption as a convenience to Holders; provided that any such
notice may state that no representation is made as to the correctness of such numbers either as printed on the Securities or as contained
in any notice of a redemption and that reliance may be placed only on the other identification numbers printed on the Securities, and
any such redemption shall not be affected by any defect in or omission of such numbers. The Company will promptly notify the Trustee
in writing of any change in the &ldquo;CUSIP&rdquo; numbers.</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
THREE</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">COVENANTS
OF THE ISSUER</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
3.1 <U>Payment of Principal and Interest</U>. The Issuer covenants and agrees for the benefit of each series of Securities that it will
duly and punctually pay or cause to be paid the principal of, and interest on, each of the Securities of such series at the place or
places, at the respective times and in the manner provided in such Securities.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
3.2 <U>Offices for Payments, etc.</U> So long as any of the Securities remain Outstanding, the Issuer will maintain in each Place of
Payment for any series of such Securities an office or agency (a) where the Securities of that series may be presented for payment, (b)
where the Securities of that series may be presented for registration of transfer and for exchange as in this Indenture provided and
(c) where notices and demands to or upon the Issuer in respect of the Securities of that series or of this Indenture may be served.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Issuer will give to the Trustee written notice of the location of any such office or agency and of any change of location thereof. With
respect to each series of Securities, the Issuer hereby designates the Corporate Trust Office as the initial office to be maintained
by it for each such purpose. In case the Issuer shall fail to so designate or maintain any such office or agency or shall fail to give
such notice of the location or of any change in the location thereof, presentations and demands may be made and notices may be served
at the Corporate Trust Office, and the Issuer hereby appoints the Trustee, and the Trustee accepts such appointment, as its agent to
receive all such presentations, notices and demands.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
3.3 <U>Appointment to Fill a Vacancy in Office of Trustee</U>. The Issuer, whenever necessary to avoid or fill a vacancy in the office
of Trustee, will appoint, in the manner provided in <U>Section 6.10</U> , a Trustee, so that there shall at all times be a Trustee with
respect to each series of Securities hereunder.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
3.4 <U>Paying Agents</U>. Whenever the Issuer shall appoint a paying agent other than the Trustee with respect to the Securities of any
series, it will cause such paying agent to execute and deliver to the Trustee an instrument in which such agent shall agree with the
Trustee, subject to the provisions of this Section,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
that it will hold all sums received by it as such agent for the payment of the principal of or interest on the Securities of such series
(whether such sums have been paid to it by the Issuer or by any other obligor on the Securities of such series) in trust for the benefit
of the Holders of the Securities of such series or of the Trustee, and</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
that it will give the Trustee notice of any failure by the Issuer (or by any other obligor on the Securities of such series) to make
any payment of the principal of or interest on the Securities of such series when the same shall be due and payable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Issuer will, on or prior to each due date of the principal of or interest on the Securities of such series, deposit with the paying agent
a sum sufficient to pay such principal or interest so becoming due, and (unless such paying agent is the Trustee) the Issuer will promptly
notify the Trustee of any failure to take such action.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Issuer shall act as its own paying agent with respect to the Securities of any series, then it will, on or before each due date of
the principal of or interest on the Securities of such series, set aside, segregate, and hold in trust for the benefit of the Holders
of the Securities of such series a sum sufficient to pay such principal or interest so becoming due. The Issuer will promptly notify
the Trustee of any failure to take such action.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anything
in this Section to the contrary notwithstanding, the Issuer may at any time, for the purpose of obtaining a satisfaction and discharge
with respect to one or more or all series of Securities hereunder, or for any other reason, pay or cause to be paid to the Trustee all
sums held in trust for any such series by the Issuer or any paying agent hereunder, as required by this Section, such sums to be held
by the Trustee upon the trusts herein contained.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anything
in this Section to the contrary notwithstanding, the agreement to hold sums in trust as provided in this Section is subject to the provisions
of <U>Section 10.3</U> and <U>10.4</U>.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
3.5 <U>Written Statement to Trustee</U>. The Issuer will deliver to the Trustee on or before April 30 in each year an Officers&rsquo;
Certificate as to the knowledge of each signatory of the Issuer&rsquo;s compliance with all conditions and covenants under this Indenture
(such compliance to be determined without respect to any period of grace or requirement of notice provided under the Indenture), or if
there has been a default, specifying the default and its nature and status.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
FOUR</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECURITYHOLDERS&rsquo;
LISTS AND REPORTS BY THE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ISSUER
AND THE TRUSTEE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
4.1 <U>Issuer to Furnish Trustee Names and Addresses of Holders</U>.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Trustee is not the Security Registrar, the Issuer shall cause the Security Registrar to furnish to the Trustee, in writing at least
five Business Days before each interest payment date and at such other times as the Trustee may request in writing, a list in such form
and as of such date as the Trustee may reasonably require of the names and addresses of Holders of Securities of each series.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
4.2 <U>Preservation of Information; Communications to Holders</U>.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Trustee shall preserve, in as current a form as is reasonably practicable, the names and addresses of Holders contained in the most recent
list furnished to the Trustee as provided in Section 4.1 and the names and addresses of Holders received by the Trustee in its capacity
as Security Registrar. The Trustee may destroy any list furnished to it as provided in Section 4.1 upon receipt of a new list so furnished.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
rights of Holders to communicate with other Holders with respect to their rights under this Indenture or under the Securities, and the
corresponding rights and privileges of the Trustee, shall be as provided by the Trust Indenture Act.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Every
Holder of Securities, by receiving and holding the same, agrees with the Issuer and the Trustee that neither the Issuer nor the Trustee
nor any agent of either of them shall be held accountable by reason of any disclosure of information as to names and addresses of Holders
made pursuant to the Trust Indenture Act.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
4.3 <U>Reports by Trustee</U>.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Within
60 days after each May 15 in each year in which any of the Securities are Outstanding, the Trustee shall transmit to Holders such reports
concerning the Trustee and its actions under this Indenture as may be required pursuant to the Trust Indenture Act. The Trustee shall
promptly deliver to the Issuer a copy of any report it delivers to Holders pursuant to this Section 4.3.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
copy of each such report shall, at the time of such transmission to Holders, be filed by the Trustee with each stock exchange and automated
quotation system, if any, upon which any Securities are listed, with the Commission and with the Issuer. The Issuer will notify the Trustee
when any Securities are listed on any stock exchange or automated quotation system or delisted therefrom.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
4.4 <U>Reports by Issuer</U>.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Issuer shall file with the Trustee, and transmit to the Holders, such information, documents and other reports, and such summaries thereof,
as may be required pursuant to the Trust Indenture Act. Delivery of such reports, information, and documents to the Trustee is for informational
purposes only and shall not constitute a representation or warranty as to the accuracy or completeness of the reports, information, and
documents. All required reports, information, and documents referred to in this Section 4.4 shall be deemed filed with the Trustee and
transmitted to the Holders at the time such reports, information or documents are publicly filed with the Commission via the Commission&rsquo;s
EDGAR.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
FIVE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EVENTS
OF DEFAULT; REMEDIES</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
5.1 <U>Event of Default Defined; Acceleration of Maturity; Waiver of Default</U>. &ldquo;Event of Default&rdquo; with respect to Securities
of any series wherever used herein, means each one of the following events which shall have occurred and be continuing (whatever the
reason for such Event of Default and whether it shall be voluntary or involuntary or be effected by operation of law or pursuant to any
judgment, decree or order of any court or any order, rule, or regulation of any administrative or governmental body):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
default in the payment of any instalment of interest upon any of the Securities of such series as and when the same shall become due
and payable, and continuance of such default for a period of 30 days; or</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
default in the payment of all or any part of the principal on any of the Securities of such series as and when the same shall become
due and payable either at maturity, upon redemption, by declaration or otherwise; or</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
default in the payment of any sinking fund instalment as and when the same shall become due and payable by the terms of the Securities
of such series; or</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
default in the performance, or breach, of any covenant or warranty of the Issuer in respect of the Securities of such series (other than
a covenant or warranty in respect of the Securities of such series a default in the performance or breach of which is elsewhere in this
Section specifically dealt with or that has expressly been included in this Indenture solely for the benefit of a series of Securities
other than that series) and continuance of such default or breach for a period of 90 days after there has been given, by registered or
certified mail, to the Issuer by the Trustee or to the Issuer and the Trustee by the Holders of at least 25% in aggregate principal amount
of the Outstanding Securities of all series affected thereby, a written notice specifying such default or breach and requiring it to
be remedied and stating that such notice is a &ldquo;Notice of Default&rdquo; hereunder; or</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
a court having jurisdiction in the premises shall enter a decree or order for relief in respect of the Issuer in an involuntary case
under any applicable bankruptcy, insolvency or other similar law now or hereafter in effect, or shall appoint a receiver, liquidator,
assignee, custodian, trustee or sequestrator (or similar official) of the Issuer or for any substantial part of its property or ordering
the winding up or liquidation of its affairs, and such decree or order shall remain unstayed and in effect for a period of 90 consecutive
days; or</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
the Issuer shall commence a voluntary case under any applicable bankruptcy, insolvency or other similar law now or hereafter in effect,
or consent to the entry of an order for relief in an involuntary case commenced against the Issuer under any such law, or consent to
the appointment of or taking possession by a receiver, liquidator, assignee, custodian, trustee or sequestrator (or similar official)
of the Issuer or for any substantial part of its property, or make any general assignment for the benefit of creditors; or</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
any other Event of Default provided in the supplemental indenture or Board Resolution under which such series of Securities is issued
or in the form of Security for such series.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an Event of Default with respect to a particular series of Securities described in clauses (a), (b), (c), (d) or (g) above occurs and
is continuing, then, and in each and every such case, either the Trustee or the Holders of not less than 25% in aggregate principal amount
of the Securities of such series then Outstanding hereunder (each such series voting as a separate class), by notice in writing to the
Issuer (and to the Trustee if given by Securityholders), may declare the entire principal (or, if the Securities of such series are Original
Issue Discount Securities, such portion of the principal amount as may be specified in the terms of such series) of all Securities of
such series and the interest accrued thereon, if any, to be due and payable immediately, and upon any such declaration the same shall
become immediately due and payable. If an Event of Default described in clause (e) or (f) occurs and is continuing, then, and in each
and every such case, either the Trustee or the Holders of not less than 25% in aggregate principal amount of all the Securities then
Outstanding hereunder (treated as one class), by notice in writing to the Issuer (and to the Trustee if given by Securityholders), may
declare the entire principal (or, if any Securities are Original Issue Discount Securities, such portion of the principal as may be specified
in the terms thereof) of all the Securities then Outstanding and interest accrued thereon, if any, to be due and payable immediately,
and upon any such declaration the same shall become immediately due and payable.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing provisions, however, are subject to the condition that (A) if, at any time after the principal (or, if the Securities are Original
Issue Discount Securities, such portion of the principal as may be specified in the terms thereof) of the Securities of any series (or
of all the Securities, as the case may be) shall have been so declared due and payable, and before any judgment or decree for the payment
of the moneys due shall have been obtained or entered as hereinafter provided, the Issuer shall pay or shall deposit with the Trustee
a sum sufficient to pay (i) all matured installments of interest upon all the Securities of such series (or of all the Securities, as
the case may be), (ii) the principal of any and all Securities of such series (or of all the Securities, as the case may be) which shall
have become due otherwise than by acceleration (with interest upon such principal and, to the extent that payment of such interest is
enforceable under applicable law, on overdue installments of interest, at the same rate as the rate of interest or Yield to Maturity
(in the case of Original Issue Discount Securities) specified in the Securities of such series (or at the respective rates of interest
or Yields to Maturity of all the Securities, as the case may be, to the date of such payment or deposit)) and (iii) such amount as shall
be sufficient to cover (x) reasonable compensation to the Trustee, its agents, attorneys and counsel, (y) all other expenses and liabilities
incurred, and all advances made, by the Trustee except as a result of negligence or bad faith and (z) all other amounts due to the Trustee
or any predecessor Trustee pursuant to <U>Section 6.6</U> and (B) if any and all Events of Default under the Indenture, other than the
nonpayment of the principal of Securities which shall have become due by acceleration, shall have been cured, waived or otherwise remedied
as provided herein, then and in every such case the Holders of a majority in aggregate principal amount of all the Securities of such
series, each series voting as a separate class (or of all the Securities, as the case may be, voting as a single class), then Outstanding,
by written notice to the Issuer and to the Trustee, may waive all defaults with respect to such series (or with respect to all the Securities,
as the case may be) and rescind and annul such declaration and its consequences; provided, that no such waiver or rescission and annulment
shall extend to or shall affect any subsequent default or shall impair any right consequent thereon.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
all purposes under this Indenture, if a portion of the principal of any Original Issue Discount Securities shall have been accelerated
and declared due and payable pursuant to the provisions hereof, then, from and after such declaration, unless such declaration has been
rescinded and annulled, the principal amount of such Original Issue Discount Securities shall be deemed, for all purposes hereunder,
to be such portion of the principal thereof as shall be due and payable as a result of such acceleration, and payment of such portion
of the principal thereof as shall be due and payable as a result of such acceleration, together with interest, if any, thereon and all
other amounts owing thereunder, shall constitute payment in full of such Original Issue Discount Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
5.2 <U>Collection of Indebtedness by Trustee; Trustee May Prove Debt</U>. The Issuer covenants that (a) in case default shall be made
in the payment of any instalment of interest on any of the Securities of any series when such interest shall have become due and payable,
and such default shall have continued for a period of 30 days, or (b) in case default shall be made in the payment of all or any part
of the principal of any of the Securities of any series when the same shall have become due and payable, whether upon maturity of the
Securities of such series or upon any redemption or by declaration or otherwise&mdash;then upon demand of the Trustee, the Issuer will
pay to the Trustee for the benefit of the Holders of the Securities of such series the whole amount that then shall have become due and
payable on all Securities of such series for principal or interest, as the case may be (with interest to the date of such payment upon
the overdue principal and, to the extent that payment of such interest is enforceable under applicable law, on overdue installments of
interest at the same rate as the rate of interest or Yield to Maturity (in the case of original Issue Discount Securities) specified
in the Securities of such series); and in addition thereto, such further amount as shall be sufficient to cover the costs and expenses
of collection, including reasonable compensation to the Trustee and each predecessor Trustee, their respective agents, attorneys and
counsel, and any expenses and liabilities incurred, and all advances made, by the Trustee and each predecessor Trustee except as a result
of its negligence or bad faith, and all other amounts due to the Trustee or any predecessor Trustee pursuant to <U>Section 6.6</U>.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Until
such demand is made by the Trustee, the Issuer may pay the principal of and interest on the Securities of any series to the Holders,
whether or not the principal of and interest on the Securities of such series be overdue.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
case the Issuer shall fail forthwith to pay such amounts upon such demand, the Trustee, in its own name and as trustee of an express
trust, shall be entitled and empowered to institute any action or proceeding at law or in equity for the collection of the sums so due
and unpaid, and may prosecute any such action or proceeding to judgment or final decree, and may enforce any such judgment or final decree
against the Issuer or other obligor upon such Securities and collect in the manner provided by law out of the property of the Issuer
or other obligor upon such Securities, wherever situated, the moneys adjudged or decreed to be payable.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
case there shall be pending proceedings relative to the Issuer or any other obligor upon the Securities under Title 11 of the U.S. Code
or any other applicable federal or state bankruptcy, insolvency or other similar law, or in case a receiver, liquidator, assignee, custodian,
trustee or sequestrator (or similar official) shall have been appointed for or taken possession of the Issuer or its property or such
other obligor, or in case of any other comparable judicial proceedings relative to the Issuer or other obligor upon the Securities of
any series or to the creditors or property of the Issuer or such other obligor, the Trustee, irrespective of whether the principal of
any Securities shall then be due and payable as therein expressed or by declaration or otherwise and irrespective of whether the Trustee
shall have made any demand pursuant to the provisions of this Section, shall be entitled and empowered, by intervention in such proceedings
or otherwise:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
to file and prove a claim or claims for the whole amount of principal and interest (or, if the Securities of any series are Original
Issue Discount Securities, such portion of the principal amount as may be specified in the terms of such series) owing and unpaid in
respect of the Securities of any series, and to file such other papers or documents as may be necessary or advisable in order to have
the claims of the Trustee (including any claim for reasonable compensation to the Trustee and each predecessor Trustee, and their respective
agents, attorneys and counsel, and for reimbursement of all expenses and liabilities incurred, and all advances made, by the Trustee
and each predecessor Trustee, except as a result of negligence or bad faith, and all other amounts due to the Trustee or any predecessor
Trustee pursuant to <U>Section 6.6</U> ) and of the Securityholders allowed in any judicial proceedings relative to the Issuer or other
obligor upon the Securities of any series, or to the creditors or property of the Issuer or such other obligor,</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
unless prohibited by applicable law and regulations, to vote on behalf of the Holders of the Securities of any series in any election
of a trustee or a standby trustee in arrangement, reorganization, liquidation or other bankruptcy or insolvency proceedings or person
performing similar functions in comparable proceedings, and</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
to collect and receive any moneys or other property payable or deliverable on any such claims, and to distribute all amounts received
with respect to the claims of the Securityholders and of the Trustee on their behalf; and any trustee, receiver, or liquidator, custodian
or other similar official is hereby authorized by each of the Securityholders to make payments to the Trustee, and, in the event that
the Trustee shall consent to the making of payments directly to the Securityholders, to pay to the Trustee such amounts as shall be sufficient
to cover reasonable compensation to the Trustee, each predecessor Trustee and their respective agents, attorneys and counsel, and all
other expenses and liabilities incurred, and all advances made, by the Trustee and each predecessor Trustee except as a result of negligence
or bad faith and all other amounts due to the Trustee or any predecessor Trustee pursuant to <U>Section 6.6</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nothing
herein contained shall be deemed to authorize the Trustee to authorize or consent to or vote for or accept or adopt on behalf of any
Securityholder any plan of reorganization, arrangement, adjustment, or composition affecting the Securities of any series or the rights
of any Holder thereof, or to authorize the Trustee to vote in respect of the claim of any Securityholder in any such proceeding except,
as aforesaid, to vote for the election of a trustee in bankruptcy or similar person.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
rights of action and of asserting claims under this Indenture, or under any of the Securities may be enforced by the Trustee without
the possession of any of the Securities or the production thereof on any trial or other proceedings relative thereto, and any such action
or proceedings instituted by the Trustee shall be brought in its own name as trustee of an express trust, and any recovery of judgment,
subject to the payment of the reasonable expenses, disbursements, compensation and all other amounts due pursuant to <U>Section 6.6</U>
to the Trustee, each predecessor Trustee and their respective agents and attorneys, shall be for the ratable benefit of the Holders of
the Securities in respect of which such judgment has been recovered.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
any proceedings brought by the Trustee (and also any proceedings involving the interpretation of any provision of this Indenture to which
the Trustee shall be a party), the Trustee shall be held to represent all the Holders of the Securities in respect to which such action
was taken, and it shall not be necessary to make any Holders of such Securities parties to any such proceedings.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
5.3 <U>Application of Proceeds</U>. Any moneys collected by the Trustee pursuant to this Article in respect of any series shall be applied
in the following order at the date or dates fixed by the Trustee and, in case of the distribution of such moneys on account of principal
or interest, upon presentation of the several Securities in respect of which monies have been collected and stamping (or otherwise noting)
thereon the payment, or issuing Securities of such series in reduced principal amounts in exchange for the presented Securities of like
series if only partially paid, or upon surrender thereof if fully paid:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FIRST:
To the payment of costs and expenses applicable to such series in respect of which monies have been collected, including reasonable compensation
to the Trustee and each predecessor Trustee and their respective agents and attorneys and of all expenses and liabilities incurred, and
all advances made, by the Trustee in the exercise of its rights or discharge of its duties hereunder and each predecessor Trustee except
as a result of negligence or bad faith, and all other amounts due to the Trustee or any predecessor Trustee pursuant to <U>Section 6.6
</U>;</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECOND:
In case the principal of the Securities of such series in respect of which moneys have been collected shall not have become and be then
due and payable, to the payment of interest on the Securities of such series in default in the order of the maturity of the installments
of such interest, with interest (to the extent that such interest has been collected by the Trustee) upon the overdue installments of
interest at the same rate as the rate of interest or Yield to Maturity (in the case of Original Issue Discount Securities) specified
in such Securities, such payments to be made ratably to the persons entitled thereto, without discrimination or preference;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIRD:
In case the principal of the Securities of such series in respect of which moneys have been collected shall have become and shall be
then due and payable, to the payment of the whole amount then owing and unpaid upon all the Securities of such series for principal and
interest, with interest upon the overdue principal, and (to the extent that such interest has been collected by the Trustee) upon overdue
installments of interest at the same rate as the rate of interest or Yield to Maturity (in the case of Original Issue Discount Securities)
specified in the securities of such series; and in case such moneys shall be insufficient to pay in full the whole amount so due and
unpaid upon the Securities of such series, then to the payment of such principal and interest or Yield to Maturity, without preference
or priority of principal over interest or Yield to Maturity, or of interest or Yield to Maturity over principal, or of any instalment
of interest over any other instalment of interest, or of any Security of such series over any other Security of such series, ratably
to the aggregate of such principal and accrued and unpaid interest or Yield to Maturity; and</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOURTH:
To the payment of the remainder, if any, to the Issuer or any other person lawfully entitled thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
5.4 <U>Suits for Enforcement</U>. In case an Event of Default has occurred, has not been waived and is continuing, the Trustee may in
its discretion proceed to protect and enforce the rights vested in it by this Indenture by such appropriate judicial proceedings as the
Trustee shall deem most effectual to protect and enforce any of such rights, either at law or in equity or in bankruptcy or otherwise,
whether for the specific enforcement of any covenant or agreement contained in this Indenture or in aid of the exercise of any power
granted in this Indenture or to enforce any other legal or equitable right vested in the Trustee by this Indenture or by law.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
5.5 <U>Restoration of Rights on Abandonment of Proceedings</U>. In case the Trustee or any Holder shall have proceeded to enforce any
right or remedy under this Indenture and such proceedings shall have been discontinued or abandoned for any reason, or shall have been
determined adversely to the Trustee or to such Holder, then and in every such case, subject to any determination in such proceeding,
the Issuer, the Trustee and the Holders shall be restored severally and respectively to their former positions and rights hereunder,
and all rights, remedies and powers of the Issuer, the Trustee and the Securityholders shall continue as though no such proceedings had
been taken.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
5.6 <U>Limitations on Suits by Securityholders</U>. No Holder of any Security of any series shall have any right by virtue or by availing
of any provision of this Indenture to institute any action or proceedings at law or in equity or in bankruptcy or otherwise upon or under
or with respect to this Indenture, or for the appointment of a receiver, liquidator, assignee, custodian, trustee, or sequestrator (or
other similar official) or for any other remedy hereunder, unless (a) such Holder previously shall have given to the Trustee written
notice of an Event of Default and of the continuance thereof with respect to the Securities of that series, as hereinbefore provided,
(b) the Holders of not less than 25% in aggregate principal amount of the Securities of such series then Outstanding shall have made
written request upon the Trustee to institute such action or proceedings with respect to such Event of Default in its own name as Trustee
hereunder, (c) such Holder or Holders shall have offered to the Trustee such reasonable indemnity as it may require against the costs,
expenses and liabilities to be incurred therein or thereby, (d) the Trustee for 90 days after its receipt of such notice, request and
offer of indemnity shall have failed to institute any such action or proceeding and (e) no direction inconsistent with such written request
shall have been given to the Trustee pursuant to <U>Section 5.9</U> during such 90-day period by the Holders of a majority in principal
amount of the Outstanding Securities of such series; it being understood and intended, and being expressly covenanted by the Holder of
every Security with every other Holder and the Trustee, that no one or more Holders of Securities of any series shall have any right
in any manner whatever by virtue or by availing themselves of any provision of this Indenture to affect, disturb or prejudice the rights
of any other such Holder of Securities, or to obtain or seek to obtain priority over or preference to any other such Holder or to enforce
any right under this Indenture, except in the manner herein provided and for the equal, ratable and common benefit of all Holders of
Securities of the applicable series. For the protection and enforcement of the provisions of this Section, each and every Securityholder
and the Trustee shall be entitled to such relief as can be given either at law or in equity.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
5.7 <U>Unconditional Right of Securityholders to Institute Certain Suits</U>. Notwithstanding any other provision in this Indenture and
any provision of any Security, the right of any Holder of any Security to receive payment of the principal of and (subject to <U>Section
2.7</U>) interest on such Security on or after the respective due dates expressed in such Security or to institute suit for the enforcement
of any such payment on or after such respective dates, shall not be impaired or affected without the consent of such Holder.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
5.8 <U>Powers and Remedies Cumulative; Delay or Omission Not Waiver of Default</U>. Except as provided in <U>Section 5.6</U> and as otherwise
provided with respect to the replacement or payment of mutilated, destroyed, lost or stolen Securities in the last paragraph of <U>Section
2.9</U> , no right or remedy herein conferred upon or reserved to the Trustee or to the Securityholders is intended to be exclusive of
any other right or remedy, and every right and remedy shall, to the extent permitted by law, be cumulative and in addition to every other
right and remedy given hereunder or now or hereafter existing at law or in equity or otherwise. The assertion or employment of any right
or remedy hereunder, or otherwise, shall not prevent the concurrent assertion or employment of any other appropriate right or remedy.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
delay or omission of the Trustee or of any Securityholder to exercise any right or power accruing upon any Event of Default occurring
and continuing as aforesaid shall impair any such right or power or shall be construed to be a waiver of any such Event of Default or
an acquiescence therein; and, subject to <U>Section 5.6</U> , every power and remedy given by this Indenture or by law to the Trustee
or to the Securityholders may be exercised from time to time, and as often as shall be deemed expedient, by the Trustee or by the Securityholders.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
5.9 <U>Control by Securityholders</U>. The Holders of a majority in aggregate principal amount of the Securities of each series affected
(with each series voting as a separate class) at the time Outstanding shall have the right to direct by written notice the time, method
and place of conducting any proceeding for any remedy available to the Trustee, or exercising any trust or power conferred on the Trustee,
with respect to the Securities of such series by this Indenture; provided that such direction shall not be otherwise than in accordance
with law and the provisions of this Indenture and provided further that (subject to the provisions of <U>Section 6.1</U>) the Trustee
shall have the right to decline to follow any such direction if the Trustee, being advised by counsel, shall determine that the action
or proceeding so directed may not lawfully be taken or if the Trustee in good faith by its board of directors, the executive committee,
or a trust committee of directors or Responsible Officers of the Trustee shall determine that the action or proceedings so directed would
involve the Trustee in personal liability or if the Trustee in good faith shall so determine that the actions or forbearances specified
in or pursuant to such direction would be unduly prejudicial to the interests of Holders of the Securities of all series so affected
not joining in the giving of said direction, it being understood that (subject to <U>Section 6.1</U>) the Trustee shall have no duty
to ascertain whether or not such actions or forbearances are unduly prejudicial to such Holders.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nothing
in this Indenture shall impair the right of the Trustee in its discretion to take any action deemed proper by the Trustee and which is
not inconsistent with such direction or directions by Securityholders.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
5.10 <U>Waiver of Past Defaults</U>. Prior to the declaration of the acceleration of the maturity of the Securities of any series as
provided in <U>Section 5.1</U> , the Holders of a majority in aggregate principal amount of the Securities of such series at the time
Outstanding may on behalf of the Holders of all the Securities of such series waive any past default or Event of Default described in
<U>Section 5.1</U> and its consequences except a default in respect of a covenant or provision hereof which under Article Eight cannot
be modified or amended without the consent of the Holder of each Outstanding Security affected. In the case of any such waiver, the Issuer,
the Trustee, and the Holders of the Securities of such series shall be restored to their former positions and rights hereunder, respectively;
but no such waiver shall extend to any subsequent or other default or impair any right consequent thereon.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Issuer may, but shall not be obligated to, fix a record date for the purpose of determining the Persons entitled to waive any past default
hereunder. If a record date is fixed, then the Holders on such record date, or their duly designated proxies, and only such Persons,
shall be entitled to waive any default hereunder, whether or not such Holders remain Holders after such record date; provided, however,
that unless such majority in principal amount shall have waived such default prior to the date that is the n<SUP>in</SUP>etieth (90th)
day after such record date, any such waiver previously given shall automatically and without further action by any Holder be cancelled
and of no further effect.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
any such waiver, such default shall cease to exist and be deemed to have been cured and not to have occurred, and any Event of Default
arising therefrom shall be deemed to have been cured, and not to have occurred for every purpose of this Indenture; but no such waiver
shall extend to any subsequent or other default or Event of Default or impair any right consequent thereon.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
5.11 <U>Trustee to Give Notice of Default, But May Withhold in Certain Circumstances</U>. The Trustee shall, within 90 days after the
occurrence of a default known to the Trustee with respect to the Securities of any series, provide notice to the Holders of the then-Outstanding
Securities of such series by mailing such notice to such Holders at their addresses as they shall appear in the Security Register, unless
such defaults shall have been cured before the giving of such notice (the term &ldquo;default&rdquo; or &ldquo;defaults&rdquo; for the
purposes of this Section being hereby defined to mean any event or condition which is, or with notice or lapse of time or both would
become, an Event of Default); provided that, except in the case of default in the payment of the principal of or interest on any Security
of such series or in the payment of any sinking fund installment with respect to Securities of such series, the Trustee shall be protected
in withholding such notice if and so long as the board of directors, the executive committee, or a trust committee of directors or trustees
and/or Responsible Officers of the Trustee in good faith determines that the withholding of such notice is in the interests of the Securityholders
of such series; provided, further, that in the case of any default of the character specified in clause (d) of <U>Section 5.1</U> , no
such notice to Holders shall be given until at least 30 days after the occurrence thereof.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
5.12 <U>Right of Court to Require Filing of Undertaking to Pay Costs</U>. The parties to this Indenture agree, and each Holder of any
Security by his acceptance thereof shall be deemed to have agreed, that any court may in its discretion require, in any suit for the
enforcement of any right or remedy under this Indenture or in any suit against the Trustee for any action taken, suffered or omitted
by it as Trustee, the filing by any party litigant in such suit of an undertaking to pay the costs of such suit, and that such court
may in its discretion assess reasonable costs, including reasonable attorneys&rsquo; fees, against any party litigant in such suit, having
due regard to the merits and good faith of the claims or defenses made by such party litigant; but the provisions of this Section shall
not apply to any suit instituted by the Trustee, to any suit instituted by any Securityholder or group of Securityholders of any series
holding in the aggregate more than 10% in aggregate principal amount of the Securities Outstanding of such series, or to any suit instituted
by any Securityholder for the enforcement of the payment of the principal of or interest on any Security on or after the due date expressed
in such Security.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
SIX</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONCERNING
THE TRUSTEE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
6.1 <U>Duties and Responsibilities of the Trustee; During Default; Prior to Default</U>. With respect to the Holders of any series of
Securities issued hereunder, the Trustee, prior to the occurrence of an Event of Default with respect to the Securities of a particular
series and after the curing or waiving of all Events of Default which may have occurred with respect to such series, undertakes to perform
such duties and only such duties as are specifically set forth in this Indenture. In case an Event of Default with respect to the Securities
of a series has occurred (which has not been cured or waived) the Trustee shall exercise such of the rights and powers vested in it by
this Indenture, and use the same degree of care and skill in their exercise, as a prudent person would exercise or use under the circumstances
in the conduct of his own affairs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
provision of this Indenture shall be construed to relieve the Trustee from liability for its own negligent action, its own negligent
failure to act or its own willful misconduct, ex that</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
prior to the occurrence of an Event of Default with respect to the Securities of any series and after the curing or waiving of all such
Events of Default with respect to such series which may have occurred:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
the duties and obligations of the Trustee with respect to the Securities of any series shall be determined solely by the express provisions
of this Indenture, and the Trustee shall not be liable except for the performance of such duties and obligations as are specifically
set forth in this Indenture, and no implied covenants or obligations shall be read into this Indenture against the Trustee; and</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
in the absence of bad faith on the part of the Trustee, the Trustee may conclusively rely, as to the truth of the statements and the
correctness of the opinions expressed therein, upon any statements, certificates or opinions furnished to the Trustee and conforming
to the requirements of this Indenture; but in the case of any such statements, certificates, or opinions which by any provision hereof
are specifically required to be furnished to the Trustee, the Trustee shall be under a duty to examine the same to determine whether
or not they conform to the requirements of this Indenture;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
the Trustee shall not be liable for any error of judgment made in good faith by a Responsible Officer or Responsible Officers of the
Trustee, unless it shall be proved that the Trustee was negligent in ascertaining the pertinent facts; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
the Trustee shall not be liable with respect to any action taken or omitted to be taken by it in good faith in accordance with the direction
of the Holders pursuant to <U>Section 5.9</U> relating to the time, method, and place of conducting any proceeding for any remedy available
to the Trustee, or exercising any trust or power conferred upon the Trustee, under this Indenture.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None
of the provisions contained in this Indenture shall require the Trustee to expend or risk its own funds or otherwise incur personal financial
liability in the performance of any of its duties or in the exercise of any of its rights or powers, if there shall be reasonable ground
for believing that the repayment of such funds or adequate indemnity against such liability is not reasonably assured to it.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
6.2 <U>Certain Rights of the Trustee</U>. In furtherance of and subject to the Trust Indenture Act, and subject to <U>Section 6.1</U>:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
the Trustee may rely and shall be protected in acting or refraining from acting upon any resolution, Officers&rsquo; Certificate or any
other certificate, statement, instrument, opinion, report, notice, request, consent, order, bond, debenture, note, coupon, security or
other paper or document reasonably believed by it to be genuine and to have been signed or presented by the proper party or parties;</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
any request, direction, order, or demand of the Issuer mentioned herein shall be sufficiently evidenced by an Issuer Request or Issuer
Order or as otherwise expressly provided herein, and any resolution of the Board of Directors may be sufficiently evidenced by a Board
Resolution;</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
whenever in the administration of this Indenture the Trustee shall deem it desirable that a matter be proved or established prior to
taking, suffering, or omitting any action hereunder, the Trustee (unless other evidence be herein specifically prescribed) may, in the
absence of bad faith on its part, conclusively rely upon an Officers&rsquo; Certificate;</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
the Trustee may consult with counsel and any advice or Opinion of Counsel shall be full and complete authorization and protection in
respect of any action reasonably taken, suffered, or omitted to be taken by it hereunder in good faith and in accordance with such advice
or Opinion of Counsel;</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
the Trustee shall be under no obligation to exercise any of the trusts, rights or powers vested in it by this Indenture at the request,
order, or direction of any of the Securityholders pursuant to the provisions of this Indenture, unless such Securityholders shall have
offered to the Trustee security or indemnity reasonably satisfactory to it against the costs, expenses, and liabilities which might be
incurred therein or thereby;</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
the Trustee shall not be liable for any action taken or omitted by it in good faith and believed by it to be authorized or within the
discretion, rights, or powers conferred upon it by this Indenture;</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
prior to the occurrence of an Event of Default hereunder and after the curing or waiving of all Events of Default, the Trustee shall
not be bound to make any investigation into the facts or matters stated in any resolution, certificate, statement, instrument, opinion,
report, notice, request, consent, order, approval, appraisal, bond, debenture, note, coupon, security, or other paper or document unless
requested in writing so to do by the Holders of not less than a majority in aggregate principal amount of the Securities of all series
then Outstanding; provided that, if the payment within a reasonable time to the Trustee of the costs, expenses or liabilities likely
to be incurred by it in the making of such investigation is, in the opinion of the Trustee, not reasonably assured to the Trustee by
the security afforded to it by the terms of this Indenture, the Trustee may require reasonable indemnity against such expenses or liabilities
as a condition to proceeding; the reasonable expenses of every such investigation shall be paid by the Issuer or, if paid by the Trustee
or any predecessor Trustee, shall be repaid by the Issuer upon demand;</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
the Trustee may execute any of the trusts or powers hereunder or perform any duties hereunder either directly or by or through agents
or attorneys not regularly in its employ and the Trustee shall not be responsible for any misconduct or negligence on the part of any
such agent or attorney appointed with due care by it hereunder; and</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
the Trustee shall not be required to take notice or be deemed to have notice or knowledge of any default or Event of Default unless a
Responsible Officer of the Trustee shall have received written notice from the Company or any Holder of the Securities or obtained actual
knowledge thereof. In the absence of receipt of such notice or actual knowledge, the Trustee may conclusively assume that there is no
default or Event of Default.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
Anything in the Indenture to the contrary notwithstanding, in no event shall the Trustee be liable for special, indirect, or consequential
loss or damage of any kind whatsoever (including but not limited to lost profits).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
6.3 <U>Trustee Not Responsible for Recitals, Disposition of Securities or Application of Proceeds Thereof</U>. The recitals contained
herein and in the Securities, except the Trustee&rsquo;s certificates of authentication, shall be taken as the statements of the Issuer,
and the Trustee assumes no responsibility for the correctness of the same. The Trustee makes no representation as to the validity or
sufficiency of this Indenture or of the Securities. The Trustee shall not be accountable for the use or application by the Issuer of
any of the Securities or of the proceeds thereof.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
6.4 <U>Trustee and Agents May Hold Securities; Collections, etc.</U> The Trustee or any agent of the Issuer or the Trustee, in its individual
or any other capacity, may become the owner or pledgee of Securities with the same rights it would have if it were not the Trustee or
such agent and, subject to <U>Section 6.8</U>, if operative, may otherwise deal with the Issuer and receive, collect, hold, and retain
collections from the Issuer with the same rights it would have if it were not the Trustee or such agent.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
6.5 <U>Moneys Held by Trustee</U>. Subject to the provisions of <U>Section 10.4</U> hereof, all moneys received by the Trustee shall,
until used or applied as herein provided, be held in trust for the purposes for which they were received, but need not be segregated
from other funds except to the extent required by mandatory provisions of law. Neither the Trustee nor any agent of the Issuer or the
Trustee shall be under any liability for interest on any moneys received by it hereunder.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
6.6 <U>Compensation and Indemnification of Trustee and Its Prior Claim</U>. The Issuer covenants and agrees to pay to the Trustee from
time to time, and the Trustee shall be entitled to, reasonable compensation for all services rendered by it hereunder (which compensation
shall not be limited by any provision of law in regard to the compensation of a trustee of an express trust), and the Issuer covenants
and agrees to pay or reimburse the Trustee and each predecessor Trustee upon its request for all reasonable expenses, disbursements and
advances incurred or made by or on behalf of it in accordance with any of the provisions of this Indenture (including the reasonable
compensation and the expenses and disbursements of its counsel and of all agents and other persons not regularly in its employ) except
any such expense, disbursement or advance as may arise from its negligence or bad faith. The Issuer also covenants to indemnify the Trustee
and each predecessor Trustee for, and to hold it harmless against, any loss, liability or expense incurred without negligence or bad
faith on its part, arising out of or in connection with the acceptance or administration of this Indenture or the trusts hereunder and
its duties hereunder, including the costs and expenses of defending itself against or investigating any claim of liability in the premises.
The obligations of the Issuer under this Section to compensate and indemnify the Trustee and each predecessor Trustee and to pay or reimburse
the Trustee and each predecessor Trustee for expenses, disbursements, and advances shall constitute additional indebtedness hereunder
and shall survive the satisfaction and discharge of this Indenture. Such additional indebtedness shall be a senior claim to that of the
Securities upon all property and funds held or collected by the Trustee as such, except funds held in trust for the benefit of the Holders
of particular Securities, and any Securities are hereby subordinated to such senior claim.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
6.7 <U>Right of Trustee to Rely on Officers</U>&rsquo; <U>Certificate, etc.</U> Subject to <U>Section 6.1</U> and <U>6.2</U> , whenever
in the administration of the trusts of this Indenture the Trustee shall deem it necessary or desirable that a matter be proved or established
prior to taking or suffering or omitting any action hereunder, such matter (unless other evidence in respect thereof be herein specifically
prescribed) may, in the absence of negligence or bad faith on the part of the Trustee, be deemed to be conclusively proved and established
by an Officers&rsquo; Certificate delivered to the Trustee, and such certificate, in the absence of negligence or bad faith on the part
of the Trustee, shall be full warrant to the Trustee for any action taken, suffered or omitted by it under the provisions of this Indenture
upon the faith thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
6.8 <U>Persons Eligible for Appointment as Trustee</U>. The Trustee for each series of Securities hereunder shall at all times be a corporation
organized and doing business under the laws of the United States or of any state or the District of Columbia having a combined capital
and surplus of at least $250,000,000, which is authorized under such laws to exercise corporate trust powers and is subject to supervision
or examination by federal, state or District of Columbia authority. If such corporation publishes reports of condition at least annually,
pursuant to law or to the requirements of the aforesaid supervising or examining authority, then for the purposes of this <U>Section
6.8</U>, the combined capital and surplus of such corporation shall be deemed to be its combined capital and surplus as set forth in
its most recent report of condition so published. In case at any time the Trustee shall cease to be eligible in accordance with the provisions
of this <U>Section 6.8</U>, the Trustee shall resign immediately in the manner and with the effect specified in <U>Section 6.9</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
obligor upon the Securities or person directly or indirectly controlling, controlled by or under common control with such obligor shall
serve as Trustee for any series of Securities.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Trustee shall comply with Section 310(b) of the Trust Indenture Act.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
provisions of this <U>Section 6.8</U> are in furtherance of and subject to Section 310(a) of the Trust Indenture Act.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
6.9 <U>Resignation and Removal; Appointment of Successor Trustee</U>. (a) The Trustee, or any trustee or trustees hereafter appointed,
may at any time resign with respect to one or more or all series of Securities by giving written notice of resignation to the Issuer.
Upon receiving such notice of resignation, the Issuer shall promptly appoint a successor trustee or trustees with respect to the applicable
series by written instrument in duplicate, executed by authority of the Board of Directors, one copy of which instrument shall be delivered
to the resigning Trustee and one copy to the successor trustee or trustees. If no successor trustee shall have been so appointed with
respect to any series and have accepted appointment within 30 days after the mailing of such notice of resignation, the resigning trustee
may petition any court of competent jurisdiction for the appointment of a successor trustee, or any Securityholder who has been a bona
fide Holder of a Security or Securities of the applicable series for at least six months may, subject to the provisions of <U>Section
5.12</U> , on behalf of himself and all others similarly situated, petition any such court for the appointment of a successor trustee.
Such court may thereupon, after such notice, if any, as it may deem proper and prescribe, appoint a successor trustee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
In case at any time any of the following shall occur:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: 0.2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
the Trustee shall fail to comply with the provisions of Section 310(b) of the Trust Indenture Act with respect to any series of Securities
after written request therefor by the Issuer or by any Securityholder who has been a bona fide Holder of a Security or Securities of
such series for at least six months; or</FONT></P>

<P STYLE="text-indent: 0.2in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: 0.2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
the Trustee shall cease to be eligible in accordance with the provisions of <U>Section 6.8</U> and shall fail to resign after written
request therefor by the Issuer or by any Securityholder; or</FONT></P>

<P STYLE="text-indent: 0.2in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: 0.2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
the Trustee shall become incapable of acting with respect to any series of Securities, or shall be adjudged a bankrupt or insolvent,
or a receiver or liquidator of the Trustee or of its property shall be appointed, or any public officer shall take charge or control
of the Trustee or of its property or affairs for the purpose of rehabilitation, conservation or liquidation; then, in any such case,
the Issuer may remove the Trustee with respect to the applicable series of Securities and appoint a successor trustee for such series
by written instrument, in duplicate, executed by order of the Board of Directors of the Issuer, one copy of which instrument shall be
delivered to the Trustee so removed and one copy to the successor trustee, or, subject to the provisions of <U>Section 7.1</U> , any
Securityholder who has been a bona fide Holder of a Security or Securities of such series for at least six months may on behalf of himself
and all others similarly situated, petition any court of competent jurisdiction for the removal of the Trustee and the appointment of
a successor trustee with respect to such series. Such court may thereupon, after such notice, if any, as it may deem proper and prescribe,
remove the Trustee, and appoint a successor trustee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
The Holders of a majority in aggregate principal amount of the Securities of each series at the time Outstanding may at any time remove
the Trustee with respect to securities of such series and appoint a successor trustee with respect to the Securities of such series by
delivering to the Trustee so removed, to the successor trustee so appointed and to the Issuer the evidence provided for in <U>Section
7.1</U> of the action in that regard taken by the Securityholders.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Any resignation or removal of the Trustee with respect to any series and any appointment of a successor trustee with respect to such
series pursuant to any of the provisions of this <U>Section 6.9</U> shall become effective upon acceptance of appointment by the successor
trustee as provided in <U>Section 6.10</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
6.10 <U>Acceptance of Appointment by Successor Trustee</U>. Any successor trustee appointed as provided in <U>Section 6.9</U> shall execute
and deliver to the Issuer and to its predecessor trustee an instrument accepting such appointment hereunder, and thereupon the resignation
or removal of the predecessor trustee with respect to all or any applicable series shall become effective and such successor trustee,
without any further act, deed or conveyance, shall become vested with all rights, powers, duties and obligations with respect to such
series of its predecessor hereunder, with like effect as if originally named as trustee for such series hereunder; but, nevertheless,
on the written request of the Issuer or of the successor trustee, upon payment of its charges then unpaid, the trustee ceasing to act
shall, subject to <U>Section 10.4</U> , pay over to the successor trustee all moneys at the time held by it hereunder and shall execute
and deliver an instrument transferring to such successor trustee all such rights, powers, duties and obligations. Upon request of any
such successor trustee, the Issuer shall execute any and all instruments in writing for more fully and certainly vesting in and confirming
to such successor trustee all such rights and powers. Any trustee ceasing to act shall, nevertheless, retain a prior claim upon all property
or funds held or collected by such trustee to secure any amounts then due it pursuant to the provisions of <U>Section 6.6</U>.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a successor trustee is appointed with respect to the Securities of one or more (but not all) series, the Issuer, the predecessor Trustee
and each successor trustee with respect to the Securities of any applicable series shall execute and deliver an indenture supplemental
hereto which shall contain such provisions as shall be deemed necessary or desirable to confirm that all the rights, powers, trusts and
duties of the predecessor Trustee with respect to the Securities of any series as to which the predecessor Trustee is not retiring shall
continue to be vested in the predecessor Trustee, and shall add to or change any of the provisions of this Indenture as shall be necessary
to provide for or facilitate the administration of the trusts hereunder by more than one trustee, it being understood that nothing herein
or in such supplemental indenture shall constitute such trustees or co- trustees of the same trust and that each such trustee shall be
trustee of a trust or trusts under separate indentures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
successor trustee with respect to any series of Securities shall accept appointment as provided in this <U>Section 6.10</U> unless at
the time of such acceptance such successor trustee shall be qualified under Section 310(b) of the Trust Indenture Act and eligible under
the provisions of <U>Section 6.8</U>.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
acceptance of appointment by any successor trustee as provided in this <U>Section 6.10</U>, the Issuer shall mail notice thereof to the
Holders of Securities of each series affected by first-class mail to such Holders of Securities of any series for which such successor
trustee is acting as trustee at their last addresses as they shall appear in the Security Register. If the Issuer fails to mail such
notice within ten days after acceptance of appointment by the successor trustee, the successor trustee shall cause such notice to be
mailed at the expense of the Issuer.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
6.11 <U>Merger, Conversion, Consolidation, or Succession to Business of Trustee</U>. Any corporation into which the Trustee may be merged
or converted or with which it may be consolidated, or any corporation resulting from any merger, conversion or consolidation to which
the Trustee shall be a party, or any corporation succeeding to all or substantially all of the corporate trust business of the Trustee,
shall be the successor of the Trustee hereunder, provided, that such corporation shall be qualified under Section 310(b) of the Trust
Indenture Act and eligible under the provisions of <U>Section 6.8</U> , without the execution or filing of any paper or any further act
on the part of any of the parties hereto, anything herein to the contrary notwithstanding.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
case at the time such successor to the Trustee shall succeed to the trusts created by this Indenture any of the Securities of any series
shall have been authenticated but not delivered, any such successor to the Trustee may adopt the certificate of authentication of any
predecessor Trustee and deliver such Securities so authenticated; and, in case at that time any of the Securities of any series shall
not have been authenticated, any successor to the Trustee may authenticate such Securities either in the name of any predecessor hereunder
or in the name of the successor Trustee; and in all such cases such certificate shall have the full force which it is anywhere in the
Securities of such series or in this Indenture provided that the certificate of the Trustee shall have; provided, that the right to adopt
the certificate of authentication of any predecessor Trustee or to authenticate Securities of any series in the name of any predecessor
Trustee shall apply only to its successor or successors by merger, conversion or consolidation.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
6.12 <U>Preferential Collection of Claims Against the Issuer</U>. The Trustee shall comply with Section 311(a) of the Trust Indenture
Act, excluding any creditor relationship listed in Section 311(b) of the Trust Indenture Act.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
Trustee who has resigned or been removed shall be subject to Section 311(a) of the Trust Indenture Act to the extent indicated therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
SEVEN</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONCERNING
THE SECURITYHOLDERS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
7.1 <U>Evidence of Action Taken by Securityholders</U>. Any request, demand, authorization, direction, notice, consent, waiver or other
action provided by this Indenture to be given or taken by a specified percentage in principal amount of the Securityholders of any or
all series may be embodied in and evidenced by one or more instruments of substantially similar tenor signed by such specified percentage
of Securityholders in person or by agent duly appointed in writing; and, except as herein otherwise expressly provided, such action shall
become effective when such instrument or instruments are delivered to the Trustee and, where it is hereby expressly required, to the
Issuer. Proof of execution of any instrument or of a writing appointing any such agent shall be sufficient for any purpose of this Indenture
and (subject to <U>Section 6.1</U> and <U>6.2</U> ) conclusive in favor of the Trustee and the Issuer, if made in the manner provided
in this Article.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
7.2 <U>Proof of Execution of Instruments and of Holding of Securities</U>. Subject to <U>Section 6.1</U> and <U>6.2</U>, the execution
of any instrument by a Securityholder or his agent or proxy may be proved in the following manner:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fact and date of the execution by any Holder of any instrument may be proved by the affidavit of a witness of such execution or by a
certificate of any notary public or other officer of any jurisdiction authorized to take acknowledgments of deeds or administer oaths
that the person executing such instruments acknowledged to him the execution thereof, or by an affidavit of a witness to such execution
sworn to before any such notary or other such officer. Where such execution is by or on behalf of any legal entity other than an individual,
such certificate or affidavit shall also constitute sufficient proof of the authority of the person executing the same. Subject to <U>Section
6.1</U> and <U>6.2</U> , the fact and date of the execution of any such instrument or writing, or the authority of the Person executing
the same, may also be proved in any other manner that the Trustee for such series may deem sufficient. The ownership, principal amount,
and serial numbers of Securities held by any Person, and the date of the commencement and the date of the termination of holding the
same, shall be proved by the Security Register.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
7.3 <U>Holders to Be Treated as Owners</U>. The Issuer, the Trustee and any agent of the Issuer or the Trustee may deem and treat the
person in whose name any Security shall be registered upon the Security Register for such series as the absolute owner of such Security
(whether or not such Security shall be overdue and notwithstanding any notation of ownership or other writing thereon) for the purpose
of receiving payment of or on account of the principal of and, subject to the provisions of this Indenture, interest on such Security
and for all other purposes, and neither the Issuer nor the Trustee nor any agent of the Issuer or the Trustee shall be affected by any
notice to the contrary. All such payments so made to any such person, or upon his order, shall be valid and, to the extent of the sum
or sums so paid, effectual to satisfy and discharge the liability for moneys payable upon any such Security.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
7.4 <U>Securities Owned by Issuer Deemed Not Outstanding</U>. In determining whether the Holders of the requisite aggregate principal
amount of Outstanding Securities of any or all series have concurred in any direction, consent or waiver under this Indenture, Securities
which are owned by the Issuer or any other obligor on the Securities with respect to which such determination is being made or by any
person directly or indirectly controlling or controlled by or under direct or indirect common control with the Issuer or any other obligor
on the Securities with respect to which such determination is being made shall be disregarded and deemed not to be Outstanding for the
purpose of any such determination, except that for the purpose of determining whether the Trustee shall be protected in relying on any
such direction, consent or waiver only Securities which a Responsible Officer of the Trustee knows are so owned shall be so disregarded.
Securities so owned which have been pledged in good faith may be regarded as Outstanding if the pledgee establishes to the satisfaction
of the Trustee the pledgee&rsquo;s right so to act with respect to such Securities and that the pledgee is not the Issuer or any other
obligor upon the Securities or any person directly or indirectly controlling or controlled by or under direct or indirect common control
with the Issuer or any other obligor on the Securities. In case of a dispute as to such right, the advice of counsel shall be full protection
in respect of any decision made by the Trustee in accordance with such advice. Upon request of the Trustee, the Issuer shall furnish
to the Trustee promptly an Officers&rsquo; Certificate (which need not comply with <U>Section 11.5</U> ) listing and identifying all
Securities, if any, known by the Issuer to be owned or held by or for the account of any of the above-described persons, and, subject
to <U>Sections 6.1</U> and <U>6.2</U> , the Trustee shall be entitled to accept such Officers&rsquo; Certificate as conclusive evidence
of the facts therein set forth and of the fact that all Securities not listed therein are Outstanding for the purpose of any such determination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
7.5 <U>Right of Revocation of Action Taken</U>. At any time prior to (but not after) the evidencing to the Trustee, as provided in <U>Section
7.1</U> , of the taking of any action by the Holders of the percentage in aggregate principal amount of the Securities of any or all
series, as the case may be, specified in this Indenture in connection with such action, any Holder of a Security the serial number of
which is shown by the evidence to be included among the serial numbers of the Securities the Holders of which have consented to such
action may, by filing written notice at the Corporate Trust Office and upon proof of holding as provided in this Article, revoke such
action so far as concerns such Security. Except as aforesaid any such action taken by the Holder of any Security shall be conclusive
and binding upon such Holder and upon all future Holders and owners of such Security and of any Securities issued in exchange or substitution
therefor, irrespective of whether or not any notation in regard thereto is made upon any such Security. Any action taken by the Holders
of the percentage in aggregate principal amount of the Securities of any or all series, as the case may be, specified in this Indenture
in connection with such action shall be conclusively binding upon the Issuer, the Trustee, and the Holders of all the Securities affected
by such action.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
EIGHT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SUPPLEMENTAL
INDENTURES</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
8.1 <U>Supplemental Indentures Without Consent of Securityholders</U>. The Issuer, when authorized by a Board Resolution, and the Trustee
may from time to time and at any time enter into an indenture or indentures supplemental hereto (which shall conform to the provisions
of the Trust Indenture Act as in force at the date of the execution thereof) for one or more of the following purposes:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
to convey, transfer, assign, mortgage, or pledge to the Trustee as security for the Securities of one or more series any property or
assets;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
to evidence the succession of another corporation to the Issuer, or successive successions, and the assumption by the successor corporation
of the covenants, agreements, and obligations of the Issuer pursuant to Article Nine;</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
to add to the covenants of the Issuer such further covenants, restrictions, conditions or provisions as its Board of Directors and the
Trustee shall consider to be for the protection of the Holders of Securities, and to make the occurrence, or the occurrence and continuance,
of a default in any such additional covenants, restrictions, conditions or provisions an Event of Default permitting the enforcement
of all or any of the several remedies provided in this Indenture as herein set forth; provided, that in respect of any such additional
covenant, restriction, condition or provision such supplemental indenture may provide for a particular period of grace after default
(which period may be shorter or longer than that allowed in the case of other defaults) or may provide for an immediate enforcement upon
such an Event of Default or may limit the remedies available to the Trustee upon such an Event of Default or may limit the right of the
Holders of a majority in aggregate principal amount of the Outstanding Securities of such series to waive such an Event of Default;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
to cure any ambiguity or to correct or supplement any provision contained herein or in any supplemental indenture which may be defective
or inconsistent with any other provision contained herein or in any supplemental indenture; or to make such other provisions in regard
to matters or questions arising under this Indenture or under any supplemental indenture as the Board of Directors may deem necessary
or desirable and which shall not adversely affect the interests of the Holders of the Securities;</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
to provide for the issuance of Securities of any series as permitted by <U>Sections 2.1</U> and <U>2.3</U> hereof and to establish the
form and term thereof;</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
to evidence and provide for the acceptance of appointment hereunder by a successor trustee with respect to the Securities of one or more
series and to add to or change any of the provisions of this Indenture as shall be necessary to provide for or facilitate the administration
of the trusts hereunder by more than one trustee, pursuant to the requirements of <U>Section 6.10</U>;</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
to modify, eliminate or add to the provisions of this Indenture to such extent as shall be necessary to effect and maintain the qualification
of this Indenture under the Trust Indenture Act, or under any similar federal statute hereafter enacted, and to add to this Indenture
such other provisions and make such other changes to this Indenture as may be expressly permitted by the Trust Indenture Act, or under
any similar federal statute hereafter enacted, excluding however, the provisions referred to in <U>Section 316(a)(2)</U> of the Trust
Indenture Act or any corresponding provisions in any similar federal statute hereafter enacted;</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
to add to or change any of the provisions of this Indenture to such extent as shall be necessary to permit or facilitate the issuance
of Securities in bearer form, registrable or not registrable as to principal and with or without interest coupons or to permit or facilitate
the issuance of Securities in uncertificated form;</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
to add any additional Events of Default;</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
to add to or change any of the provisions of this Indenture with respect to any Securities that by their terms may be converted into
securities or other property other than Securities of the same series and of like tenor, in order to permit or facilitate the issuance,
payment or conversion of such Securities;</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)
conform any provision in the Indenture to the prospectus, offering memorandum, offering circular or any other document pursuant to which
the Securities of such series were offered;</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)
to add a guarantee with respect to the Securities of any series; and</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)
to release a guarantee with respect to the Securities of any series as permitted under this Indenture and any applicable guarantee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Trustee is hereby authorized to join with the Issuer in the execution of any such supplemental indenture, to make any further appropriate
agreements and stipulations which may be therein contained and to accept the conveyance, transfer, assignment, mortgage, or pledge of
any property thereunder, but the Trustee shall not be obligated to enter into any such supplemental indenture which affects the Trustee&rsquo;s
own rights, duties, or immunities under this Indenture or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
supplemental indenture authorized by the provisions of this Section may be executed without the consent of the Holders of any of the
Securities at the time Outstanding, notwithstanding any of the provisions of <U>Section 8.2</U>.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
8.2 <U>Supplemental Indentures With Consent of Securityholders</U>. With the consent (evidenced as provided in Article Seven) of the
Holders of not less than a majority in aggregate principal amount of the Securities at the time Outstanding of all series affected by
such supplemental indenture (voting as one class), the Issuer, when authorized by a Board Resolution, and the Trustee may, from time
to time and at any time, enter into an indenture or indentures supplemental hereto (which shall conform to the provisions of the Trust
Indenture Act as in force at the date of execution thereof) for the purpose of adding any provisions to or changing in any manner or
eliminating any of the provisions of this Indenture or of any supplemental indenture or of modifying in any manner the rights of the
Holders of the Securities of each such series; provided, that no such supplemental indenture shall (a) extend the final maturity of any
Security, or reduce the principal amount thereof or the method in which amounts of payments of principal or interest thereon are determined,
or reduce the rate or extend the time of payment of interest thereon, or change the coin or currency or units based on or related to
currencies of payment thereof, or reduce any amount payable on redemption thereof or reduce the amount of the principal of an Original
Issue Discount Security that would be due and payable upon an acceleration of the maturity thereof pursuant to <U>Section 5.1</U> or
the amount thereof provable in bankruptcy pursuant to <U>Section 5.2</U> , or impair or affect the right of any Securityholder to institute
suit for the payment thereof or, if the Securities provide therefor, any right of repayment at the option of the Securityholder without
the consent of the Holder of each Security so affected, or (b) reduce the aforesaid percentage of Securities of any series, the consent
of the Holders of which is required for any such supplemental indenture, without the consent of the Holder of each Security so affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the request of the Issuer, accompanied by a Board Resolution authorizing the execution of any such supplemental indenture, and upon the
filing with the Trustee of evidence of the consent of Securityholders as aforesaid and other documents, if any, required by <U>Section
7.1</U> , the Trustee shall join with the Issuer in the execution of such supplemental indenture unless such supplemental indenture affects
the Trustee&rsquo;s own rights, duties or immunities under this Indenture or otherwise, in which case the Trustee may in its discretion,
but shall not be obligated to, enter into such supplemental indenture.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
shall not be necessary for the consent of the Securityholders under this Section to approve the particular form of any proposed supplemental
indenture, but it shall be sufficient if such consent shall approve the substance thereof.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Promptly
after the execution by the Issuer and the Trustee of any supplemental indenture pursuant to the provisions of this Section, the Issuer
shall mail a notice thereof by first class mail to the Holders of then Outstanding Securities of each series affected thereby at their
addresses as they shall appear on the Security Register. Any failure of the Issuer to mail such notice, or any defect therein, shall
not, however, in any way impair or affect the validity of any such supplemental indenture.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
8.3 <U>Effect of Supplemental Indenture</U>. Upon the execution of any supplemental indenture pursuant to the provisions hereof, this
Indenture shall be and be deemed to be modified and amended in accordance therewith and the respective rights, limitations of rights,
obligations, duties and immunities under this Indenture of the Trustee, the Issuer and the Holders of Securities of each series affected
thereby shall thereafter be determined, exercised and enforced hereunder subject in all respects to such modifications and amendments,
and all the terms and conditions of any such supplemental indenture shall be and be deemed to be part of the terms and conditions of
this Indenture for any and all purposes.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
8.4 <U>Documents to Be Given to Trustee</U>. The Trustee, subject to the provisions of <U>Section 6.1</U> and <U>6.2</U>, may receive
an Officers&rsquo; Certificate and an Opinion of Counsel as conclusive evidence that any supplemental indenture executed pursuant to
this Article Eight complies with the applicable provisions of this Indenture.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
8.5 <U>Notation on Securities in Respect of Supplemental Indentures</U>. Securities of any series authenticated and delivered after the
execution of any supplemental indenture pursuant to the provisions of this Article may bear a notation in form approved by the Trustee
for such series as to any matter provided for by such supplemental indenture or as to any action taken at any such meeting. If the Issuer
or the Trustee shall so determine, new Securities of any series so modified as to conform, in the opinion of the Trustee and the Board
of Directors, to any modification of this Indenture contained in any such supplemental indenture may be prepared by the Issuer, authenticated
by the Trustee, and delivered in exchange for the Securities of such series then Outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
NINE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONSOLIDATION,
MERGER, SALE, OR CONVEYANCE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
9.1 <U>Issuer May Consolidate, etc., on Certain Terms</U>. The Issuer covenants that it will not merge or consolidate with any other
corporation or sell or convey all or substantially all of its assets to any Person, unless (i) either the Issuer shall be the continuing
corporation, or the successor corporation or the Person which acquires by sale or conveyance of substantially all the assets of the Issuer
(if other than the Issuer) shall be a corporation organized under the laws of the United States or any state thereof and shall expressly
assume the due and punctual payment of the principal of and interest on all the Securities, according to their tenor, and the due and
punctual performance and observance of all of the covenants and conditions of this Indenture to be performed or observed by the Issuer,
by supplemental indenture satisfactory to the Trustee, executed and delivered to the Trustee by such corporation, and (ii) the Issuer
or such successor corporation, as the case may be, shall not, immediately after such merger or consolidation, or such sale or conveyance,
be in default in the performance of any such covenant or condition.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
9.2 <U>Successor Corporation Substituted</U>. In case of any such consolidation, merger, sale, or conveyance, and following such an assumption
by the successor corporation, such successor corporation shall succeed to and be substituted for the Issuer, with the same effect as
if it had been named herein. Such successor corporation may cause to be signed, and may issue either in its own name or in the name of
the Issuer prior to such succession any or all of the Securities issuable hereunder which theretofore shall not have been signed by the
Issuer and delivered to the Trustee; and, upon the order of such successor corporation instead of the Issuer and subject to all the terms,
conditions and limitations in this Indenture prescribed, the Trustee shall authenticate and shall deliver any Securities which previously
shall have been signed and delivered by the officers of the Issuer to the Trustee for authentication, and any Securities, which such
successor corporation thereafter shall cause to be signed and delivered to the Trustee for that purpose. All of the Securities so issued
shall in all respects have the same legal rank and benefit under this Indenture as the Securities theretofore or thereafter issued in
accordance with the terms of this Indenture as though all of such Securities had been issued at the date of the execution hereof.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
case of any such consolidation, merger, sale, lease, or conveyance, such changes in phraseology and form (but not in substance) may be
made in the Securities thereafter to be issued as may be appropriate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of any such sale or conveyance (other than a conveyance by way of lease), the Issuer or any successor corporation which shall
theretofore have become such in the manner described in this Article shall be discharged from all obligations and covenants under this
Indenture and the Securities and may be liquidated and dissolved.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
9.3 <U>Opinion of Counsel to Trustee</U>. The Trustee, subject to the provisions of <U>Section 6.1</U> and <U>6.2</U>, may receive an
Opinion of Counsel, prepared in accordance with <U>Section 11.5</U>, as conclusive evidence that any such consolidation, merger, sale,
lease, or conveyance, and any such assumption, and any such liquidation or dissolution, complies with the applicable provisions of this
Indenture.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
TEN</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SATISFACTION
AND DISCHARGE OF INDENTURE;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">UNCLAIMED
MONEYS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
10.1 <U>Satisfaction and Discharge of Indenture</U>. (A) If at any time (a) the Issuer shall have paid or caused to be paid the principal
of and interest on all the Securities of any series Outstanding hereunder (other than Securities which have been destroyed, lost or stolen
and which have been replaced or paid as provided in <U>Section 2.9</U> ) as and when the same shall have become due and payable, (b)
the Issuer shall have delivered to the Trustee for cancellation all Securities of any series theretofore authenticated (other than any
Securities of such series which shall have been destroyed, lost or stolen and which shall have been replaced or paid as provided in <U>Section
2.9</U> ) or (c)(i) all the Securities of such series not theretofore delivered to the Trustee for cancellation shall have become due
and payable, or are by their terms to become due and payable within one year or are to be or may be called for redemption within one
year under arrangements satisfactory to the Trustee for the giving of notice of redemption, and (ii) the Issuer shall have irrevocably
deposited or caused to be deposited with the Trustee as trust funds the entire amount in cash (other than moneys repaid by the Trustee
or any paying agent to the Issuer in accordance with <U>Section 10.4</U> ) or U.S. Government Obligations, maturing as to principal and
interest in such amounts and at such times as will insure the availability of cash (without consideration of any reinvestment of such
principal or interest), or a combination of U.S. Government Obligations and cash sufficient to pay at maturity or upon redemption all
Securities of such series not theretofore delivered to the Trustee for cancellation, including principal and interest due or to become
due to such date of maturity as the case may be, and if, in any such case, the Issuer shall also pay or cause to be paid all other sums
payable hereunder by the Issuer with respect to Securities of such series, then this Indenture shall cease to be of further effect with
respect to Securities of such series (except as to (i) rights of registration of transfer and exchange, and the Issuer&rsquo;s right
of optional redemption, (ii) substitution of mutilated, defaced, destroyed, lost or stolen Securities, (iii) rights of Holders of Securities
to receive payments of principal thereof and interest thereon, upon the original stated due dates therefor (but not upon acceleration)
and remaining rights of the Holders to receive mandatory sinking fund payments, if any, (iv) the rights, obligations, duties and immunities
of the Trustee hereunder, including those under <U>Section 6.6,</U> (v) the rights of the Securityholders of such series as beneficiaries
hereof with respect to the property so deposited with the Trustee payable to all or any of them, and (vi) the obligations of the Issuer
under <U>Section 3.2</U> , and the Trustee, on demand of the Issuer accompanied by an Officers&rsquo; Certificate and an Opinion of Counsel
and at the cost and expense of the Issuer, shall execute proper instruments acknowledging such satisfaction of and discharging this Indenture
with respect to such series; provided, that the rights of Holders of the Securities to receive amounts in respect of principal of and
interest on the Securities held by them shall not be delayed longer than required by then-applicable mandatory rules or policies of any
securities exchange upon which the Securities are listed. The Issuer agrees to reimburse the Trustee for any costs or expenses thereafter
reasonably and properly incurred and to compensate the Trustee for any services thereafter reasonably and properly rendered by the Trustee
in connection with this Indenture or the Securities of such series.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)
The following provisions shall apply to the Securities of each series unless specifically otherwise provided in a Board Resolution, Officers&rsquo;
Certificate or indenture supplemental hereto provided pursuant to <U>Section 2.3</U>. In addition to discharge of the Indenture pursuant
to the next preceding paragraph, the Issuer shall be deemed to have paid and discharged the entire indebtedness on all the Securities
of a series on the 121st day after the date of the deposit referred to in subparagraph (a) below, and the provisions of this Indenture
with respect to the Securities of such series shall no longer be in effect (except as to (i) rights of registration of transfer and exchange
of Securities of such series, (ii) substitution of mutilated, defaced, destroyed, lost or stolen Securities, (iii) rights of Holders
of Securities to receive, from the trust fund described in subparagraph (a) below, payments of principal thereof and interest thereon,
upon the original stated due dates therefor (but not upon acceleration) and remaining rights of the Holders to receive sinking fund payments,
if any, (iv) the rights, obligation, duties and immunities of the Trustee hereunder, including those under <U>Section 6.6</U>, (v) the
rights of the Holders of Securities of such series as beneficiaries hereof with respect to the property so deposited with the Trustee
payable to all or any of them and (vi) the obligations of the Issuer under <U>Section 3.2</U> ), and the Trustee, at the expense of the
Issuer, shall at the Issuer&rsquo;s request execute proper instruments acknowledging the same, if</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
with reference to this <U>Section 10.1(B)</U> the Issuer has irrevocably deposited or caused to be irrevocably deposited with the Trustee
as trust funds in trust, specifically pledged as security for, and dedicated solely to, the benefit of the Holders of the Securities
of such series (i) cash, (ii) U.S. Government Obligations, maturing as to principal and interest at such times and in such amounts as
will insure the availability of cash, or (iii) a combination thereof, in an amount sufficient, in the opinion of a nationally recognized
firm of independent public accountants expressed in a written certification thereof delivered to the Trustee, to pay (x) the principal
and interest on all Securities of such series on the date that such principal or interest is due and payable and (y) any mandatory sinking
fund payments on the day on which such payments are due and payable in accordance with the terms of the Indenture and the Securities
of such series;</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
such deposit will not result in a breach or violation of, or constitute a default under, any agreement or instrument to which the Issuer
is a party or by which it is bound;</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
the Issuer has delivered to the Trustee an opinion of independent legal counsel satisfactory to the Trustee to the effect that Holders
of the Securities of such series will not recognize income, gain or loss for federal income tax purposes as a result of such deposit,
defeasance and discharge and will be subject to federal income tax on the same amount and in the same manner and at the same times, as
would have been the case if such deposit, defeasance, and discharge had not occurred; and</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
the Issuer has delivered to the Trustee an Officers&rsquo; Certificate and an Opinion of Counsel, each stating that all conditions precedent
provided for relating to the defeasance contemplated by this provision have been complied with, and the Opinion of Counsel shall also
state that such deposit does not violate applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
10.2 <U>Application by Trustee of Funds Deposited for Payment of Securities</U>. Subject to <U>Section 10.4</U> , all moneys deposited
with the Trustee pursuant to <U>Section 10.1</U> shall be held in trust and applied by it to the payment, either directly or through
any paying agent (including the Issuer acting as its own paying agent), to the Holders of the particular Securities of such series for
the payment or redemption of which such moneys have been deposited with the Trustee, of all sums due and to become due thereon for principal
and interest; but such money need not be segregated from other funds except to the extent required by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
10.3 <U>Repayment of Moneys Held by Paying Agent</U>. In connection with the satisfaction and discharge of this Indenture with respect
to Securities of any series, all moneys then held by any paying agent under the provisions of this Indenture with respect to such series
of Securities shall, upon demand of the Issuer, be repaid to it or paid to the Trustee and thereupon such paying agent shall be released
from all further liability with respect to such moneys.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
10.4 <U>Return of Moneys Held by Trustee and Paying Agent Unclaimed for Two Years</U>. Any moneys deposited with or paid to the Trustee
or any paying agent for the payment of the principal of or interest on any Security of any series and not applied but remaining unclaimed
for two years after the date upon which such principal or interest shall have become due and payable, shall, upon the written request
of the Issuer and unless otherwise required by mandatory provisions of applicable escheat or abandoned or unclaimed property law, be
repaid to the Issuer by the Trustee for such series or such paying agent, and the Holder of the Security of such series shall, unless
otherwise required by mandatory provisions of applicable escheat or abandoned or unclaimed property laws, thereafter look only to the
Issuer for any payment which such Holder may be entitled to collect, and all liability of the Trustee or any paying agent with respect
to such moneys shall thereupon cease; provided, the Trustee or such paying agent, before being required to make any such repayment with
respect to moneys deposited with it for any payment, may at the expense of the Issuer mail by first-class mail to Holders of such Securities
at their addresses as they shall appear on the Security Register notice that such moneys remain and that, after a date specified therein,
which shall not be less than thirty days from the date of such mailing, any unclaimed balance of such money then remaining will be repaid
to the Issuer.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
10.5 <U>Indemnity for U.S. Government Obligations</U>. The Issuer shall pay and indemnify the Trustee against any tax, fee or other charge
imposed on or assessed against the U.S. Government Obligations deposited pursuant to <U>Section 10.1</U> or the principal or interest
received in respect of such obligations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
ELEVEN</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MISCELLANEOUS
PROVISIONS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
11.1 <U>Incorporators, Stockholders, Officers, and Directors of Issuer Exempt from Individual Liability</U>. No recourse under or upon
any obligation, covenant or agreement contained in this Indenture, or in any Security, or because of any indebtedness evidenced thereby,
shall be had against any incorporator, as such or against any past, present or future stockholder, officer, or director, as such, of
the Issuer or of any successor, either directly or through the Issuer or any successor, under any rule of law, statute or constitutional
provision or by the enforcement of any assessment or by any legal or equitable proceeding or otherwise, all such liability being expressly
waived and released by the acceptance of the Securities by the Holders thereof and as part of the consideration for the issue of the
Securities.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
11.2 <U>Provisions of Indenture for the Sole Benefit of Parties and Securityholders</U>. Nothing in this Indenture or in the Securities,
expressed or implied, shall give or be construed to give to any person, firm, or corporation, other than the parties hereto and their
successors and the Holders of the Securities, any legal or equitable right, remedy or claim under this Indenture or under any covenant
or provision herein contained, all such covenants and provisions being for the sole benefit of the parties hereto and their successors
and of the Holders of the Securities.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
11.3 <U>Successors and Assigns of Issuer Bound by Indenture</U>. All the covenants, stipulations, promises and agreements in this Indenture
contained by or in behalf of the Issuer shall bind its successors and assigns, whether so expressed or not.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
11.4 <U>Notices and Demands on Issuer, Trustee, and Securityholders</U>. Any notice or demand which by any provision of this Indenture
is required or permitted to be given or served by the Trustee or by the Holders of Securities to or on the Issuer may be given or served
by being deposited postage prepaid, first-class mail (except as otherwise specifically provided herein) addressed (until another address
of the Issuer is filed by the Issuer with the Trustee) to JanOne Inc., 325 E. Warm Springs Road, Suite 102, Las Vegas, Nevada 89119,
Attn: Chief Executive Officer. Any notice, direction, request, or demand by the Issuer or any Securityholder to or upon the Trustee shall
be deemed to have been sufficiently given or made, for all purposes, if given or made at the Corporate Trust Office.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where
this Indenture provides for notice to Holders, such notice shall be sufficiently given (unless otherwise herein expressly provided) if
in writing and mailed, first-class postage prepaid, to each Holder entitled thereto, at his last address as it appears in the Security
Register or as so filed. Any notice which is mailed in the manner herein provided shall be conclusively presumed to have been duly given
when mailed, whether or not the Holder receives the notice. In any case where notice to Holders is given by mail, neither the failure
to mail such notice, nor any defect in any notice so mailed, to any particular Holder shall affect the sufficiency of such notice with
respect to other Holders. Where this Indenture provides for notice in any manner, such notice may be waived in writing by the person
entitled to receive such notice, either before or after the event, and such waiver shall be the equivalent of such notice. Waivers of
notice by Holders shall be filed with the Trustee, but such filing shall not be a condition precedent to the validity of any action taken
in reliance upon such waiver.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
case, by reason of the suspension of or irregularities in regular mail service, it shall be impracticable to mail notice to the Issuer
and Securityholders when such notice is required to be given pursuant to any provision of this Indenture, then any manner of giving such
notice as shall be satisfactory to the Trustee shall be deemed to be a sufficient giving of such notice.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
11.5 <U>Officers</U>&rsquo; <U>Certificates and Opinions of Counsel; Statements to Be Contained Therein</U>. Upon any application or
demand by the Issuer to the Trustee to take any action under any of the provisions of this Indenture, the Issuer shall furnish to the
Trustee an Officers&rsquo; Certificate stating that all conditions precedent provided for in this Indenture relating to the proposed
action have been complied with and an Opinion of Counsel stating that in the opinion of such counsel all such conditions precedent have
been complied with, except that in the case of any such application or demand as to which the furnishing of such documents is specifically
required by any provision of this Indenture relating to such particular application or demand, no additional certificate or opinion need
be furnished.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
certificate or opinion provided for in this Indenture and delivered to the Trustee with respect to compliance with a condition or covenant
provided for in this Indenture shall include (a) a statement that the person making such certificate or opinion has read such covenant
or condition, (b) a brief statement as to the nature and scope of the examination or investigation upon which the statements or opinions
contained in such certificate or opinion are based, (c) a statement that, in the opinion of such person, he has made such examination
or investigation as is necessary to enable him to express an informed opinion as to whether or not such covenant or condition has been
complied with and (d) a statement as to whether or not, in the opinion of such person, such condition or covenant has been complied with.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
certificate, statement, or opinion of an officer of the Issuer may be based, insofar as it relates to legal matters, upon a certificate
or opinion of or representations by counsel, unless such officer knows that the certificate or opinion or representations with respect
to the matters upon which his certificate, statement or opinion may be based as aforesaid are erroneous or in the exercise of reasonable
care should know that the same are erroneous. Any certificate, statement or opinion of counsel may be based, insofar as it relates to
factual matters, information with respect to which is in the possession of the Issuer, upon the certificate, statement or opinion of
or representations by an officer or officers of the Issuer, unless such counsel knows that the certificate, statement or opinion or representations
with respect to the matters upon which his certificate, statement or opinion may be based as aforesaid are erroneous or in the exercise
of reasonable care should know that the same are erroneous.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
certificate, statement or opinion of an officer of the Issuer or of counsel may be based, insofar as it relates to accounting matters,
upon a certificate or opinion of or representations by an accountant or firm of accountants in the employ of the Issuer, unless such
officer or counsel, as the case may be, knows that the certificate or opinion or representations with respect to the accounting matters
upon which his certificate, statement or opinion may be based as aforesaid are erroneous or in the exercise of reasonable care should
know that the same are erroneous.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
certificate or opinion of any independent firm of public accountants filed with the Trustee shall contain a statement that such firm
is independent.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
11.6 <U>Payments Due on Saturdays, Sundays, and Holidays</U>. If the date of maturity of interest on or principal of the Securities of
any series or the date fixed for redemption or repayment of any such Security shall not be a Business Day, then payment of interest or
principal need not be made on such date, but may be made on the next succeeding Business Day with the same force and effect as if made
on the date of maturity or the date fixed for redemption, and no interest shall accrue for the period after such date.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
11.7 <U>Conflict of Any Provision of Indenture with Trust Indenture Act</U>. If and to the extent that any provision of this Indenture
limits, qualifies or conflicts with another provision included in this Indenture which is required to be included herein by any of Sections
310 to 317, inclusive, of the Trust Indenture Act, such required provision shall control.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
11.8 <U>New York Law to Govern</U>. This Indenture and each Security shall be deemed to be a contract under the laws of the State of
New York, and for all purposes shall be construed in accordance with the laws of such State, except as may otherwise be required by mandatory
provisions of law.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
11.9 <U>Counterparts</U>. This Indenture may be executed in any number of counterparts, each of which so executed shall be deemed to
be an original; but such counterparts shall together constitute but one and the same instrument.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
11.10 <U>Effect of Headings</U>. The article and section headings herein and the table of contents are for convenience only and shall
not affect the construction hereof.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
11.11 <U>Securities in Foreign Currencies</U>. Whenever this Indenture provides for any action by, or the determination of any of the
rights of, or any distribution to, Holders of Securities denominated in Dollars and in any other currency or currency unit, in the absence
of any provision to the contrary in the form of Security of any particular series, any amount in respect of any Security denominated
in a currency or currency unit other than Dollars shall be treated for any such action or distribution as that amount of Dollars that
could be obtained for such amount on such reasonable basis of exchange and as of such date as the Issuer may reasonably specify in a
written notice to the Trustee or, in the absence of such written notice, as the Trustee shall so determine.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
11.12 <U>Separability Clause</U>. In case any provision in this Indenture or in the Securities shall be invalid, illegal, or unenforceable,
the validity, legality, and enforceability of the remaining provisions shall not in any way be affected or impaired thereby.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
11.13 <U>Patriot Act</U>. The Issuer acknowledges that in accordance with Section 326 of the USA PATRIOT Act, the Trustee, like all financial
institutions and in order to help fight the funding of terrorism and money laundering, is required to obtain, verify, and record information
that identifies each person or legal entity that establishes a relationship or opens an account with the Trustee. The Issuer agrees that
it will provide the Trustee with such information as it may reasonably request in order for the Trustee to satisfy the requirements of
the USA PATRIOT Act.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
11.14 <U>Waiver of Jury Trial</U>. THE PARTIES HEREBY IRREVOCABLY WAIVE, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL
RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS INDENTURE OR THE SECURITIES.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
TWELVE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">REDEMPTION
OF SECURITIES AND SINKING FUNDS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
12.1 <U>Applicability of Article</U>. The provisions of this Article shall be applicable to the Securities of any series that are redeemable
before their maturity or to any sinking fund for the retirement of Securities of a series except as otherwise specified as contemplated
by <U>Section 2.3</U> for Securities of such series.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
12.2 <U>Notice of Redemption; Partial Redemptions</U>. Notice of redemption to the Holders of Securities of any series to be redeemed
as a whole or in part at the option of the Issuer shall be given by mailing notice of such redemption by first class mail, postage prepaid
at least 30 days and not more than 60 days prior to the date fixed for redemption to such Holders of Securities of such series at their
last addresses as they shall appear upon the Security Register. Any notice which is mailed in the manner herein provided shall be conclusively
presumed to have been duly given, whether or not the Holder receives the notice. Failure to give notice by mail, or any defect in the
notice to the Holder of any Security of a series designated for redemption, as a whole or in part, shall not affect the validity of the
proceedings for the redemption of any other Security of such series.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
notice of redemption to each such Holder shall specify the principal amount of each Security of such series held by such Holder to be
redeemed, the date fixed for redemption, the redemption price, the place or places of payment, that payment will be made upon presentation
and surrender of such Securities, that such redemption is pursuant to the mandatory or optional sinking fund, or both, if such be the
case, that interest accrued to the date fixed for redemption will be paid as specified in such notice and that on and after said date
interest thereon or on the portions thereof to be redeemed will cease to accrue. In case any Security of a series is to be redeemed in
part only, the notice of redemption shall state the portion of the principal amount thereof to be redeemed and shall state that on and
after the date fixed for redemption, upon surrender of such Security, a new Security or Securities of such series in principal amount
equal to the unredeemed portion thereof will be issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
notice of redemption of Securities of any series to be redeemed at the option of the Issuer shall be given by the Issuer or, at the Issuer&rsquo;s
request, by the Trustee in the name and at the expense of the Issuer, provided the Issuer has provided the notice to the Trustee at least
five (5) Business Days prior to the date by which such notice must be sent to the Holders (or such shorter time period as the Trustee
shall accept).</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
later than 11:00 a.m. New York City time, on the redemption date specified in the notice of redemption given as provided in this Section,
the Issuer will deposit with the Trustee or with one or more paying agents (or, if the Issuer is acting as its own paying agent, set
aside, segregate and hold in trust as provided in <U>Section 3.4</U> ) an amount of money sufficient to redeem on the redemption date
all the Securities of such series so called for redemption at the appropriate redemption price, together with accrued interest to the
date fixed for redemption. If any or all of the outstanding Securities of a series are to be redeemed, the Issuer will deliver to the
Trustee at least 35 days prior to the date fixed for redemption an Officers&rsquo; Certificate stating the date of redemption and the
aggregate principal amount of Securities to be redeemed.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
less than all the Securities of a series are to be redeemed, the Trustee shall select, in such manner as it shall deem appropriate and
fair, Securities of such series to be redeemed in whole or in part. Securities may be redeemed in part in multiples equal to the minimum
authorized denomination for Securities of such series or any integral multiple thereof (in accordance with the applicable procedure of
the Depository in the case of any Global Security). The Trustee shall promptly notify the Issuer in writing of the Securities of such
series selected for redemption and, in the case of any Securities of such series selected for partial redemption, the principal amount
thereof to be redeemed. For all purposes of this Indenture, unless the context otherwise requires, all provisions relating to the redemption
of Securities of any series shall relate, in the case of any Security redeemed or to be redeemed only in part, to the portion of the
principal amount of such Security which has been or is to be redeemed.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
12.3 <U>Payment of Securities Called for Redemption</U>. If notice of redemption has been given as above provided, the Securities or
portions of Securities specified in such notice shall become due and payable on the date and at the place stated in such notice at the
applicable redemption price, together with interest accrued to the date fixed for redemption, and on and after said date (unless the
Issuer shall default in the payment of such Securities at the redemption price, together with interest accrued to said date) interest
on the Securities or portions of Securities so called for redemption shall cease to accrue and such Securities shall cease from and after
the date fixed for redemption to be entitled to any benefit or security under this Indenture, and the Holders thereof shall have no right
in respect of such Securities except the right to receive the redemption price thereof and unpaid interest to the date fixed for redemption.
On presentation and surrender of such Securities at a place of payment specified in said notice, said Securities or the specified portions
thereof shall be paid and redeemed by the Issuer at the applicable redemption price, together with interest accrued thereon to the date
fixed for redemption; provided that any semiannual payment of interest becoming due on the date fixed for redemption shall be payable
to the Holders of such Securities registered as such on the relevant record date subject to the terms and provisions of <U>Section 2.4
</U>hereof.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any Security called for redemption shall not be so paid upon surrender thereof for redemption, the principal shall, until paid or duly
provided for, bear interest from the date fixed for redemption at the rate of interest or Yield to Maturity (in the case of an Original
Issue Discount Security) borne by the Security.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
presentation of any Security redeemed in part only, the Issuer shall execute and the Trustee shall authenticate and deliver to or on
the order of the Holder thereof, at the expense of the Issuer, a new Security or Securities of such series of authorized denominations,
in principal amount equal to the unredeemed portion of the Security so presented.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
12.4 <U>Exclusion of Certain Securities from Eligibility for Selection for Redemption</U>. Securities shall be excluded from eligibility
for selection for redemption if they are identified by registration and certificate number in a written statement signed by an authorized
officer of the Issuer and delivered to the Trustee at least 40 days prior to the last date on which notice of redemption may be given
as being owned of record and beneficially by, and not pledged or hypothecated by either (a) the Issuer or (b) an entity specifically
identified in such written statement directly or indirectly controlling or controlled by or under direct or indirect common control with
the Issuer.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
12.5 <U>Mandatory and Optional Sinking Funds</U>. The minimum amount of any sinking fund payment provided for by the terms of Securities
of any series is herein referred to as a &ldquo;mandatory sinking fund payment&rdquo;, and any payment in excess of such minimum amount
provided for by the terms of Securities of any series is herein referred to as an &ldquo;optional sinking fund payment.&rdquo; The date
on which a sinking fund payment is to be made is herein referred to as the &ldquo;sinking fund payment date.&rdquo;</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
lieu of making all or any part of any mandatory sinking fund payment with respect to any series of Securities in cash, the Issuer may
at its option (a) deliver to the Trustee Securities of such series theretofore purchased or otherwise acquired (except upon redemption
pursuant to the mandatory sinking fund) by the Issuer or receive credit for Securities of such series (not previously so credited) theretofore
purchased or otherwise acquired (except as aforesaid) by the Issuer and delivered to the Trustee for cancellation pursuant to <U>Section
2.10</U> , (b) receive credit for optional sinking fund payments (not previously so credited) made pursuant to this Section, or (c) receive
credit for Securities of such series (not previously so credited) redeemed by the Issuer through any optional redemption provision contained
in the terms of such series. Securities so delivered or credited shall be received or credited by the Trustee at the sinking fund redemption
price specified in such Securities.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
or before the sixtieth day next preceding each sinking fund payment date for any series, the Issuer will deliver to the Trustee a written
statement (which need not contain the statements required by <U>Section 11.5</U> ) signed by an authorized officer of the Issuer (a)
specifying the portion of the mandatory sinking fund payment to be satisfied by payment of cash and the portion to be satisfied by credit
of Securities of such series, (b) stating that none of the Securities of such series has theretofore been so credited, (c) stating that
no defaults in the payment of interest or Events of Default with respect to such series have occurred (which have not been waived or
cured) and are continuing and (d) stating whether or not the Issuer intends to exercise its right to make an optional sinking fund payment
with respect to such series and, if so, specifying the amount of such optional sinking fund payment which the Issuer intends to pay on
or before the next succeeding sinking fund payment date. Any Securities of such series to be credited and required to be delivered to
the Trustee in order for the Issuer to be entitled to credit therefor as aforesaid which have not theretofore been delivered to the Trustee
shall be delivered for cancellation pursuant to <U>Section 2.10</U> to the Trustee with such written statement (or reasonably promptly
thereafter if acceptable to the Trustee). Such written statement shall be irrevocable and upon its receipt by the Trustee the Issuer
shall become unconditionally obligated to make all the cash payments or payments therein referred to, if any, on or before the next succeeding
sinking fund payment date. Failure of the Issuer, on or before any such sixtieth day, to deliver such written statement and Securities
specified in this paragraph, if any, shall not constitute a default but shall constitute, on and as of such date, the irrevocable election
of the Issuer (i) that the mandatory sinking fund payment for such series due on the next succeeding sinking fund payment date shall
be paid entirely in cash without the option to deliver or credit Securities of such series in respect thereof and (ii) that the Issuer
will make no optional sinking fund payment with respect to such series as provided in this Section.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the sinking fund payment or payments (mandatory or optional or both) to be made in cash on the next succeeding sinking fund payment date
plus any unused balance of any preceding sinking fund payments made in cash shall exceed $50,000 (or a lesser sum if the Issuer shall
so request) with respect to the Securities of any particular series, such cash shall be applied on the next succeeding sinking fund payment
date to the redemption of Securities of such series at the sinking fund redemption price together with accrued interest to the date fixed
for redemption. If such amount shall be $50,000 or less and the Issuer makes no such request then it shall be carried over until a sum
in excess of $50,000 is available. The Trustee shall select, in the manner provided in <U>Section 12.2</U>, for redemption on such sinking
fund payment date a sufficient principal amount of Securities of such series to absorb said cash, as nearly as may be, and shall (if
requested in writing by the Issuer) inform the Issuer of the serial numbers of the Securities of such series (or portions thereof) so
selected. Except as aforesaid, any moneys in the sinking fund for such series at the time when any such default or Event of Default shall
occur, and any moneys thereafter paid into the sinking fund, shall, during the continuance of such default or Event of Default, be deemed
to have been collected under Article Five and held for the payment of all such Securities. In case such Event of Default shall have been
waived as provided in <U>Section 5.10</U> or the default cured on or before the sixtieth day preceding the sinking fund payment date
in any year, such moneys shall thereafter be applied on the next succeeding sinking fund payment date in accordance with this Section
to the redemption of such Securities.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the parties hereto have caused this Indenture to be duly executed, and their respective corporate seals to be hereunto
affixed and attested, all as of ___________ __, 202__.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JANONE
    INC.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[INSERT
    NAME OF TRUSTEE]</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">STATE
OF ________ )</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 1in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)
ss.:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">COUNTY
OF ________ )</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
this ____ day of ___________, 202__, before me personally came ____________ to me personally known, who, being by me duly sworn, did
depose and say that s/he resides at ________________, _________; that s/he is an officer of JANONE INC., one of the corporations described
in and which executed the above instrument, and that he signed his name thereto by authority of the Board of Directors of said corporation.</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notary
    Public</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Notarial
Seal]</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">STATE
OF ________ )</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 1in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)
ss.:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">COUNTY
OF ________ )</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
this ____ day of ___________, 202__, before me personally came ____________ to me personally known, who, being by me duly sworn, did
depose and say that s/he resides at ________________, _________; that s/he is an officer of [INSERT NAME OF TRUSTEE], one of the corporations
described in and which executed the above instrument; and that he signed his name thereto by authority of the Board of Directors of said
corporation, by like authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notary
    Public</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Notarial
Seal]</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 26; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>













</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>ex5-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
5.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: left; font: 10pt Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"></P>

<P STYLE="font: 10pt Aptos; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex5-1_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Aptos; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 70%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Randy
                                            Katz</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">T
    (213) 417-5310</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F
    (213) 488-1178</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:
    rkatz@clarkhill.com</FONT></P></TD>
    <TD STYLE="font-size: 10pt; width: 30%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clark
                                            Hill LLP</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">555
    Flower Street, 24<SUP>th</SUP> Floor</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Los
    Angeles, CA 90071</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">T
    (213) 891-9100</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F
    (213) 488-1178</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
17, 2024</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Via
e-mail: <U>t.isaac@isaac.com</U></FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JanOne
Inc.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">325
E. Warm Springs Road, Suite 102</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Las
Vegas, Nevada 89119</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
Tony Isaac, President and CEO</FONT></P>

<P STYLE="font: 10pt Aptos; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font: 10pt Aptos; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Aptos; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Re:</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Aptos"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JanOne Inc.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dear
Mr. Isaac:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have acted as counsel to JanOne Inc., a Nevada corporation (the &ldquo;<U>Company</U>&rdquo;), in connection with the filing of a Registration
Statement on Form S-3 filed on April 17, 2024 (the &ldquo;<U>Registration Statement</U>&rdquo;) under the Securities Act of 1933,
as amended (the &ldquo;<U>Securities Act</U>&rdquo;). The Company has provided us with a prospectus (the &ldquo;<U>Prospectus</U>&rdquo;),
which forms part of the Registration Statement. The Prospectus provides that it will be supplemented in the future by one or more prospectus
supplements (each, a &ldquo;<U>Prospectus Supplement</U>&rdquo;). The Registration Statement, including the Prospectus as supplemented
from time to time by one or more Prospectus Supplements, provides for the registration by the Company of one or more of the following
securities with an aggregate offering price of up to $100,000,000: (i) shares of the Company&rsquo;s common stock, par value $0.001 per
share (the &ldquo;<U>Common Stock</U>&rdquo;); (ii) shares of the Company&rsquo;s preferred stock, which may be issued in one or more
series (the &ldquo;<U>Preferred Stock</U>&rdquo;); (iii) debt securities, in one or more series, which may be convertible into shares
of Common Stock or shares of Preferred Stock (the &ldquo;<U>Debt Securities</U>&rdquo;); (iv) warrants to purchase shares of Common Stock,
shares of Preferred Stock, or Debt Securities, or any combination thereof (the &ldquo;<U>Warrants</U>&rdquo;); (v) rights for the purchase
of shares of Common Stock, shares of Preferred Stock, or Debt Securities (the &ldquo;<U>Rights</U>&rdquo;); and (vi) units comprised
of one or more shares of Common Stock, shares of Preferred Stock, Debt Securities, Rights, or Warrants, in any combination (the &ldquo;<U>Units</U>&rdquo;).
The Common Stock, the Preferred Stock, the Debt Securities, the Rights, the Warrants, and the Units are each described in the Registration
Statement, and are collectively referred to herein as the &ldquo;Securities&rdquo; and are sometimes individually referred to as a &ldquo;Security.&rdquo;
The Securities may be issued by the Company in one or more series and may be offered and sold from time to time in amounts, at prices
and on terms to be determined at the time of the offering as set forth in the Registration Statement, any amendments thereto (including
post-effective amendments) and one or more Prospectus Supplements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
have requested our opinion as to the matters set forth below in connection with the Registration Statement. In connection with this opinion,
we have examined and relied upon originals, or copies certified to our satisfaction, of such records, documents, certificates, opinions,
memoranda, and other instruments as in our judgment are necessary or appropriate to enable us to render the opinion expressed below.
As to certain factual matters, we have relied upon a certificate of an officer of the Company and have not independently sought to verify
such matters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="text-align: left; font: 10pt Aptos; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JanOne S-3 exhibit
    5.1 april 2024.1</FONT></TD>
    <TD STYLE="font: 10pt Aptos; width: 50%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">clarkhill.com</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JanOne
Inc.<BR>
Attn: Tony Isaac, President and CEO<BR>
April 17, 2024<BR>
Page 2</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
rendering this opinion, we have assumed without independent verification: (i) the genuineness and authenticity of all signatures on original
documents; (ii) the authenticity of all documents submitted to us as originals; (iii) the conformity to originals of all documents submitted
to us as copies; (iv) the accuracy, completeness and authenticity of certificates of public officials; (v) that each natural person signing
any document reviewed by us had the legal capacity to do so; and (vi) the due authorization, execution, and delivery of all documents
where authorization, execution and delivery are prerequisites to the effectiveness of such documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent relevant to any opinion below, we have also assumed that, at the time of the sale or delivery of any Securities pursuant to
the Registration Statement: (i) the Registration Statement, as amended by any amendments thereto (including post-effective amendments),
will have become effective under the Securities Act and the rules and regulations promulgated thereunder, and such effectiveness will
not have been terminated or rescinded, and will comply with all applicable laws; (ii) one or more Prospectus Supplements relating to
the Securities being offered will have been prepared and filed in compliance with the Securities Act and the rules and regulations promulgated
thereunder, and will comply with all applicable laws; (iii) if the Securities being offered are to be sold pursuant to a purchase, underwriting,
or similar agreement (an &ldquo;<U>Underwriting Agreement</U>&rdquo;), such Underwriting Agreement relating to the Securities being offered,
in the form filed as an exhibit to the Registration Statement, any post-effective amendment thereto, or a Current Report on Form 8-K
under the Securities Exchange Act of 1934 (the &ldquo;<U>Exchange Act</U>&rdquo;), will have been duly authorized, executed, and delivered
by the Company and the other parties thereto, and will constitute a valid, binding, and enforceable obligation of the Company and the
other parties thereto, enforceable against each of them in accordance with its terms, and any Securities offered and sold pursuant thereto
will have been offered and sold in accordance with the terms thereof; (iv) any indenture (&ldquo;<U>Indenture</U>&rdquo;) relating to
the Debt Securities, any warrant agreement (&ldquo;<U>Warrant Agreement</U>&rdquo;) relating to the Warrants, and any unit agreement
(&ldquo;<U>Unit Agreement</U>&rdquo;) relating to the Units, in each case in the form filed as an exhibit to the Registration Statement,
any post-effective amendment thereto, or a Current Report on Form 8-K under the Exchange Act, will have been duly authorized, executed,
and delivered by the Company and the other parties thereto, and will constitute a valid, binding, and enforceable obligation of the Company
and the other parties thereto, enforceable against each of them in accordance with its terms; (v) the Securities being offered and any
related Underwriting Agreement, amendments to the Articles of Incorporation, Indenture, Warrant Agreement, or Unit Agreement, as applicable,
describing such Securities will conform in all material respects to the description thereof in the Registration Statement, any amendments
thereto (including post-effective amendments), and the Prospectus Supplement relating to the Securities being offered; (vi) the Securities
being offered will have been issued and sold in compliance with applicable federal and state securities laws and for the consideration
set forth in, and otherwise as contemplated by and in conformity with, the Registration Statement, any amendments thereto (including
post-effective amendments), and the Prospectus Supplement relating to the Securities being offered; (vii) any applicable listing or other
requirements of any stock exchange on which the Securities being offered may be listed will have been complied with; (viii) the rights,
powers, privileges, preferences, and other terms, if any, of any Security to be established after the date hereof, and the terms of the
issuance, sale, and delivery of any Security being offered (a) will be in conformity with the Articles of Incorporation and Bylaws as
then in effect, (b) will not violate any applicable law or result in a breach of or default under any agreement or instrument to which
the Company is then a party or which is then binding upon the Company, and (c) will comply with any requirement or restriction imposed
by any court or governmental body having jurisdiction over the Company; (ix) with respect to any shares of Common Stock or Preferred
Stock being offered, there will be sufficient shares of Common Stock or Preferred Stock, as applicable, authorized, designated (in the
case of Preferred Stock), and available for issuance, and that the consideration for the issuance and sale of the Common Stock or Preferred
Stock is in an amount that is not less than the par value of the Common Stock or Preferred Stock, as applicable; (x) any Securities issuable
upon conversion, exchange, or exercise of any Security being offered will have been duly authorized, created, and, if appropriate, reserved
for issuance upon such conversion, exchange, or exercise, and that upon the issuance of any shares of Common Stock or Preferred Stock
issuable upon conversion or exercise of any of the Securities, the total number of shares of Common Stock and Preferred Stock of the
Company, issued and outstanding, as applicable, will not exceed the total number of shares of Common Stock and Preferred Stock that the
Company is then authorized to issue under its Articles of Incorporation; and (xi) the Company shall be a corporation duly organized,
validly existing, and in good standing under the laws of the State of Nevada and shall have the necessary power and authority to issue
and sell such Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="text-align: left; font: 10pt Aptos; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JanOne S-3 exhibit
    5.1 april 2024.1</FONT></TD>
    <TD STYLE="font: 10pt Aptos; width: 50%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">clarkhill.com</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JanOne
Inc.<BR>
Attn: Tony Isaac, President and CEO<BR>
April 17, 2024<BR>
Page 3</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
opinion herein is expressed solely with respect to the federal laws of the United States and the Nevada General Corporation Law (including
the statutory provisions and all applicable provisions of the Nevada Constitution and the reported judicial cases interpreting those
laws currently in effect). Our opinion is based on these laws as in effect on the date hereof. We express no opinion as to whether the
laws of any jurisdiction are applicable to the subject matter hereof. We are not rendering any opinion as to compliance with any federal
or state law, rule, or regulation relating to securities, or to the sale or issuance thereof. As to any facts material to the opinions
expressed herein that were not independently established or verified, we have relied upon oral or written statements and representations
of officers or other representatives of the Company and others.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
the basis of, and in reliance on, the foregoing examination and subject to the assumptions, exceptions, qualifications, and limitations
contained herein, if the board of directors of the Company has taken all necessary corporate action to authorize the issuance and terms
of the applicable Securities, including the terms of the offering thereof and related matters in accordance with the applicable underwriting,
purchase, or similar agreement for such offering, and when issued and paid for as described in the Registration Statement (including
any shares of Common Stock or shares of Preferred Stock issuable in connection with the exercise of any Warrants, or any Units), we are
of the opinion that the Securities will be validly issued, fully paid, and non-assessable, enforceable against the Company in accordance
with their terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
opinion is for your benefit in connection with the Registration Statement and may be relied upon by you and by persons entitled to rely
upon it pursuant to the applicable provisions of the Securities Act. We hereby consent to the filing of this opinion as an exhibit to
the Registration Statement and to the reference to our firm under the caption &ldquo;Legal Matters&rdquo; in the Prospectus included
in the Registration Statement. In giving such consent, we do not thereby admit that we are experts with respect to any part of the Registration
Statement or the Prospectus, within the meaning of the term &ldquo;expert,&rdquo; as used in Section 11 of the Securities Act, or the
rules and regulations promulgated thereunder, nor do we admit that we are in the category of persons whose consent is required under
Section 7 of the Securities Act, or the rules and regulations of the Securities and Exchange Commission promulgated thereunder. Our opinion
is expressly limited to the matters set forth above, and we render no opinion, whether by implication or otherwise, as to any other matters
relating to the Company, the Securities, or the Registration Statement. This opinion is expressed as of the date hereof, and we disclaim
any undertaking to advise you of any subsequent changes in the facts stated or assumed herein or of any subsequent changes in applicable
law. We bring to your attention that our legal opinions are an expression of professional judgment and are not a guarantee of result.</FONT></P>

<P STYLE="font: 10pt Aptos; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font: 10pt Aptos; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Aptos; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very
    truly yours,</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font: 10pt Aptos"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Aptos"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font: 10pt Aptos"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Aptos"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Clark Hill PLC</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="text-align: left; font: 10pt Aptos; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JanOne
    S-3 exhibit 5.1 april 2024.1</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Aptos; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">clarkhill.com</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>4
<FILENAME>ex23-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
23.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Consent
of Independent Registered Public Accounting Firm</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
consent to the use of our report dated April 8, 2024, with respect to the consolidated balance sheets of JanOne Inc. as of December 30,
2023 and the related consolidated statements of income, changes in stockholders&rsquo; equity, and cash flows for the year then ended
included in the Annual Report on Form 10-K of JanOne Inc. for the year ended December 30, 2023, filed with the Securities and Exchange
Commission on April 8, 2024, which is incorporated by reference in this Registration Statement on Form S-3 and related Prospectus of
JanOne Inc., and to the reference to our firm under the heading &ldquo;Experts&rdquo; in the Registration Statement and related Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
Hudgens CPA, PLLC</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Houston,
Texas</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
17, 2024</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.3
<SEQUENCE>5
<FILENAME>ex23-3.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 23.3</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>Consent of Independent Registered Public Accounting
Firm</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
hereby consent to the incorporation by reference of our report dated April 17, 2023, with respect to the consolidated financial statements
of JanOne Inc. as of and for the year ended December 31, 2022, which are incorporated by reference in this Registration Statement on
Form S-3 and related Prospectus of JanOne Inc. Our report contained an explanatory paragraph regarding substantial doubt about the Company's
ability to continue as a going concern.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also consent to the reference to our firm under the heading &ldquo;Experts&rdquo; in the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
<I>Frazier &amp; Deeter, LLC</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tampa,
Florida</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
17, 2024</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 8pt"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>6
<FILENAME>ex107.htm
<DESCRIPTION>CALCULATION OF FILING FEE TABLE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
107</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Calculation
of Filing Fee Table</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Form
S-3</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Form
Type)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>JanOne
Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
Name of Registrant as Specified in its Charter)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Table
1. Newly Registered Securities</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Security</FONT></P>
                                                                     <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Type</FONT></P></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Security</FONT></P>
                                                                     <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class Title</FONT></P></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fee</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Calculation</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rate</FONT></P></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registered</FONT></P></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proposed</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maximum</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Offering</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Price Per</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unit</FONT></P></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maximum</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aggregate</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Offering Price</FONT></P></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fee Rate</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount of</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registration</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fee</FONT></P></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 9%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fees to be Paid</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 9%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 9%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common Stock
    (1)(2)</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 4%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">457(o)</FONT></TD><TD STYLE="width: 1%; text-align: left"></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 7%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)(2)(3)</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ndash;</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 7%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)(2)(3)</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.00014760</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 6%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)(4)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fees to be Paid</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preferred Stock (1)(2)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">457(o)</FONT></TD><TD STYLE="text-align: left"></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)(2)(3)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ndash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)(2)(3)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.00014760</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)(4)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fees to be Paid</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rights (1)(2)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">457(o)</FONT></TD><TD STYLE="text-align: left"></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)(2)(3)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ndash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)(2)(3)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.00014760</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)(4)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fees to be Paid</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants (1)(2)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">457(o)</FONT></TD><TD STYLE="text-align: left"></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)(2)(3)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ndash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)(2)(3)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.00014760</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)(4)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fees to be Paid</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Debt</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Debt Securities (1)(2)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">457(o)</FONT></TD><TD STYLE="text-align: left"></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)(2)(3)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ndash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)(2)(3)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.00014760</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)(4)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fees to be Paid</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Units (1)(2)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">457(o)</FONT></TD><TD STYLE="text-align: left"></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)(2)(3)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ndash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)(2)(3)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.00014760</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)(4)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unallocated (Universal) Shelf
    (1)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)(2)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">457(o)</FONT></TD><TD STYLE="text-align: left"></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)(2)(3)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ndash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100,000,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.00014760</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)(4)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total
    Offering Amounts:</B></FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100,000,000</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>14,750</B></FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>(1)</U></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
    securities that may be offered and sold from time to time in one or more offerings by JanOne Inc..</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>(2)</U></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
    is being registered hereunder an indeterminate number of shares of (a) common stock, (b) preferred stock, (c) rights, (d) warrants,
    (e) debt securities, and (f) units, consisting of some or all of these securities in any combination, as may be sold from time to
    time by the Registrant. Any securities registered hereunder may be sold separately or as units with other securities registered hereunder.
    There is also being registered hereunder an indeterminate number of shares of common stock, preferred stock and debt securities as
    shall be issuable upon conversion, exchange or exercise of any securities that provide for such issuance. Pursuant to Rule 416(a)
    promulgated under the Securities Act of 1933, as amended, this registration statement also covers an indeterminate number of securities
    that may become issuable as a result of stock splits, stock dividends or similar transactions relating to the securities registered
    hereunder. In no event will the aggregate offering price of all types of securities issued by the Registrant pursuant to this registration
    statement exceed $100,000,000.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>(3)</U></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    proposed max mum aggregate offering price for each class of securities to be registered is not specified pursuant to General Instruction
    II.D. of Form S-3.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>(4)</U></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registration fee of $14,750 is calculated in accordance with Rule 457(a) of the Securities Act.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>forms-3_001.jpg
<TEXT>
begin 644 forms-3_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !# 24# 2(  A$! Q$!_\0
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M^TP/^6Z?^A"OIU!A:5*K[17L/-,L^H2C'FO>XZBBBMCR HHR*,T %%)D49%
M"T49I,B@!:*3(HS0 M%&::\BHK,S  #))I-I*[ ,U')/#$,R2(@]6.*Y75/$
MDDC-%8D*@.#+CD_05@/(\S%Y79VZDL<UX&*SNE2ERTES/\#TZ.75)KFF[(]"
M_M.QSC[7!G_?%3I<0R_ZN6-_HV:\S^4>GT-.5FC8%&*MVVG!KBCQ!-/WH'2\
MKC;W9'IU**XS3/$D]NRQWA\V+IOQ\R_XUV$,J21!T8,K#(([U[^#QM+%1O3>
MO8\JOAYT7:1)129%&17<8"T49HR* "BC-&: "BBC- !129%+F@ HI,CUHW#U
MH 6BBB@ IKC*FG4'I0!SWB#PI8^)#"-0DN-D.2B1R;5SZX[FO-/'OA+3/#-M
M8O8"4&>1E?S'W< 9KVHBO,_C /\ 0]*_Z[/_ .@UA7C'D;/=R7$U5BX4U)\M
M]CR^T_X_[3_KM'_Z$*^G,XQ7S':?\?\ :?\ 7>/_ -"%?31.#@=:RPFS/2XI
M_B4_1_FAD]S#:P/-/(L<2#+.QP /<UQUY\4?#MM*R127%R1U,,65_,UP'COQ
M5/KVK3644A&FV[E%0=)6'5C^/2N:L[*ZU&Y6VLK>2XF;I&BY/U]J*F(=[1'@
M<@I^R57%RM?6W^;/;-+^(_A[4YE@^T/;3,<!;A-N?H>E:&K^,=$T.Y2WO[LQ
MRNF]0$)^7\*\:N? _B6VMS+-I,CQ@9(1PY'X5D7%W<W0@6XD9_LR&)-_+*N?
MNGZ>])XB<8ZK4N&0X2O4O1J7CUU/?-&\8Z+KUXUGI]T9)E3>5*$<?C6CJFJV
MFC6#WM])Y<"8#,!G&>*\B^%7'B^3_KU8?J*[SXEC_BAKW_>3_P!"%;PJ.4.8
M\;%Y?3HX^.&B_==OQ%3XD^%W=5&H'+' _=MUZ>E;&J>(M*T>V6XOKV.%&&5!
M/S-]!UKYT!(=3W# CW(Y'%:UMIFN^*KM[N"VFO')P9FP$7_9!/&!6$<3)]#V
MJ_#N'IM2=3ECUN_R/3G^+&@+(0L5\ZC^(0\?SK>T/QEHNOL8[&Z_? 9,4@VM
MCZ5XCJOAO6=$42:C8O'$3@2 AE!^HZ5FPW$UI/'=6\C)-"WF(X.""/\ /2DL
M1-.TD:SR#!UJ+EAI-M>=T?3V<C-<QXHU%E"V,9QO&9"/3TK8T2^_M/0[*][S
MPJY^I%<9JTQGU:ZD/0/M'X<5PYQB)4L/:+U9\Q@J%Z[4^A44%F5%7+$X51W/
MI76:9X:ACC62\ ED(R5/W165X:MA/JF]L8A7</J:[4 UPY-@(3A[:HKWV-\P
MQ,E+V<="M_9MGLVBVB _W163J7AF&2)I+,"*4<[?X3^':NAQ2-TKWZN#HU8\
MKB>7"M4@[IGF3*R,R,"K#@@]171>%K]E=K%S\N-T?MZBJOB>V6#4Q(HP)EW$
M>XJCI<IAU:U<'_EH%_.OC*+E@\;R+H['T%2V)PSDUTN=]//';P--(<(@R3CH
M*S1XDTSKY_'^Z:L:SG^Q[K_KF:\_&"O2O?S/,JF%G&,$G<\O!X2-=-R9Z++?
MVL%MY\LZI&1D$FLQ_%6GJ?E$KCU"\5RZ0WNIR@HC2L@P#T"BG7&EWUJGF36Y
M"=V!SBN*KFN*DN:C"T3HIX*C%VJ2U.QL]<L;UPD<A63^XXP3]*T@<]*\PR<A
ME.&'(8=J]!TBZ:[TN&=N6*X/U'%>AE>92Q3<)K5'/C<&J%I1>A>)&:J7FIVE
MB,SS*I_N]_RJEKVK?V?;A(L&XDSM]O>N,_>W,^27EF<]>K$T8_-%0E[*FKR%
MAL%[5<\W:)UI\5V /W)B/7;5VSUVPO&V)-M?^Z_!KF$\-:DZ;]L2D_PEN:S[
MFTN+.417$9C;JI['Z&O._M+'TK3JQ]WT.KZGAJFE.6IZ%<>8]N_DDB0K\I'K
M5*%=0%TH<YB#9)XZ8Z?GS6;X=U>29A93MO8#,;'N/2NDKW:%2&*BJL&>;4A*
MC)PDA]%%%>@<X44W)IAF4.(RR[SR%SSBDVNH[$AKS+XP_P#'GI7_ %V?_P!!
M->EDUYE\7G#6>E@=1,__ *":QK? SU<F_P!^I^OZ'F-I_P ?]I_UWC_]"%?1
M7B"Y:R\/ZA=(<-' S _A7SQ81M+J=E&@RS7$8'_?0KZ"\30O=>%]3@099[9P
M!^%8X;X9'O<1<KQ-%/\ K5'SFIQ$"Q.<9)/K7N7P[T.'3?"]O=;1]IO%\V1\
M<\]!] *\-7YX0,]5ZU[YX#U.+4/"%AY; O"GE2+W5EXJ<+;F;9T\22DL+!1^
M%O7[CI-N.AX]*\4^)]G!9^+(S!&J&6W#OM&-S9QFO;L@CUKQ;XK,&\66X!!Q
M:\\]/FKHQ%N0\'AYOZZEY,;\*_\ D;Y/^O8_^A"N]^)G_(BWO^\G_H0K@_A5
MSXOE_P"O4_\ H0KO/B9_R(U[_O)_Z$*SI?P3LS+_ )'$/6)X:J[I%4]&=0?H
M37TKIUI!:6$$-O$L4:Q@!5& .*^:X_\ 71_]=$_]"%?3< S;Q?[@_E4X7J;\
M4-_NUZ_H9OB2UCN?#>HQ2J&4P/\ RKYQ4YA!/]VOI76^-!O_ /KW?_T$U\U)
M_J!_N_TI8K=&G"[?)47H?0W@K_D2M(_Z]EKEKY=FHW2GKYK5U/@D?\45I'_7
MNM8_B:T:#4O.4?),,Y_VAV_*O+SNE*6'C)=#Q,--1QE2+ZM_FRQX3<+?3QYY
M* _K77],5YSIUZVGWT5P,D+PP'<&N_MKJ.ZB26)@R,,@BKR3$1E0]G?5=#FS
M&E)5>?HRQ36Z4N?:J]Y=Q6ENTLSA4 _/Z5[LI**O(\Y)MV1S'BR0->VR#JJ$
MG\ZQK%2^HVJCJ95Q1?73WU[)</P6/"^@'2M'PW:-<:F)L?) ,D_[1Z5\')_6
ML=S0[GTL5[#"V?8ZC6?^0-=?]<S7GV<)^%>@ZQ_R!KK_ *YFO/3_ *O\*[<^
M7[V"\CFROX)'HFG0QPZ? L:A 4!X'?%3SHLD$BL 592#3;(?Z#!_US7^52N/
MW;?0U]3!+V*5NGZ'BR?OW\SS0C!(]"1^M=MX:_Y </U;^9KB6^^W^\?YUVWA
MK_D!Q?5OYU\IDO\ O<O1_F>YF/\  C?R.:UZ8S:S-D\1X0>W>C1[ZVT^X>:=
M'9B,+M&<>M,UJ,QZU<@_Q-N'T(I-+TY=2F>+S_+=1N QG(KB<JOUYN'Q7=KF
M]J?U9<VUCH?^$LL?^><__?-9VL:S9ZG9^6D4@D!!1F7O4_\ PB)_Y_/_ !S_
M .O1_P (B>][_P".?_7KUZO]IU8.$HJS]#@A]2A)2C)W,"RE:VOX)5/W7'\\
M5Z0.0#7+CPD0ZG[8< @_<_\ KUU"@A0#79D^&K8>$HU%8QQ]:G6DG =1117N
MGG#)&"(S'@ 9KSV]U&:ZU%KQ'9&!Q&0<$"O1" 5YK)U'1HKN,M D$<_9VB#C
M\17EYCA*N(BE3E:QV82M3I2;FKG-)X@U0@1I('=N!A,L:\^\9ZM]NOH;-9O-
M%KN,K@Y#2MU ^@&/S]*[O4/!?B*]5HH]=M;:%QAEM[7RRP]SG-5M.^$EC;R(
MVH7TETH/^K1?+7\>Y_.L,/@J\/XLG(]["8K!8>?MI-76R1S/PY\/RZKKJ:BZ
M$6=D=P?L\G8#UQUKVQ@'0JPR",&H;*SMK"U2VM8$AA0 *B+@"K.!Z5Z].FH1
ML>+F&/GC:WM7MT/GGQ7H$WAW79K9D/V>5C);/V92>GU!XJ'0_$6I>';HSZ?,
MH#_ZR)QN1_J/7WKWG6-$T_7+1K6^MUE0]">"I]0>QKS^[^$.Z0M9:JRIV6:/
M<1^((KEG1DI<T#Z7!YWAJU!4<8O+R9FW/Q8UJ6#9!96L$A&/,R6_('%<5=W%
MU>3F\O)))99\MYLG\?T]ATKT_2_A);0SB35+][E1SY4:[%/L3R3^E:VO_#G3
M];NH)4N)+1((1"D4*C:!G-*5*K./O%4<TRS"U>6A&RZLXGX5?\CA+C_GU/\
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L8AZ4 444NA/44T4450"8&:.]%%+H4!ZT444WN2@I:**"A:***8@HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>forms-3_002.jpg
<TEXT>
begin 644 forms-3_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #" : # 2(  A$! Q$!_\0
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M?)?O<![B>\G,DMPTIW!\\ >F.U=QV-<K'X?NKC2Y;*8B$>;(ZE6()8G*M^%
M&_9B&S@BLA<^8T2!<NV6('<U/Y\?F+'YB[V&0N>2/:N?D\,M,J2FXVWNP"28
M9^8COBGVVF:C'JUE-=.DPAC8-*..O08H Z(4M(*6@ HHHH **** "BBB@ HH
MHH **** "BBB@#%\2>';/Q/IO]GWK2+&)%D!C."".15/2?!=AI6LG5A+-/>>
M5Y2NYP%7TQ4WB6>ZB;3_ +*T@#3D.$Z'C@'VS5'S?%:H'Q&S>4'V;?X\\K^5
M '6=*6N2\WQ6V'VQKE&;9M'4=!5OP[<7DVH:DMRSE59,!APIQR!0!T=% HH
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MK,L/^1DU/_=2MFL:P_Y&74O]U* -JBBB@ HHHH **** "BBB@ I.:6DSSWH
MJZG_ ,@N[_ZXM_*L[PC_ ,BK8?\ 7/\ K6AJ?_(+N_\ KDW\JS_"'_(JV'^Y
M_6D Z[_Y&JQ_ZXO6K/\ \>\O^X?Y5E7?_(U6/_7%ZU)XWE@=$<(S#&2,XI@5
M-"_Y EK_ +O]356Y_P"1LLO^N#U>TVS:QLX[9IO-V<!L8JC=?\C99?\ 7!Z
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M#_D9-3_W4K:K%L/^1EU/_=2@#:I#2TAZ4 <'J/\ R-NH?]<TH-&I?\C9?_\
M7-** $[<U?\ "7_(6U/Z)5#M6AX3_P"0KJ?T2@#KJ*2EH *;DYYIW:L3Q!;7
MMS:Q)9P^:P?)!E* #UXZT :&I?\ (+N_^N3?RK.\(?\ (K6'_7/^M5I=.OX/
M#1A2_D1HX6WF50Y;CUJQX/S_ ,(II^3D^7R?QH ?=_\ (U6'_7%ZV16-=_\
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M2UTW:N/%O=6_Q!T_[3>&XS:2;<H%V_E78#I0!B:?_P C5JO^Y'_*MRL+3_\
MD:M6_P!R+^5;M !6+8?\C)J?^ZE;58MA_P C)J?^ZE &U2'I2TAZ4 <)J/\
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M/*;D'/:J?ACCPW9?]<Z (Y_^1OL_^O=ZVATK%N./%UG_ ->[UM#I0 M8T_\
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K %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>forms-3_003.jpg
<TEXT>
begin 644 forms-3_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #  (\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#WQAN0KZC%
M<TWAR]5U\K4G5!R5)/)_P':NHQ1B@#'M9+A->N;62Y>6+R5D564#8<XXK7%9
M47_(U7'_ %ZI_P"A&M:@"&6;RY8DV.V\XRHX'UJ45#-&[21,DI15.64#[U3"
M@!:*** "BBB@ HHHH **** "BBB@ HHHH 0G%,\U1_&OYBFSQ>?;R0[BN]2I
M8=1FN:3P<L00"^E;:<@,,_A_A[T :D6?^$IN/^O1/_0C6MFL.SMUA\4WA#RM
MOMD)WL3CYCT]*W * ,V]E87<)"R;8#O? .&!XX]:TA5:Y,XN+<1 ^7N_>8]*
ML@4 +1141GC65(RP#OG:/6@"6BBB@ HHHH **** "BBB@ HHHH 3%&*"P R2
M *K?;[0@$7,6#R/F% %*'CQ5<?\ 7JG_ *$:UZR(N?%-P?\ IU3_ -"-:V:
M(9H1)+$YD9=AS@'AOK4PJE>([WEFRJ657))'0<5=% "GI5=UD^T1D(A3G<QZ
MCZ58/2HS(BR*A8!V^Z#U- $@HHHH 3-+4+),;A&5P(@#N7'4U*.E "T444 %
M%%% !1110!%(JS1O&V"",$ U@Q^#[!"K"28[3D=.">N/;VJ/P^ZW&IW,BQK"
M47:\8E+DL3U.:Z8=* ,2TMXH/%5WL!!>V0L2V<_,:VZR8_\ D:;G_KU3_P!"
M-:QH S[VX\N[A <A8SNE'L>!^M: Y -4KF&T>1C,X#%0&RV,#/%7%H =6?/=
MQQW\4;*">[%>5],5?/2J4\DHNU"W$"KQ\C#YC0!>HS133D=.M "Y'K2YK)D6
MY^W0J\B&;8^T@$ >G%:<881J'(+XY(]: 'T444 %%%% !1110!RWAW8VL:NQ
M^1EE(V8Q@9Z^]:QUS3=PQ>1'/ (.?;BLW1(H?[3U&-;J"8ECY\:*<Y/]*LKX
M6TE,;+;8%)("L< ]\?6@!\#J_BBYVLIQ:IG!SCYC6OU-8]M#'%XINBB*NZU0
ML0.OS&M=F"+EB .Y)Q0!ERW4<DY5[:-VWF,D]< 9J_:3?:+:.4@#<.@Z"LZ_
MGVW64VGR@'7'=B<'/KQ6I&Z-@*R],X4]J )#T-8=S*YOT:2V02+T4D'=Z<XK
M=[5F7-C++?"92FT%<Y)SQ0!>B9VB5I%V.1RN>E2T4E %&:YA6]4%5)3Y6?NI
M/0?C5X=*RI;B,ZBD@&5C^5O<GN/I6HI!&001[4 *3BH_/C^T>1N_>;=V/:DE
M,PFCV;?+YWYZ^V*K>9=>9Y6V/SL[M^T[=F>F?6@"_14*>=YS[BIBXVXZ^^:F
MH A$\9G:$-^\ R1CM4U)@9S@9]:6@#C/!XC.J:LZR-([/\TA&-W/6NR %<QH
M4EG'K6KQP/(TJONDW1[<<]CW%75\4Z6S;1,V<E<;><CJ/P[T 2Q?\C5<?]>J
M?^A&F:]::S=0QKI%Y:6Y&?,%S 9 _IC!&*2VFCE\4W7ER*Q6U0-CM\QK1N85
ME"N6<&/+ *>#QW]: .%>Q\;1.Q?6M)1Q^\*FT/!/&/O>E:ND:9XMM[R)[W4M
M->W0[66.T*NZ=N=W!JT6S%DY8F)0<G))W5HV42S2O(7D^24E<,<$?UH T02:
MRKNYF341&LI5,KQQWK4=A'&SG) &<#K6)/?QR7L<RQ@J@Q\R\GUH WJ::BM[
ME+B+S$#;<XY&*E- &/+Y:7FU8E"(?+*Y^]N[^U:Z*L:*J@ *, #M6"RE':-O
M]8"5)SGEON_Y[5N0*4@C5CEE4 T 2&L_>?L^?MW_ "VQOV^_W:N3RK!$TK*S
M!1G"C)JB(+;'V?$W7[1G'Z9H TLTM103+<1+*JL W(W#!J6@ HJ$3@W#08;<
MJ[LXXQ]:FH Y7P_)YFL:Q!*"Q\P_,>XST_"M0>'=+SN^R+G.[.3U]:Q?!P6Y
MNK_46;$UP07B /R]\\UU^: ,B!%7Q3<;54?Z*F<#'\1K1N!*8F\EL/C(.,U0
MB_Y&JX_Z]4_]"-:IH PC#-O\TV[ [C)C'KQCKUJ[IZS1KL?Y8HQL"XZGU'M4
M-TUR;A4)9/.8HH5N@'.:T8C(8E,JA7(^8 YQ0 VYN%@0G 9NR;@"?IFN?=H6
MGW1HBQYY4R+GJ<]ZF\3:'I.K112:C;&:1 5B(D9<9Z]*Y,>!?#(S_P 2Z0_]
MO,G^?2@#T"QN8Y(Q&D?EJ!\BEP<CVP:L3EA"Y1PAV\,>@]ZY+PWX7T'3[T36
MEDT=S%EHW:9VX/4<G%:FNZ)J.J31O9Z_<Z;&J%72)%8/GN<T 2/&#> &5&+E
M'+]ACM]36G;,YAR\BR')^9?KTKC&\)>(Q(=OB^\(#+@^2G('?I6II'AW5=.O
MXY[GQ/=WL"A@;>2-0K9[\4 =,347VB(KN\U<9VYSQGTJ0=.*J?*+O[-]G7R]
MOF9VG[V: +@I:3/(_P *6@!,4M)D4M $)"0HSA54 9. !6&/%VG%E&V;).T?
M*.W6M]D#HRL,JPP1ZBJ@TFP4*%M(@%  ^7H!0!2M9XIO%5V(VR5M4#<=/F-;
M#9P=N V.,UEPC'BFYP /]%3M_M&M:@#)N5N/.M?,9#*3A&4<!NY/X5H1+,"W
MFLK<_+M'0>]5KR%7G3=<&-VXB&,[3W(J\* &2HCQ,KXVD<D]JYIT\N1T+!L'
M&Y>0?U],5OW5K)<,-L[1I@@J!UK$FMC#<- 02<X49ZCM_GVH VK")(K10C*Q
MZL1SS2W5HMP"P)$H4JISP,U%:V#VQ7%P^P<F/'%2W2-@R_:'B15(.!Q]: ,A
M2<AAWPV/9.#WK2LK55CBF8DN Q4Y[$YYK.9560JOS(&0 _W@>OYUIVD9(1TN
M6DB4%=I'7G^E &7KGA6+6KD7)U'4+:54V!;>?8GU(Q68/ %MYNPZYJ^-G*_;
M.<^O3I77R/()8U6/<ASN;/W?\:HEY#?>;Y7[_&T19_@S][/]* *&A>%(M%NO
MM1U+4+F8H499Y]R?E70/(D:Y=@HZ9)Q4:M(9I%:+$8 VOG[U8.M>(UL+MK-]
M!U.]4 -YD$09#^)(YH VUA9;Z2Y9AY90#'I5A75E#*00>A!ZUQI\9N9&9O#>
MOM&R[?+,"X_]"K4T/7_[5G:V71M1L$B3<&N8PJGV&": .@HIC':">O'2N>?Q
M9$DB(;28,_ !(X/<&@"]%_R-5Q_UZI_Z$:U:P[2Y2?Q3>!5D&RV0$LA'\7;U
MK<% &;?,?M<#"-R(#O; ZYXXK16G44 !KG[JV9KYL2QGS22&W?=QCK6^>AKG
MI;!HKQ80=QD.0V!ZG/?MF@#>C_U:\@\#D=Z4@'@C(J.WA\B!(MV=HQG'6I:
M,N:&%M10!OW<GSN0> 5Z<UJ+C;\N,>W2LYX%5FC2P)0':&#=0W6M"-5C1448
M51@"@!QK,*7'VS=@?:,??P=FS/3ZU?G5Y(F6-S&QZ-C.*9Y4HE#>>=NS;MQW
M]: )Q2U# DD<2K)(9&'5\8S4W:@!NY=Q7<,^F>:=5)'C.IRH(@) @)?/4>F*
MNT )VIC0QL<F-#]5%244 9,7_(TW _Z=4_\ 0C6M63%_R-5S_P!>J?\ H1K6
MH **** "J[K(;B(JJ&,9W$]1]*L48H 2EHHH JRQR&_AD# 1JIR-W?Z594Y%
M9T\$[:DC@\?POCA!W!^M:(Z4 !K-\IA=_9=\OEG][OR<YSTSZ5I&HO,;[3Y?
MEMLVYW]L^E $H'-+1BB@"NL""[>8-\[*%*^U6*JJJ_V@Y\E@VP?O>Q]JM4 %
M9VJZA+80I)% 92SA2/2M&DQG/2@#(M%GD\07-R]L\41@6-6<CYSG/%:X-)BJ
M,NH2QRL@L+AP#C<N,&@#0HK(EULPRQ1R6%T&E;:G Y-2_P!IS?\ 0.NOTH T
MJ*S?[2F_Z!US^E1OK+)/'"UA="20$J,#G% &M16;_:4W_0.N?TH_M.;_ *!U
MU^E &CB@# K*;676=(3I]UYC@LHP.@ZU)_:<W_0.NOR% &E28YK._M.;_H'7
M7Y"H_P"VF^T"#[!=>85WXP.E &M16;_:<W_0.N?TH_M.;_H'77Z4 :.*6LA=
M;+7+VXL+KS$4,1@=#4O]IS?] ZZ_2@#2HJ#[;:_\_$?_ 'U1]MM?^?B/_OJ@
M":BH?MMK_P _$?\ WU1]MM?^?B/_ +Z% %.^FOH]0M$MH0\+$^82,X_'M6D,
MYJ WEM_S\1_]]4?;+;/^OC_[ZH G/2JDS70U"V$:J;<JWF$CD'MBI/MEM_SW
MC_[ZKEH]:URVN)%GMH[B+#E&C(&3N.T'\* .PS1D5R)UO7%:$O:V^UCEE1L]
MON^WUJQ::WJDJ3//901%$8JGF9+-V'\Z -26XO/[<AACB_T7RRSR%>,^@/K6
MB#Q7+1:OK+6T\K10>8TBB*,MC"8Y;\Z2RUS69[PI<6<4,'E-B3?P) ./J#0!
MU9^M9WG7G]N"(1YL_*)9RO1NW-<_%X@UW:89;*)7"_Z_/REN>,?E4G]OZV("
M180%E3)R_5O04 =:*6J<%_#)!&\LL:.5!92PX/I4OVVV_P"?B/\ [Z% %6*6
L^.MSQR6RK9"-?+E!Y9NX-:-5_MEM_P _$?\ WU2_;;7_ )^(_P#OH4 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>forms-3_004.jpg
<TEXT>
begin 644 forms-3_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $> 7 # 2(  A$! Q$!_\0
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M4M)2T#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6X&(L'Y1]*]*T;7;.#1[6+5-=T^>^2,":6.50&;UJA_PJKP3_P! *'_OMO\
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M]]M_C0!O?\))HG_06LO^_P M+'K^D32+%%J=H\CG"JLP))]*Y_\ X55X*_Z
M4/\ WVW^-<UXE\/^&O!VN^&VTWP_;>;=WPB\QG;,?N.: /5Q2TG>EH ****
M"BBB@ HHHH **** *6I:G::18R7M].L,$8RS,?T'O60?&NDKH=IK#"Y^RW6?
M+*PECQZ@=*U-7L8+[3IHYX$F"HS(K+GYL'!^M<7;#4]/^%4-O;VTRWTG[G8%
M^9 S$$X^E(#;?Q_H*Z5;:D);AX+F1HX@D#%V(ZX7K6]I]_%J5E#=P+((I5W*
M)%VL![@]*XCQ-H]G8VND(T&JA+.%DCFT_JCD=^_)K4L[+Q'J/@6"VEU)].UE
ME'^E>6'90#QE?7'6F!UN:6O-_"%WXAM/B%J>@:QKC:I#!9I,C-"$P2?:O2*
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MQK_R5/P1_OS?RKTFN/\ $7AJ]U7QMX<U>"2(6^FM(9E;[QW#C% '84&DS0:
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M\+C^'_>[5]0>#M?D\3^%[+5Y85@:X4DQJ<@5\R72B3Q-XD7[.\Q6YE?,9P5
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MKILWA"WCNKO=]GB+DF0+UQSVKT_PS=ZO?:%!<ZW8QV5^Y.^",Y"CM7*^+/\
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MMIUS=?$;Q'>K?+!9644,MY;E]INH\<H!WK+\_1;D2>)K6U-OX4@N$CGT,O\
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MH-7@DNH97N\YV-TV=3]: /J 4M)2T#."^,7/PUU 8ZR1#Z_.*M6^FR&UA/\
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MQ6DL;247%O:VCQQW7_/<9SN_7%:/Q:BUV;XA:2OAQW34/L$ARK!3LR=W7VH
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M/S#IBMOXB?\ )'[S_KTB_I0 FA3V_P#PCVF@Z[J2'[-'D*A(''3I2>()H/\
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M *":Z9/^/7PS_P!=_P#VF] &#X/_ .2K^-?K#_Z#7H]><>#_ /DJ_C7ZP_\
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M9[\]!4NC:/\ $[0]2U2^MM/T1Y-2F$TH>5L*1Q@8[4 :?A?_ )*+X^_W4_\
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MM,6W"RCLR'H10!VXI<4@)I: $VCTI:** "BBB@ HHHH **** "BBB@ HHHH
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M7=]!3V%N-EE2"%Y9&VHBEF8]@.M>=:WKZ^*TM=-2&]TR.YEW65[+&&BN"O\
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M\\SS7(LY97.]F\[&7 P&X]/2F_\ "JOB!Y8BS:!%)=1YO1V^\WX^G2OHZDH
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7^BI,4EEN+B=MTUQ,<NY]ZUA2T4 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>forms-3_005.jpg
<TEXT>
begin 644 forms-3_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $M ;0# 2(  A$! Q$!_\0
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M10&0?-$02')[=#Q70:3K-GJUM%+!*N^2,.8BWS+]10!IT444 %%%% !1110
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MT_NBO/Q&-]E/EL>5B<P5"?)8^A[C6M,.JV;#4+; 5\GS1[5=_MW2O^@E:_\
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MW:^(+FYU/4K9+(D6H;:V3@D=CQWH Z/.*,UR>J:YK5K9VEW%IXVE'>XA52[
M#ICW[U+H6KZC?:M-!=H?+\O<N(BH7V)/>@#J**0<4N: "BBB@ HHHH ****
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M2M(Q459&L(1@K1.7\2^#$\5:2=-U+4[@P%P_[M0IR*XW_A0'AX'_ )".H?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHS10 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%(6
MQ0 M,D<1QLQ_A!/6L2;Q7813-&D5W,%;:SPP,R@_7O\ A6I:W5OJ-JL\#>9"
MX(!(Q]00: .3C\97<UPEJD$8FG<"%F!  P2<COTZCBNAT76H=7LXY%(68IN>
M+T[?E4#>%-(:*2/[.PW$$-O.Y<= I[#D\"EM($M?$'V>$JL$=HH2-1]WGN>]
M &W1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%&:3/M0 M%9,^OZ=;7-U;R2GS;9%>10O9C@ >I)J(^)]/!4,95).'!3_5G
M./F]* -NBD5@PR.1ZTM !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %,..?UI]-.* /&+K53;:_/:Z7XHN-8<3Y:V\P0"#G
ME=_0X]*]DA55A7"@9&2!ZUYOKMACQ3-&NGW,=CM1HGT^T5U=R?FWGUKT,OLL
MF>+YBL9('N!TH L$\9K+16'B>1BJ!3:C##J>3UKC(]?U1_)BFNY(A<E7GE1@
M1;@@\9QP<CI6_P"'+NXOKV*YNH'CE:S +L>)/F/..U '544G:J]Q>P6I42E@
M6Z84G^5 %FBLT:YIYD,?FOO W%?+;./7I5FVO8;LL(BQV]=RD?SH LT4"B@
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M6"C:/6N@K"T,DZCK)8O_ ,?0QN '&T=,=JW:8!11FC- !1110 4444 %%%%
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M7E_P@D06NIY=1F1>X]#7IOG1_P#/1?\ OH5U8;^%$[L&K4(H^;?CMS\0(O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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;P7,FIR31Q$G8Y)W$CZUTXZ"C%+0,**** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>forms-3_006.jpg
<TEXT>
begin 644 forms-3_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )6 ; # 2(  A$! Q$!_\0
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MJ'YK7S.*<$8@D*2!U.* /I;_ (:-\._] K4/_':7_AHWP[_T"]0_\=KYFI*
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MPGUH RY(1AY(UD\G.%9A5?O5N>5VDF\T%6W'*$8 /TJH>M "44O>DH ****
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M $C;0W!RO>GB)9,L'51V!/-0C&1FI98XUY5\\4 1'BFTI-)0 49HHH ****
M/?\ ]FS[VN?2.OH"OG_]FS[VN?2.OH"@#YF_:(13XRLFWC<+-1M_X$:\:KVO
MX^VPN?B!IJ,Q5&LP"0.@W&O)M7TLZ?<;4W-$0,.1Q0!0 7RR2?F["DSC'M24
M^9%1@%</P#D=J )#=OMD"JJ;^NT5#NQWYIE+0!.US(T(A!(3N ?O?6F+,R#
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M(]S'D@?=(X-1$@MD?D* '8#ELOCJ<GO41Q03WQ0: "@"@5,DIC&8UYQ@Y&:
M(BI&,@C/M1TJ1Y7DQO8MCUH6&1D+A6*C ) Z4 1U)!"UQ*(TQN/J<4Y;65U+
MJAP#CWITME<6Z[Y8G10<9([T 1$,KE#U!Q2.AC<J>HIN32'.<T /\MC&7VG:
M#@FF8I=QQC)QZ9I\BHIPKAAC.: (J*** /0_@E_R572?I+_Z+-?7E?(?P2_Y
M*KI/TE_]%FOKR@ HHHH ^5OV@?\ DHW_ &ZQUY37JW[0/_)1_P#MUCKRF@ I
MZ(SL H)/M3*MV%RMK=+*T8<#L30!#)#)"0)(V7ZC%1FM?4;NYU:<$?,%&%1>
MPJ72M"^V>9Y[,FT< =: ,/!HQ6A>V4%O*T<4Q+*<$.,9JM'"C1NQF5&7HI')
MH KU/;P^>Y4L%XJ$]:FMG".23CCB@")UPQ&<XIM.;DYIO:@ HHHH 4&E!P<T
ME.*$#)! /0D=: %>5Y/ONS$="3FF<T8YQ3@N1GGCK0 T=*4G- J9+5Y+=Y@5
MVJ>1GF@"O13B.,TV@!<TE&*7% 'OW[-GWM<^D=?0%?/_ .S9][7/I'7T!0!\
MQ?M%?\CO8_\ 7D/_ $(UY'$$SF3[N.!ZUZ_^T.I;QM:-V2R7//\ M&O(/, C
M9-JDD@[NXH UM1:%=$T^*%(SRS-*#\Q/I^%8V['0G\ZL6MK)=%MA50B[F9S@
M"EM+999X_.+) 6"M(!T_&@"K5BSF6"ZCE:/S54YVGN:6>U*7$J19D16*AP.#
MBGPS16\<<@+&9)-P0@;2* (IB\]R["/:S,3M4=/:IYTCM6CC:(EU(:3<,?A4
MB:I.+][E5C\R4]QP*JW=S-=73RSR;Y&/)H GCNH6N-LB>7:O)N9%Z@?7TK4U
MZULFLX;BR0#G'R#@CWKG,X-:,NL7,UHEL^T1CKM')'I0!6BLIYKI;=$/FMV-
M.O[";3I_)G W$9!!R"*TM(29W>2V5Y)8QE0#C'^]FLR_GN+BZ=KEB90=I'I[
M4 51R:L6YC$H$V_R_P"(+U-,A19'P9%C&/O$5/,]L$VQ([G'+OZ]\"@#533[
M&YE98I#L4<1H>Y]6I]OX?U.)"8)HU.<D!NU4+1K<6<GEQ*+A1DO))@#_ '1W
MJP_B6Z^S"*)$C.W!?')^E &?>B6*[=&E9G4_,>G-0//-*H1Y791T!;(H=G,F
M^7<6;DL3R:="L)),K' YVCO[4 0D$8.",]":::N7EPLT@6)66-!A5/:JA'O0
M VBBB@ HHHH ]#^"7_)5=)^DO_HLU]>5\A_!+_DJND_27_T6:^O* "BBB@#Y
M6_:!_P"2C_\ ;K'7E->K?M _\E'_ .W6.O*: "ESQ244 30W$ENX>)BK>HJ7
M[?<^:91,ZN>I!JJ*DCD\MPPP2.Q&10!O:K'#!I%HS@&:X3>><GZUSQZ\U+/<
M23R;W;)Z#T'TJ'- "4444 +14B1.Z.RKE4Y8^E"1L[JJ@ECP!ZT 1XH K72U
ML[1"+_<TQZ)&?NCWJ"9-.9PT,DJ)CE67)S0!G]*F%Q((S'NRO8$9Q]*=,( @
M\LECCDD8P?2BVMTG8JTZQ-VW#@T 0=ZLVU[/:*RQ,H5^&!4'-:,F@K:^6UU>
M1JC]".<UGWL$$5QY=M(THQUQ0!!+(97WE0,]E&*L)>[8/),,3+ZXYJICD^U(
M: )#)F+9@<'KWJ.@G-)0!)&JEN3QCM2F,EMJJV?0TP'!XJ03NK;@W/3- 'O7
M[-HP^N@\<1U[]7@/[-Q+/KI/4B.O?J /F7]HCGQQ9 ?\^(SC_>->/8STZU[%
M^T/(R>-;55. UBN??YC7C\4K0R+(A 93D<4 -&5)Z_2M6PU9+& QB+S%/)5O
M[WK6;-*\TK2OC<W7 Q5V73/+M(I#/&TDBY6-3SCWH =?ZBMQM:%1&S#]X%X&
M?:LS/.:4@\#I2^6Q)4 DCTYH 3=C.1VIN:<%)/ Y]*=+"\+E)$96')!&#0!%
M2BD-** -.PN[VVM9OLSE$'+$+G/UJC)O9RTF2QY.:U=&EE5)8SY8MF(\PN0/
MPJ37=3MY9&M[*.-H< >:4PQQV'M0!B1N$<,5# ?PGO0[[W9L!<G.!VIAY.:,
M<T *,FG 9&?3KS4D"9<.R,T:\OCTHN9(Y9F:*,1QG[JCTH ;++YBQC8!L7&1
MWYZTPE21@8IN:2@!V3FKEE;VT[,MQ<>3QE3C.:IJ-S 9Y)Q5^_TN33TB:22-
M_,&0%/2@"I+$R8W*0&Y4GN/6H:F=WEVJS9"C"Y/ 'M46* $HIQ0J,FFT >A_
M!+_DJND_27_T6:^O*^0_@E_R572?I+_Z+-?7E !1110!\K?M _\ )1_^W6.O
M*:]6_:!_Y*/_ -NL=>4T %%%% "TN*05I0:=']G2XNK@0QO]T 99AZXH SL<
M9_2C!/ K88V2L8["+S5(P99NN?84DUVUJ0GV2W4X],XH R-M)TJW/=":( A0
M<Y(5 *J'DT 2+*Z*RAL*W4>M+#,T$Z2K]Y#D41P^8"=ZJ1V/>EDMIHL%D(4\
MANQ_&@ N)_/GDE*A=YS@=!46>*,>]&* $SQ1FC%&V@"1IY)%5'=F5>F>U/BN
MI8;A9DQO7H2*B ^;U%798U%OA;9@Q_B- %>XN//(;8JM_$1_$:@S4CPR(,LA
M J*@!Y*E>!S2 $FDZ5-#)"JOYB$MCY2#TH -D10D/AAU!'6H<=:DC42$[FQG
MN:L6MM%<%U:X6)U&5W=&H ]R_9L^]KGTCKW^O OV;T*MKN1Q^[P?6O?: /F3
M]HK_ )'>R_Z\A_Z$:\=%>Q?M%?\ ([V/_7D/_0C7CH]* ) R[6##D]#0LC(=
MRE@<8R#VITT<JL/-1E)&1D8R*85&!@YH LQ12W%J^Q1MA&YCT.*B19D0RIN"
M9VEQT^E$:S,-D8<[AT'<4PR.(_+W';G.W/'Y4 7%BCLS'-(ZRY&56-N5/O4V
MIZA!J.QTMQ'*.&;JS<5E=:7)!XH 1@02",8I*D7!<%@6'>HR.: %SV/2@MFD
MQ10!+!"9G(!5>.K' J;R(COVS)\H!&[O57IBC.!S0!,QDAWQB3Y6^]M/!%09
MIRGCV[BE8*'.,[?>@!H SR:0]:OM;VIT_P U)_WP;F-NX]J99"S,Q%XSA,<%
M/6@"I3G/S<$D8[U(41KG:K[8RV YZ8I)82@+ [H]Q4,.^* &* QY;:/>E;9E
M=N3QS4>:4,0<@T 22,"/ER!Z$U%2\^]-H ]#^"7_ "572?I+_P"BS7UY7R'\
M$O\ DJND_27_ -%FOKR@ HHHH ^5OV@?^2CG_KUCKRFO5?V@/^2CG_KUCKRJ
M@ HHHQ0 X$"I'E9T568E5&%SV%1=J.: '!RI^4D?2D+%CDDD^II".*2@!<TE
M%% #LUHV>LS6L#0%$EB/17&<?2LREH EFDCD?<D>P'MFK%I=6\$J&>U$RCJ-
MV,U2S0* -^35])>-E&C(AQA2K]*S88[&8GS)I(3GCY=PJE10!K0V^FPW \R\
M+C[P*+Q^-7KP1O%&+:^C>$@%U/#9KG./6ES@]: -V:">_B\NR!EP,L#C(K+;
M3KH#)BP<X SR?PJ&.5XCE)&0^H.*>UU(Y4LPR!@'% $3Q/&Y1U*L.H/:FX)X
MJU%+%,V+DGD??[BHF0%F$>"HZ'IF@"(=.:*E10L@+XP#R#W]JEO;J*ZD5XX%
MA"KMPO>@#W3]FXDMKF23Q'7OU> _LVXW:[CTCKWZ@#YE_:'0OXYL@,?\>(Z_
M[QKQY3AO;->P?M$_\CO8_P#7D/\ T(UXZ30!<N;I;B;S"F!QA<Y_"III\VV)
M(ML;+B-E Z^]9H-2&1B@0L=H.0/2@!0[I@HQ4^QIJH\APJECZ"KMEI=Q?1,\
M0X!XST-681-9V5P@4Q3H^2^.HZ;?UH RD1G;8H)8\  <U)<6_P!FE",P+XRP
M'8U+#J$UN@$>P,#D,4!.?K3'5[A)+EI$)W?,,X)]\4 -AFEMRS*!AP5.1D5!
MGFK<(MV@9KB=PRGY(U'7\>U,EN?,@CB$<:A"?F48)^IH K\\U/';/)!),-H1
M.#DT^&W5HFD9C\I&%V\'VS27=QY[C;$L04;<+W^M %;''2EVL03@X'4TJJSM
MM')JXD+K;MAL'J5)X('K0!1'!S3G?>Y8X!/7 Q33SSQS3XUW_*H)<G  H EC
M-K]GD$BR^=_ 0?E_&H"K#!(X-6'/D.BFWV2*,$,/O>]1E8S&C!_G).X$<+[T
M 1\T9)&,\>E78WLH4RT9N'92.NT*?ZU&L<"Q"65]VXD>6AY'O0!4(-*%)YQF
ME/J*=YC+&45CM/49H 6/!RK'&>]1'Z]Z,BB@#T+X)?\ )5-)^DO_ * :^NZ^
M1?@H/^+IZ0<@Y$OX?(:^NJ %HHHH ^8/CGIUW?\ Q/B@M86EEF@C2-5ZLWI7
M(?\ "K/&W_0O7?Y"NW^,UWJ.G?%>WO[".5I+:**1"$++N%4S\;OB!G_CWA_\
M!&H X+6O!OB#PY;QW&KZ9-:12-M1I,8)]*P37=>+?'GBSQK80V>K6V8HI/,7
MRK=E.:XXZ?>?\^D__?IO\* *M%6?[/O/^?2?_OVW^%']GWG_ #Z3_P#?MO\
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MLMO_ ,\(O^^!1]DM_P#GA%_WP*FHH A^S08QY$>/38*/LMO_ ,\(O^^!4U%
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MHKT$4 &*SY/^1@M_^O=__0A6B>E9TO\ R,-O_P!>[_\ H0H T:*** "BBB@
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M2'DC38,9)  [5>35[!T#)=(RGH1R#5F=%\B3Y5^Z>WM5/1%7^QK7Y5^[Z>]
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MJ;XR%0>0_<_2N:,7Q';(;76;(P<V<'/XXID-I\1+>%(H=;943@#[' 3_ "H
M]CC8.@8=",BG5XR=4\>:1K6B_P!H:V\UK=WR6\B-;1#(()ZCGM7LH.2: %JG
MJO\ R"[G_KF:N53U7_D%77_7,T 6(/\ CWC_ -T?RJ2HK?\ X]XO]T?RJ6@
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M!:IZK_R"KK_KF:N53U7_ )!5U_US- $]O_Q[Q?[H_E4M1V__ ![Q?[H_E4E
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M[GKR,UZ77EE]=VEI\6]8-VUBH;3X-OVN0H.IZ8ZT =3LM_\ GTU/_P "A_\
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MYKVH=*\6^%1W?$OQ'(68M):QLQ88?)/\0_A;U X%>O:DQ73+L@X(A<@CKTH
MLNRHI9B%4#))/ %9&J36E[;11Q7]H"LT<A+2KT5LGO7SMX3TN3Q#I%_/KGB+
M4]-P#]G$ER56]ZY"!L9].,U6M? ]I-X7NKZXEU"UUJ-B+?1WDQ-..S*I^8_@
M* /J6"ZM[AF$$\,I'4(X;'Y5-7R_/X4ATKP_97^C:CJDVKW!47FF6\Q\VV!Z
M[PO/'N*](^%""T\3^)M/AUJ75K2W\GRIWEWYR,GGIP>* .S^(/\ R3W7O^O*
M3^5<5X<M[IO"^DL#J.#:1?=TZ-AC:.A/6NU^(/\ R3W7O^O*3^5>=>'].>3P
MWI;K)8 -:1D;M;D0_='5=O!]J .C^RW?KJG_ (+8J46MUD9.I]?^@;%6=_9<
MO]_3O_!_)_\ $T#2I=P_>:=U'_,>D_\ B: -+X1AETWQ &W[AK,P.]0IZ+U
MX%:?Q7_Y)AKO_7O_ %%97P?39I6O+E>-8F'R2&0=%Z,>OUK5^*__ "2_7O\
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M[_C\OO\ N%_^C!67K/\ K/#_ /V-3_UH ]<HHHH **** "D)I:BN(Q-$\1)
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MM/T8R_V9X@UJS\W'F>1,%W8]: .J^(.?^%>Z_P#]>4G\JY/PS;D^%-(.(?\
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MM7IMGI\$4QO7MK87\J*L\T:8+D#UZXHTZWGM[&&.[F%Q<HNUYMN"WUJZ/I0
MM+FBHY6*Q,57<P!(4=SZ4 $CJ@+,P48Y)KRF^NM7\5>(532YKC[ TJ7%LDI
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MF6<-WB26V']TMWP<X/IBCP-I-S::1,;U6$<TQ=(7CVJ.?OA?X<\''8UUP&*
M +@4ZBB@!,UQ?C'Q1<63#3]);%Z2A><KNBB!8#$G<!N1D=*EUSQ!/;ZO=V)G
MBLK:&T\TR.,O.6!XC[94@9]<T[P]X3MK-X[V8++,T:D%=PR2.203WST]10!6
M\$^'/L^FB;4[,B<3L\/VGYIE7.0';HV#R#Z8KM@* H%+0 'BFE@ 2> .M./2
MLG7](;6]'FL5O)[1WP4F@<HRD=.1V]10!R'BOQNR6<UK8*8Q*N%OC\Z1C/#;
M1R03\N>QZUJZ-X.T\7D6M3VT@N'Q,EO.V[[.Y'S 'N,\X[=JA\(>!(=#EDO[
MN2>>[D)^29E98VZ%D('&X<FNT Q0 H'%+110!'*ZHI+,% YR:X3Q)XUB87.F
M6)F602+'<W*#/D1.,"5,?> ; ([5I>.H-5GTL"R:,V1.V[01LTH7/#Q[2.5Z
MU#X:\'I:.NHZCY<]VP!^4?NR1TEP?NN1C/KB@"/PEX.DTYS?:I,MY=8Q"S'<
M4'?G^+/!&>F37:@'\*%&.U.H **** "BBB@ HHHH *AEGAA>-994C,C;4#-@
ML?0>M2UR/B71M5DUVTUG2X8+R6&)H1;W#[1$QZ2H3D!AWXY H Y_5_$-SXJ\
M20^'[2)H[*02X:6%9$N&0X(<=H\\=CG&*[+P[X>@T&T*JS23R >9(Q!( Z(#
MU*CD#-.T30+?3%%U+! =5F0?:[F--IE? W'V!-;0QF@!*=110 4PT^B@"NMM
M"DS2K"BR/]YE4 M]3WJ<=*6B@ HHHH **** "BBB@ HHHH 3'-+110 4444
M%%%% !1110 4UV5%+,0% R23@"G5@>,-*N]9\.W%I9NHF)5Q&Y(64 Y*,1V;
MI0!E^*?%J6K3:5IMP5U%XD99U3='%O.%!/0,V#MZBJWA7P2EC=IJ=S,\C;S-
M'&4VY=@,RL.TG4''''2K>AZ-)J,PU#6-'BLO)*+9V>X'RE48^;'!&<D9SBNO
M6@  P:=110 4444 5+K3K.^:,W=K#.8FWQF1 VP^HST-6E&!2T4 %%%% !11
M10 4444 %%%% #2*%&!3J* "BBB@ HHHH **** "BBB@ HHI": %HIH)I<T
M+12$TF3F@!U%)GWI,G/K0 ZBFD^]&30 ZBFY/XT ^] #J*0G'>DR2?2@!U%)
MFC)H 6BDS10 M%-8XHS[T .HIN31S0 ZBFY- )H =1110 444AH 6BDR:,T
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MH^(I(;6!(+9+B/?]IN)8=L<CKM^13NQWZ@GZ5Z^NFV2>=LL[=?._UN(E&_\
MWN.:3^R[$P) ;.W\J,[DC\I=JGU ]: .<\6:GXB@\/VMUH5A'-<2F,RCS""@
M)7( P<CKSV%'BGQ!J6BZ%8S,MK8W5U<+!+/(3)#:Y!.\],C@#MUKK0H P*CN
M+:"[B:&XACFB;[R2*&4_@: /(=3M];\4^)6MK*]$T_\ 94;I<0W+PQ1R;B/,
M5<'=]*W6T 0^-]/CNKN\EE.G/<S$3L$>9"HW;>GKQ7H$=I!$X:.&-"%" J@&
M%';Z4\Q(7#E%W@;0V.<>F: /#-!OXKW3HF\5:S=VL L9'L6\]D\Q]QW,2.K
MX %>G^ KC4[GP5IDNK(XO6B^8N,,RY^4GW(K=DTVQE2..2RMW2,Y16B4A3ZC
MCBK04 8% "T444 %(:6D)Q0!X5J=YI%Q\3?%%KXD\5:AI<$#0_9$@NC&#E1N
MXP?:O1_ 5MHT6F7$NAZ[=ZO;22X:6XG\W8P'0' Q6#H'AR.Z^)_C*YU/25EM
MI6@-O+<0Y5OEYVDC^5>A66GV>FQ&*RM8K>(G<4B0*"?7 H S/&1D7P9K)B+B
M06<FTIG(..V*\GT_Q"FG06FIZ#->R-#HP.IX1Y(DD^0*=IQE^N<'IS7NI4,I
M5@"#P0:B2U@C1D2&-4;[RJ@ /UH \=C\9^)[/1#>RWGVM#=2:9$5C +2.JM%
M)GV)(]*ZKQC!=Q>!K**[>XN-7=HK=987,>)GP"QV]AD_E7676A:=>36LL]JC
M&U?S(EQA5;UP.":OF-6^\ >_(S0!@Z4^J6U__9,NG.+"W@58]0><,TKCKE>O
MKS7)ZQ;ZKI.G>+?L^HW5Y<M%%+YLY_U:'[X0#H N>G->F;::T2-NW*#N&#D=
M10!X!<ZL3I44T5^\5O:32M&D23>3J3[>%7NISQUQFO4M4\5-HFGZ!<740M(+
MOY9UERS1?NRP7CJ<C%=5]E@\M8_)CV*<JNP8!]<56O-(LK^[M+FZ@666T9GA
M+<A21@G'TH \@/Q&UR_NK2X.H)91N;7RK9+<D72NV)&W'[N.E:.M7NMZ0]M=
M6DLWE73S2W-W&N\PP-)\KJO0D+@?2O0[GPOH]W?1WDUDC2Q[=HZ+D<@X]JUO
M)3;MV+MQMQM&,>GTH \KT[QAK5UX\@TZXOC%$]^\'V/R.3"J I)OZ?-UQ4'B
M^^L8O%GB"#4)[I)VM;=M.6$ON,N3]S'?.,UZ0GAO2DU8ZF+4&[W%@Y.=K$8)
M ]<5HM;0O()&BC:1>C%02/QH \SN?%>N6GB6&V,Q%TKQ6_\ 9;0D^:AC#-/O
M'H<C\*Q;7QOXE:UU:%]0$[F12EY';XBMU9RIP3R" .A%>T&&,RB4HOF 8#[1
MD#TS31:6X5U$,>V0Y<;!AOKZT <QIE]K&H^!1<6\]O<:@R2*DVUE64 D!L$9
M!( _&C2I]?L/ <D^H0I+JD,#/'&F26('&[WKJUC5%"JH"@8  P!2XYH \)O=
M;U/5FT*"+5FUK.H1^8&@>V0%E;=$[ <@'CIQBM;7]!OM"\/^&K>\N'GN7UV-
M9#$[,$A8D^5GJ5'J:]<6VA086)% ;=@*!SZ_6G/&C@!E!P<C(S@T >4ZI>W%
MKJU]+=2W2Z/#KB"[\O=\L7E_*./X-V,XKHO <RW-WKUQ8RRR:+)=*UD7W;>G
MS[-W.W/X5V;0QLK*44AOO# Y^OK2I$D:!$4*HZ*HP!0 ^BBB@ HHHH *0TM-
M89[XH 898U0LTBA1U.>!2":)BNV9#N^Z PY^E<A::/>66@7VE/I1NTF>XE7S
M9@P)+90,<YYS^&*S8/"5_9:_I$NG6HMQ!:K&]P[B2-,[BP"DY#Y/!Z8H ]%!
M!/%.KSWX:>)-9UJZ\0:?K%Q%<OIEWY,<R1["PYZC\*]"H **** "BBB@ HHJ
M.61(4+R,%4=S0!)TI,UB:Y=O<Z/<0Z9=K%=NN(W8' ^M9<Z:A'I\<4.J"38%
MW*H*ECSNY].F* .OS1N%<=++J,D47^D?.((UD(<C<P/S8^HQS46G?VU'J$4U
MYJ8,*R9D09(<;F_]EVCZ@T =O2$XJBVKZ?$466Z2/><+O.,FHKG5K%K:40ZA
M;B4H0A\P<'''ZT :>X49KC+&2]M] C@D\06C7NQC*^X<N3Q@]J9?W-]-801V
M&J6T$R1L"TDX/SY&"?48W?F* .VW"@$&N*M)KQ)+GS=9MP"RF!EF'"?+\I'K
M][GWKJH=2LIY%CBNX7D;HJN"30!<HI :6@ HHHH *0\TM(: &>8%;#,!DX /
M4_2D^T0Y8>;'E>6!8<?6N;UO3+R7Q?HVJ6\+RQ6D4PE D  ) QQW)]:RM<\*
MMJ-SK%Z-*82SVT<:>3*%>3G+\YQGH.<#B@#NUD5U#*P93T(.13LUY/<ZAXN\
M*ZAX6CN;VU%I?7 M7L%@ \M>H)8'KC&?>O6![4 +1110 4444 %%%!H 0G H
MS5.75M/B<QR7L"..JEP"*Y^<0S^(IM0&NQQ1?9UCA5)^%;/)*]#0!UFZC-<4
MIEBNKMSK5I.DT.P%KC;N;'I_#SGI5;R[DR*S:G9>6#&3&+P] !Q^!S]: .^S
M2UCVNI:9;Q;3J<#$L229@<Y_STJS_;&FKPU];@^\@H O9]J P-8&JW&F:FL$
M9U2)(TD#MY=QL8CZBLF<2_:X77Q!;3*DI8,TNS8N1@8'WN,C\: .US2YKS^:
M*[DN)&35;*(-*Q!6\)P">3CW'&.U;.B7$-C'F\U:VD;8%P)]P7!/'/\ .@#I
MZ*CCE29%=&#*1D$'((J2@ HHHH **** "D)'6L[6-6AT6S-Y<QSM I =H8RY
M0>I [>]+IFK:=KED+K3+V&ZMVX\R%P1]/8T 61=VS1O()XRB$AVW#"D=<FFQ
MWMK*\:QW,3-(-R!7!+ =Q7*0^'-0L_#E[HT-K;RP7#3/B24_Q-D*3UY&>>U8
MVG>!M=@\3:;J$\T'DPHFXALM"%#A8Q_>X8<GKB@"#X2_\C+XX_["?^->JUY)
M\'(I(-;\9QRSO.Z:AAI7&"QYYKUOM0 4444 %%%% !6;K S#;Y_Y^8_YUI5F
MZQ_J;?\ Z^8_YT 7P@_NC\J78O\ ='Y4ZB@!NU?[H_*F2O#!&TDA1$499FP
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M^!2?9H/^>$7_ 'P*FHH R=!'^@.!VG?'YUK5E:#_ ,>,G_7>3^=:HH ****
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M]'MK+1]/EBTLVS?VE -YL$A_B_O#FO=(O]6OT'\J\5^)&F-:Z%82,TA_XF4
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MD<>]7]1T.*^U:RU+SWCGLUD$> #]\ 9/Y5B77P^LKO4+R\>[N0]SEL#&$<@
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M_D4M6_Z\Y?\ T$UYMX9M;)_"FD,]MH!8VL9)EM7+_='4]S7I/BS_ )%+5_\
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MG\7J!7KD7^J7_='\J 'T444 96@_\>,G_7>3^=:HK*T'_CQD_P"N\G\ZU10
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MUB!V)6);=/-+%?O#G&,5VO@SQG8>-M,FO].@N88XI3$RW"@'/X$T =/1110
MR0C8Q.0 .HZUYMX-O!=^+KB&+4KF[M;..186>,*,NVXAFW$LPSZ#%>@ZA>PZ
M?8SW<[%8H4+LP4G ^@Y-<%X(BO;C7Y[\WMO=V,JN\?V=45$+'D8'S9SZT =%
MJ7BV'3?%%IHK6LC^?M#3*>$+DA1COG!JIK'CVVTB_O;&6QG%S  (%D^471(!
M_=GOC//I6W?>'M,U'4(;^YM@]U",))D@CT_+M5>[\)Z/?S/->6OGR,NS+L3L
M&,?+_=)[D4 >;>+_ !=I>O\ B'P5:V\FV^34%EEMB#F,$$<GH>157XB@#XR6
M+-LV?V7\V^3RT^^WWI/^68_VOP[UN>/]*L--UCP.EG:PQ;-26,$+\VT#H3U-
M<_\ $S;_ ,+;MS(PCB&D?/(4\P(-YY,?_+3Z?CVH K$XB<DC(C;EFP0W\)V]
MW_NQ=)!R::K%ER2X)"G)B ./XN._^T?^6?:DD PY)PP=0 5W$OCY4W>I'27^
M#I4B[B5'ED':VT>9G(_CY[!>X_Y:4 8WB@.NAK@R &XCW;( ^X>8N-Q_Y9CT
M<??[U](6O_'I#_N+_(5\Y>)"_P#84P5&;$D&\^?LV+O&TD?\M >R?P5]&VO_
M !Z0_P"XO\J )J3(K,O_ !!H^E3K#J&J6MK*PR%FE"DCUYKF-4^(,4%[LTN;
M1+RWVY,LFIK&0>XQ@T =A91O#$ZNN"96(^A/%6LBO-HOB7>2(&^SZ"HW$<ZP
MO&#U^[75Q^,?#<K*JZ[IQ=R  MPIR3V'- &_FO-]4D6/XR99=P_L4?\ +41_
M\M#WKT8<\BO)_%R6TGQ<C%U/9PI_8XP;N(R*?WAZ $8H [/[5#_SP_\ )X?X
MT?:HO^>'_D^/\:X_[-H__02\/_\ @#)_\52_9M'_ .@GX?\ _ &3_P"*H J_
M%.9)/#ECMC"_\3*W_P"7H2?Q>F:]=B_U2_[H_E7@?CN+3X]*T_[->:5-)_:,
M'RVMJT;@;N3DDU[W%_JE^@_E0!)15:>_M+9@D]U!$V,@22!3C\:Y/6?BIX1T
M#46L+[4P)U4,?+0NN#TY% '0:#Q8R?\ 7>3^=:@->:VWQD^']JGE0ZG(%9RW
M^I;J>O:N\AU;39]GE7]JYD *JLRDG/H,T 7Z*0<BEH **** .?U_PQ%XCEC2
M]O;I;%1A[.)@J2GU<XR:MV]E9^'-"^SZ?:K%:V<3,D2D] "<<^M:M-8 @@@$
M'J#0!Q>B>,;K6?#.H:CY-G;3VS<&:4B,*45\L<=@V/J*KV?C>_%]ID=]IX2W
MNH0?.A.[=)\VT!>H#!<CZUU3:'IC0- ;"W\IL[DV<'/7(J2#1]/MGA>"SA1H
MEVH0O*C/:@#RGX478O9/'ER(981+<LWERKAE^5N"/6N0\+G/AVVQ",#S<@RY
MYWG][GVZ>3WZUV_PU)_M/XAG/_+X_/\ P%JXCPP<^'+9AL S)%E8^-Y<X&/^
M>GI+]T=* -AD&UA]GQ]WY/M.0/4;L\[O7_EG3%4JP_==5.1YOWO0Y_AV_P#D
M3WIQ>(J2KPE6Q@_9R!A?O$+V']X?Q]J;\H8.9%V@$8\HX&[[N1_%G^'_ )Y]
MZ -7X3\?$GQ"#@G[)%ENF_G[VW^'_=[5[++*D$+ROPB*68^PZUXU\*!CXD^(
M5.-R6D2MGELY_B;^(_[0ZUZ_J63I5YCD^0_7Z&@#A6^-G@@)(4OYY"@R52W<
MY]NE93_'SPA+'N:SU-HP<Y\@$ C\:X7P0MQ!X?8^$[:'4))PW]NBY4?Z,,G!
M3=C/RY/&>E:%O!I<>A3V6D-Y_@"0DZCJ;I^_A<]0H(W8SCH#UH [6U^.W@Z=
M\3_;[5",B2:W.&/H,9KK?#/C;0O%SW"Z/=/,;;'FAHV0C/3J*\?NHK>?1[6U
M\0HMIX+B"_V/J$2CSK@@?N]^,MR.N0*ZGX62ZO+XS\5OKMI#::B?(\V&$ (H
MV_+C''(Q0!Z#XL_Y%'5_^O27K_NUP7ABWB;PKI+?V3K3DV<1W)>H%;Y1R 7X
M%=[XL_Y%'5_7['+_ .@FN.\)C23X/T;S'T@.;*+(=SN^Z.OO0!:^RQ?] ;7?
M_ ^/_P".4GV2+/\ R!==_P# ^/\ ^+J]MT;_ )Z:+_W\/^-)MT;_ )Z:+_W\
M/^- %'X;JJ:SXK589X@+Y/DGD#N/D'4@D?K70>//^1"UW_KRD_\ 0:POA[Y7
M]N^+1!Y7E?;DV^2?E^X.E;OCS_D0M=_Z\I/_ $&@#BM%9A\+-/\ F/\ R+EQ
MW^E*['^S!\Q_U>C=_P#IHM-T7_DEFG?]B[<?TI7_ .0:/^N>C_\ HU: +$+M
M_P )%I7S-_Q^ZEW_ -DU3^ 7_(L:M_V$'JW#_P C%I7_ %^ZE_Z":J? +_D6
M-6_["#T >MT444 4M2MKBZL)X+6Y^S3R)M2;9OV'UP>M8GA[P5IWAZ\FU 2S
MW6ISC$UW*<%AZ!1@ 5U%(: ./UGQ9<:;XQL-)2WC:VE*"5F/S?.2 1],<_6H
MM1\3:S::UJ5G:VEI=QP0!XUCD 9"3PKDX&X\\>P]:ZN>PM;F=)Y;>*25 0KL
MN2*@_L/2_.FF-C#YDR;9&V\N/>@#R/Q1XRL_$?B3P;:0070EBU .\KP[8\\@
MJ#W((-,^(R&7XQ64*B0M+I>U1"P64_.QPC'A3[GMFNE^)$$5OJ_@B*&-(XUU
M4 *BX XKFOB*T:_&:P:41&$:7F19\B(C<WWR.0OT[XH HE2Z.Z!@"C394_(%
M7@DCKY0_C3JQY%,5P03YD9VA5R$.T%^F1W)_Y9X^YWJ5<*HW!?,VLH)^_P":
M3\A Z>:!]P=".M)\[;@3/NRI4LH#8'^LV^Q_Y:>G:@#'\42JFB#FW7S+B.-1
M)&6+%77(C_NN/XV/#=J^C[3_ (](?]Q?Y"OF_P 3K+_8N$:X!$\9E\L @J9!
MM$N>B#^ CD]Z^D;7_CTA_P!Q?Y4 >'?%/P^?%/Q.M-%C>&*>YTW]W-,/EC*M
MN)_(8K)DT;2?$(MX[/3+6T/A;#7Y>,#[=LZA<=<X/7UK:^)UE9:E\3;:RU*_
M.G6,NF_O;P=8L-D?F0!^-59]VIBR34E&F?V00=)8<?VL1C:#ZYP/7K0!2=]
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MB2YU_3K6:#?!)'G B(,Z_/\ O,]ONK_WU7IWE1C^!>_;UI1&@((4 @8!QTH
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M%^=_0<5=_P"$B^)&3_Q2-S^2_P"%>Q.-,U6Y,<GV:ZFLI VTX9H6['V-: H
M\,\/:]X^T*]U6X;P-/<OJ$XF),FW;A<8X^E7];\7>/=:T*^TQOA_-$+J%HMX
MFSMR,9Q7LM(>* / K/4/'5IX7M]&'@:=A#ITECYAEQD-CYL?A52Z\3>+;6:T
MTR?P;(EQ=K:I AE.9#;,&/YXKZ&S63'JFBZCJGEB6&2\M)C"A=>5DVY95)ZG
M'7% 'CRZIX[34+6Z_P"$$FS!-<RX\WKYHQC\*A\"7WCOP3I5W9Q^!Y[KS[AI
M]S2;<9[8KW^EH H:5<W-YI5K<WELUK<RQ*\L!.?+8]5S[5?I,"EH *0TM% '
M$Z[XIO\ 3/&FGZ8@C%I+Y>_<O+*Q(9L]MN!^=8NI^.M8MM:U>VA\D16P(3*$
M^6H"E9#Z@[C^5>FM$C,&9%)'&2,TA@B)8F-,L,'Y1R* /$O%>O>(-;/ABZM_
M#%_>R6$XNY)H(\12CD87TK#\0W_BS7/'=IXC3P7JD'V>V\A5V;F!R3N /!ZX
MP:^C H50%  '0"EH ^;DN?%J@(/!6I@")XU&#C:QR5SZ$\YZCM52TU3Q!?1R
MO:>#KZ5%F57,9)&^/H#Z%?U[U]'W^J6>F1+)>7"PJ[;8]QY=L9V@=SQTJ'19
M]-N; SZ2(Q!([,P1=OS_ ,6X=F]: /F[5;+Q1J=FL(\$:BKK-YJN0WRG<&)
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MC).2<?6@#P;Q;KOBSQ-I=O9K\/[NV\J[CN"Z1<G:<XZ5UJ_$WQ2H _X5WJO
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M:M,Q20CK\X] >BGI5WPIX8U&TNUOM6E:2:- L3?:&D))^\<G^$_W>U=L!0
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M.*P-<\0K9//8V""[U5+=K@6JN P0<$_7G@=\4 7=:U-]*TV:\CLYKSR1N>&
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M-+6PM_+C1=H+,68J.@+'D@9HT?1K?1K4P0/+(7<R/)*^YG8]R?PK3H ****
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M HHHH ***2@!:BGEC@@>:5PD:*69B> !W-9FNZVFDVD@BV2W[QNUK;,VWS6
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M0&!(_'&*U:,4 <1X>\'1QW/]H:I:)%?1W#R%(FS#(Q&/,4=1D?P] :[8=:7
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1%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>forms-3_007.jpg
<TEXT>
begin 644 forms-3_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %! I0# 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBFG/-
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M_IS2@#J:*** "BBB@!*S-:U_3M MDN-2G,,3OL5@C-D_@#6F2*:55NH!]B*
M/+_$FK?#WQ3>V=SJ-_*TMG\T.VW?@YSD_+S_ "KT32=3LM8L(KW3Y"]L^0A*
M%>G'0BHQ&AU]OE4_Z(O\/^V:T  O08'M0 ^BDSFEH **** "BBB@ HHH- !1
M5>>]MK8H)[B*(N0JAV R3V%3[@<8/7O0 M%%% "9YI-W.,4&N'OO$^I0^,CI
MWVB""U#H(Q]G,IE4CD[@<+SQ0!W.ZC[U<QXT\6#PAI\%\UNMPCR;#$&(=O\
M=X(S]<5MV5^EUIL5\T;0I)$)2LF,J,9YQQ0!;V^]<;\51CX8:_S_ ,N__LPK
M27QQX>>*RD&HH([S<86*G! )!)/89!ZUS7C_ ,1:5KGPL\1O8W:2".,Q,&^4
M[@PXP>M '1^ >? .A_\ 7G'_ "KI*YOP!_R(.A_]><?\JZ2@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH ***3- "T444 %%%% !2-TI:1NE 'G_ (SL
M1!KEI?Q_;WFE4HAAN"H5@RX!7(^4C.3["N\B)\M=V,X&?RK@OB%YL>J:/+:V
MUW-/&&YM\$!"Z Y!4^WY5WT>/+4GK@9H JZP?^)+?_\ 7O)_Z":XCX)?\DSL
MO^N\W_H=9,.G^,[*V\236Z_/.K,!?N3&%YSC!Z[>F,"M7X(Y_P"%96.>OG39
M_P"^Z /1J*** "BBB@ HHHH **** "BBB@ I&&:7-)F@#&U/PCH&M70N=3TF
MTNYPH7S)8PQP.U9MU\/?""6LK+X=T\$(2/W(KK*KWO\ QY3?[AH YR+X>>#W
MA0GPYI^2H/\ JA5VP\&>'-*O$N]/T:SMKA/NRQQ@,OT-;,'_ ![Q_P"Z*EH
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M/_4US,OPV\:30O%+\0KMHW4JRF$8(/!%16'PO\8:98PV5C\0;N"UA7;'$D6
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M_"E_X3?P[_T$D_[Y;_"O";1P& )R*T@JE>!Q1]67<%-GLP\:^'V^[J,9_P"
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M:0D)( 0#@X/7W%7*X[X8((_ EHHZ":<#_OZU=E3.U;:A1110,**** "BBB@
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MG<Z<@V07"F>!<],CI6KBD]!0=IIFY\-/^1(MO^N]Q_Z-:NNKDOAL,>"K<?\
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M7-:_W8?_ $&N_KIO<S:LPHHHH$>)?'-MNJ:-[Q2?TKS:!^5![UZ+\>-YU71
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MXJSJ6O1Q+KLL.KQM--!&+4*WS)Z@>_6M8UIVV%:QS">']0>6**%/-DDA,VT
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M$TP'(N]5_P# Y_\ &NHHH%[./8YY/"%G&,+J&K ?]?S_ .-2#PM /^8IK/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
7!1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>forms-3_008.jpg
<TEXT>
begin 644 forms-3_008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &X :T# 2(  A$! Q$!_\0
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M=Q<HW9@^M->//%3[<TUAQBD4D4FC(XINSC!JTRYJ(H*ELNQ79...:J36J/\
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M=K__ " ;_P#ZX/\ RH \!$?R\T,@-3(,K3BE(VL4RE-Q@\5<,5,:$]J+ R$
M8IAZU*ZD"J\CMLP!S0V)#6 +;0>::$R:J/?[&#-$V5.#BKRW*@HVT[6Z\4MR
MF[$9C(.<5')'Z5H,5;A5)_"H9(G/(&T>O>D-.YE-'B3 Y/>B2+>I!J^T(4'
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MVN=EA;3=0CF4<JV2/6J9A.-CW)""@*FGC!K,T:Y6[TZ&= 0K*.,]ZU.N.*1
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MT@5(X@H _6KWV.,EE*C!HU%<\:TK1I)-7CMID.W<-Q]JL>+-*:RU9ECCPA
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M=H]Z-0N06=A#:1E(HPJG'&*FDMXW(RHR<Y..O%3=J,YHL!7M+2.U@$48PH/
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M4 %%%% !1110 4444 &:*3O10 M%&:3(H 6BC-&<4 %%&:,B@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "N=\97\VF^'Y;J"YN+=T(PUO!YK?
M]\^E=%7+^/+FWM?#I-Q]I822K&L<$GEEV)X!;L/6@#%\!>+=8\0W=Q%?K9M!
M&N4D1@LI_P!Y!TKT$>]>>^#!8Z9X@GTF3P]#I>IM!Y_F13>;YB9[MZUW[,%0
MEB H&23T% $E%5Q=6YMOM GC, &3)O&W'UI([NWFM_/CN(WAQDR*X*_G0!9K
MS/Q!=W,?QM\.6Z7$JP20.7C#?*W!ZBO18+JWNH_,MYHYD'&Z-@1^E>:>(_\
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MT45YCX#*V?B9K2?2K2VGN;%;N&6UF9P(R?NMD]:].]Z %HHS29H 6O+/$?\
MR77PS_UP?^1KU+->6^(_^2Z^&?\ K@_\C0!ZD*6D%+0 4AI:0B@#G_%7AZ/7
M]+>(@"=!F)O?TK#\!^(Y9=^@ZDQ%]:@B,MUD4=OJ*[HUY[XZT&:"XC\0:83'
M<PL&8K_/_&LY*SYD=5*2G%TY?(]#SSTI:PO"_B"'Q%I"72X6=?EFC[HU;@-:
M+5',TXMICJ3-&::[!022 !W- @9@ 2>!W-<5J>K77B*_;1]&8K"#BXNAT ]
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ME(H(<Y[YJ[X-M=031H;O4-5FOGN8UD'F*!LR.@Q0!TW6BD%+0 4444 %%%%
M!1110 4444 (:XKQ%I/@O4M;D_MJ6-;XQJCJ9RFY3T!P>:[4]:X/XD:;H@TI
M=3O]+AN;H2)&DCL4 )/&YAVH U=!\,>&](U!KK2=C7)C\LD7'F$)Z=3@5T_:
MO-_!+6MEXJN-,.GZ<EV;;S1<Z=*739G[K9/!KTCM0!S/C6WLAH4VH7]S=PQ6
MBF3_ $:787/8?G7&QZ3K]E\.,QZA*VIZI,C@37&WR8R<A58]\5Z3JNDV6N6#
M6.H0^;;N0S)DC.#D=*;J>AZ=K&F_8+^V6:W&,*21MQT((Z4 <+X4U:72_P"V
MK-[&]FU6QC5WMVNO.$@_V3V/M7.PZ]>:_P#&;P]/>:/<:6Z1.HBF.2PVGFO5
MM%\-Z7X?CD33K7RS*<R2,Q9W^K'FN%\1_P#)=?#.?^>#_P#H)H ]1%+2"EH
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M% !69KD^E6^F3-K+0+8D8D\\94^U:=<MX]M+6[\-M]KOTL8XI%D$SQ^9A@>
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M?;WT]_JD!CE54ALI,>8Q/''K[T 5O!<,LWB6>^U.?4+K4OLWEI)<6H@58\]
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MV-_,\[2+(T()53T'- &E_P +-\'_ /0=MOSI/^%F^#O^@[;?F:U/^$1\.?\
M0#T__P !U_PH_P"$1\.?] /3_P#P'7_"@9E_\+-\'?\ 0=MOS-'_  LWP=_T
M';;\ZU/^$1\.?] /3_\ P'7_  H_X1'PY_T ]/\ _ =?\* ,S_A9G@\C/]N6
MWYT@^)O@_OKMK^=96O?#&RU+Q3I.HV=M8V]G:Y\^W$( E^H%=0/"/AS_ * 6
MG_\ @.O^% &;_P +-\'_ /0=M?S-)_PLWP?_ -!VU_,UJ?\ "(>'/^@'I_\
MX#K_ (4?\(CX<_Z >G_^ Z_X4",O_A9O@[_H.VOYF@_$SP>>FNVWTR:U/^$1
M\.?] /3_ /P'7_"J6J^"=#O=*N[:VTFPAGEB9$D^SJ-A(Z]* (#\3/!XZZ[;
M9^M'_"S?!W_0=M?S-5?"'P[TS0_#<%AJ=C87UTA)>=H 2V3[UO?\(AX<_P"@
M'I__ (#K_A0,R_\ A9O@[_H.VOYFC_A9O@__ *#MK^9K4_X1'PY_T ]/_P#
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M5&-=L*Y2?P9]N\01:CJ&IS7%M;RF:VL]@58V^HY-=6* %I"<"@G!IK. "3P
M,DT #-A20,\9P.]>9V?Q+F.N7_VZVF2&!C$FG00E[@ =97]%K>U7QS9V-U92
M6TL%U82S>3<S1R9: G@9'I6CJOA\7XDGTV[_ +.O9MHDNX8P7D0=CF@"_H^L
M66O:9%?Z?+YD$G0D8(/H1V-:-9/A_0;3PYI26%H79 2[.YRSL3DDUK4 %(31
MFLS4M:L=.989KJ".ZE4F"*5]OF$=!F@#!\7Z_KEN[:9X<TUIK_RC*]S*,11*
M/?NQ]*V?"^KKKWAVSU .K/(@$N.SC@C\ZK>$_$8\2Z6\TD8@NX9&BN(,YV,/
MZ$5)HOAJ#0=1O[BSN)1;WC^9]E/W(W[E?K0!O4444 %-W#.,\^U!/%>?Z[H/
MBS_A*KGQ!HE\BB*)4CLW;*7 'W@?0^] $$7Q*ETOQ-JMAXBM1;Z?!<>7#>H,
MJO&0'^H[UZ!8WEO?V<5W:R"2"4;D8=Q7":7X=T7QI?3:]J-C>0SL/*N=/GXC
M$BC&['?V-=QING6VE6$5E9Q^7;Q#"+G.!0!<HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *3-*>E8^N^(],\.VJSZA<%=YPD:*6=S[ <F@#7R*P-5\2VF
MGZE!I$1\W5+H-Y,"\E>"06]%XK.U7QK!:Z5:ZC'97<FG7&5FF5<26P_O%#SC
MWKAX-.GU_P 1+8P7YOWA7S[+7[9AYMMGD)+_ 'AVQ0!FW<]]>,9I[B_/BG>T
M-U97*8MI8L]/0+COFNT^'?AW0KBP@UJWM+B.2-V5+>:4O'"_0F,>GO767?AV
MUUG3+>UUI1=N@4R.OR;V'TYQ[5IVUM!90);6T2Q0QC:D:#  H FQB@<5FZYK
MEEH&G/?7TC+&"%55&6=CT51W-8#^,KN[T>::STW[+J*-^ZL]0D6-IE_V1F@#
M2\5>+;+PK8Q3W*M))/((H8QQN8GH3T'XUYQXFTZ[;4]4FU^PO[@R$2Z7>VTN
M$M>.%/.!CN:8]RGB/65ATN":Y^WL1JNC7Z,!!@<NK'[I],5Z?I'AN#3= _L:
MXGFO[49 %R=Q"=E)[@4@.%^'NF66L7%S/JFFVEU>VC*!J$/^KG/N.A8>M>J
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MBDWQIQRWU-=-H&@6?AZR>UL@Q5Y&E=G.2S'J: -4#]:<!BBB@ HHHH ****
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M7CZ=H<[&5],GC#F)AQB-CT4UZ:!SF@""UM([:- %4R*@5I"HW/@=SWJQ2T4
M%%%% !2$<YI:* $'O2T44 %%%% !30/RIU% !1110 4444 (12 <TZB@ HHH
MH **** $- I:* "D-+10!SWB7PI8>);91.&ANXCF"ZCX>(^Q]*K>&O"3:/=/
MJ.I7LFIZO(@C:ZD&-J#H%':NJHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4F!110
M8%+110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>forms-3_009.jpg
<TEXT>
begin 644 forms-3_009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %7 DP# 2(  A$! Q$!_\0
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MS$\*Y!D#C:,=>: +5%5[:]MKQ2UM<13 '!,;AL?E4DDJPQM)(ZJBC)9C@ 4
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M]&BU"ZM(])U6=K:0QR&&+< 0<5T'A'XC:-XQN9K.S\^WOH1N>VN4VOM]1ZT
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M==^*X_X8Z1=:)\/=*LKQ/+N%CW.AZKDYP:[ 4#"BBB@ HHHH **** "BBB@
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M6/\ #GITK1\#_$*Q\4&#3XC//>I:K)<7'DE8F?'(!H [JBBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MBB@ HHHH **** "BBB@ HHHH **** /']:4:E^T7H<!&5LK1I"/^ G'ZXKV
M5Y'H7^E_M%:[,1Q;:>$'UR/_ *]>N4 %(>M+2'K0!YQ\;_\ DG%Q_P!?$?\
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M-X!OO,50I\M?E./3BO4-!U&35M$M;Z2T>T>9-Q@?[R>QJ@-(4M(*6D 4444
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M?]?W^->LUY-\'O\ D-^+O^O[_&O6:]R'PHYI;BT4458@HHHH **** "BBB@
MI-P]10:\X\2_#&^UW7[C5+;Q7J-B)L8@B/R+@=J /2,TA.*\A;X??$72\/I7
MCII\=([E3@U&?%GQ0\+?\AWP[#JMJOWI[,_-CUXH ]BR*6N#\-?%CPSXBE%L
M;A]/O>AMKP;#GT!Z&NZ# @$$$'H10 ZBBB@ HHHH **** "BBB@#R7P"//\
MC'XWN6Y9"D8^E>M5Y)\+SYOQ(\=38X^T(/YUZW0 4AZTM(>M 'G'QO\ ^2<7
M'_7Q'_.O+;3_ (\X?^N8KU+XW_\ ).+C_KXC_G7EMI_QYP_]<Q7LY9NSYS//
MAB34445[A\L1W'_'M+_N&O3_ ('_ /)/(O\ KYD_G7F%Q_Q[2_[AKT_X'_\
M)/(O^OF3^=>)FFZ/J,CVD>DCI10.E%>*?2!1110 4444 %<A\1O$EUX6\*2W
MMBB-=RRI!"S_ '49CC<?I77UROC\Z#_PB=TGB0LNFR81G0$LK=B,=Z0T>?VG
M_"9:?_PD]G/XD6YU&&QBNXIG_P!7%R2P'U'%>E^#-:E\0^$].U2= LT\0+@=
M-W>OGQ+7P9]L?S_B!J4MG( CQ>0P=T'12WI7M_@SQ=X3U*VAT?P_>(?LT85(
M&&UBH[C/6J)ZG9T5&[JD;.QPJ@DGV%>2S_%#Q));WWB"PT:U?PW8W!AD9W/G
M. <%AVQ2&>O453TZ^BU/3;>^@.89XQ(N?0BO/M=\>>(T\;WGA_P]IEC=?9(E
MDD>YEV<GMUH ]-KP#XZ?\CMX<^@_]#%>S>'KO5KC189M?MX+.^).^*)\J!VP
M:\8^.3J_C7PX592,#H1_>% &U\??^1(T;_KY7_T"OGL]:^A/C[_R(^C?]?*_
M^@5\]GK3$%%%% "-]QOI7V-\/_\ DGV@_P#7G'_*OCEON-]*^QOA_P#\D^T'
M_KSC_E2&=+1110 5YA\=K(S?#\7B#]Y974<P/H,X->GURGQ*L1J'P[URW(R?
MLS,/J.: -G0+P:AX>TZ[!SYULCD^^T5I5QGPJO#>_#71)"<LL&P_@:[.@!#7
MA'QP_P"1PT#_ *Y-_.O=S7A'QP_Y'#0/^N3?SJX?$BX?$CBZ***]<]EA6?K'
M_'M'_P!=D_G6A6?K'_'M'_UV3^=9U?@9G6^!GUG8?\@ZU_ZXI_(5B>/?^1#U
MK_KU;^5;=A_R#K7_ *XI_(5B>/?^1#UK_KU;^5>0>.><>"?^1+TO_KE_6MZL
M'P3_ ,B7I?\ UR_K6]7B5/B9TQ^$*5?O#ZBDI5^\/J*@91^#W_(:\7?]?W^-
M>L]J\F^#W_(;\7?]?W^->LU[D/A1S2W%HHHJQ!1110 4444 %%%% !1110 A
MHI:* .2\4?#OPYXKA87^GHEQ_#<P#9(I^HZUY\+GQE\(YU%Z\NO>%LX\T?ZV
M ?T_E7MU0S0QW$+PS(LD3C#(PR&% %#0=?TWQ)I<>HZ7<I/;R=U/*GT([&M6
MO$==TB]^$/B+_A)-"623PW<R 7UD#D0Y[CVKV'3-2M=7TVWO[&99;:= \;@Y
MR#V^M %VBD%+0 4444 %%%% 'D?PG&/'?CD?]/:_UKURO(_A:#'\1/'43#YO
MM*G^=>N4 %(>M+2'K0!YQ\;_ /DG%Q_U\1_SKRVT_P"/.'_KF*]2^-__ "3B
MX_Z^(_YUY;:?\></_7,5[.6;L^<SSX8DU%%%>X?+$=Q_Q[2_[AKT_P"!_P#R
M3R+_ *^9/YUYA<?\>TO^X:]/^!__ "3R+_KYD_G7B9INCZC(]I'I(Z44#I17
MBGT@4444 %%%% !7!?%W[:? -S]CA:9?-C-PJ+EO*S\V/PKO*YWQKXEA\*>&
MKC4Y8?/88CBA_P">CMP!2&>4^(/%_P -KWP7+8Z;IT;7S0A+>&.VQ(DG;GKU
MJ32[=I/'O@BVBTT6VJVMH9=1DCCV@J5XW8[_ .-(?^$]TE3XGG\+Z$;91YTD
M$<"B14ZD@]<XKU[P]J%CKNDVNN6L*H;N(,6*C=]"?:J)+U\C3:?<QH#N>)@,
M>I!KP32]4LK'X'^(=+N+B-;];F6(P,?G+%N..M?0@%<_<^"/#-WJW]JSZ-;/
M>!MWF%>I]2.A-+J,I^%+ZTT;PMX=TS4+J."\FME6*)S@N<=!7$WVA?#[5?$W
MB6:^U&Y_M1 6F6>8Q"(XX*8QG\<UZA>Z#IFHWUI>W=G'+<V9S;R'K']*I:OX
M+\.:]>+=ZGI-O<7"C'F$8)'OCK^- 'F&@:+KWCGX0)8QZ@\4L5ZPMKF9B"\*
MGCD<UYQXJ\':GX.\1Z3;ZI?K>23NKHRL3M 8>M?6%M:P6=O';VT210QC"(@P
M *\&^.G_ "._AOZ#_P!"% &S\??^1(T?_KY7_P! KY[[U[W\<6NV\%6'VI(@
MHO@(-A^\FSJWO7@AZTQ!1110 C?<;Z5]C?#[_DGV@_\ 7FG\J^.6^XWTKZT\
M&/JR^ -,^QQ6[ :?']GWL>7[AO:D,[>BL=I=<W3[8;3:+93#\QYF[@_[-)++
MK@+^5!:G_1LKECS-Z?[M &S6=KT NM U& ]'MI%_\=-<7XO\=:IX3:W2\L<Q
MSV3,9X8RZQ7&.-WHN:X"Q^+7B?4_#L5G8Q)J&HO#(UQ,;<[5QGY>,#I0!W/P
M+E9_AM!&QR8IY$_6O2Z\!^ >H^([F.\M(DA&C0%W8LN&,S= #Z>M>PQ2^(C)
M8>=;V80JWVPACE6_AV>OO0!N5X1\</\ D<- _P"N3?SKV!)-;\VPWPVVQM_V
MSYCE?[NVO%OC&UTWB;P_]L6-9O+?B,Y&,\?I5P^)%P^)'*4445ZY[(5GZQ_Q
M[1?]=D_G6A6?J_\ Q[1?]=D_G6=3X&9U?@9]9V'_ "#K7_KBG\JQ/'O_ "(>
MM?\ 7JW\JEL9=;^Q "&UV Q" [CS%@;B?>LCQQ)JY\$^)!)%;B,1$6^&.3'C
MDGWKR#QSBO!/_(F:7_UR_K6]6#X)_P"1,TS_ *Y?UK>KQ*GQ,Z8[!2K]\?44
ME*OWQ]:@91^#W_(:\7?]?W^->LUXQ\+&U)=<\9?8HX67SV*>8?\ EIV'TKU2
MPDU=C;?;XK9<PYG\IB<2>@]J]R'PHYGN:E%(*6K$%%%% !1110 E&:9(6V-L
MQNP<?6O.O$?C_6_#NLZ3I/\ 8T5[>W:/(Z0R8''0#-3*2BKL#LM?\1Z;X9L!
M?:M<>1;E@@;&>37-?\+@\%?]!;_R&:P+GQEXKOHHX;[P+#<1AR721PPQVQGO
M6=/JNLS" ?\ "M[%=LNY\*O*@\ <5R?7L/\ SK[R^278[W2?B7X6UO4H=/L-
M2\VYE/R)L(S76@Y[UX]!XC\06DD<]O\ #JRAF60_.FT$)[$=ZDO/BAXJTF&.
M;4_"J01/<",R>;D!2>GUJH8RA-\L9IOU%RM+8]?I,>U8$5QXCD@ED,%F";A?
M)&X\P'J3_M8J9Y=?S/Y<%H0+A1#ECS#_ !$_[5=1)>U"PM]3L9[*[C$D$Z&-
MT/0@UY3\,Y[KP=XSU7P#?2%H%)N=/=CU0\X'^>N:]+N7UD?:C;16S$2H+?>Q
M&4Q\V??KBO"?BSXDUOP_\4].U)=-ACDM$_T249(N%/9OH2>*8'T8*6N2TN\\
M7W&BM<7=KIZW<D4;P(I(&3@L&],"M*>7Q );T006AC$2FU+,<M)W#>U &W25
MBW$OB#9<^1!:%A;J8=S'F;N#_LTOFZ_Y;?N;3?\ 9,CYCCS_ $_W: -FL'Q%
MXOT3PH(#K%X+<3$[/E)SCZ52NO%']G71MM1O]+MIA:ABCRX/G8Z8_NU0G\2:
M)J%Q -1O- N(5MR29'#,LWH,_P - KI'GG@WQ]X=TKXC^+-0N;WR[*]96@DV
M'YL5ZOH'CSP]XGU![+2;[SYTC\QEVD?+G&?UKE;G4O#)GTX@>&AA7,NW;CS=
MIVC_ ':O:9X@T6QEMI8Y_#EK(\#"Z:!PI#_PA<=O6BX71Z%0:XO3_&!N[C38
M&U+1GFE+K<)%-D[OX GKGC-;"3>(O-L!);V81F?[9ASE1_#M_K0!RGQO_P"2
M<7'_ %WC_G7EMI_QYP?]<Q7H'QB?5V^&Y^V16RYNQYWEL3A=WRX]_6O/[7_C
MSA_W!7L97O(^>SSX8DU%%%>Z?*D=Q_Q[2_[AKT_X(?\ )/(_^OF3^=>87'_'
MO+_N'^5==\-I?$<?PKSHD4+7 U#$>>\>[Y\UXF:;H^HR/:1[2.E+3(R=B[OO
M8&?K3Z\4^D"BBB@ HHHH 3-<QX\\+MXN\+SZ=%-Y-R&66!R. ZG(S[5TQX-<
M!J.C>,DL=7*^)X+=Y[A6LI9  ($SRM(#F;F3XLZIIK:!+I5G"DJ>1)?AOX.A
M(]\5Z?X8T1/#OARQTE'WBVC"EO[Q[FO,CH?Q#P?^+BV _%:].\._:8]$M8+V
M_BO[V- )IXV!#-Z\4P-?%%(#2T %%%% !7@'QT_Y';PY]!_Z&*]_[UX!\=/^
M1V\.?0?^AB@#9^/G_(D:-_U\K_Z!7SV>M?0GQ]_Y$C1O^OE?_0*^>SUIB"BB
MB@!K?<;Z5]C_  _Y^'^@_P#7G'_*OCEON-]*^QOA_P#\D^T'_KSC_E2&=)TI
M.]-F?RHG?&=JEL?09KQZT^-FIW\;2V7@Z]N85<KYD.6&1^% '<^.]$G\3:'_
M &3;ZNE@LDB^>"1EX\\K[5F^$O!EGX/UG4'T_4XO['N44+8LP.U@,$YSWKR_
M7=2C\1:I)J-_X"U\W$@ ;RY74?D*RQ:6?F.6\!^(BAQM'GOQ0!]$>'-!TOP_
M936VDHBPRS-*VT@_,QR>:V:\)\-^-KWPK9/9Z9X#UD1.^\^:6<Y^IKM/!/Q*
MF\6>(+G2+C1I=/FMXO-82GGKTQ0!Z$17A'QP_P"1PT#_ *Y-_.O=Z\(^.'_(
MX:!_UR;^=7#XD7#XD<71117KGLA6?K'_ ![1?]=D_G6A6?K'_'M'_P!=D_G6
M=7X&9U?@9]96 _XEUM_UQ3^0K%\>C_B@]:_Z]F_E6W8?\@ZU_P"N*?R%8GCW
M_D0]:_Z]6_E7D'CGG'@G_D2]+_ZY?UK>K!\$_P#(EZ7_ -<OZUO5XE3XF=,?
MA"E7[X^M)2K]X?45 RC\'_\ D->+O^OW_&O6<#%>3?![_D->+O\ K^_QKUFO
M<A\*.:6X8YI:**L04444 %%%'>@!,5Y)XW_Y+'X9_P"O>2O6Z\D\;_\ )8_#
M'_7O)7'CO]WGZ/\ (J'Q(Z]OO&C-!ZFDK\8<G?<]4,GUKBOBB?\ BEH?^ON/
M^==K7$_%'_D5H?\ K[C_ )UZN3M_7:?J95?@9Z[:#_0H/^N:_P JFP*AM/\
MCR@_ZYK_ "J>OUU;'FB8ZUSOBGP?IOBM+(7R?/9W"SQ.!R,=1]#715P_C[QP
M/"@6W>SNS'<P/_ID"%E@8#Y<_C3 [< #@# ]/2EZUY'\,OB4^L6FDZ/<I>7^
MH2AS=7IC_=H<G )Z=,5ZX*!!B@@4M(:0SYS^(EO!<?%B_$\2R*+=#AAFL?\
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ML7_79/YBLZOP,RK? SZSL/\ D'6O_7%/Y"L3Q[_R(>M?]>K?RK;L/^0=:_\
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MOJOB&RUNYT^Q^V6:%(MLBA<&N?$TW4HR@MVAQ=G<]0/4TE<";;XP$Y^P:?\
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M1+2]O-'TZ7Q)9VSZK",DJ P5O[P]#0A&^****!A1110 4444 %%%% !1110
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M0OBMIFD>%;VZO(TBQJT4K^9&J^A[?A7I'C3P)8>,-/C29O(OX,&WO$'SH?\
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M2="T#Q%-HVJ-+!(D:R))L)64G^$>] %OQ5?:KIL]E>VEU!'I\&Z2\A*[I95
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MDQD?W2>Y->Y1Q1QL3'&B;N254#-97AKPSIWA31XM.TV$)&O+N1\TC=R3WK9
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M72>"_%$^OZ;$FJQ16NK>7YDEJI^8(>C$=L^E>6W4&C^--;TS7/#>JVUIKDS
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MFGL+WPK=;GQ,_-H?05Z)#;06^[R8(X]QRVQ0-Q]ZEQS3A0 @&!2T44 %%%%
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,0 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>forms-3_010.jpg
<TEXT>
begin 644 forms-3_010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %> <(# 2(  A$! Q$!_\0
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M?V5]9?8=7TV3RKJW#[E]F4^E6/$W@/P[XLGCN-:T_P"TS01E(V\QEP.N."*
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M=P)HS]: '44W>",CIZTNX4 +129HW"@!:*3<!2!@1F@!U%)NI-X- #J*!10
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MCU0_W@.M=6=*N;CQ#I'FJ1::3;[@V.))2NWCZ#- '3"EI!2T %%%% !1110
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MM'CCWO?Q*NQY<\_=0X8_@:8_B;0@S*^H090Q!@03@R?<[=ZLYCQ7_AH?7/\
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M3;HY4#HWJ",BIZ\_^#VN_P!O?#G3R[%IK0?9I"?]GI^F*[^@0M%%% !1110
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M:I6E%:+2]SWZS:=K2%KE$2X*#S$0Y ;OBK/.*:H&*?78CYY[@****!!1110
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M80W;,#P</%_B*(7_ /PD 6WAN3')&T0)8*>>?>O4I;F&VB,D\J1H!DL[8%>
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M.H *0TM(: /)/C[HOV[P9#J<2_OK"<-D=E/!KL_AYK8\0>!-)U#=ES (Y/\
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M@#Y\^$W_ "6KQ/\ 2;_T.OH.OGSX3?\ ):O$_P!)O_0Z^@Z "BBB@ IIIU%
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MW]S6B!2 4ZNY*VB/E92<FY2W88HHHIDA1110 444AZ<4 +13<FEH 6BDS2T
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MI<020R E)$*,/8C!J7.137<(I9B  ,DDT ?..K_#_P .VGQKTOPW#:N-,N(
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MBF?&%F4;9%^C#FO,;GX8^,/!,YO/ >O2S0#EK"Y/;Z'@_P Z /;\TC.%&6(
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MKGA'P[I^K7TMO<Z= RN(0&!9SN(R?3I0!R/PNU&QM?C%XDN)[RWBA<2[)'D
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M]!BP_P# A?\ &OGGX=_!>T\7^&#J>HWEY97'GO%Y7E8X &#S]:ZS_AF[1O\
MH-WO_?"T >M?\))H?_08L/\ P(7_ !I/^$DT3_H+V'_@0O\ C7DW_#-VC?\
M0;O/^^%H_P"&;M&_Z#=Y_P!\+0!ZP?$6A,,'5[ _]O"_XTS^W?#_ /T%-/\
M^_Z_XUY5_P ,WZ,/^8W>?]\+7GW@CX61>)O%>KZ5?37EK;V:DPS"''F8;'<8
MZ4#NT?3/_"1:&/\ F+V'_@0O^-._X230_P#H,6'_ ($+_C7DO_#-VC?]!N\_
M[X6C_AF[1O\ H-WG_?"T"/6O^$DT/_H,6'_@0O\ C45QKV@7,$L,FL6.R1"C
M8N%S@C'K7E7_  S=HW_0;O/^^%H_X9NT8?\ ,;O/^^%H LGX3?#%F+'5N?\
ML(#_ !KN_#C^&/"^C0Z58:U;-;0D[/-NU8C)SC.:^>/$'PNCTCXCZ?X<MY;R
M6QN?+\RZ\G.S<3GIQVKT/_AF_1B3_P 3N\_[]K0!ZU_PDFB?]!>P_P# A?\
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M<? ZQ\,>%+K5;+4+R[N(BH6'RP=V3CMS1X(^!UCXG\*6FJWNH7EI<3%@\/E
M;<$COS0![Y_PDFA_]!BP_P# A?\ &C_A)-#_ .@Q8?\ @0O^->2_\,W:-_T&
M[S_OA:/^&;M&_P"@W>?]\+0!ZU_PDFA_]!BP_P# A?\ &C_A)-#_ .@Q8?\
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M"*-#]XY[^U6FT?Q=XCTK1O"^I^'8K%=,N(G?51*I0I'_ ,\U'()P*]@&2<T
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M5K9QQ7EYCSY4&#)CUJIH'A'2/#ES?W.GVP2>]F,L\C<L2>P/8>U;M "T444
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M.-!@*!V%6*8#<8ZUSGB3QWX=\*2Q0ZOJ"Q3R#(B52[A?[Q Z"NBD!*$*<$C
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MA+=3+M>:1AS$!W"]S7JY'%,BACB39'&B+R=JJ * $BC2-=J*JKZ*,5+1BB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
IBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>forms-3_011.jpg
<TEXT>
begin 644 forms-3_011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )% :X# 2(  A$! Q$!_\0
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MN?I0!PU_8$@G9M....M9"V*338[@=1WKM;V/;PX..YSUK-C@7YG7;A>F..*
M/-M9TU[5VW 8)R#CI]:QMN>2N*[C5K42L[D-DMTSP:X^\C\JZ9-NWU&: *Q
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MBJT]LHYQ@#CB@#-HI[H5/MZTW% "4444 %%%% !1110 4444 %%%% !1110
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M@"O:A]B]>IJO/<84 G&30!-B)5)VC(JC.4<DJ,$TDC;T&')/M5.64J#G) H
MBG7=RAR!_#5.2)G.#T%(]P"Q93S_ "I\<V>K=.XH 2V@>&3=AL=ZM2SC'7'U
MJ&2Z4+MSG/3!YJA*1,2F[KWS0!;:97&QL$'O6;>VB2!AN4#&1VJM-)+!,Z,W
MRD<-FHY)Q)%DG[O&2: ,VYT\H#C<WN*P;V!D.3D#OQ6]+,Z' DP/7I564&;.
M<[<<8Z4 <=>IG+-N ' SQ5%E7 !RV 1TQ_DUT-U&5X(ROOUK(NXMBLRDE1VZ
M8- '-ZII%O=PB2$D2]N/YUR<]O+;RE)%P?YUV4[-N(,@XXQGH*CN+"*^LRA'
MSKT?OF@#BS14US ]O.T;CD5#0 4444 %%%% !7L'[.O_ "/-Y_UYM_Z$*\?K
MV#]G7_D>;S_KS;_T(4 ?1^LSFVTYY!V(KD9]9GWG (P,YKIO$C;=(8@X.X<U
MYM-?&*0AR-PX^49- &X^J-Y98EL=&.>]95YJK$$#/ QC'-4FOMZ@%\*.P[U3
M-ZAD(<\GUZT +=M-=1N0NT#[QSUK(NKT6MN3\F\ +CJ36K-<Q/9&(R XY'..
M:XN^5U!RY;!Y/OF@"S+J G)$B$,S<\57#23X51\@;!XYJI&&\W#9"YP,]:TH
M)A$^#)@MUXYH <MMERQ1LYYY[>U,G@"Y#*Q)_AZUL*$>,8;CCI5>>)=K9.2>
MGM0!R=]I^X':AR>N.F:R+G1$,9;(!V]*ZX1R32"*(-(_940DG\!5@^"]>NU1
MDTV:-&/WIB(U_$DT >47-I+;OM=3D=^U5RI':O4+KX=W\8Q=ZQI%L&)),ET&
MP/3Y<UGM\/X0K$^+?#P(Z*97_P#B: //<45VK?#R5G$=KXBT&XD8XVI=;?U8
M 5%<?#3Q3"3Y-A'>*%W%K.=)1_XZ: ./HJY>:9>Z<Q2^L[BU;L)HF3/YBJA%
M "4444 %%%% !1110 "OMCX??\D]T+_KSC_E7Q.*^V/A]_R3W0O^O./^5 '3
MUYI\6K6>\@TV,()K8&5I(8Y5CE+!<JP+ _*O5@.U>EUY;\891!%I4J65V\H>
M1/M5NS+Y:E?F0[0?O=* .]\->9_PB^EB6:&63[+'NDA^XQVCE?:K-Q<)#*BM
M@!V(S[U4\,*B>%M*6.U:U06L86!LYC&T?+SZ5S]_K2/=7]NX!^SS8*YQVZT
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M?UJU_:'@KQ(0NH:?+X>O6X^TV?[RW)]6C/*CZ9KEK^P:VE(5BP&<FL\D@XH
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M>((;>V18YW5\G*G@_G5Y_$7G6ZQ[4'4@+T^M &Q)=H.9"!R.M4;NY:3>N=K
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M]*KB=QG!ZF@#T/PS:OKNO6^GQR"-7R\\G]R)1EF_*K_B'Q1'JM^L=JR1:9;
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M^4/^6$X_UD?TSR/8UQV*[712VH_#+Q#8L<_8)X;V'OMSE7_/BN*:@!****
M5]L?#[_DGNA?]><?\J^)Q7VQ\/O^2>Z%_P!><?\ *@#IZ*** $/6OD?XL3"[
M\5ZJS8#V]X4'/5<"OK@]:^,/B<Q_X6/KRYX^U$XH Y-$,CA5!R>.*W-8U>1K
M2+35<.D:@._][VK#21HR2IP3WII.>M  32444 %%%% !1110 4HI** %S4D4
M[PN&1B,?E45% &@^KW,B@.4./]G%59)C)DYZ]1BH:* %I*** "BBB@ HHHH
M**** "O8/V=?^1YO/^O-O_0A7C]>P?LZ_P#(\WG_ %YM_P"A"@#UOXT7)M/
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M - &?\Q1_P *A\<_] &?\Q7OI^)E]_#ID)_[:$8J3_A9-VR_+I\1;O\ .>*
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M\<_] &?\Q7>_\-)W_P#T +;_ +^M2_\ #2=__P! "V_[^M0!P/\ PJ'QU_T
M9_S'^-'_  J#QU_T 9_S'^-=[_PTG?\ _0 MO^_K4?\ #25__P! "V_[^M0!
MP7_"H/'/_0!G_,4?\*@\<_\ 0!G_ #%=[_PTE?\ _0 MO^_K4?\ #2=__P!
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M8CI7)ZQX<M-2@=)8>HX8=5]Q0!XC16WKWAVZT23YR)(&/RR#^M8AZT %%%%
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M_6KU>X #8!SGJ>E,E*2VYB=-^1C&.M 'SP:2NJ\6^'1I=VUQ;J3;NW/^R?\
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M7/[N3<.F/>KD=_L&T29SU([4 =0DT8 PF3ZYK1AO81;,,8('0=ZY.VNMZ##
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M<G_EIT_.@#U*;4!$/O CU%5)=2#K\C;@3@?7O6 +ZU>V6=;Z-]_92"*J'4X
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M.]?%_P 3_P#DI6N_]?)_I7VB:^+OB?\ \E)UW_KY- '(T444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %;1\.7WV?2GA\N>34]WD1Q-
MN8$'&#Z&L6NS\'*-1FM_M'B>QT4Z6QEM3=1EMQ8Y.,?3O0!3_P"$ \3&7RQI
M4A;&<[AC\\]:]%^!.FW>D_$6^M+V%H9ULB2I.>"1S5.2UCMK&[\GXF:'+N E
M,:P-EV7D >AS5OX#7]QJ7Q!NYKAP[K8>6"!C@$8H ]%^/7_),+C_ *^8OYU\
MGU]8?'K_ ))?<?\ 7Q%_Z%7R?0 4444 %%%% !5[2]4O=%U&&_TZY>"ZA.Y'
M0\_0^H]JHT4 >@R'PWXZ(D:2WT#Q WW]W%G=-ZY_Y9L?RKF=<\+ZQX<G\O5+
M&2$'[D@^:-QZJPX(K%S71Z)XWUS0X#:PW2W%B?O6=V@EB(]-K=/PQ0!SA]J2
MNX?6/!.MD_VEH5QI-PW6?3)-T>>Y\ML_D#2'PCX:OB6TKQG:*#]V+4(6A8?4
M\B@#B**[9/AEK-PI:RO='O!G&8+Y3G\\4G_"K/%6/^/.W_\  N/_ !H XO/O
M1DCUS7:GX7>(8X_,N6TZU0#),]Z@P/PS2+X'TRV4MJGC+1X#_<MBT['\L4 <
M:LCCD$UHZ5!JNHWD=MIL-Q<7#$!4A4L:Z3S?A[I S'!J>NS#IYI%O%^('S$?
MC5?4/B'JTUL]GI<=MHMBPP8=/CV%A_M/]X_G0!V,$MCX9L63QO=I=7;J,Z3:
MN&9AV,K#A#].:X;QEKE[KEY%*7C73(ALLK> ;8H5] O8^I/)KFG<LY9B2Q.2
M2<DF@2,%*Y^4]10 TT@ZT4#K0!I:+I,FMZK#I\,\$,DI.'G?:H_'UJ[8>$M:
MU..>2QM#/'!*8F8,!\P^M9%I=265U%<PD"6)@R$C(R*]-T_1+**T1D^)&B0F
M3,S1M"Q*L^-P/O0!Q=UX+\0V5@][<:;)' B;W.1E1[BOKCX>?\D]T'_KS3^5
M?-'BS4KK2)'-GXJL-9:_1A<&UB(V#&WG/J*^E?A[Q\/-!_Z\X_Y4 =11110
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MCMPNWC ''TKE]4TO#;6!#Y[8P*] O[%O]9L;@\!NN:YZ]LY)SC8P/J!C!^E
M'#7%E-;DAU/3/2J=>@C3G8!98]S$8%8.IZ $8M;@J0/F4],^U '.44]T>-RK
MJ5(Z@TR@ HHHH **** "BBB@ %?;'P^_Y)[H7_7G'_*OB<5]L?#[_DGNA?\
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MD)0+R1R: /F]U*L01@C@CTIM=UXQ\-!))=0LXP%ZR(/YUPQH 2BBB@ HHHH
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M 1&QW(#V%>NV-Z+H>7N8'J#W/L:Y7QIIYOH$=(P94R02><4 >944K#'!ZTE
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MD#!K0U/QU+J<<1E9?D&% &#^-<)10!M3:W(ZA5. .GK3(M7DW NPR/UK(HH
ML7<HGE,@ 4D\@57HZT4 %%%% !7L'[.O_(\WG_7FW_H0KQ^O8/V=?^1YO/\
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M*** $[U\7_$__DI6N_\ 7R?Z5]H=Z^+_ (G_ /)2==_Z^30!R-%%% !1110
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M3?\ P)_^RKY(\^7_ )Z/_P!]&CSY?^>C_P#?1H ^M_\ A6WPR_Z!^F_^!/\
M]E1_PK;X9?\ 0/TW_P "?_LJ^2//E_YZ/_WT://E_P">C_\ ?1H ^M_^%;?#
M+_H'Z;_X$_\ V5'_  K;X9?] _3?_ G_ .RKY(\^7_GH_P#WT://E_YZ/_WT
M: /K?_A6WPR_Z!^F_P#@3_\ 94?\*V^&7_0/TW_P)_\ LJ^2//E_YZ/_ -]&
MCSY?^>C_ /?1H ^M_P#A6WPR_P"@?IO_ ($__95K^'/"/@_0M1>Y\/VUI%=,
MFQC#-O.WZ9-?&/GR_P#/1_\ OHUZ]^SP[OXYO-SL?]#;J<]Q0!]$Z[HFE^(-
M-:QU>V2XM"P8H[$#(Z5RW_"I_A\/^8+:?]_6_P :Z/Q/N&BOMZ[A7GLS;PV.
MOKDT ;__  JCX>_] 6T_[^G_ !I#\*_AX/\ F#V?_?X_XURVXA_OG)[9-49E
M<Y R>^2QH [4_"WX=#KI%D/^VY_QI#\+OAR.NDV(_P"VY_QKS:XL@<R-*3W/
MS&L2^_>,P5B!VY- 'L?_  K'X;#KIFGC_MX/_P 52?\ "L_AH#@Z;IW_ ($G
M_P"*KP.:VSG$A.#_ 'S61=6TC$E9"<=MQXH ^DO^%:_#/_H':=_X$_\ V5'_
M  K7X9?] _3O_ G_ .RKY9N(9(QO,C8_WSS5%I90>)'_ .^C0!]:?\*V^&?_
M $#]-_\  G_[*D_X5M\,O^@?IO\ X$__ &5?)1GE_P">C_\ ?1H$TO>5_P#O
MHT ?6W_"MOAG_P! _3?_  )_^RI/^%:?#+_H'Z=_X%'_ .*KY,\V7 /FM_WT
M:#-*#_K'_P"^C0!]:?\ "MOAE_T#]-_\"?\ [*D_X5M\,O\ H'Z;_P"!/_V5
M?)?FRC_EJ_\ WT:!-+S^];_OHT ?6O\ PK7X9?\ 0/T[_P "?_LJ/^%;?#/_
M *!^F_\ @3_]E7R49I1_RU;_ +Z- FDQ_K'_ .^C0!]:_P#"M?AE_P! _3O_
M  )_^RH_X5K\,O\ H'Z=_P"!/_V5?)?G2_\ /5\_[QH$TG_/1O\ OHT ?6J_
M#CX:(P9;#3@1R"+G_P"RITGPZ^&LS;GL--+>OVG_ .RKY(,LH_Y:-_WT:!-+
MWD;_ +Z- 'UI_P *U^&?_0/T[_P)_P#LJ/\ A6OPR_Z!^G?^!/\ ]E7R8LTF
M,^:^?]XT&63IYCY[_,?\: /K+_A6WPRP<Z?IW_@3_P#95W6F6EG8:;;VNGHB
M6D2!(E1L@*.F#7PAY\O3S'_[Z-?:?P]/_%OM")Y_T-* .GHHHH 0]:^>O%I#
M>-M3#+P9"N>I_"OH7O7A_B:U1O%E_(!\QE/0=>* .5:**-5$<;$OW/<^]1-#
M-&@VHP)/89.*ZB/3%;DE@.^*AGL4)QN/3! [_6@#!A9=WEF)]K?QD8'TI\@2
M7**CH,8Z?K6C#$).0"=O0XJ<VZ.B]<C@T <W/:A1A!(RXZ$C\ZI75IY:^9M)
M'I[_ $KI6M%+JV\JPYSUJ.2W5@=P]^>,T <5=VJ/PR'=T I+:QCBC:1$.X=L
M\&M^[LUC)S[]352'<L@CQQ_2@#B-3A9[EVVG/4[CWK+*E>#7HESHD<TS..1C
MN*Y?6M(:U)= 2%^]_C0!A44M)0 4444 %%%% !1110 4444 %%%% !7L'[.O
M_(\WG_7FW_H0KQ^O8/V=?^1YO/\ KS;_ -"% 'T%XM.-"D/^VM>>Y+C=TS\O
M%>A>+<'0G'^VM<(( O*KC//UH K26X9U 4+GJ::]J0I& U:#6Q8!@.?2A(CG
M 4*>] '.7EHTB8 &,>E84]FZ@C!QQNW5W\UFK1Y!R1U(K#OM/Q'EEV\YY/)%
M '%S6A&0OWCTR.A]:R;FS=9!L!PPR3Z5V$MJJ$Y!4#IDUFSV2EV!' Y^E '(
M7-HW0H.G'%<_?631YD '!X KN[BP?&, _P!TUDS:8&YV\XR=QH X@@^E.52
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M2I@RD,-H]!DXJ-V0C Z]NU $9VXQWQ49P./UJ0X<';@8[5&1M;KUH :<#_\
M52$@TYL9SFFMUH ./2@]>E)1VH 7/K249XI* %K[7^'O_)/=!_Z\X_Y5\3BO
MMCX??\D]T+_KSC_E0!T]>-_&'_B8ZQIFG36&H%8HY98Y(98UCF 7+ [B,8_6
MO9*\O^+_ )K0:4)((Y+#S'\TE(RROCY=I<@"@#M?![1MX-T9HBYC-G$5+_>Q
MM'6N3UB:.'6[HM&7._MVKMM"W_V!I^]2K_9TRK* 1QZ+Q^5<GK%NK:G=$'DM
M0!G"]A=]LD>T8X!&0*5C;28"X7'&11);XX#@C P*1[<2C:PY'0]* %D$*DA6
M )')-46E^<8R1VQWJR]G"@^9S\O:HIHXBI\MOF8]QT% $#%=W7:2>@YJ2.(9
MVJ#UY8U&EL0VX-G'0>]:=K;O(1QP.O:@"WIMGER2C8)QM/I716NEB,$ DCL#
MVJGID7E3DC.",<UT&X$9!XH KK9QQ[F4 L1BL]K9@^<8([8K9')Y-(T:O]X4
M 9:V((! 4]\XJ*XTF%XSE 3ZUM+'M&!22#(]* /.]:\.03P21/&)$.=R,."/
M2O%_%?PVDLEEN]+#%5Y:W/4#_9_PKZ9N[59<D9S7/:CIQ*-QP.I H ^064JQ
M#*58<$$=Z8>M>V^,_AZFKJ;RQ18+L#)XP''O[UX[?6%SIUY):W<1BF0X*F@"
MI12GK24 %%%% !1110 5[!^SK_R/-Y_UYM_Z$*\?KV#]G7_D>;S_ *\V_P#0
MA0!](ZKC["<]-PK##IG:>!VK6U^;[/I,DGH17#G6,R8X( ZD=* .G5DQP>:9
M(G\2J.>IK%3401G. .]68]3]OEZ4 69XB!G:=H]>M8URZF5VP3GG'H*OW5YN
MW!"!QALFLBYE!9F;D' QWH :RY7:!M'IBHVB5'<$DC/..U/C82[=H/+'.3TJ
MVD!EV[5QGJ?44 4TMP>0-Q_AJ.6WVN.,+MYR*V[>Q;S Q7&35MK!"A##)H X
MF>V'F $=!S5"2-(I055BW.,"NQO=-" ,J5F2:?N#!& ('&?6@#CKJ..1F5AG
M)SR.E8M_IR$_O%#(3T/>NTN=-=48L%R1UK-FTJ1L!\'///0B@#SK5/#:(ADM
M!\W4J>AKF626.4K*C*X[$8->R3Z9Y<'(S$1^-<WJVDP3@JR=OE8=10!YT2",
M@'(J-V!(!&/QJ]?Z7-8E@?FBSD.O./K68Q&X'&!0 O'IBF'FE./7-(: $I:#
M1GB@ [4&DHH !7VQ\/O^2>Z%_P!><?\ *OB<5]L?#[_DGNA?]><?\J .GKS'
MXK+:/<Z.LDZV]P$N6CDG16A("?,I#<;B/NGUKTZO*_C.UY_9^F+!>6,4(E>2
M6*Y=4+X'!!/I0!W?A+[/_P (AH_V7SOL_P!DC\OSOO[=HQN]ZRM6A07\K$G.
M[-;/AIY9/#&EO-.D\AM8RTJ?=<[1R*SM4D@2_"L>78]?7TH P)XXU^8@CTIH
MPL(9N.RD]ZU9[:T>-99)<'J,'I[5@7CF641!E5 W!S0 R5#(V5;))P<5!@*Y
MW9)'2I%EBC:4HZY3Y0!TQ]:SKB_3=\S@GN!0!?C<*Y^7J:V;60L%9@!_6N+;
M45R<..#G-3V>KNQ'[T>P/:@#TB"ZB'#, >E65EW#",:XFRU$-@EP>>N*W[>[
M&T8<9':@#9CN721HV4D9X:KZ-N7-9*S!@.15J*7:/O"@"Z6/%-+@]3]*$8'J
MP-.= 4XH JO,,XQTJI<?.20!@]>*GECP" <'-4IY"D;=#^M &%J,(92#D8[^
ME>>>+?#%EK-H^8E%R!\DH&"/\:[[4+D*"&Q\WM7-7,V^39QSQUZ4 ?.U[936
M-T\$\91U..>_N*K&O5_%_AM-2A>2(_Z4G*<?>]J\JDC:-V1U*LIP0>QH 911
M10 4444 %>P?LZ_\CS>?]>;?^A"O'Z]@_9U_Y'F\_P"O-O\ T(4 ?0?BQMNA
MR'&?F48]:\P>X$4C*X*G&!N->J^(;1KS2VB7@[@<UY_<>&IQG"AFSR2: *L%
MV&7+$ ?6M!+F+8"C=>2Q[U3/A^>)<YY'8\U6DT^XCY(RV.QZ4 :4S!HRNXD]
M>#UK/WL%7<6W ]??TJKLO%SD[0?>GK$1RS,3Z4 :=L T@R#@MP:W[3Y,=.3G
M)%8MMAMN1@CK6G"&8C## Z<T ;<8!P1C\*5DW!L9!IMHCR?*@)(ZXZ"K&;>$
M_O',CG^%>GYT 9YB9^,DGTJG/H]RWSI QR?I6^+DA/W2J@] .:I7/F2CEF/U
M- &(V@7!!\Q[<%S_ !2 8J@^AMEE-Y9Y'&?,%:\]J67:5Z=#6=)9_+@\CN:
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MB4W$1"0H7;&?05\O_P#"-:]VT34O_ 1_\* ,JBM3_A&=>_Z FI?^ C_X4?\
M",Z]_P! 34O_  $?_"@#+HK4_P"$9U[_ * FI?\ @(_^%'_",Z]_T!-2_P#
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M9Y7GD,;>85V(/NC '?/Z5@_\(WKRMQH>I<?].C_X5W<'C7QW!;Q0KX1M&6-
M@+:(22 ,<G% &?J">!'L[ZWM%$<D<9^SW'FL3(<9'&/7BOI;X><_#W0<_P#/
MG'_*OESQ+=^+?%1@-[X:>#R 0OV33&BSGUP.:^IO ,4L'@+1(IHWCD6T0,CJ
M5(/H0>E '24444 )BEHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH /QI,>]%% "T444 %)C-%% !BE_&BB@ HHHH **** "BBB@ HHH
HH **** "BBB@ H_&BB@ HHHH **** "C\:** "BBB@ _&BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>forms-3_012.jpg
<TEXT>
begin 644 forms-3_012.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $( ?0# 2(  A$! Q$!_\0
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MS#0K<G'0RGD5X?&9(I&AD7!R5/M5FWDV$QO@X.!GN*06/8K'XV2VBE8?#=I
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MG^R(1_VT-<#9:=<7@8QHJQH/F8G@58BA"/C<&QW%:**%<]!C^)=U)UTN(?\
M S5Z+QQ<W,?S:?$%;CE^M<196+SE0%.WN:W)1!#:+#$ 9!U8]J.5&T(-ZFS_
M ,):8[;[(=*B6#&WRPW&*DMO%HM;98K?388HAT1#@"L:VA<VI9\8'.2.:BS'
M*6].@-'*BY4['1CQO-G_ (\D_P"^J7_A-I_^?%>?]JN;-M\I((( Y J2VB+0
MJ74+]:.5&+5CH3XUF _X\TSZ;J8WCB91_P >4>?3?7/S.@!V#\:HR<FERHBY
MT[>/[A?^7",_\#K4\-^*9M=O9X)+581&@8%6SGFO.I!SP374_#X?\3:[./\
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M7O@V^E$KQ7+E<_*S=ZWO"OAJ/3E2XOYPY3E(QZ^M<[B[DS7*C5TNR&EZ<D(
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M/*CY35+4]+CO[5@P!!Z@]*?);K(NQI6C1?2J<DHMAM21V7W-#0(\[U_X<3W
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MBF_->;6F=O7:.!3U,I5HRV.F37Y7/E6J!@O60]!3;AY+T 7$S%>N%X%9]LV
ML:*JJ.F!6[:V44D1:3<#UX-6MM3GE)MZ%-0D*;8U"\4XRMY84'BG,EMN)7S,
M ]Z2$P^9\S8SV-"(LV3VUG)<,-H_&NAM+*.V0< MW-5K&[A7"!1@=ZEGU&.(
M,57CM0*Q;=\YYJM(<GK6#<:[<J?EV'GJ14*Z[.[8;RP._%%Q6-IVP#6QX1;.
MH7'_ %S'\ZYZSGBNOORKSZ5UWARS@M[F62*0LS( 16<I7T*BCI#12T5!9SL_
M_(^VG_7@W_H=<;J^DROKE[>%"\?GG[IR1793_P#(^VO_ %X/_P"AUP>K7TMK
MXHO_ "Y& $YR,\55/<SD=(EM:W.E^38 K.1\R]S7,RQ-!*R/\K*><UK:#KEG
M)J^ZX_<EN-XZ9H\1Z7-%<^<!YD,G*NG(K:X6N9*ZI-;KMC8D5N:+XGF281W)
M\V!^"#VKF2!$VW'X>E/#-YH*+CZ4/4$CK-;\+I<;[W32A4C)C%<;);%2=S8<
M'H:Z+2M:>T_=!RI/#9I;W3(I)7N(I0ZMR1CI22[CMJ<Z '&&(X%0/#O.0,8Z
M&MAK))X'085UZ>M4(I,.;>4 2+Q]:;5BG'2Z"SU$Q-LD'R^M:X9)%W+R*PY[
M;)R*2TOGM)-CG*^](AHVWCW57=63E35F.9)TW*1C%1R8- B2WUJ\M%VK*2AZ
M@US'BZY6:R\T(%._DBMN117/>)8C-IXC7DE_RJ6.)YPZR7M\L,1/SGD_W:Z1
MI=-TBP6UM%,TQ'[R5O7T%4?*ALHFA@.9V^^]5PH8['QD_P 0[5*1;'?:HYYM
MLB@)^5:%H@0,5!8D?*3R*I"%I"JF,%!_$.]6XXQ'$O;!Z9YJKV%8T;*W+2;0
M@1G_ (MW%=/8V0MB,HN>[5RVFO,)QE  #\OTKM$F5U5MH'&#[U2):L$\OEIQ
MR2/P%8\=[YDQC51NSU IVM795-L;$'VK-^WB&R!<H''RJ>Y-6WH2E=G0).L>
M5VL[XZ 9K"O?%-TESY$</DJ#C)ZBMW0$"0&5V^8C))J+5K.UU9F\U%5@/OJ,
M&LY1;6AV0II;G'WEU,DYM;*[NYWNL%T!//M7H'A+P^NC:<6E&VXEY8=2/:LS
M0K+2]'W2(SW%ZQP,KT^E7]0N]:$+26J1HHZCO6<8-:L<[O1&]<W5O91&6XF2
M-!W8]:9HOCC3)[@V5C'++,6 +A.!^->;:/I/B'Q5KS',K0HWS,_W5^E>DZ;I
M%MHLB01 >;O&YL<DT7;,G%1/2U.5!]13C34^Z/H*4U))S/C89T=/^N@KA$4<
MG Q7>^,QG2$_ZZ"N'1=P((&*VAL1(=&@)&,596+L16=<6TT7[RWW>X!IT%Y,
M.&<HW^T*I,%&Y8N;!'7='E6'I51H9%YCE.\?PL:M2:B\3+NA#@]T-,:[L[CA
MPR-[C&*>A2BUN5/[1EMQ_I$1 ]15VWN(;I0T;@^W>J4Z*K96594/OR*KR6?S
M+-;.8Y!Z4NI;@F;IC&*H/\[L&) %,AU79B*]4H_]X#@T^)HIF90X93T(--ZD
M*#(+A50 A00>]9TP!;I4UQ-]FF\MV^1C@$^M1S#T-9O1C:L0E, XK;TV!UL/
M,&36*%(YR,5J17TZZ=Y:LJQ \CO31!S>J$F[DX[TR#=QFG:EY9D+J^23FFPM
MD 4,1I0ENM2W+$6S&H83P,4^])6S;'6@9AI UT^6?!SQS6C%;31@+\I JCIR
MYD.1DYJ_--(9Q;P+ER,D^E XQOL6H&E1_FCS6C*+E8O-DRD8'W<U7L4734$M
MRP8]<,>]%U)<ZFWF?ZN(&@ZJ=);LHZG>:D;7-A "Y[GFG:+Y\L8>^VBY'! K
M14F:-8479$O5NYJU#9K&P$2C+^G-))DU(JVA:@98QGS M07$XD)"29]>*NFR
M\I/G(SZ57EA3JO"]ZNQSM6,.=U').<54+[AQ6Q,B,,8&/I51H$W<<4A!86TC
MLH5\9->A^#K.>WO)WDEW*8P ,].:\^@B8RC8YXKN_!!F^WW(D;($8Q^=9L:9
MW-%%%9E'.S_\C]:_]>#?^AUYIXB*_P#"3:CN/_+<]*]+G_Y'VT_Z\&_]#KS?
MQ %'B;4#MR?.)JZ>YFR@AR?D4D^M=%I>K2+;26%_(YM91@8/*>XK#3) [?2I
MD8#BMD26+NTFL+H+#(+B!QN5CU(IL=Y#N*$,C^XJ5[DF)%7JM6A-9RVNV>!M
MW>3' IV-8M$D#V4D6V9>2/OBHDEU#3I&DLU%S;GJAZU1;2S*=]E> 9_A)J2*
M75=-93)&KQD\D4/4VT8^74[.:8'<UM.>L;C&?I27FG?:X/.@.)D&0:LWL-MJ
MEN3+:GS ,@K5>"=M.1(N3Z*1FBS2U*Y;HIZ?<2W6Z&9-LZ<,/7WIT]O;LQ5V
M96],4\N(=56X"C##DFM#4((+VUW*P27'#+4\I$H& +G[ ^(W9E]ZTH[R.X0,
MA^M<[=WXM)/)O4VCH)1T-11W0B?S()5=/8U*=C!Q9TKR$CK6-K<_DV1;J":N
M6]VER@((#=Q5#7%#:>1NP=U#")QA@:23<S%5)S3)I6B0D!'QP*M.Y50-NX].
M:S+E5<G P1VSQ04-3561A&JY8=?2FKJJO,RE]A/7ZU#) RIY@1>.OS5FO/&[
MX< MGJ!BDP1U%CJ#"1"7?(/6O0K&19;8-G(QUKR*QN)4N5*C<N?XNU>GZ=J4
M5II9F=5R%Z&G$&KE'6IE$H4')SP!6?>Q-%8B21@LA(\L=<5>FT6YU.!;N%L.
MS;OH*COO#NJ,L+*AD"_>:E.31O2I+=G6Z/82S:7$&?)91N(J\-#'4@G'7)J#
M25NH+9$<[>!P*V(Y)2A!//>M8NZ-):/0P;F1=.N/+MXO,D/8#.*GM;'6-9F"
M,%AC)ZD=JL_:;2UD=BA,AZG&34D7B#R_WBP2[?I4R;,W*3.DAMX-#TPVL)ZC
M)?U-9*RB6\C?!SN'6N=U'QU$Y,8M9BP_@-6="U6YU"6)I-/> ;QRQK.Z,G%]
M3UQ/NK]!2TB?<'T%+4".<\9#_B4I_P!=!7!?:O(D(DB;9_>%=]XQ&=)3_KH*
MXL!'7:PR*VAL9RL$=_:.!LD)/<5(;RQV[96!!]15&31HY&WQ2-&QZTO]E7J)
MMBGCD_WQ5HM<G<)X]-9P8;DQM[<BH)7,0 $T<H[<=:4:9J@.?(A;Z&AK34/N
MM9#CTI:FB:74IRZ:;E@X78W7Y33HXY(Y HE.!U%2R/J,' LW*]\#-/,)FA\W
MRI$?'*D8JK&B:$VB8,K%0.@!%01P?9)-L2G).3Z4^*%)HV*EU*]<TGVQEVH5
MR5ZG'6E;4NR$U+3O/B)8$Y&1CL:Q!-<6D?E/$TJJ>HZUT\6I1E?+E=0,_=J*
M\MX94S&=N>I'6DXF4D8:WMNZ L2N>S#%!D.W"G*FKDVG0RVIC9]Q[$CFL9K2
M[MF/DON4?PM4V9FX$=V/WN*DMR!C<,FJLKW&=\D7UQ5FW.Y V.M!#31+=O)#
M#YT9'':G-?&YT_YE8/\ SITBAK=@1D>E6[>*.>R 0#>O8=Z5K&L(J:,BV?R5
M)_B/0>IK?T:R,<<EW,I+MUK'MK"2/5&DD!96^[[&NVMI8;:".-QR?:J1K&GR
MG/7%M/?7Z*X(A7FK\Q$01%B8ITX[UHR2++. B?*.O%-GGCB8%5#-T"XJK%MZ
M$=M8M*5>?]U$.@SUJZRQQY^RC '\1JIN>7#2M\W91VIX+D@<D>U%CGE,NP0E
MSOD8MFJU]M4X48%7K<XBQD9]*S[T,QSTH,')LR)N]5&<@FKLT8 .35%\<U+
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MKB--[*"6 0NGR =,U4'AW2P<BV&?J:U.U%%P,P^'M,;K;#\S1%X>TR%P\=L
MP.0<FM2B@!H&.*<>E%% %.^TZUU*$0W40D0'.":H?\(IHP_Y=!_WT:VZ*+@8
MP\+:0.EH/^^C6+KUQX?\-7-E%=6,C+=/L#IDA/<^U=GQ67J&BVFIWUM=7(9F
MMB=BY^4Y'?UHNQ61AB]\,AI?,0*J, I!SYF>X HEU#PC"R!IH]SKNPN3Q[^E
M/A\ Z5:AS9R7-M(93(CJ^3&3U SV]JL0>#-+MXI47SCYL1CD8MDMDY)^M.["
MR%O8=$M;1+CR%E1B -C9X/>J<6H>$K@S+'-'^Y!WDD@#%7&TO0UG324CV7&P
M/\O#,!W)K''A;PT;ZZFGO) 03&RR2!0&//'K1=AH+<:OX4BFMHVAD83Y ;:W
M'X5.]QX,58BTT)\T97YB>/?TI)+'0-+":C>ZQ-<F#Y [RAMH;@<"FQ> O#MV
ML<MK,[@9#.D@;>"<XHNP&S7G@E)FMW==P;;QN()ZX!]:B*^"0YRD8BV;M^\\
MG/3'K6VOA#2U\D*LH$4_GJ-W\6,?E5=O 6CEF;,XD8[@^_E3G.1^-*[&%AX=
M\,:C!Y]M9[DS@[LC!^AJX_@W09DVOIZ$?4U?TW3_ .SX#']IGN&8[F>5LD_X
M5?7I0!S2> ?#2/N&EQD^Y-1W'P\\,7,;1RZ:NQNH#D5U5% '&P_"[PA !Y>D
MJ,?[9J^G@;P_& %L  /]HUT5% [F#)X-T*08:Q4_\"-8.J^'/".F75G:W.F\
M73, ^\X7 SS7>5DZGH=IJMQ;37&_?;%BFUL#D8-.X79RUG;^ 8[=IK9(Q&C!
M<C=DD],>M#ZIX/34?LCP.JB'S3+AL#G&#Z5-<>#M"T2QN;^>YNX_+(D\\-S&
M1T( [U:&@:-:?Z9<7=U*]_#]G,LKYRK'.?:E=B&,?!BW7D&6#S#C^,D<\@9]
M:@CO_!!?".NX@D<-\P'!(]A3%\(^$_M0FBOT$>5W1B8%68< _6KUEI7AUYH[
M:WNB9K9'@6-I.<-U^M.["R&F_P##"-+%(%&QU1 I+%\C/ %;EA8:9)$L]M"I
MC<94\\BLD^"-.64SV\US!<9!69'^9<+MP/P%=%96HL[:.!9)) @QND;+'ZFB
M[%9$J011CY4 IX4#H*7%%(8TJ",'I3$@CC<NJX)XSFI:* "BBB@#G;C_ )'N
MU_Z\'_\ 0ZZ$5SUQ_P CW:_]>#_^AUT(ZTD)!2TE+0,2EQ0**8%+5++^T-+N
MK,-L\^)H]^.F17/0>&M5.CV^F7>H6SP0!0C1Q%6.!CFNM/2J]W>VUA;O<W4Z
M0PH,L[G % ')P_#^SBAB7,1D2"2)G,?+%FSN^HJI;_#N6&Z=I-0BDCD>.1F\
MG]X"G8-V!KH['Q;HFHW2VUO?*9GY164KO'MGK6X,$4 -C&U0.>!WI^*** #%
M&*** "BBB@ HHHH **** &L*YV;0]4CU^XU*PO;>-)U"O'+&3T]#72$9HQ0!
MP8^':R3W$US=1RM-&RKF/.PMW%-N?AWOEC>WO(D"(@,;Q91V7N17?8I,"@#%
M\/Z&-#M)8O,$CRR&1MJ[5!/]T=A6T!Q1@4M !1110 4444 %%%% !1110 48
MHK(U?Q-I6ARQ17]SY<LO*(%+$_@* ->FL*S=+\0Z7K.\6%XDS)]Y!PR_4&M,
M'- '/:EHNHRZ[%JFGWD$++'Y;)-&6X]L5FIX%$EQ//>7$4QF=I"OE_*&(QQ7
M9X%+@4 >?7?PW$ME#;P7D<6Q-K?NLASG/([UT?A_0/[&^T.\J-+.066)=L8Q
MZ#M6[@48H 7%&*** "BBB@ HHHH **** "C%%% &5X@THZUH5WIJR^29T*A\
M9VUAWOA75=5TZWLK_4;8I 1M,41!.!CFNQI,"@#AX_AW;11Q*)(=R67V8GRN
MK9SO^M+!X$>+4DG>\B,2W"W'RQ8E)4=-WI7;X%& : $')Z4ZD  I: "BBB@
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M9&>^TC^=>?>&_'_A*T?5?/UVRC$MXTB9/WEP.>E;O_"R?!7_ $,=C_WT?\*
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M_*I: "BBB@ HHHH **** .=N/^1[M?\ KP?_ -#KH1UKGKC_ )'NU_Z\'_\
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M 8\]*A>:V8X88]Q4:N@7]X34#B,C(S6K\CS7JRU D3WL!5PP\Q>"/>O?X?\
M41_[H_E7SA;.T>HVXPV/,7^=?1UO_J(_]T?RK-F=16):***DR"BBB@ HHHH
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M6\^MZN\4BE74W'4?E0!L:3_R"+/_ *XI_*K9.*YZ/PP88EC37=75$ 51]HZ
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M>3XI_P"?K3/^_;T44P#R?%/_ #]:9_W[>CR?%/\ S]:9_P!^WHHH /)\4_\
M/UIG_?MZ/)\4_P#/UIG_ '[>BB@ \GQ3_P _6F?]^WI/)\4?\_6F?]^WHHH
M7R?%'_/UIG_?MZ/)\4_\_6F?]^WHHH /)\4_\_6F?]^WH\GQ1_S]:9_W[>BB
MD >3XH_Y^M,_[]O2>1XI_P"?K2_^_;T44 'D>*/^?G2_^_;TOD^*/^?K3/\
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=Z>FL)*_]HS6DD>/E$"L#GWS110!I#I1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>forms-3_013.jpg
<TEXT>
begin 644 forms-3_013.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !1 ?0# 2(  A$! Q$!_\0
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MI+LF=0VTD?(2#CMGU]JGM_$]U=6\<\7EF.10PX_G7.W\-Q=7'E"US$JG9(7
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MX#'_ !J#O335+.<9W_ /J=$L?\)%XG_Z"%E_X#'_ !II\2>)Q_R_V7_@,?\
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M$G_[^K3?^%FG/_($G_[^K5<^$\@Y:OF63\,-,[ZA?_\ ?P4G_"K]+_Y_[_\
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MTT_#SQ ?^7S3?^^7K191B2?K=,Y5JB:NN/PYU\];W3O^^7IA^&VO?\_VG?\
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L(.A^M%%-[@AXZ4444QA1110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>forms-3_014.jpg
<TEXT>
begin 644 forms-3_014.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $L ?0# 2(  A$! Q$!_\0
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MWKC_ ,!)?_B:/^$@T[^]<?\ @)+_ /$T :=%9G_"0:=_>N/_  $E_P#B:/\
MA(-._O7'_@)+_P#$T :=%9G_  D&G?WKC_P$E_\ B:/^$@T[^]<?^ DO_P 3
M0!IT5F?\)!IW]ZX_\!)?_B:/^$@T[^]<?^ DO_Q- &G169_PD&G?WKC_ ,!)
M?_B:/^$@T[^]<?\ @)+_ /$T :=%9G_"0:=_>N/_  $E_P#B:/\ A(-._O7'
M_@)+_P#$T :=%9G_  D&G?WKC_P$E_\ B:/^$@T[^]<?^ DO_P 30!IT5F?\
M)!IW]ZX_\!)?_B:/^$@T[^]<?^ DO_Q- &G169_PD&G?WKC_ ,!)?_B:/^$@
MT[^]<?\ @)+_ /$T :=%9G_"0:=_>N/_  $E_P#B:/\ A(-._O7'_@)+_P#$
MT :=%9G_  D&G?WKC_P$E_\ B:/^$@T[^]<?^ DO_P 30!IT5F?\)!IW]ZX_
M\!)?_B:/^$@T[^]<?^ DO_Q- &G169_PD&G?WKC_ ,!)?_B:/^$@T[^]<?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 9FK?\?&E?]?H_]%O6G69JW_'QI7_7Z/\
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M:C=)_<'_ 'U_]:GT4 ,W2?W!_P!]?_6HW2?W!_WU_P#6I]% #-TG]P?]]?\
MUJ-TG]P?]]?_ %J?10 S=)_<'_?7_P!:C=)_<'_?7_UJ?10 S=)_<'_?7_UJ
M-TG]P?\ ?7_UJ?10 S=)_<'_ 'U_]:C=)_<'_?7_ -:GT4 ,W2?W!_WU_P#6
MHW2?W!_WU_\ 6I]% #-TG]P?]]?_ %J-TG]P?]]?_6I]% #-TG]P?]]?_6HW
M2?W!_P!]?_6I]% #-TG]P?\ ?7_UJ-TG]P?]]?\ UJ?10 S=)_<'_?7_ -:C
M=)_<'_?7_P!:GT4 ,W2?W!_WU_\ 6HW2?W!_WU_]:GT4 ,W2?W!_WU_]:C=)
M_<'_ 'U_]:GT4 ,W2?W!_P!]?_6HW2?W!_WU_P#6I]% #-TG]P?]]?\ UJ-T
MG]P?]]?_ %J?10 S=)_<'_?7_P!:C=)_<'_?7_UJ?10 S=)_<'_?7_UJ-TG]
MP?\ ?7_UJ?10 S=)_<'_ 'U_]:C=)_<'_?7_ -:GT4 ,W2?W!_WU_P#6HW2?
MW!_WU_\ 6I]% #-TG]P?]]?_ %J-TG]P?]]?_6I]% #-TG]P?]]?_6HW2?W!
M_P!]?_6I]% #-TG]P?\ ?7_UJ-TG]P?]]?\ UJ?10 S=)_<'_?7_ -:C=)_<
M'_?7_P!:GT4 96JES<Z5N4 ?;!WS_P LWK5K,U;_ (^-*_Z_1_Z+>M.@ HHH
MH **** .+^(FCRZAIUM)IVDV%UJ4DZP?:+BPCN6BC(8\!QTW;0?0,3VIWPS2
MZC\-3BZLVM3]K?RU;3ULBR[5Y\I0,<[AD]=N>F*=\2VM4\)YNUL2GVA-KWAE
MQ&V#AD$/SLX[!2._( JUX#58O#8A'B";7'BF='N9E*LC#&4PQ+8';<2><Y/%
M '345GZKJPTJ-&^Q7=VS!F*VR*=JJ,EB6(4#\<GL#5%?%NGR7,211W,EN[0H
MUVJ#RHWF ,:-DALL&3H"!O7)&: -ZBL+3O%=CJ8A$,%RKSR(L2.JY9&3S!)P
MQPNWGG!'3&2 =V@ K,\._P#(O6/_ %R%:=9GAW_D7K'_ *Y"@#3HHHH ***C
MGF2V@DFE.$C4LQQG@4#2OHB2BLU=:MUN1;W2FT=AE?.D3]<,<'ZU8_M/3_\
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M_P!IZ?\ \_UM_P!_5_QH_M/3_P#G^MO^_J_XT70>SGV?W/\ R+5%5?[3T_\
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M^N0JU<2W:.!;VT<JXY+3;,'\C5+PZ9/^$>L<(/\ 5#^*@#6HIFZ3^X/^^O\
MZU&Z3^X/^^O_ *U #Z*9ND_N#_OK_P"M3)C.8F\L*KXX)^;'X=Z )J*YRTDU
M_P UR(8P'Q(1/QR1C QT QTZU=\S7O\ GA8_]]M4\QA&M=7Y7]QK45D^9KW_
M #PL?^^VH\S7O^>%C_WVU%RO:^3^XUJ*R?,U[_GA8_\ ?;4>9KW_ #PL?^^V
MHN'M?)_<:U%9/F:]_P \+'_OMJ/,U[_GA8_]]M1</:^3^XUJ*R?,U[_GA8_]
M]M1YFO?\\+'_ +[:BX>U\G]QK45S)D\1G4 _E1<#R@<'9SSGU[8S6AYFO?\
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M "+UC_UR%:=9GAW_ )%ZQ_ZY"@#3HHHH **** "BBB@ HHHH **** "BBB@
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M &9:?\\OU-']F6G_ #R_4T<U?^5?>_\ (+0[LM;U_O#\Z-Z_WA^=5?[,M/\
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M'.O/[C/_ .%<^'?^>-U_X%R?XT?\*Y\._P#/&Z_\"Y/\:T/MVO\ _0&A_P#
MH4?;M?\ ^@-#_P"!0HY'_3#G7G]QRFJ_#*$:M;W>DV\,D2P/%)'=7TR')92"
M"H;T/'O4VA_#&P@BNWU6'$\]P9%2VO)65$VJ ,G!)R">G>MG4=4UZ* *=/BM
M0[;?.^T*0OXD8&?4U-:ZIK\]K'(-(B8,/O>>%W>^#T!I^S=KB]HKVU^XJ_\
M"N?#O_/&Z_\  N3_ !H_X5SX=_YXW7_@7)_C6A]NU_\ Z T/_@4*/MVO_P#0
M&A_\"A2Y'_3'SKS^XS_^%<^'?^>-U_X%R?XT?\*Y\._\\;K_ ,"Y/\:T/MVO
M_P#0&A_\"A1]NU__ * T/_@4*.1_TPYUY_<9_P#PKGP[_P \;K_P+D_QH_X5
MSX=_YXW7_@7)_C6A]NU__H#0_P#@4*/MVO\ _0&A_P# H4<C_IASKS^XS_\
MA7/AW_GC=?\ @7)_C1_PKGP[_P \;K_P+D_QK0^W:_\ ] :'_P "A1]NU_\
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M_P# N3_&M#[=K_\ T!H?_ H4?;M?_P"@-#_X%"CD?],.=>?W&?\ \*Y\._\
M/&Z_\"Y/\:/^%<^'?^>-U_X%R?XUH?;M?_Z T/\ X%"C[=K_ /T!H?\ P*%'
M(_Z8<Z\_N,N;X;^'W@D1(KD,RD FZDP#CZUDZ+X)UG2["PT\0Z9'!#<6LT\R
MWDTCOY+ _*K)@9P>,]ZZK[=K_P#T!H?_  *%5],U74[C4F6YB5=S[#;*03$
M/O'T[=>N1CW?LW:XO:*]CHZ***S- HHHH S-6_X^-*_Z_1_Z+>M.LS5O^/C2
MO^OT?^BWK3H **** "BBB@ HHHH *X^^UG4HM6O;B.Z*6UCJEGI_V3RU*RK-
MY.YR2-V1Y_&"!\G(.:["LZ;0M-GU1-1DM\W*E6SYC!2RYVLR [689."02.U
M'*VWB#5M,GBM_$%P\)#":9A$DC;?+)*(L0/R,RR,I(W!(GSC@UW2LKHKHP96
M&01T(K-O?#^F:@LPN;=G,T@E=EE=6W;/+X*D$#:2,#CYCZG.DJJB*B*%51@
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MG!./O^QK<J&>W6=X&8D>3)Y@QW."/ZT 9G]O3?\ 0!U;_OW'_P#%T?V]-_T
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M[C2XKU;D@1OJES%M'E)C8JL!C\.N:]=^WWW_ $"I/^_JT?;[[_H%2?\ ?U:
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>forms-3_015.jpg
<TEXT>
begin 644 forms-3_015.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %% <(# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*1#1I))LXD1%4A3D@<]\XH U/^$\T+_GM-_WY-'_  GFA?\ />;_ +\FL?\
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M9VHEXP R<\#M0!U>.E4+[1K/4KFVFNXO--N2R!NF2,<BL;_A"(3_ ,QS6_\
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M/_(<UO\ \#&H V=,TQ-,\\1GY99-P '08 _I6ABN7_X0F(C_ )#NM_\ @8U
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M'N/^/70NG]Z3_&L37_#^JZ?:6US=>)[V[B2]M]T,NT*V9!WQ7H?GPY_UT?\
MWT* .6\_QYG'V;0LGMOD_P :077CH@D0Z 0.IWR<?K6KJVFVVK-"S7QA,?\
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M+VW2$X"MYBY'KWH R'LO#B0M(WAXD+P/E)W4Y-)T2>T:2W\/IY@=1L;/.?\
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M5=Q10!R/C73;"/PTY2RMP?/@_P"68_YZ+70_V3IQY-C;?]^A61XW_P"19?\
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MLKM,T2R8],@&@"RO!Q_6G48&<T4 %%%% !1110 4444 %%%% !1110 4444
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M_(.'_?QO\:QWT,"]2]?QC="X$9C67Y<[,Y(Z>M3)IL\RJ4\;7WS'@_+SS]*
M-+_A /#7_0.'_?QO\:/^$ \-?] [_P B-_C4?AA[^+6M:TZ]U":]2V:-HGF
MW#<#D<?2J<T6IZKXGUB--=N;&TLECVQ0@=P22<CVH T#X!\-#!_L[_R(W^-<
M_P"#[JPLOB1XBT&PL;F!(8HF^<DH,9R1GUR,?C5X:9>E&?\ X2_4EVKN8,JY
M ]>G2JPT9(KF6_3QC=I/,%CDEPN6"\ =/>@9Z%17#Q:;<3S^1%XUOF8\@?+D
M_CBK/A\ZA:>*M2TJ[U.>^ABMXI4:;&5)^@H$=?1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !@&C%%% "8%&!2T4 9]]H>EZDNV]L()Q_MH
M*Y^;P0;?Y]"UF_TM@<A _F1?]\&NPI,8Z4 <FMUXQTN/%Q:V>KQJ>9(&\N0C
M_=Z?K3X/'NFB4PZE;WFER@XQ=0G&?J,BNH*YILT$<\9CE1)$/577(/X4 06N
MI6=\H-I=P3YY_=R!JL!CW_*N?O/ ^A73%XK4V<I_Y:6CF(Y_X#57^P?$FF@?
MV9X@%P@Z0W\>1]-PYH ZP4M<B?$NNZ8VW5O#LDBYP9[%MZ?]\GFK]EXTT&])
M7[<MO(.-ET#$<_\  L4 ;]%-21)$#HP9#R&!R#2[A0 M%&:* "N:\7]=#_["
ML/\ 6NEKFO%_70_^PK#_ %H Z6BBB@ HHHH *:!S3J;GV[T <SX.ABN/"ZQS
M1AT,\I(/^^:V%T?3U*,+5 R'*D=17(Z/?>(M#LVL!X5N+D)-(RS)<( X)R#@
M\UH?\)-XC_Z$VZ_\"8_\: +VJ6VGZ?)',-/20R,=Q Y%%HECJ-W+]HT\1SA0
MVX_Q#UJ@?$?B)B,^#+DX_P"GF/\ QH_X23Q$,$>#+G(_Z>8Z .@?2;"9W9[9
M&9NI(YJ"ZL+6QT?4/LT0C#P-NQWPIK'_ .$E\1_]";=?^!4?^-0WFO\ B2YL
MIX%\'70,D;(#]ICXR,>M $!_Y G@C@#]]!_Z!753:582;Y);9&+ DL>M<U?V
M.JVWAOPVUOIYNKK3GA>:W1PIX7!P3Q5C_A)?$)'/@V[_ / F.@"/=IN"&THM
M$"%W<],XS701:/IP"NELN."#^M8'_"0Z^!@>"[H#&#BXCZ>E/_X27Q".G@R[
M_P# F/\ QH FT/GQEXCY/_+'_P!!-+HZ+)XO\1JR@J?(R/7Y6J+PLFI2ZQK&
MI:AICZ>+IHQ'$[AB0H(SD55?4;O0O%NKRG1[RZANEA:.6  CY001^M '3RV=
MI:VLCF(,!&58MR2OI6#"^GR$*^D[(F(0L.<9[T-XRF92I\-ZF0>H*"FCQ?(.
M!X:U,#_KF* -R/0]/A,9C@">6P9<>M9-C_R4?5_^O.'^=1_\)G-G/_".:I_W
MP*C\/375_P"+]4U.73KBTMY+>*-#,,%B#S0!V-%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2&EHH ;M_SFJ=
M[I-AJ*%;RQ@G!ZEXP3^?6KU% '*?\(+:6CM)HU[>Z6YYQ#*60GZ-FF&/QIIA
M'EO8ZO"/X6_<R?F>*ZZB@#E1XT2T^75]*O\ 3SG[YC+Q_P#?8XK9T[7M*U92
M;"_MY\=0C@D5>9 Z;7564]B,BO/]5E\.7VHWL"^&+^XN+=]DES9PA<-[,"*
M/0LBN;\7\G0^1_R%(>_UKD1=ZI8'.CMXD5!SY-];+,GT!R,5R^JOXQ\3ZU:+
MK^@:@NG6EZMQ%/:H 2@ RN,]Z />@0>AI:Y0>,B"1_PCNM_3[..GKUI?^$R9
MN!X<US\+<?\ Q5 '545E:%K4&O6/VNWBFA =HVCG7:X9>N16K0 4W!).?RIU
M% "8P**6B@ HHHH *3FEHH : <YI:6B@!*.:6B@!I^E'-.HH ;S1S3J* &\T
MF#WSFGT4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !12$X%)NH =129HS0 M074C0VL\J]41F ]P,U-GZ5FZ[-/!H=_+;0B>=;=
MRD6<;C@T <YHY\6ZQI5OJ":Q:1+."P3[.#M&3Q5W^SO%_P#T';/_ ,!A4?PV
MO+J^\":=->6GV5]K 1D\D GFNKR/:@#F?[.\7_\ 0=L__ 84?V=XO_Z#MG_X
M#"NGR/:C(]J .8_L[Q?_ -!VS_\  84?V=XO_P"@[9_^ PKI\CVII;T% '-C
M3_%W_0;M/_ <5@:&MZK:E#+J]O'>1:L9)GW! ZXZ8KT;%8-WX,T"^O9;NXTY
M'GE;<[[B-Q_ T 93WGB"1F9-8TN($D!693M&>#^56[B\U(M%]FUG3B!'B0LR
M\OGG%/\ ^$!\,\?\2M./]MO\:7_A O#7_0+C_P"^V_QH&48Y];2(*-=TW<&.
M2S*>*=%<ZXLL>_7-+= R[EW+DC//Z5<_X0+PU_T"T_[[;_&C_A O#7_0+C'N
M';_&@1@>&[;7KJ'4)M+U:VBM3?3;%,0?OUS6W_9WB_\ Z#MG_P" PK<TW2K+
M2+-;2P@6"W4DA%Z9/6KF* .7_L[Q?_T';/\ \!A1_9WB_P#Z#MG_ . PKJ,5
M US"I(:6-2.H+#(H Y[^SO%__0=L_P#P&%']G>+_ /H.V?\ X#"NA^UVW_/>
M'_OL4&[M_P#GXA_[[% '/?V=XO\ ^@[9_P#@,*0Z=XO_ .@[9_\ @,*Z+[7;
M_P#/>'_OL4AN[?I]HAY_VQ0!B>&+[4[B\U:RU2>.:6RF6-7C7:""H;I^-='7
MG_@^^U7_ (3/Q6NII:16GVA##(K8\SY?EQS_ '<?C7<_;+?_ )^(?^^Q0!/1
M4'VNW_Y^(O\ OL4OVNW_ .?B'_OL4 345#]KM_\ GXA_[[%*LZ29\MT;'<'(
MH EHI%.1G&*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@"AK;O'H=\\;%76!BI'4'%<MHW@ZSO=%L;J74=3,LT".
M["X/4C-==J-LUYIMS;(0K2QL@)Z D5S6GV_C*PT^VLUBTAE@B6,.9'RP QD\
M4 3?\(+8?]!#5/\ P*/^%'_""V'_ $$-4_\  H_X4_?XT_YX:/\ ]_'_ ,*-
M_C3_ )X:/_W\?_"@#.N?#6BVC,)M3U4$-MQ]I/7&?2HET'09('E&J:OY8;:<
MW!_PZ5HM#XL9BS66ALQ.22[_ .%1RKXKM[:1S8Z&40%RN]\-@?3K0,SAH?AQ
M%4#5-4">JSD*H_*GP:'H-Q<>0FIZN)#T!N#S^E2Z7<>)M6TNWOH].T14F7<
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M_08UG_P*_P#K4 =A^=5K\?\ $NNN.L+_ ,C7,?\ "O;/_H,:S_X%?_6J"\\
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M \+$ C5D((R#Y3_X5;\7#/A/5/\ K@>OUJUIMG;'2K3-M#_J4_@']T4 9?\
MPG_A?_H*I_WZ?_"J&L^-?#U]HM[:VNMB&XEA=8Y%B?*MCCM71WMLD=J[VUG"
MTJ_=4H.:S%>]51OT6!GQECM'Y4#.9\!>*M*T7P=8V6L:Z)KY%)D+1O\ +D\*
M.*Z7_A/_  O_ -!5/^_3_P"%/5[R0*3H=NI)Y! J[I@BO(Y&FTZ&%D?;CRQS
M0!GGQ_X7 S_:J?\ ?I__ (FKC>*=%71!K!OHQ8%M@F(.-V<8QC/6M'[%:'_E
MVA_[X%>=+&@\)11[5,?]O*",<8\T4".H/C_PN/\ F*I_WZ?_  I!\0/"Q!(U
M5./^F3_X5JW]M'':NT%K%OR.1&,@5F[KM+A2=(@:$CKL&X>] ##X_P#"_P#T
M%5'?/E/_ (5QO@SQ!8:/KOB2YU+Q#YUO=7>^U4Q/]S'7I^'X5VJF\DM_,&CV
MZLTFW85'W<=:53=>7<,VCV^^/&Q=HY'>@8P?$#POT_M5<_\ 7)_\*/\ A8/A
M?/\ R%4_[]/_ /$TXS7B@,NB0'/5< $4X2W0FB#Z+ %8_,0H^44 )%X\\-33
MQPIJB&21@B QN,D]!DBKNJ^)-*T-HEU.[2V:;/EAE)+8Z] :R/&]M!'H,3)#
M&C?:X<%5 _BJ?48HY?'>E+)&LB_9)^&4$#E:! /B#X7/_,50?6)_\*/^%@^%
M\X_M50?^N3_X5)(;R.YDC.CP2Q[OD;:.14!FU"-F#:) XR<,$' H&/\ ^%@>
M%S_S%4_[]/\ X5QWC[Q!8Z[::8FB>(_L\D-[&\P6)\% >3T[5VLKSQ01%=%A
M>1E#,H4<'ZTT/>"1P=&@*\;<*!CU% $<?CWPPJ*AU=6(&"QB?GWZ4[_A/_"_
M/_$U7C_ID_\ A3EN+GSF5M!B"#^+:*<DMR]W''_8D*Q.<,^T?** (O\ A8'A
M?_H*K_WZ?_"AOB!X6 R=63UYB?\ PJ5Y+I0=FA0D;R!P.GK5?58C)X7UA[FP
MAA80/L"H,XQ0(Z..XCE@6XC8-$R[U8=-OK6 /B!X7)(_M6/CTC<_TJ]I9_XI
M6V/ _P!#'3_=JAX+M+9_"&F-Y$+9A&24&30 O_"P/"__ $%4_P"_3_\ Q-'_
M  L#PN!G^U4_[]/_ (5O?8K7_GV@_P"^!4-Q9Q+;R-#:0&0*=H*#DT <!X^\
M4:7K?@^^L]&UX0WK[2I$3_, 1D=/\XK<TOQOX=LM*M;:YUP33Q1*LDC1/EF
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M1J/]DV]GJ%O/,=3@8)&V3@$\UT_]BZ;_ ,^%M_W[%.CTNPAD62.R@5U.0PC
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M>$]/E&@R1:C9>4TUS)*8)@"0"<C(H MCQ;X>S_R&+3_OY2_\);X>/_,8M/\
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M@#E_$6O:3J$^C0V>H03R_P!H1G:C9.,'FNV'6JD>EZ?%('BLX%<="$ (JV*
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MNZ6-]#<,@RPC?)% '-:EHWC'5-.GLIM4TP), "5B/RC.:D32O'*1JBZ_I^%
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M]#+%_P" 24#%6?Q"KG?:PA 0,H.:BTDG_A.]9W<-]F@S]>:?_97BG_H98O\
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544 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>ex5-1_001.jpg
<TEXT>
begin 644 ex5-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  B )$# 2(  A$! Q$!_\0
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MHV<J% !_"BB@!EK:V]NK>1!%%GKL0+_*I'BC>9'>-69<[21DCZ444 34444
?%%%% !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
